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In society there is a discrepancy that has developed in what the public understands about 
what Ecstasy is, in relation to the term ‘MDMA’. MDMA, the abbreviation for 3, 4-
methylenedioxymethamphetamine, is the chemical constituent that has most commonly been 
associated with the street drug known as Ecstasy.  Though the use of Ecstasy was reportedly 
on the decrease, a new product has emerged known as crystal or MDMA powder. This is 
alongside new competing compounds entering the market, most notably Mephedrone.  
 
The research examined explores the changing perception around what the terms Ecstasy and 
MDMA represent, comparing their popularity and prevalence with that of Mephedrone. This 
was investigated using an interdisciplinary approach, utilizing methods drawn from social 
sciences and analytical chemistry. Two online social research surveys were employed to 
establish what the public knew and understood about the terms, Ecstasy and MDMA and the 
drug Mephedrone. The surveys included both quantitative questions regarding specific drug 
knowledge and qualitative questions which asked participants about their reasons behind 
selecting to use a substance.  The surveys provided a social context and highlighted specific 
perceptions that were held about these drugs.  The results from the surveys were compared to 
seizure data collected from the Cambridgeshire Constabulary, which provided a timeline of the 
emergence and prevalence of the types of Ecstasy/MDMA and Mephedrone being seized. 
The perceptions were also compared to a qualitative chemical analysis of seized samples 
using Gas Chromatography – Mass Spectrometry (GC-MS). 
 
In the findings from this research there is a definite gap between what the public know and 
perceive about the terms Ecstasy, MDMA and Mephedrone. A key finding from this research 
is what is reportedly known about Ecstasy has not translated into what is known about MDMA. 
There is an observed disassociation between these two terms. Mephedrone, on the other 
hand appears to have fallen into obscurity post its media high of 2010.  The responses to the 
social surveys indicate a clear preference for MDMA over ‘Ecstasy’ or Mephedrone, as the 
former is seen as being of better ‘quality’.  The user preference was supported by the findings 
from the seizers recorded in Cambridge, with the new crystal form being the most dominant 
type seized post 2012 and Mephedrone seizures declining after its control in 2010. In 
reporting the purity of street samples, the public perception was again supported as the crystal 
materials contained a higher percentage of the chemical MDMA. This is the first reported 
study of the relative purity of the alternate forms of MDMA. 
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Chapter 1 Introduction 
The research outlined in this thesis incorporates an interdisciplinary approach, adopting 
methods from both social research and analytical chemistry to answer the question – 
 
How have the perceptions around what is considered Ecstasy changed in 
the past decade? 
 
 
1.1 Background to Research 
 
The drug Ecstasy is not a new product. Since it first emerged onto the recreational drug scene 
in the late 1980s there has been a substantial body of research that has examined this 
product from a range of different disciplines, the background of which is discussed in depth in 
Chapter 2.  However what has yet to be established is what Ecstasy means in a modern 
context, with the advent of new forms and competing products such as Mephedrone, entering 
the recreational drug market. In 2009, there were reports of a new form of MDMA, the 
chemical most commonly associated with ‘Ecstasy’ being used (Smith, Moore and Measham, 
2009). There has subsequently been very little published on the emergence and prevalence of 
this new form known as MDMA powder or what impact it has had on the use and perception of 
‘Ecstasy’.  
 
1.2 The Research Project 
 
The aim of the research project was to examine the drug Ecstasy, how the public’s 
perceptions and the use of this drug has changed in the last decade. The perceptions were 
investigated in relation to the emergence of the new crystal form of the drug and the 
introduction of competitor products, such as Mephedrone entering into the recreational drug 
market. The research was framed into three main projects. The first project was the 
implementation of social research surveys, the second was the collection of seizure data from 
collaborators and the third was a chemical analysis of seized products.   
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Social Surveys  
 
The social survey project was divided into two independent surveys. The first survey asked 
what the participant knew about drugs, how informed they felt and the information sources 
they trusted to give them accurate drugs information. The second survey examined personal 
drug use, asking about preference and compared specific drug choices as set out in the 
survey.   
 
Seizure Data 
 
The seizure data was collected to give a real time perspective of the drugs seized in 
Cambridge, comparing the data to governmental and international statistics. There has been 
little published work on the emergence of the new form of Ecstasy, known as MDMA powder 
(Smith, Moore and Measham, 2009). Although often mentioned it is still unknown when and if 
MDMA powder has come to prevalence. Also examined is the impact that the New 
Psychoactive Substances (NPS) has had on the levels of Ecstasy seized in Cambridge.  
 
Chemical Analysis  
 
The chemical analysis project examined seized materials provided by Cambridge Police, 
analysing them using Gas Chromatography – Mass Spectrometry (GC-MS), and utilizing a  
method validated by the United Nations Office on Drugs and Crime (UNODC, 2006a).  This 
was done to establish if what people believe they are taking is actually what they are taking 
and whether there is a difference in the purity between the forms seized in Cambridge. To 
date there has been no published data on the comparable purity of Ecstasy tablets compared 
to MDMA powder, or to the NPS Mephedrone that is reportedly replacing them. 
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1.3 Overview of Thesis Chapters  
 
In Chapter 2 a thorough literature review of the historical and social context in which this 
project was based has been compiled. As ‘Ecstasy’ is not a new product there is a substantial 
body of work, from a range of disciplines that has been summarised. The chapter opens with 
the history of the chemical and the mechanisms of synthesis.  It also covers the biological, the 
social and legal aspects that have impacted the use of this drug. The emergence of competitor 
compounds and the profile of who uses this substance is also examined. The chapter provides 
the background context for the three projects within this research and ends with a summary of 
the research questions.  
Chapter 3 focuses on the application of social research surveys as a means of examining the 
social perception of what Ecstasy is considered to be. It provides a critical analysis of 
contemporary research surveys in this field; the Crime Survey for England and Wales (ONS, 
2012) and the Global Drug Survey (Mixmag, 2012). It outlines the methodology and approach 
adopted to answer the first research question reported at the end of chapter 2.  
Chapter 4 is split into two data analysis sections. The first section discusses the results for 
Survey A, which asked about the knowledge and perception around the two terms used to 
describe Ecstasy. The second part discusses the results of the second survey, Survey B on 
the popularity and preference of substances.  
Chapters 5 and 6 describe the method and results from the examination of the seizures of 
Ecstasy.  Chapter 5 critically assesses the size of Ecstasy markets as estimated by 
international organisations such as the UNODC and the European Monitoring Centre for 
Drugs and Drug Abuse (EMCDDA). It also outlines the method of data collection employed in 
this research. In Chapter 6 the results of the seizure data of selected controlled substances as 
collected in Cambridge between 2003 and 2013 is discussed. 
Chapters 7 and 8 examine the chemical element of the research, discussing the method 
chosen for this research and the results of the chemical analysis of the seized samples. The 
method described utilizes the technique of GC-MS, making use of a well-established and 
validated method published by the UNODC (2006). The samples that have been analysed 
provide quantitative data on the levels of MDMA discovered in the different types assessed. 
There is also a comparison between the purity of MDMA and of Mephedrone. 
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Chapter 9 is divided into three mini monographs, drawing together the findings from the three 
projects to answer the questions set out in Chapter 2.  The first section examines how the 
terms Ecstasy and MDMA have come to represent different products in relation to the two 
forms that are now found. The second section deals with the questions around the 
perceptions, the prevalence and the purity of MDMA by comparing whether the users 
perceptions collected in the second social survey correlates with the findings from the 
chemical analysis of the street samples.  The final section evaluates the impact of 
Mephedrone on the perception and use of Ecstasy, answering the question of whether NPS 
can/have replaced the more established traditional drugs. Chapter 10 outlines the major 
conclusions, limitations and recommendations found over the course of this research.  
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Chapter 2 Context  
‘Not-so-new’ Kid on the Block’ an Introduction to the Historical and Social 
Context of the drug Ecstasy 
 
2.1 The Origins of a ‘Wonder’ Drug 
 
2.1.1 It began with a discovery 
 
 Before it became the ‘drug du jour’ of a generation (Rushkoff, 2001 p.353), the discovery of 3, 
4-methylenedioxymethamphetamine (MDMA), the main component in the street drug known 
as ‘Ecstasy’, can be traced back to a German laboratory at the turn of the 20th century. First 
discovered by the chemist Anton Kollisch, a patent for MDMA was granted to the German 
chemical company E. Merck of Darmstadt on the 24th of December 1912 (Freudenmann, 
Öxler and Bernshreider-Reif, 2007).  
 
There is an apocryphal story concerning the original use for this chemical that has often been 
cited, that MDMA was developed as an appetite suppressant (Gimeno et al., 2002, Palhol et 
al., 2004). However after an extensive review of the Merck archives no evidence was found 
that this was the case (Freudenmann, Öxler and Bernshreider-Reif, 2007). The origin of this 
story actually relates to tests run by Smith, Kline and French in the late 1940’s and early 50’s 
on the drug 3, 4-methylendioxyamphetamine (MDA) a chemical analogue of MDMA (Iversen, 
2008). This is but one example of the misinformation surrounding MDMA that has proliferated 
throughout the literature and information sources on this compound. Misinformation is a 
central theme that will be explored throughout the thesis.  
 
The actual use for which MDMA was developed was as an intermediate chemical in the 
production of a haemostatic compound in a bid to circumvent a patent on a competitor’s 
successful patent (Karch, 2011). At the time there was very little interest in the action of 
MDMA as a compound in its own right. It was first documented under the name 
‘Methylsafrylamine’, yet it would go on to be known by a multitude of names, including its most 
infamous moniker ‘Ecstasy’ (Freudenmann, Öxler and Bernshreider-Reif, 2007).  
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The first record of a pharmacological test of MDMA was in 1927, performed by Dr Oberlin who 
was investigating the effects of adrenaline and ephedrine type products (Freudenmann, Öxler 
and Bernshreider-Reif, 2007). There is very little information available regarding the results of 
Oberlin’s testing, the reason for this being that much of the data was lost as a result of the 
Second World War (Freudenmann, Öxler and Bernshreider-Reif, 2007). Oberlin is credited 
with the oldest recorded structure for MDMA, recorded under the name ‘Safryl-methyl-amin’.  
  
  
A further mention of MDMA was found in the Merck archives in 1952 under the chemical name 
1-(2-methylaminopropyl)-3, 4-methylenedioxybenzol (Freudenmann, Öxler and Bernshreider-
Reif, 2007). Yet it was not synthesised again until 1959 by Dr Wolfgang Fruhstorfer, who was 
interested in the production of stimulants. Again the results of this trial appear to have been 
lost, and it is unknown whether Fruhstorfer performed human trials with this substance (ibid.). 
 
Since it was patented under the name Methylsafrylamine, MDMA has had a number of 
different names as chemical naming conventions have changed.  The most commonly used 
chemical name is 3, 4-methylenedioxymethamphetamine, which is abbreviated to MDMA. 
Although the official IUPAC reference is 1-(1, 3-benzodioxol-5-yl)-N-methyl-2-propanamine, 
for the purpose of this thesis MDMA will be used throughout. 
  
The first organization to take an interest in MDMA’s potential was the US military in 1953 
(Shulgin, 1990). Under the code name ‘Edgewood Arsenal’ the project worked in collaboration 
with the University of Michigan and documented animal trials of hallucinogenic drugs 
conducted on small mammals (Karch, 2011). The documents around these trials were 
declassified in 1969 and published in 1973. This series of experiments examined the use of 
eight compounds that were derived from structural variations of the compound Mescaline 
involving ring substitutions and variation in chain length. MDMA was the only N-methyl 
compound examined (Shulgin, 1990). Mescaline is derived naturally from peyote cactuses, its 
chemical structure and MDMA structure are shown in Figure 2.1, with the variation in the 
structure colour coded.  
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  Mescaline     MDMA 
Figure 2.1: The chemical structures of Mescaline and MDMA (red indicates the ring-
substitution, yellow indicates variation in chain length and pink indicates the N-Methyl 
variation) 
 
The study examined the reactions of five species of animal, evaluating not only the toxicity of 
the compounds but the behavioural effects as well.  It is the first known conclusive study into 
the animal toxicity of these substances (Holland, 2001; Karch, 2011, Shulgin, 1990).  The 
results of this and subsequent studies has found that MDMA is either equally toxic or 
moderately less toxic than its analogue MDA (Davis, Hatoum, and Waters, 1987). The toxicity 
of MDMA limited its ability to be weaponised and the military lost interest (Karch, 2011).  
 
2.1.2 The Godfather of Ecstasy 
 
One crucial figure when discussing the history of MDMA who is always mentioned is Dr 
Alexander Shulgin, known as the Godfather of Ecstasy. He was a driving force in the 
development of psychedelic substances and is recognised as the creator of over 200 
psychoactive compounds, all of which he personally experienced, writing and publishing 
extensive notes on the subjective experience felt with each new compound (Shulgin, 2013). 
These experiences were collated into two semi biographical books, Phenethylamines I have 
known and loved (PIHKAL) and its sequel Tryptamines I have known and loved (TIHKAL) 
(Shulgin and Shulgin, 1991, 1997). These books provide not only his subjective experience of 
a host of substances but also provide an instructional guide for the manufacture of each 
structure. The impact of Shulgin’s work is still being seen today in the emerging market of 
novel psychoactive compounds.  The current trend of creating new substances to circumvent 
existing drug laws has been influenced by the work of Shulgin and his wife (UNODC, 2013, 
p.60). As Shulgin adapted molecules by single functional groups to assess the change in 
affect, so now do the clandestine chemists to negotiate loopholes in legislation.   
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2.1.3 An Overview of the Chemical Synthesis of MDMA 
 
There are three main routes of synthesis that can be used to manufacture the compound 
MDMA. These are; the safrole bromination method, the reductive amination method and the 
Leuckart method. The mechanisms of these methods are detailed in a paper on the 
manufacture of the homologue MDA (Dal Cason 1990). Due to the similarity in structure of the 
two homologues MDA (Figure 2.2) and MDMA, with the difference being a single methyl group 
on the amine, the synthesis routes can be used interchangeably to clandestinely manufacture 
both compounds depending on the precursor reagents used (Dal Cason, 1990).  
 
 
Figure 2.2: Chemical Structure of the drug MDA 
 
Safrole Bromination Method 
 
Safrole bromination is the method that was first patented in 1912 by Merck of Darmstadt 
(Freudenmann, Öxler and Bernshreider-Reif, 2007). The method requires the use of safrole as 
the starting product for the reaction. Safrole is an essential oil that occurs naturally and can be 
extracted from over 360 different tree species found in South-East Asia (UNODC, 2008). 
Safrole is extracted and purified to produce fragrant oil, which has historically been used in the 
manufacture of perfumes (CosIngs, 2011d). However due to the status of safrole changing to 
that of a controlled chemical, owing to the fact it is used in the illicit production of MDMA, it is 
no longer used for commercial purposes (CosIngs, 2011d). In 2008 the UNODC cracked down 
on the production of safrole in Cambodia in an attempt to disrupt the production and supply of 
MDMA (UNODC, 2008).   
 
There is copious literature on the different routes that can be used in the synthesis of MDMA 
(Biniecki and Krajewski, 1960; Cason, 1990; Elks and Hey, 1943; Gimeno et al., 2005; 
Renton, Cowie and Oon, 1993; Swist et al., 2005 and Verweij, 1990) as well as the detailed 
guides provided by Shulgin in PIHKAL (Shulgin and Shulgin, 1991). However not all that has 
been published comes from academic sources, others are generated specifically as guides for 
the illicit preparation of recreational compounds with much clandestine literature easily 
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accessible on the internet. One such example of clandestine literature that is readily available 
is from the author known only as ‘Uncle Fester’. The author has self-published a variety of 
tomes on a range of illicit subjects (Fester, 2002). His book ‘Secrets of Methamphetamine 
Manufacture’ sets out the precise methods to synthesise not only methamphetamine but has 
an accurately detailed description of the safrole bromination method (Ibid., pp.69-71). This 
method can be used to not only to produce MDMA but also its homologue MDA by the 
substitution of the reaction chemical methylamine for ammonia. The method described in 
‘Secrets of Methamphetamine Manufacture’ requires very little specialist equipment to achieve 
the desired result. Figure 2.3 shows the variety of routes and materials that can be used to 
synthesis MDMA, route 1 indicates the reaction for safrole bromination.  
 
Figure 2.3: Routes of synthesis for MDMA using safrole bromination and reductive amination 
(A – Safrole, B – Isosafrole, C – Piperonal, D – Bromosafrole, E – Piperonal Methyl Ketone, F – 3,4-
Methylenedioxyphenyl-2-nitropropene, G – MDMA)   
 
The Reductive Amination method 
 
The second route of synthesis displayed in Figure 2.3 is the method described by Shulgin 
(1991). The method uses the precursor compound piperonal methyl ketone (PMK), which can 
be derived from safrole, isosafrole and also from the compound piperonal. In his book Shulgin 
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describes methods of generating PMK from all three starting compounds, illustrated in Figure 
2.3, following routes 2 and 3 with compound E indicating the chemical structure for PMK. The 
need to generate PMK clandestinely, as opposed to using a laboratory supply is due to the 
fact that it is a controlled substance with no legitimate reason for its production (European 
Parliamentary Commission, 2004). Safrole and piperonal however have had legitimate uses 
as perfume ingredients (CosIngs, 2011d and 2011e) and so were comparatively easier to 
divert into the clandestine manufacturing process pre-2008 and the UNODC crackdown.  
 
From PMK, Shulgin describes the process of reductive amination using aluminium foil and 
mercuric chloride (HgCl2/Al) as the reducing agents, identified in Figure 2.3, route 4i. He gives 
exact quantities and observations about what happens at each step. However this is just one 
method of reductive amination. Other methods include those described by Swist et al. (2005) 
that use sodium borohydride (NaBH4) or sodium cyanoborohydride (NaCNBH3) as alternative 
reducing agents (routes 4ii and 4iii). In all cases the reductive amination is an exothermic 
reaction and so requires strict temperature control, with Shulgin (1991) stating that the 
reaction must be kept below 60˚C.   
 
The Leuckart Method 
 
The final method is most commonly associated with the production of the compound 
amphetamine, via the precursor material benzyl methyl ketone (BMK). It can be used with 
substitution to produce methamphetamine, MDA and MDMA (Renton, Cowie and Oon, 1993). 
This method works on the chemical principal of reflux, which heats the chemicals to between 
150˚c and 170˚c and then cools them, repeating the cycle for 7 hours. Figure 2.4 illustrates the 
process of the Leuckart reaction through the intermediate N-formylMDMA. 
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Figure 2.4: Leuckart Synthesis route to produce MDMA (i= PMK, ii= N-FormylMDMA, iii = MDMA) 
All of these methods have been recorded in academic literature as ways to produce MDMA, 
however after the aforementioned crackdown on the precursor safrole, there have been 
reports that production has shifted to a new uncontrolled precursor known as Methyl 3-[3,4-
(methylenedioxy)phenyl]-2-methyl glycidate (MMDMG) or PMK-glycidate that was first 
detected in 2004 (UNODC, 2013).  Little research has been published into the prevalence of 
use of this new material over the more established materials. Collins et al. (2007) reported its 
discovery in a suspected shipment of MDMA in Australia, with a further two international 
papers discussing its appearance into the market in Switzerland (Bovens and Schläpfer, 2011) 
and in the Netherlands (Vijlbrief, 2012), Figure 2.5 displays the proposed structure for PMK – 
glycidate.  
 
Figure 2.5: proposed structure for PMK-glycidate (Collins et al., 2007) 
 
With guides on how to produce MDMA readily available on the internet anyone with an 
understanding of the basic principles of organic chemistry could attempt to synthesis it.  
Although the starting materials are tightly regulated and controlled at a global level, production 
persists because there is a demand and a market for illicitly produced compounds.         
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2.2 The Biology of MDMA 
 
2.2.1 The Biological Mechanisms of an Entactogen   
 
This research examines the social and chemical analysis of Ecstasy, yet to understand why it 
became popular the biological mechanisms must be considered. The following section briefly 
summarises how MDMA works, starting with its interaction with the brain.   
 
MDMA is known to trigger the release of two important neurotransmitters in the brain; 
serotonin and dopamine (Liechti and Vollenweider, 2001). Serotonin or 5-hydroxytryptamine 
(5-HT), is found in neural cells of the brain. It is an important neurotransmitter chemical 
responsible for the regulation of a number of biological functions including, mood regulation, 
heart rate, sleep, appetite and pain (Malberg and Bonson, 2001). It is the chemical that makes 
human beings ‘happy’ and its release is responsible for the primary subjective effects felt 
under the influence of MDMA (Cole and Sumnall, 2003; Malberg and Bonson, 2001). 
Serotonin producing cells can be found throughout the brain, hence its vast impact on a range 
of different biological functions depending on where it is being released and the responding 
cell (Malberg and Bonson, 2001). 
 
Dopamine (DA) is the second neurotransmitter released by MDMA. It is responsible for the 
energised feeling and rewarding effects attributed to the use of stimulant drugs (Laurelle et al., 
1995; Liechti and Vollenweider, 2001). Studies have proven that MDMA exhibits weak 
dopaminergic effects compared to serotonergic effects (Liechti and Vollenweider, 2002; 
Malberg and Bonson, 2001; Oberlender and Nichols, 1988; Schechter, 1989).  
 
Stages of MDMA stimulated Serotonin release  
 
When MDMA enters the body it excites the neural cells into releasing high levels of serotonin 
into the synaptic region (Liechti and Vollenweider, 2001; Malberg and Bonson, 2001). This 
increases the likelihood of binding to a corresponding receptor on a neighbouring cell.  The 
high levels of MDMA cause the receptors to become saturated (Malberg and Bonson, 2001). 
MDMA also then binds with the serotonin reuptake receptors (Ibid.), due to its chemical 
structure being similar to that of serotonin as shown in Figure 2.6.  
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Figure 2.6: Structures of Serotonin and MDMA (Corresponding structural similarities shown in 
red) 
 
Once bound to the reuptake receptors the MDMA effectively blocks the system so that the 
serotonin cannot be reabsorbed, prolonging the exposure and the resulting effects of the 
serotonin release (Malberg and Bonson, 2001). Once the MDMA has been removed from the 
reuptake receptors the serotonin makes its way back into the cell. If there is any residual 
MDMA, this will cause the vesicle to redistribute it back out into the synaptic region (Ibid.). 
Thus the MDMA depletes the body’s store of serotonin, resulting in a lack of readily available 
serotonin, which can cause feelings of depression that may last days after the original 
ingestion (Curran and Travill, 1997; Liechti and Vollenweider, 2002; Malberg and Bonson, 
2001; Parrot and Laskey, 1998).  It is the release of serotonin that is responsible for the many 
favourable effects engendered by the use of MDMA.  
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2.2.2 The Effects of MDMA  
 
One of the most important areas when understanding the historical and social context of 
MDMA and how it came to become a recreational drug are the effects. It is the effects of this 
compound that brought it to prevalence in the recreational drug market. 
 
The first paper published that investigated what the effects of ingesting a dose of MDMA had 
on a human participant found that: 
 
 ‘MDMA has a higher threshold than does MDA, but otherwise it is very similar in 
potency… there are few physical indicators of intoxication and psychological sequelae are 
virtually non-existent… It can be compared to the effects of marijuana, to psilocybin devoid of 
the hallucinatory component or to low levels of MDA’ 
(Shulgin and Nicholls, 1968 p.77) 
Since the publication of that first paper there has been considerable investigation into the 
reported effects of MDMA with sources of this information ranging from academic study 
(Curran and Travill, 1997; Downing, 1986; Freese, Miotto and Reback, 2002; Greer and 
Tolbert, 1986; Harris et al., 2002, Kirkpatrick et al., 2015; Peroutka et al., 1988; Sumnall, Cole 
and Jerome, 2006; Vollenweider et al., 1998) to subjective reports from the users 
documenting their experiences on web forums such as Bluelight.org, Urban75 and drugs-
forum.com.  
 
The reported average onset time stated for the effects of MDMA ranges from 20 to 90 
minutes, with the peak effects lasting between 1 to 2 hours (De la Torre et al., 2000). An 
active dose of pure MDMA is stated as being between 75 – 150mg (EMCDDA, 2015). A dose 
can be defined as either the weight of the drug or the weight of the drugs as a proportion of 
the body weight of the subject (Cole, Sumnall and Wagstaff, 2002). It is important to note what 
the recognised dose is when comparing the quantities and relative purities found in the street 
samples. Does what is found on the street contain an active dose? In this research a dose is 
stated as being 75mg, in line with the EMCDDAs use of the term dose.  
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From the literature both academic and the ‘grey’ literature, the effects of MDMA that have 
been reported can be divided into two main categories; the physiological and the 
psychological (Harris et al., 2002; Erowid, 2011; Dancesafe, n.d.; TalktoFrank, n.d.). Table 2.1 
lists the physiological effects, rating them as either negative, neutral or positive based on the 
users perspective.  The distinction of which category each effect falls into is based on the 
report by the online database EROWID (2011), which was derived from the paper by Harris et 
al. (2002).  
 
Table 2.1:  The reported physiological effects of MDMA  
  Negative Effects Neutral Effects Positive Effects 
Mild to extreme jaw clenching 
(trisma), tongue and cheek 
chewing, and teeth grinding 
(bruxia) 
Moderately increased heart 
rate and blood pressure 
(dose dependant) 
Increase in energy 
(stimulation) 
Short periods of swooning 
Analgesic, antinociception, 
decreased pain perception 
Increased awareness of 
sense 
Muscle tension Decreased appetite Increased tactile sensation 
Insomnia Visual distortion Rushes of exhilaration 
Erectile dysfunction 
Rapid involuntary eye jiggling 
(nystagmus) 
 
Increased body temperature, 
hyperthermia, dehydration 
Mild visual hallucinations 
(uncommon)  
Hyponatremia Bright and intense sensations 
 
 
Restlessness, nervousness 
and shivering  
 
Table 2.2 lists the effects that relate to the psychological impact that MDMA has on the user. 
Again distinguished between positive, negative and neutral, there is a distinct difference in the 
number of positive psychological effects compared to the physiological reported in Table 2.1. 
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Table 2.2: The reported psychological effects of MDMA  
Negative Effects Neutral Effects Positive Effects 
Tendency to say things you 
might feel uncomfortable 
about later 
Ego softening Mood Elevation 
Inappropriate and/or 
unintended emotional 
bonding 
Highly controllable 
experience 
Euphoria 
Agitation 
Increased willingness to 
communicate 
Decreased fear, anxiety and 
insecurities 
Short term memory scramble, 
loss or confusion 
Upwelling of unexpected 
emotion, emotional lability 
Feelings of comfort belonging 
and closeness 
Short term- anxiety, panic 
attacks, confusion, paranoia 
and psychosis 
Increased awareness and 
appreciation of music 
A sense of inner peace and 
acceptance 
Difficulty concentrating and 
problems with activities 
requiring linear focus 
 
Feelings of love and empathy 
Strong desire to do or want to 
do more when coming down 
  
Forgiveness of self and 
others 
 
It is the positive effects of MDMA that place it into the category of empathogenic or entactogen 
chemicals (Harris et al., 2002).  One criticism of studies into the effects is the difficulty in 
measuring a subjective experience (Sumnall, Cole and Jerome, 2006) as not all users will 
experience all symptoms described in the tables. There is also the point that each users 
experience is subjective not only to their own unique biochemistry but to the settings in which 
they are using this substance and so what may be thought of as an undesirable or negative 
‘side’ effect in one person may be neutral or even positive in another.   
 
One effect most identified with MDMA is the feelings of acceptance of self and a feeling of 
connectedness that Shulgin coined ‘The Open Window Effect’ (1991). It is this effect that 
interested the psychotherapeutic movement of the seventies into the possibilities of using this 
compound therapeutically (Stolaroff, 2004).   
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However, despite all the positive effects reported that have made MDMA and by extension 
Ecstasy so popular there are a number of adverse effects that have also been identified. The 
negative effects, often called side effects, have an adverse response compared to the ones 
that are originally sought or can occur alongside the more pleasurable events. The negative 
effects associated with MDMA fall predominately in the physiological category with very few 
reports of negative psychological effects such as paranoia or anxiety being linked to MDMA 
use (Harris et al., 2002). When anxiety is reported, it is often a result of combining MDMA with 
other substances, whether knowingly or unknowingly by consuming contaminated or 
adulterated products (Mohamed et al., 2011).  
 
Some of the physiological effects can have serious health implications, one being the risk of 
increased heart rate and blood pressure, which if unanticipated can cause unnecessary 
anxiety for a first time user (Parrott, 2011).This effect has subsequently been found to be dose 
dependant (Harris et al., 2002). Another possible fatal effect that can arise from the use of 
MDMA is a loss in body temperature control. In a review on the thermal effect MDMA had on 
the human body it was found that MDMA is ‘clearly a thermal stressor’ (Parrott, 2011, p.7).  
Despite the fact that that negative effects of this compound have been thoroughly researched 
and publicised, it remains one of the most prevalent substances on the recreational drug 
market (Karch, 2011). One aspect this research has sought to examine is how the perception 
and use of certain substances changes based on experience, which is explored in section 4.2.  
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2.2.3 MDMA and the Mind 
 
The popularity of MDMA did not begin with its recreational use. Another section of society 
were interested in its unique properties before it made it to the social scene. In the 
semibiographical work PIHKAL, Alexander Shulgin recounts the story of how he introduced 
this chemical to the world of psychotherapy and to the influential psychologist Leo Zeff 
(Shulgin and Shulgin, 1991, p.74).  Zeff had made use of other psychoactive substances such 
as Lysergic acid Diethylamide (LSD) and MDA, to help untangle the psychological knots 
encountered in the course of therapy. It was Shulgin who first introduced Zeff to the properties 
of MDMA believing he would be able to appreciate the unique effect it had over MDA. The 
result was that Zeff abandoned his plans for a quiet retirement and set up a network of over 
4000 psychiatrists and psychologists who introduced this magical new chemical to their 
patients (Stolaroff, 2004).  
 
Zeff was just one of many American psychologists of the late 1970s and early 80s who 
appreciated and made use of the psychological effects of MDMA. The psychologists saw it as 
the answer to dealing with a number of difficult psychological ailments with one anonymous 
psychologist stating that 
 
 ‘MDMA is like Penicillin for the soul, and you don’t give up penicillin, once you’ve seen 
what it can do’ 
       (Shulgin and Shulgin, 1991 p. 74) 
 
When the Drug Enforcement Agency (DEA) and the American policy makers decided to 
evaluate MDMA for scheduling after learning of the emerging trend in its misuse on the 
recreational drug scene, the psychologists who had been using MDMA appealed (Holland, 
2001). The first attempt to schedule MDMA in the United States was in 1986, deeming it to 
have no medical benefit and categorising it as Schedule 1 (Pilcher, 2008). The appeal was led 
by Dr Grinspoon, stating that the full medical benefits had yet to be investigated. The appeal 
was successful in un-scheduling MDMA, in what has since become known as the Grinspoon 
window (Pilcher, 2008). However the use of MDMA continued to spread across the United 
States, with the DEA needing to react. In 1988 the DEA was finally successful in scheduling 
MDMA with no subsequent appeals (Holland, 2001). The concept of control and the legislation 
behind drug policies is examined in the next section with an evaluation of the British system in 
which MDMA was controlled much earlier.  
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The control of MDMA caused the investigations into the medial applications of this drug to 
cease and research into its properties were stalled. (Pilcher, 2008). Modern study of 
psychoactive chemicals is still impacted by the laws created over four decades ago under the 
United Convention on Psychotropic Substances (United Nations, 1971), when MDMA was 
placed in Schedule 1, which states that it has no known therapeutic value. With the control of 
these chemicals as stringent as ever, very little research has been done into the possible 
medical benefits of a number of psychoactive drugs. This has recently been stated by 
Professor David Nutt who claims that our current drugs laws are ‘hindering research’ 
(Gallagher, 2013). Professor Nutt has been a vocal advocate of drug legislation reform, most 
notably publishing a relative scale of drug harm (Nutt, King, Saulsbury and Blakemore, 2007), 
which is discussed further in section 2.3.3. 
 
Though research into the therapeutic use of MDMA has been limited in the UK, there is one 
organisation dedicated to studying these chemicals that are trying to provide scientific 
evidence for the basis of therapeutic and medial use, and so potentially challenging the 
restrictions on these drugs. MAPS, the Multidisciplinary Association for Psychedelic Study, 
was established to examine the use of novel psychoactive compounds (MAPS, n.d.). Founded 
in 1986, they have been a driving force in setting up and carrying out studies into the benefits 
of using MDMA assisted therapy (MAPS, n.d.). In 2000 they were able to convince the DEA to 
allow for a pilot study to go ahead in the United States; looking at how MDMA assisted therapy 
can help sufferers of post-traumatic stress disorder (PTSD) (Ibid.). It is believed that MDMA 
can assist in a therapeutic setting due to its empathogenic properties, which Shulgin coined 
the ‘open window’ effect (Shulgin and Shulgin, 1991). MDMA enables the users to examine 
internal conflicts safely, with the added serotonin release resulting in a more enjoyable 
experience. The organisation has completed a number of trials in the US and has 
subsequently taken their mission internationally with trials completed in both Spain and 
Switzerland, and others just beginning in Australia and Canada. The research into the 
possible benefits of MDMA are still on-going (MAPS, n.d.).  Yet despite evidence that MDMA 
does have therapeutic use it remains strictly controlled.  
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2.3 The Legal Perspective  
 
2.3.1 The Misuse of Drugs Act 1971 
 
The legislation that dictates current drug policy in the United Kingdom is the Misuse of Drugs 
Act 1971 (MoDA c.38, 1971); the main function of the act was to identify and control the 
substances that posed a risk to society. Since its inception the MoDA 1971 has undergone 
numerous amendments to keep current with the changing trends of drug use in Britain. The 
concept of changing trends is another theme in this thesis, and will be explored further in later 
chapters.  
 
When the MoDA 1971 was originally transcribed it did not include the ‘novel’ synthetic 
psychoactive compounds, such as the ones mentioned in PIHKAL (Shulgin and Shulgin, 
1991), as they were not readily available in the British market at the time of its creation. It was 
not until an amendment in 1977 that the ring-substituted phenethylamines were officially 
controlled (MoDA 1971, amendment 1977). The paragraph that covers all the ring substituted 
phenethylamines categorised them all as Class A which is a classification above its more 
established homologue amphetamine. There is however no direct reference to the term 3, 4-
methylenedioxmethamphetamine or MDMA in the Act and all ring substituted 
phenethylamines have subsequently become known as the ‘Ecstasy’ group due to the popular 
street name used for MDMA. MDMA was originally categorised as Class A due to perceived 
hallucinogenic properties, believed at the time to be similar in effect to another Class A drug - 
LSD. Hallucinogenic properties are now considered an uncommon side effect (Green et al., 
2003).  
 
The decision on how to classify the substances and any subsequent new compounds that 
emerge in Britain is completed in accordance with the Advisory Council on the Misuse of 
Drugs (ACMD). The ACMD was set up to determine the state of society, the impact that drug 
use and abuse may have on it and the ways of limiting this impact (Home Office, n.d.). The 
Advisory Council review and give opinions based on scientific evidence to help the 
government deal with the problems associated with drug use. In 2009 the ACMD published its 
review of MDMA. 
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2.3.2 MDMA (‘Ecstasy’) A Review of its Harms and Classification under the 
Misuse of Drugs Act 1971 
 
In 2008 the ACMD was asked to reassess the impact of MDMA in Britain as it had been over a 
decade since the previous report and a greater body of scientific information had become 
available (ACMD, 2009). The report was led by the then chairman of the ACMD Professor 
David Nutt, who was subsequently dismissed after government criticisms of a number of 
controversial articles he wrote on the relative harm of drugs, including Ecstasy, comparing 
them to everyday activities. He has most often been quoted for the statement that ‘Ecstasy is 
less dangerous than horse riding’ (BBC, 2009; Nutt, 2009). Professor Nutt has subsequently 
become an outspoken voice in the field demanding a more evidence based drugs policy.    
 
The ACMD review focused on the compound MDMA, as opposed to the whole group of ring 
substituted phenethylamines. This was due to its recorded prevalence over the other 
compounds in that class, all of which were considered under the title of Ecstasy (ACMD, 
2009). It considered the impact MDMA had on society and the individual users in four mains 
categories of concern; the physical harms, the acute psychological effects, the mental health 
effects and the societal harms.  
 
The first few points considered in the review looked at the physical and psychological harms 
associated with MDMA use, which have been discussed in the previous section. On the topic 
of dependence it is stated that there is little evidence of long term physical dependence on 
MDMA, compared to analogous recreational drugs like cocaine or amphetamine (ACMD, 2009 
p.24; Iversen, 2008; Nestler, 2005).  It is the unique pharmacology of MDMA that is believed 
to be responsible for the ‘relative lack of dependence liability’, as MDMA has more effect on 
serotonin than dopamine (ACMD, 2009 p.24) 
 
The second consideration examined the societal harms caused by MDMA. As a drug, the use 
of MDMA is considered  to be purely recreational, as opposed to one that is daily or 
dependant like other drugs found in Class A, for example heroin (ACMD, 2009). There is also 
a low association between the use of MDMA with acquisitive crime or other negative impacts 
on society (Ibid., p 27).  There is also a contrast discussed between the use of MDMA, alcohol 
and other stimulants and public order offences, with few offences being related solely to 
MDMA use (Association of Chief Police Officers, 2008).  The findings in the report are 
supportive of those published by Professor Nutt and colleagues on the relative scales of harm, 
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which placed ‘Ecstasy’ at the lower end of the scale (Nutt, King, Saulsbury and Blakemore, 
2007). 
 
One aspect this research examines is the societal awareness of MDMA and the change in 
usage over time, which was also a focus of the 2009 review. The report makes use of data 
collected by the British crime survey to examine the drug use trends for MDMA. The data 
suggested that since 1996 the use of MDMA had been ‘relatively stable’ (ACMD, 2009 p.9).  In 
2006/07 the number of participants 16-59 years old reporting to have used ‘Ecstasy’ in the last 
year was 1.8% (ONS, 2007). This then fell to 1.3% for the year 2012/13 (ONS, 2013), 
suggesting that Ecstasy use was on the decline. However, there are a number of reasons why 
this data should be considered circumspectly; firstly the method by which the data is collected, 
secondly the sampling methodology and lastly what the data shows in comparison to other 
surveys on drug use. These considerations are critically examined in section 3.3, which 
compares the methodologies used to estimate drug use when developing a survey.  
 
The second aspect of the report that impacted this research was recommendation 5, which 
stated that further research needed to be completed in the type and form of MDMA that is 
being taken recreationally (AMCD, 2009 p.30). This relates to an apparent emergence of a 
new form of MDMA known as MDMA Crystal/powder (Smith, Moore and Measham, 2009), 
which is a key focus in this research. In 2014 a paper was published exploring the changing 
use of language used to describe Ecstasy, finding that there had been a shift away from using 
Ecstasy towards the use of the term MDMA (Turner et al., 2014, located in Appendix I). It is 
how this change in the use of these terms relates to the form being consumed and the 
perception around this substance that will be examined throughout this thesis 
 
One final point made in the report was recommendation 6, that the ACMD advised the MDMA 
should be reclassified as a Class B. This recommendation was not accepted by the 
government at the time, nor by the subsequent government. However in the last few years 
there has seen a sea change with the call for reformation of drug policy becoming a dominant 
topic.   
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2.3.3 Call to Review Current Policy  
 
The call to reform the current system of criminalisation of drugs has been a battle between 
prohibitionist and pro-drug groups. A turning point in the debate came in 2009, when the then 
head of the advisory council Professor David Nutt published a paper in which he compared 
the dangers of Ecstasy to that of horse riding (Nutt, 2009). After the publication of this paper, 
and other statements criticising the government’s stance he was asked to resign by the then 
Home Secretary Alan Johnson, who it is reported expressed; 
 
‘surprise and disappointment over Professor Nutt's comments which damage efforts 
to give the public clear messages about the dangers of drugs’ 
(Tran, 2009) 
 
This coincided with the governments’ rejection of the ACMD’s findings on the reclassification 
of cannabis, with the subsequent move back to a Class B (MoDA 1971, amendment 3130, 
2008).  Professor Nutt went on to start the Independent Scientific Committee on Drugs in 
2010.  He was the first of a number of prominent governmental officials to promote the 
concept of an evidence based policy, focused on harm reduction as opposed to 
criminalisation. Having first published the development of a rationale scale of drug harm (Nutt, 
King, Saulsbury and Blakemore, 2007), Professor Nutt and colleagues published a second 
paper, using multi-criteria decision analysis to review the comparative harms of a range of 
drugs in the UK (Nutt, King and Philips, 2010). Of the 20 substances examined Ecstasy was 
shown to be comparatively low on the developed harm scale, coming in at 16th behind 
anabolic steroids and above LSD (ibid.).  Ecstasy has frequently been used as an example of 
a relatively safe drug. 
 
In 2013 a report was published by the All-Party Parliamentary Group for Drug Policy Reform 
(APPGDPR).  The inquiry report titled ‘Towards a Safer Drug Policy: Challenges and 
Opportunities arising from ‘legal highs’’ was published in response to the newly emerging 
substances that had entered the market. In the report it is suggested that there should be a 
shift away from blanket criminalisation, finding that banning drugs did not decrease the 
demand or use of drugs but was detrimental to employment, increased levels of 
homelessness and was a drain on the tax payer (APPGDPR, 2013) 
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In an interview discussing the report on the Today Programme on BBC Radio 4 Baroness 
Meacher is quoted as saying that; 
 
‘There are drugs a great deal safer than alcohol and tobacco, and one can use the 
example of Ecstasy’ 
(Baroness Meacher, 2013 speaking on BBCRadio4 Today Programme) 
 
One month after the release of this report, MP Caroline Lucas launched an online e-petition 
requesting that the Home Office investigate into the impact of the MoDA 1971 and whether it 
was still ‘fit for purpose’. Only petitions that receive over 10,000 signatures are eligible to be 
debated in the House of Commons. Ms Lucas’s petition received a total of 134,758 signatures 
(HM Government, 2013). The success of the petition may be due in part to celebrity 
endorsement, most notably from the comedian Russell Brand who is an outspoken supporter 
of a harm reduction and health-based approach to drug policy.  
 
In May of 2013, the Home Office sent Liberal Democrat MP Jeremy Browne on a fact finding 
mission to examine the policies of other nations who have chosen different approaches to the 
criminalisation of drugs (Wilson, 2013, Travis, 2013). The findings from this expedition were 
published in a report on the 30th of October 2014 (Home Office, 2014), which coincided with 
the date of when Ms Lucas’s e-petition was to be debated before the House of Commons.  
The debate was attended by only 21 members of parliament out of a possible 650, a low level 
of attendance (Palmer, 2014).   
 
When the report was released it caused some controversy between the parties of the coalition 
Government in power. This is due to one of the key findings from the report that found that 
there was ‘no obvious link between tough laws and the levels of drug use’ (BBC News, 2013).  
The Deputy Prime Minister accused the conservative colleagues of trying to ‘block the report’ 
(Ibid.), the Conservatives in turn accused Mr Clegg of sending ‘an incredibly dangerous 
message’ also stating that ‘drug use in the UK was "plummeting" because of existing policy’ 
(Ibid.). The statement about the level of drug use plummeting is misleading, as discussed in 
section 2.3.2 the issues surrounding the methodology by which this data is collected is 
critically examined in section 3.3. Although the current government’s rhetoric states that drug 
use is in decline it is still evident in society.   
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2.3.4 Theories of control 
 
There are many theories that have been applied to the study of illicit drug use (Becker, 1963; 
Cornish and Clarke, 1985; Hirshi, 1969; Young, 1971). The following section examines a 
selection of these theories, applying them to the context of this research and specifically to the 
use of the drug Ecstasy. As Ecstasy is generally considered to be a purely recreational drug 
and therefore non-addictive (Peroutka, 1990), the focus in this section as with the rest of the 
thesis only examines recreational users.  
 
Social Control Theory 
 
Unlike other criminological theories, which focus on why individuals commit deviant and 
criminal acts, social control theory instead investigated the factors which stopped people from 
committing them. First established by Hirshi (1969, p.31), who proposed that it was not 
necessary to explain motivation behind the acts as ‘we are all animals and thus all naturally 
capable of committing criminal acts’.  From this he proposed a comprehensive theory as to 
why many are able to desist from crime, based on four key tenets: attachment, commitment, 
involvement and belief.   Often held to be the most influential factor, attachment is the aspect 
believed to be responsible for the internalisation of values and norms. Thus under this theory it 
is believed that when an individual has positive and non-deviant connections they are less 
likely to engage in criminal activities. This is further compounded by the second element, 
commitment described as ‘stake in conformity’ (Vold, Bernard and Snipes, 2002 p.184). The 
third element, involvement, identifies the importance of conventional activities while the final 
tenet requires the belief in following a non-deviant life. Social control theory states that if the 
individual has strong connections to their society they are less likely to deviate from that 
societies norms. This can be applied to the use of illicit drug use, in that the majority of society 
reportedly does not engage in the use of controlled substances (ONS, 2013). The fact that the 
majority does not use the substances may reflect the criminal nature of their use and so would 
be in contravention of commitment to society which is regulated by the law.  However 
conversely the tenets can be applied to use of drugs if an individual’s attachments are 
involved in a culture of drug use, which is explored further in section 2.4.3. 
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Containment Theory 
 
Similar to social control theory is containment theory, which provides an explanation not only 
for deviant behaviours but also conforming ones. Set out by Walter Reckless (1961), 
containment theory explores the middle ground between pathological deviance (biological or 
psychological) and where deviance is expected and part of the norm, such as  with certain 
communities and within organised crime (Ibid. p. 284).  Containment theory assumes that 
strong inner control and reinforcing outer containment would insulate an individual from 
normative deviancy. The aspect of inner control included concepts such as: self-control, good 
self-concept, ego strength, frustration tolerance, resistance to diversion, sense of 
responsibility and positive goal orientations (Ibid.).  Whereas outer control related to the social 
buffer that holds the individual within the boundaries of society, similar to Hirshi’s attachment. 
There a number of ways in which containment theory can be applied to the use of drugs, and 
specifically to MDMA.  
 
Outer control factors in this case can be divided between the desires to abide by the law; the 
aspect of outer control represented by the implementation of the MoDA 1971, and the 
opposing outer control aspect would be an individual’s conformity within user groups.  
Whereas inner control could be reflected by the individuals desire to experience the substance 
or not. For example if an individual’s inner control, the desire to use the substance, outweighs 
the containing aspect of the outer controls, the fear of recriminations by law enforcement, then 
drug use would occur. Conversely there will also be individuals with no inner desire to 
experience substances no matter the out controls and so drug use would never occur. There 
is a spectrum between the two extremes, of those who will use no matter what and those who 
would not. But the reasons behind the inner choice can be further explained using the rational 
choice model.   
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Rational Choice Theory  
 
The final theory explored in this section relates to the classical school of criminology, originally 
a component of the work of Beccaria (1764), rational choice theory assumes that deviant 
behaviour is a result of an internal cost-benefit analysis by the individual.  The perspective 
largely assumes that offenders are largely rational in their decision making process, and that 
the crime is purposeful with the intention to benefit the offender (Cornish and Clarke, 1985; 
Vold, Bernard and Snipes, 2002). This theory is therefore applicable to drug use, which is 
seen largely as a victimless crime when focused solely on the impact on the end user (Hunt 
and Joe-Laidler, 2015; Measham and Shiner, 2009).  
 
When someone decides to use a recreational drug, like MDMA they are making a rational 
choice based on the analysis of the information that is available to them. It is based on this 
principle that this thesis is examined, that all participants are making a rational choice to use 
the selected substances. What will also be examined is the perceptions and information on the 
drugs and how public perception of the terms Ecstasy and MDMA has affected usage and 
whether the perception about these terms is reflected by the analysis of seized samples.  
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2.4 The Social phenomenon  
 
2.4.1 Introduction of MDMA to the Recreational market – a Time line 
 
There have been many books written on the emergence of ‘Ecstasy’ as a recreational drug, 
tracking it as it became popular around the world (Collin, 2009; Crictcher, 2000; Holland, 
2001; Kavanaugh and Anderson, 2008; Pilcher, 2008 and Saunders, 1993). A summarized 
timeline of the events leading up to its eventual emergence in the British recreational drug 
scene is shown in Table 2.3. 
 
Table 2.3: Timeline of the emergence of MDMA (Holland, 2001; Pilcher, 2008; Kavanaugh and 
Anderson, 2008) 
1960s 
Before MDMA was introduced its chemical analogue MDA was finding 
popularity as a recreational drug, known as the ‘love drug’. 
1971 
UN convention on Psychotropic Substances and MoDA 1971 enacted in the 
UK 
1972 MDMA was first forensically identified in a street sample in Chicago. 
1977 MDMA controlled under the 1977 amendment to the MoDA 1971 in the UK 
1980s 
MDMA use became popular across the United States on the back of emerging 
music scenes of ‘House’ ‘Techno’ and ‘Dance’ 
1983/84 
Proto-rave with Balearic music started to emerge on the Spanish island of 
Ibiza, the beginnings of a new youth movement was founded 
1984-86 MDMA use grew popular in Spain 
1985 
Ecstasy is brought to the attention of the British public by Peter Naysmiths 
article in ‘The Face’  
1987 
Ecstasy use increased in discos on Ibiza, along with the new music sound was 
then exported back to the UK 
1988 British ‘Summer of Love’ marked by increased Ecstasy consumption 
1989 Large outdoor dance parties become popular in Britain 
1990s The rave scene continues to grow in popularity in Britain 
1991 First large American rave is recorded in San Francisco 
1993 Dance safer campaign established in the UK to reduce rave-associated injury 
1995 The schoolgirl Leah Betts dies after consuming an Ecstasy pill 
1997 
5.3% of participants in the British Crime Survey reportedly had taken Ecstasy 
‘ever’ in their lifetime, with 1.8% taking it within the last year. 
2000’s 
Shift in venue from outdoor ‘Raves’ to indoor licensed nightclub venues saw 
the spread of Ecstasy from underground rave movement into mainstream 
youth culture 
 
  
29 
 
The above timeline depicts how Ecstasy became a part of the recreational drug scene in the 
early 1980’s, spreading quickly across the United States to the Balearic Islands and eventually 
the UK.   The key events listed impacted the use and perception of this drug throughout its 
long history. From obtaining its infamous moniker to the culture of consumption that 
developed, the following sections examine in more detail the culture of Ecstasy use and the 
changes that have been observed within the last decade.  
 
2.4.2 Ecstasy – a Brand name 
 
So far the terms Ecstasy and MDMA have been used synonymously to describe this 
recreational drug. As with many recreational drugs MDMA acquired a street name fairly early 
on in its emergence. It is reported to have got its name from an anonymous American dealer 
in the early 1980’s who is quoted as saying;  
 
‘Ecstasy was chosen for obvious reasons, because it would sell better than calling it 
Empathy. Empathy would be more appropriate but how many people know what that means?’ 
        (Pilcher, 2008 p.24)  
 
Subsequently the terms have been used interchangeably, in both the media and academic 
literature where one term has become synonymous for the other. Yet with Ecstasy tablets 
frequently being found to contain substances other than MDMA (Erowid, 1996; Saner, 2013), 
it would be more accurate to say that - ‘All MDMA is Ecstasy, not all Ecstasy is MDMA’. 
 
It has been found that there is a strong correlation between prevalence and the emergence of 
drugs and them gaining a street name. As was found with the compound 6-(2-aminopropyl) 
benzofuran (6-APB), which became more popular once it was branded as ‘Benzo Fury’ 
(Power, 2013). The idea of branding drugs to make them more recognisable is a key concept 
when understanding the prevalence and persistent popularity of the drug Ecstasy. As stated 
there are two names that are being used interchangeably to describe the same compound; 
Ecstasy and MDMA. The changing use of these two terms has been examined and published 
as part of this research (Turner et al., 2014). What has yet to be explored is whether the two 
terms are understood by the public, does MDMA still equal Ecstasy? 
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2.4.3 The Culture of Ecstasy consumption 
 
As much has been written on the history and use of Ecstasy, so too has there been much 
investigation into the cultures and subcultures that have surrounded drug use, from Becker’s 
(1963) work ‘Outsiders’ on cannabis subculture to the current theory of ‘Normalisation’, which 
is discussed below. One influential piece of writing to this thesis was Jock Young’s ‘The Drug 
Takers’ (1971).  Young argued that drug use has to be considered within the context of the 
subculture in which it takes place, challenging the view that drug use ‘was a disease at the 
edge of society’ (Hunt and Joe-Laidler, 2015. p470). Sumner (1994) remarked that Young’s 
analysis saw drug use as an individual solution to the problems of modernity (Ibid.).  
 
Young also argued that society’s reaction to drug use was not based on the substances 
themselves but rather was based on the reasons behind that use (Hunt and Joe-Laidler, 2015: 
Measham and Shiner, 2009). This can be linked with the use of Ecstasy, as the emergence of 
MDMA in the British recreational drug scene occurred simultaneously with the subcultural 
phenomenon known as raves (Holland, 2001), which were massive social gatherings where 
people would come together in an enclosed environment to listen and dance to music. 
 
‘The object of a rave was to experience a reality that went beyond itself.’  
(Rushkoff, 2001 p.353) 
 
Raves were most commonly associated with the new synthesised music, which had 120 beats 
a minute, the same as a foetal heartbeat (Rushkoff, 2001). The enclosed spaces would 
produce a womb-like environment that fostered the feelings of inclusion and togetherness. 
This feed into the experiences felt while intoxicated by MDMA (Rushkoff, 2001). So MDMA, 
known as Ecstasy, became the drug of choice at these social gatherings. With the 
empathogenic effects acting as ‘social lubricant’, and the amphetamine-like side effects 
enabling the users to dance for longer, the use of Ecstasy pervaded this scene (Rushkoff, 
2001).    
 
‘The ‘E’ kicked in and I was off! Big smiles all round. Somehow we all got split up and 
I found myself alone, wandering aimlessly looking for my mates. Everyone I saw was my best 
friend, until I got close to them and realised I didn’t know them’ 
(Pilcher, 2008 p.58) 
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The use of Ecstasy quickly spread from the subversive underground culture of raves, 
proliferating into the mainstream consciousness as the ‘drug du jour’ for the party and dance 
scene (Rushkoff, 2001). A legacy of ‘normalisation’ had begun, whereby drug taking was no 
longer seen as a strict taboo, but an experience and ‘part of the broader search for pleasure, 
excitement and enjoyment framed within consumption-oriented leisure lifestyles’ (Measham, 
and Shiner, 2009, p. 502). The thesis of normalisation remains one of the most important 
developments in the understanding of the drug use as a part of society (Parker, Aldridge and 
Measham, 1998), whereas previous study attributed use to individual or social pathology, 
normalisation saw use as a ‘Unremarkable feature of young people’s lives’ (Measham and 
Shiner, 2009 p. 502). In the late 1990’s Ecstasy had made its way into use by the general 
public, no longer restricted to being taken in fields or warehouses it was being consumed on a 
weekly basis in nightclubs and dance clubs up and down the country (Measham, and Shiner, 
2009). By the mid-1990’s it had become to be seen as the ‘cultural signifier of a generation’ 
(Shapiro, 1999, p.23). As Young (1971, p. 222) insisted all those years ago, we must ‘learn to 
live with psychotropic drug use’ because ‘it is only by treating citizens as responsible human 
beings that any sane and long-lasting control can be achieved’ (Measham and Shiner, 2009 
p.507). A sentiment that is conducive to the rational approach taken in this research.   
 
Yet as the use of Ecstasy proliferated there were a number of high profile fatalities that were 
attributed to its consumption, including the widely publicised case of Leah Betts (Harris et al., 
2002). One question which was examined was why use continued despite an apparent risk. 
This can be contextualised using the conceptual framework of the social amplification of risk 
(Kasperson et al., 1988). Kasperson et al. (1988) defined risk in two ways; firstly based on the 
consequence of the harm, either low or high and secondly on the probability of the harm 
occurring. They concluded that society viewed low consequence/high probability risk and high 
consequence/low probability risk as being of equal value (p.177). The risk analysis an 
individual makes regarding whether or not to take a substance can be described by three 
levels. The first level or micro-level examines the risk in the context to the use, what is the 
probability of harm to the user. The second level examines the harm outside the user but at a 
local level; harm within their peer group or within the family, the final or macro level would be 
impact to society as a whole. Studies have found that most people have a comprehensive 
conception of risk, while public perceptions were seen as a product of intuitive biases, 
economic interests and therefore reflect more general cultural values (ibid. p.178).  One issue 
highlighted that is reflective of the issues around the risk perception of drugs was that: 
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 ‘As risk analysis incorporates a variety of methods to identify and evaluate risks, 
various groups present competing evidence based upon their own perceptions and social 
agenda’ 
(Kasperson et al. 1988 p.178) 
 
The debate that can arise from conflicting perceptions of risk has clearly been seen in the 
debate around drug use. As discussed in previous sections there has been much debate 
around the individual harms of these drugs, with a former government adviser losing his 
position as a result.  The multi-criteria analysis published by Nutt et al. (2010) took a radical 
view of the relative harms of 20 drugs. Debate and controversy between experts has been 
seen to erode confidence in risk analysis (Kasperson et al. 1988). This also includes the 
analysis reported within the drug using community, whose risk analysis of substances would 
be different to a non-user as the information on which they make their analysis is based on 
subjective knowledge. The difference between subjective and objective and the importance of 
information sources are examined in the social research surveys of this thesis.  
 
When examining the historical context, the dominance of Ecstasy as the king of party drugs at 
the start of the millennium was at risk, with issues around the purity and quality of the product. 
These factors combined led to a decline of trust of the product on the street (Measham, 2004), 
which in turn caused an apparent decline in use, evidenced by reports from the British Crime 
Survey/Crime Survey for England and Wales (Office of National Statistics, 1996-2014). 
However, this apparent decline in the use of Ecstasy focused predominately on the use and 
perceptions around the tableted form, and did not take into consideration other forms of 
MDMA such as powders and crystals. There is little to no published literature on the 
emergence of alternate forms, their prevalence in usage in modern British society or what they 
actually contain.  
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2.5 The Decline of MDMA in Pills 
 
2.5.1 The Decline in the Purity of Ecstasy Tablets 
The growing popularity of the Ecstasy pills in the late 1980s and early 1990s was aided by the 
clear branding imprinted on them in the form of recognisable insignias of luxury brands such 
as Mitsubishi and Nike (Pilcher, 2008).  Users would identify tablets they had taken before and 
assume that subsequent purchases would be of a similar quality. However purity issues arose 
in the mid-1990s when demand of MDMA began to outstrip supply and the drug content of the 
pills started to decline (Parrott, 2013). As the tablets contained less and less of the active 
component, the consumers then needed to purchase more and more of the tablets to maintain 
the same level of intoxication. When pills first emerged they sold for as much as £25 a pill 
(DrugScope, 2015) yet as the quality went down so too did the price with some tablets now 
being sold for as little as £3 (Binney, 2013).  There were a number of factors that influenced 
the reported decline in the usage of this drug; one being the user’s perception of the drug, the 
other being the actual composition of the products being sold.  
 
2.5.2 Perception and Experience Studies 
Since Ecstasy first emerged into the recreational drug markets at the end of the 1970s in the 
US and towards the mid-1980s for the UK, the quality and purity of the products available 
have fluctuated. The following section examines the studies covered in Parrott’s (2004) paper, 
critically evaluating the reported perceptions on purity.   
 
The first study referenced by Parrott was by Peroutka et al. (1988), which claims to be the first 
study that examined the subjective experience of Ecstasy users. The sample of 100 self-
identified Ecstasy users asked users about their experiences of Ecstasy.  Parrott (2004, 
p.236) summarises that there were no subjective reports of issues with purity reported by the 
users within this study, however purity or the perception around the quality of the MDMA is not 
reported to have been discussed by Peroutka et al. (1988). 
 
The next study published that focused on the subjective experience of users investigated 
Ecstasy use in Australia, (Solowij et al., 1992).  The sample for this study was also comprised 
100 participants. The participants were asked about their experience of using Ecstasy 
comparing their experience to their use of other amphetamine and hallucinogenic compounds. 
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The authors note that analysis of street samples would have provided a ‘useful corollary’, but it 
was not possible at that time (Solowij et al., 1992 p.1162). It is reported by the authors that at 
the time of the study evidence from police seizures indicated a high level of purity in the 
tablets being examined.  Yet of the participants who reported a decrease in the effectiveness 
of MDMA (49%), 24% attributed this to a decline in purity (Ibid.). It was also reported that 70% 
of participants noticed variations in the effects felt over time, attributing the variations to 
fluctuations in quality and purity of what was available.  
 
Of the studies conducted in the UK, Hammersley et al. (1999) examined patterns of Ecstasy 
use in 229 participants. Though this paper does scrutinise how Ecstasy was used and in what 
context there is no discussion on the perception of whether there are any purity issues with 
the product. Parrott (2004, p.236) claims in his review that there were no subjective reports of 
purity problems in this study, yet purity is not discussed by Hammersley et al.  One paper that 
does touch on the subject of perception was produced by Handy, Pates and Barrowcliff 
(1998). In their study of drug use in Wales they examined the patterns of use, identified 
perceived risks and assessed potential gender differences. The sample size comprised 389 
participants, with a gender ratio stated as 2:1 male to female, the impact of gender differences 
in drug surveys is further explored in this research in section 2.7.2.  On the question of 
perceived risk, 50.5% of the participants considered taking Ecstasy as ‘risky business’ (Handy, 
Pates and Barrowcliff, 1998, p86). The main reasons given were: mental health, physical 
health, adulterants and legalities. What is not reported is which of these reasons was the most 
dominant or prevalent reason given or whether it impacted a change in the use of this 
substances.   Though in these early studies only one truly identified a perception of a decline 
in quality, there has been a pervading opinion that the quality of tablets was on the decline 
(Parrott, 2004).  
 
One survey that has consistently reported on the user’s perception of MDMA and Ecstasy is 
the work by Dr Adam Winstock, in collaboration with the dance magazine Mixmag. Winstock 
et al. (2001) published a study of 1151 participants on the use and perception of Ecstasy. 
When asked to compare how the participants perceived the quality of pills compared to the 
previous year, 43% thought they had improved, 28% thought they were the same and 29% 
thought they had got worse (Winstock et al., 2001, p.13). When these figures are tested using 
a one way chi square test the values returned are χ2 value of 4.16 and a P value of 0.125, 
which is not significant at the critical significance level of 0.05. This suggests that perception 
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around the quality of Ecstasy at the turn of the millennium was mutable, with no significant 
difference between those who thought it was better, the same or worse. Since that first study 
at the turn of the millennium the magazine Mixmag has published an annual report on drug 
preference and prevalence in the dance scene. In the 2010 edition it reported that 76% of 
respondents thought that the quality of pills had gone down and increase of 47% from the first 
study a decade earlier (Mixmag, 2010). In 2011, the survey distinguished between two forms 
powder and tablets for the first time. This is one of the first studies that acknowledged the use 
of the alternate form, with 55% of participants reporting to prefer powder (Mixmag, 2011).  The 
survey also asked questions on the perception of the different types, with 13% of the 
participants reporting that they thought the quality of pills had increased and 68% that there 
had been a decrease in quality. The perception surrounding the powder form was more 
divided: 14% reported an increase, 31% claimed it was the same, 31% stated a decrease and 
23% did not know (Mixmag, 2011). In the 2012 survey, 13% of participants reported an 
increase in the quality of pills compared to 45% who reported a decrease, and 18% though 
that powders had increased, however 22% thought they had decreased (Mixmag, 2012).  
 
As the studies are looking at subjective experience there are issues with quantifying personal 
experience, especially in relation to purity when considering factors such as tolerance levels. 
Another issue is relying on the fact that the participants are discussing what they believe they 
have taken without categorically knowing what the substance actually is.  One way perception 
can be assessed is in the comparison to the analysis of seized samples, however as 
highlighted by Solowij et al. (1992), it is difficult to correlate exactly what people take with the 
evidence from the analysis of seized samples. However analytical analysis can provide an 
insight into the changing trends in what is available.  
 
2.5.3 Chemical Analysis of Ecstasy Pills 
The users’ perception of the varying quality of Ecstasy tablets has been confirmed by studies 
into the chemical composition of seized samples. Studies in this area can be separated into 
those that examine number of samples containing MDMA and studies that examine content of 
MDMA in samples. Table 2.4 summarises findings from studies published over a period of two 
decades that reported the number of samples of Ecstasy that contained MDMA, its analogues 
as well as other unrelated compounds.  
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Table 2.4: Summary of studies examining content of Ecstasy samples from 1986-2006. Data expressed as a percentage of total samples tested (as reported by 
the authors) 
Study Sample size 
MDMA  
(% samples) 
MDMA + 
Other 
(% samples) 
MDA 
(% samples) 
MDEA 
(% samples) 
Otherh 
(% samples) 
Uncontrolled 
(% samples) 
Unidentified 
(% samples) 
Renfroe   
USA 
(1986) 
101 Tablets 58 24 14 - - - 2 
Spruit  
 The Netherlands  
(2001) 
 
373b 
1053c 
1745d 
2102e 
2653f 
47.7 
49.4 
53.1 
60.6 
44.1 
8.1 
8.9 
11.2 
15 
13.7 
4.6 
4.4 
2.7 
2.5 
1.7 
20.4 
11.5 
16.7 
12.6 
6.8 
19.4 
25.8 
20.2 
9.3 
33.7 
- - 
Milroy, Clark and 
Forrest  UK 
 (1996) 
13 Tablets - 23 15 23 23 - - 
Sherlock et al.  
UK 
(1999) 
25 Tablets 32 16 - 16 16 16 4 
Baggott et al.  
USAa 
(2000) 
107 Tablets 63g 29  8 
Ramsey et al.  UK 
 (2001) 
156 Tablets 
90 Powders 
29 
6 
- - 
2 
0 
8 
59 
28 
23 
33 
12 
Tanner-Smith – 
USAa  
(2006) 
1214 Tablets 39 15 5 <1 29 - 11 
a samples analysed by Dancesafe, b for 1993, c for 1994, d  for 1995, e for 1996, f  for 1997, g samples recorded as containing either MDMA, MDEA or MDA and any combination thereof 
h samples containing any other psychoactives i.e. cocaine   
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Table 2.4 can be used to demonstrate that the content of tablets considered to ‘Ecstasy’ has 
varied over the years, with earlier studies reporting greater observance of other 
methylenedioxy (MDxx) compounds such as MDA and MDEA.  It also shows the occurrence 
of other substances being included not only in combination with MDMA but also in place of it. 
Two papers, Baggott et al. (2000) and Tanner-Smith (2006) assessed data provided by the 
organization Dancesafe, which runs a harm reduction campaign in collaboration with Enlighten 
harm reduction (Pillreports.com, n.d.). The website continues to posts analysis of submitted 
samples from the US as a harm reduction tool (ibid.). What these papers examined was the 
percentage of samples that contained MDXX compounds but not the amount of compound 
each sample contained. 
 
One paper that has assessed the longitudinal changes in the content of MDMA in Ecstasy pills 
is by Cole et al. (2002). The authors examined findings collected by the Forensic Science 
Service (FSS) on the decline in levels of MDMA being found in seized Ecstasy tablets 
between 1991 and 2001. The data provided by the FSS gave an average content of the 
Ecstasy tablets examined year on year. The maximum average content that was presented 
was 103mg per tablet in 1993, with the minimum being 73mg recorded in 2001.  A summary of 
the data is presented in Figure 2.7. 
   
 
Figure 2.7: The mean MDMA content of Ecstasy tablets year on year, as analysed by the 
Forensic Science Service in the United Kingdom between 1991 and 2001 (Cole et al., 2002) 
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To assess whether the decline in content was significant a Spearman’s correlation co-efficient 
was applied to the data by the authors. A significant negative correlation was observed 
between the average content and the year of the seizures (Cole et al., 2002). This supports 
the perception that the quality of tablets was on the decline leading into the early noughties. 
There has not subsequently been the same content analysis published that gives a clear 
overview of the trend since. The reason for this can be clearly observed with the closure of the 
Forensic Science Service in 2010 (House of Commons Science and Technology Committee, 
2011). As the field of forensic science has been privatised, the analysis of seized material is 
shared between a number of different organizations. The closure of not just the FSS but also 
the Drugs Intelligence Unit has resulted in a void in quantitative data available on national 
drug seizures as work is done in isolated local laboratories.   
 
One organisation that does publish information on the purity of street drugs is the EMCDDA.  
They collect and publish the data provided by the host nations within Europe that are involved.  
In 2011, the EMCDDA reported that the mean level of MDMA found in retail tablets from the 
UK was just 71mg, with a range of 17mg to 116mg (EMCDDA, 2011). As the active dose for 
MDMA ranges from 75mg to 150mg, this suggests that the declining trend observed by Cole 
et al. (2002) continued a decade later with Ecstasy tablets still being of a low content, thus 
supporting the perception reported by the Mixmag survey (2011) that the quality of pills had 
gone down. The issue with the EMCDDA findings are that they are based on a sample of only 
10 Ecstasy tablets, and ignore the other forms of MDMA (EMCDDA, 2011). 
 
The latest data suggests that this trend may have changed. In 2014 the average MDMA 
content of Ecstasy tablets in the UK, as reported by the EMCDDA, was 102mg from a sample 
of 108 tablets (EMCDDA, 2014). This is within the range considered an active dose. Yet when 
the other descriptive statistics are considered there is greater variability observed. The range 
given for the tablets was between 3mg and 208mg, with a median of 113mg and a mode of 
96mg being reported. This data can be used to support the theory of the transient nature of 
the Ecstasy market, with such a vast range in the content of MDMA being found in the street 
samples, it is understandable why the users may be sceptical of the quality of pill they may 
receive.  
 
There has also been the additional issue of pills sold as ‘Ecstasy’ containing para-
Methamphetamine (PMA) (Figure 2.8), a toxic analogue of MDMA (Byard et al., 2002; 
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Caldicott et al., 2003; Dams et al., 2003; Kraner et al. 2001; Martin, 2001 and Refstadt, 2003).  
In the summer of 2013 a number of deaths were attributed to the distribution of Ecstasy pills 
contaminated with PMA (Holden, 2013).  
 
 
Figure 2.8: The chemical structure of PMA 
 
As has been alluded to in previous sections MDMA is not just found as ‘Ecstasy’ tablets. A 
new form has emerged, which is known as MDMA powder. There has been very little data 
published on the purity of the other forms of MDMA or a comparison between the two 
available types. The only published data, to date, on the purity of alternate forms of MDMA is 
in a footnote on the EMCDDAs website (EMCDDA, 2014). The EMCDDA report that of the 
487 samples examined,  which was over four times as many as tablets reported for that year, 
the average content of MDMA found in the crystal form was 81.1%. The median is given as 
88% and the mode is 92%.  This data is not comparable to what is recorded for the tablets as 
they are not reported consistently. Tablets are reported as milligram weight whereas powders 
as a relative percentage.  This research will provide a comparison between the two types of 
MDMA seized, to see whether there is a significant difference in the relative purities between 
Ecstasy tablets and powder MDMA.  
 
A further issue that has impacted the content of MDMA relates to a UN embargo on the 
production of safrole. In late 2007 over 50 tons of the precursor, safrole oil, was seized in 
Thailand smuggled from Cambodia (UNODC, 2008). As stated in section 2.1.3, safrole is a 
key starting material in the synthesis of MDMA.  This was the largest crackdown in safrole 
production and subsequently led to a marked decrease in the availability of MDMA around the 
globe (UNODC, 2011 p.151). The post crackdown deficit of MDMA coincided with a shift in the 
recreational market and the emergence of new and unknown compounds (UNODC, 2013). 
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2.6 Introduction of the New Psychoactive Substances (NPS) 
 
2.6.1 Global Overview of World Drug Markets 
 
The last few years has seen an increase in attention on the newly emerging psychoactive 
substances, with both the UNODC and the ECMDDA releasing reports addressing the global 
and continental trends emerging from the misuse of these relatively unknown compounds 
(UNODC, 2013b; EMCDDA, 2011a). The numbers of new chemicals being reported is 
increasing year on year with currently over 280 new substances being documented on the 
ECMDDA’s early detection radar (ECMDDA and Europol, 2013). The analysis of drug trends 
and the data generated on seizure levels for the UK is one focus of this thesis, which is 
explored in Chapter 5. 
 
2.6.2 A Change in Terminology 
 
Over the years there has been a shift in the terminology used to describe the newly emerging 
drugs into the recreational drug market. Beginning in the 1980s the newly emerging synthetic 
drugs were coined ‘designer drugs’, with Ecstasy being one of the substances included in this 
new group (UNODC, 2013a, p.60). The phrase ‘designer’ refers to the fact that these 
compounds where being chemically designed to circumvent strict phrasing in the already 
established drug laws by adjusting the structure by as little as a single functional group 
(UNODC, 2013a, p.60). The title also has a secondary association, in that when Ecstasy first 
emerged into the recreational drug scene it was popular with the ‘Glitterati elite’ (Pilcher, 2008 
p.30). Thus giving Ecstasy a status symbol comparable to the ones of the elite fashion 
designers, whose insignias were often plagiarised and imprinted onto the tablets.  
 
However, the term was soon deemed inappropriate as the substances it related to were 
already controlled in the UK, and so the term ‘club drugs’ replaced it (UNODC, 2013, p.61). 
This term is still used to refer to those substances often taken in the specific social setting of 
nightclubs/ raves; and encompasses not only controlled substances like cocaine and Ecstasy 
but also un-controlled substances like amyl nitrate (Ibid.). The terminology changed again at 
the ends of the 1990s and into the start of the new millennium, with the phrase ‘Research 
Chemicals’ becoming popular. The producers of these new substances tried circumventing 
legislation by disguising their intent, marketing the chemicals for ‘so-called scientific research’ 
and being labelled as ‘Not for human consumption’ (UNODC, 2013, p.61).  
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In the mid-2000s there was a massive revolution in the terminology, with recreational drugs 
going mainstream under the title of ‘Legal Highs’ (UNODC, 2013, p.61). These were 
substances that were marketed as legal alternatives to popular controlled substances, like 
Ecstasy. The term caused a media storm and the substances themselves being deemed a 
new moral panic (Power, 2013). These included the newly emerging piperazine compounds, 
the synthetic cannabinoids and the synthetic cathinones. Despite the fact that the majority of 
the substances considered to be legal highs have subsequently been controlled under the 
MoDA 1971, the term persists in the British media reporting on these substances. Like with 
the ‘Research Chemicals’ some of the suppliers of ‘Legal Highs’ used misdirection in their 
selling to disguise their intent; most notably that of the drug Mephedrone, which was sold 
under the moniker of plant food, and with other synthetic cathinones being sold as ‘Bath Salts’ 
(UNODC, 2013 p.59).  
 
Consequently the UNODC, following the lead of the EMCDDA has begun using a new term to 
describe newly emerging substances. As using the term ‘Legal Highs’ suggests that the 
substances are in some way legitimate. The new term was introduced by the Commission on 
Narcotic Drugs in its resolution 55/1 (UNODC, 2013 p.62). The terminology brought in was 
‘New Psychoactive Substances’ (NPS), and relates to any substances that newly emerges 
into the recreational drug market. This means that some drugs that are already established 
can fall under this umbrella term if they emerge into a new market, as the term is being 
adopted internationally (UNODC, 2013 p.62). It was first legally defined by the European 
Union and has been adopted by both the EMCDDA and the UNODC (Ibid.). 
 
According to the ECMDDA, the new groups of substances that have been identified as falling 
under the purview of this new terminology are phenethylamines, tryptamines, piperazines, 
synthetic cathinones and synthetic cannabinoids (EMCDDA, 2011 p.94). The UNODC would 
also include other substances such as ketamine, the plant-based psychoactives, i.e. Khat, and 
Aminoindanes (UNODC, 2013a, pp.65-67).  Technically the synthetic cathinones could fall 
under the category of phenethylamines based on their chemical structure. As such, the group 
of phenethylamines could subsequently be divided into two sub groups of the synthetic 
cathinones and new amphetamine type substances. There has been many changes to the 
terminology used, both in a legal context and by what is used  on the street to describe 
controlled substances, how well the terms are recognised by the public is assessed in Chapter 
4 the results from the social surveys.  
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2.6.3 A focus on Mephedrone  
 
Over the last few years a number of NPS products have emerged into the British market, as 
alternatives or replacements to the controlled Ecstasy group (EMCDDA, 2013). As mentioned 
above they were originally introduced under the guise of ‘Legal Highs’. One such product is 
the drug Mephedrone that is part of the focus of this research. Mephedrone has had the most 
media presence of the NPS, as well as often being cited as the replacement for MDMA, with a 
BBC documentary on drug use stating that; 
 
‘Cocaine and Ecstasy are out and Mephedrone and Ketamine are in’ 
 (BBC, 2013) 
This statement, which was used as the tag line for the BBC documentary, makes an assertion 
about the drug trends within the UK. As part of the research conducted in this thesis the four 
substances mentioned in the above statement were assessed in the social research surveys 
to ascertain to what level this statement is true. 
 
What is Mephedrone? 
 
Mephedrone is the brand name given to the compound identified as 4-methylmethcatinone (4-
MMC). It is part of the substituted and synthetic cathinone class of drugs that emerged in the 
late 2000’s in the British recreational drug market (Measham et al., 2010).  These new 
synthetic compounds are derived from the naturally occurring compound cathinone that is 
found in the Khat plant (Catha Edulis) (Coppola and Mondola, 2012).  Mephedrone was one of 
many substances in this class that emerged as an alternative product to MDMA, at a time 
when the global availability of MDMA was reported to be low (UNODC, 2013). Mephedrone is 
often sold as a white crystalline powder, either loose or in capsules (Measham et al., 2010, 
Wood and Dargan, 2012). Taken by insufflation (snorting) or through oral ingestion, either by a 
method known as ‘dabbing’ or by ‘bombing’ (Measham et al., 2010).   
 
 
Figure 2.9: Chemical structures of MDMA and Mephedrone (4-MMC) 
 
a) MDMA b) Mephedrone 
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The structure of Mephedrone is similar to that of MDMA in that it has the same central 
structure of a phenethylamine, as shown in Figure 2.9. However where MDMA has the 
methylenedioxy- functional group attached to the 3rd and 4th carbon atoms of the benzene 
ring, Mephedrone has a single methyl group attached at the 4th carbon only. In addition to the 
difference found on the benzene structure Mephedrone also has a ketone group attached at 
the Rβ carbon. 
 
What does it do? 
 
The ingestion of synthetic cathinones is reported to cause an increase in the release of the 
catecholamines; dopamine, serotonin and norepinephrine into the synaptic region, this is in a 
similar manner to what is experienced with the amphetamine type stimulants and by extension 
MDMA (Coppola and Mondola, 2012). It is this similarity that generates the effects that led to 
Mephedrone being touted as an alternative to MDMA.  The reported effects of Mephedrone 
include both mental and physical stimulation, euphoria and feelings of empathy and openness 
that are most commonly associated with the use of MDMA (Measham et al., 2010; Winstock, 
2011a). 
 
 
The popularity of Mephedrone and the impact of Media  
 
Much is unknown about the emergence of Mephedrone before it came to prominence in the 
British Media in 2009/10. The first reference that could be found by this author that referred to 
the substance as Mephedrone in an academic context is by Archer (2009) who noted the 
emergence of these substances online in the wake of the control of piperazine compounds in 
2009.  The media’s impact on promoting the awareness of this substance and the modern 
‘moral panic’ that ensued has been examined in a paper by Alexandrescu (2014). The 
popularity of the drug Mephedrone appeared to go hand in hand with the ever increasing 
presence of news stories relating to its use by the youth of the United Kingdom, with the 
highest frequency of these stories reported to be in March and April of 2010 (ibid.).  
 
The popularity and use of this substance in the United Kingdom has been tracked by two 
surveys; the Global Drug Survey (GDS), formerly the Mixmag survey, and the Crime survey 
for England and Wales (CSEW). The GDS first included Mephedrone in the publication of the 
2010 survey, and the CSEW included it into their 2010/11 publication, the reported use is 
recorded in Table 2.5.   
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Table 2.5: Percentage of Participants reporting to have taken Mephedrone in the UK 
CSEW 2009/10 2010/11 2011/2012 2012/2013 2013/2014 
Mephedrone Use 
in Last Year 
n/a 1.3% 1.0% 0.5% 0.6% 
GDS 2010 2011 2012 2013 2014 
Mephedrone use 
in last 12 months 
33.6% 51% 30% 13.8% 7.9% 
 
As year of publication refers to use in the previous year it is clear from both surveys that the 
use of Mephedrone peaked in 2010, as shown in the reports published in 2011. What is noted 
thereafter is a decline in the reported usage in the following years, which correlates to when 
legislation was introduced to control Mephedrone and its chemical analogues. Though 
introduced on the back of the ‘Legal Highs’ trend, the synthetic cathinones including 
Mephedrone were controlled in April of 2010 as a Class B Substance (MoDA 1971, 
Amendment 1207, 2010).  Though there was much publication in the media of the emergence 
and impact of Mephedrone use, whether the prevalence has been significant and sustained 
has yet to be assessed, and the possible reasons for this apparent decline in the use of 
Mephedrone is discussed throughout this thesis.     
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2.7 Profile of a Drug user 
 
This chapter has so far discussed the historical and cultural context of the drug Ecstasy; 
reviewing the literature from chemical, biological and sociological disciplines. The next section 
will examine the studies on who uses this substance.    
 
2.7.1 Typologies of drug use  
 
The World Health Organisation (WHO) categorises drug use into five broad types: 1) 
experimental use, 2) functional use, 3) dysfunctional use, 4) harmful use, 5) dependant use 
(Sumnall et al., 2006 p.6).  The last three categories represent what is known as ‘problematic’ 
drug use, and it is often the problem drug users and addiction that is the focus of the debate 
around drug use and policy concerns.  
 
One criticism of the above typologies would be in how the terminology can be interpreted. The 
terms are vague and there is opportunity for significant overlap between categories (Rehm et 
al., 2005, p390). If someone is managing their addiction they may not want or seek help, 
likewise the interpretation of the terms by the users themselves and self-categorisation may 
mean that users don’t identify their use as being ‘problematic’.  Yet perhaps the majority of 
use is not problematic? One estimate states that up to 90% of consumption of illicit 
substances could be unproblematic (Seiffert, 2013). There is also evidence that: 
 
“‘Escalation’ to harder drugs, long term continuation of use and development of dependency is 
confined to the minority “ 
 (Measham and South, 2012, pp.690-691) 
 
As with the emergence of designer drugs in the late 1980’s, ‘research chemicals’ in the 1990’s 
and the more recent ‘legal highs’ there are subcategories of use that can be applied and are 
often self-identified by the recreational user. Werse and Morgenstern (2012 p.228) have 
identified a further five typologies of the ‘legal’ highs users; 1) experimental users, 2) 
substitutors, 3) potheads 2.0, 4) specialist psychonaughts and 5) omnivores. Though the 
definitions are applied specifically to legal high users responding to surveys in Germany the 
terms can be applied to broader recreational drug using communities.  
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An experimental user, much like the description by the WHO, may try a substance or range of 
substances on few occasions. The substitutors try a substance and then when it is unavailable 
or as in the case of ‘legal highs’ are controlled, will switch to a secondary substance (Werse 
and Morgenstern, 2012, p.228). This is reportedly what occurred when MDMA became 
unavailable in 2009/10 and Mephedrone emerged (Brunt et al., 2011).  The typology of 
‘potheads 2.0’ relates to users interested in the use of cannabis and cannabis related 
products, such as ‘Spice’ (Werse and Morgenstern, 2012 p.228). The specialist 
psychonaughts and omnivores are differentiated only by the purpose of their use. Werse and 
Morgenstern (2012 p.228) suggest that omnivores are likely to use ‘virtually all kinds of drugs’ 
basing use on availability, mood and setting. Psychonaughts on the other hand are reported to 
be selective of the substances and experiences that they seek, with the expansion their drug 
experience given as their main motivation (ibid.).  
 
 
There is also a sixth group not mentioned in any of the above typologies, which is the group of 
people who refrain from using controlled psychoactive substances. That is not to say that they 
refrain from the use of alcohol or uncontrolled substances but in the context of this research 
non-users are considered to be anyone who reports to have never used any substance that 
has ever been controlled under the MoDA 1971.  
 
2.7.2 Who uses Ecstasy?  
 
Within the fields that study drugs there is a dominant focus on the ‘problematic’ drug use and 
the harms it causes to the individuals and to society. The use of ‘Ecstasy’ however is not 
included under the umbrella of ‘problematic drug use’. As defined by the EMCDDA 
problematic drug use is; 
 
‘Injecting drug use or long duration or regular use of opioids, cocaine and/or 
amphetamines’. This definition specifically includes regular or long-term use of prescribed 
opioids such as methadone but does not include their rare or irregular use nor the use of 
ecstasy or cannabis.’ 
(EMCDDA, 2012) 
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Ecstasy, and by extension MDMA are considered ‘social’ drugs, as reported in the ACMD 
report in 2009 there is little evidence of dependence or negative social impacts arising from its 
use (ACMD, 2009 p.28). The use of this substance will therefore be considered solely in 
regards to the social user without examining concepts of abuse or addiction.  To derive a 
‘profile’ of the Ecstasy user a review of selected representative studies published on Ecstasy 
use, including those mentioned in section 2.5.2 was compiled examining the gender ratio and 
mean age as reported in the studies, shown in Table 2.6. 
 
Table 2.6: Summary of the demographic variables reported in studies on Ecstasy use shown 
as a percentage of respondents (Age variable is stated as described in each study)  
Study Year Male (%) Female (%) Age  Sample size 
Solowij et al. 
(1992) 
1992 61 39 
Range:16 to 
48 
Mean: 27.13 
100 
Webb et al. (1996) 1996 52 47 Mean:20.9 3075 
Handy, Pates and  
Barrowcliff 
(1998) 
1994-
1995 
66.7 33.3  Mean: 22.6 389 
Hammersley et al. 
(1999) 
1993-
1995 
56 44 
Range: 14 to 
44 
Mode:  
Male – 21  
Female – 20  
229 
Sherlock and Conner 
(1999) 
1996 63.7 36.3 
Range: 15 to 
51 
Mode 21 
Mean 22 
4042 
Gross et al. (2002) 2002 61.2 38.8 
 Range: 16 to 
32 
Mean: 21.4 
210 
McCambridge et al. 
(2005) 
 
1999 60.9 39.1 Mean: 23.9 1151 
2000 62 38 23.9 795 
2001 62.3 37.6 24.1 787 
2002 52.1 47.9 24.5 335 
2003 64.1 35.9 24.2 805 
Ogeil, Rajaratnam 
and Broadbear 
(2013) 
2013 54.1 45.9 
Mean: 
Male – 24.66 
Female – 
25.91 
268 
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One key observation of the studies chosen is the gender ratio, where the proportion of male 
participants has consistently outweighed the proportion of females, this is reflective of what is 
often reported in drug use studies. It is also true for the Global Drug Survey, in the 2012 
survey the gender ratio reported was 69.7% male to 30.3% female (Global Drug Survey, 
2012).  The ratio of 2:1 male to female is usually cited to describe the gender of drug users 
(Measham and South, 2012 p.692), however this figure may not accurately reflect actual 
levels of drug use as there are a number issues that can affect survey responses. The 
majority of the surveys above relied on a referral sampling method. The issues impacting drug 
use surveys are discussed in detail in Chapter 3. The age of the Ecstasy user is also relatively 
consistent within the studies with most citing mean values in the early to mid-20s. There 
appears to be little variation in who is self-reporting to have taken Ecstasy in the previous two 
decades with the studies finding that majority of Ecstasy users responding to these surveys 
are young adults and male. 
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2.8 Research Questions  
 
Through the course of the literature review there were four areas where a gap in knowledge 
was identified from which the research questions addressed in this thesis were derived. The 
first question was developed to address the gap in knowledge on the changing use of 
terminology and the inconsistency in the use of the terms ‘Ecstasy’ and ‘MDMA’.  
 
Question 1:  Has there been a change in what is meant by the terms ‘Ecstasy’ and MDMA, 
and how are they being used in relation to the recreational drug in modern UK society?  
 
The terms ‘Ecstasy’ and ‘MDMA’ have been used synonymously since the epithet was first 
assigned to the newly emerging party drug in the 1980s. Although MDMA is the most common 
compound reported to be found in the recreational drug sold as Ecstasy (ACMD, 2009), the 
legal definition includes any of the ring-substituted phenethylamines (MoDA 1971, c.38).  
During the course of the literature search it became apparent that there had been a change in 
how the term Ecstasy was being used, with an increase in the use of the alternative term 
MDMA being found (Turner et al., 2014). What is addressed by this research is whether the 
terms still have the same connotations or if they have come to mean different things, at both 
an academic level and to the general public. Additionally, whether the general public are 
aware that Ecstasy and MDMA are the same thing or if MDMA is now considered a product in 
its own right is addressed.  The awareness of this change in terminology was explored 
through the use of an online social survey into the social perception of drugs. The results from 
the survey provide an understanding of whether one or the other names is more commonly 
recognised, and whether there is a direct association between the two terms.  
 
The second question addresses a comparison between what is found in street seizures 
relative to stated user preferences. 
 
Question 2: What are the differences in the types of Ecstasy being seized on the streets of 
Cambridge, and how does this relate to user preference?  
 
The second question was developed to study whether the change in the terminology and the 
naming of recreational drugs, as examined by the first question, reflects a change in the form 
in which Ecstasy is being found. There has been a lack of acknowledgement in the literature 
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of the alternative powdered form and its relative prevalence compared to the traditional 
tableted form. The current awareness of an alternative form can be found in its inclusion in the 
Global Drug Survey (Mixmag, 2013) and in the recommendation in the Advisory Council on 
the Misuse of Drugs 2009 report on MDMA, which states better data is needed on identifying 
alternate forms of this drug  (ACMD, 2009).  Question two is addressed in the findings from 
the data that has been collected in collaboration with the police at Cambridgeshire 
constabulary, through the examination the seizure records and is compared to the findings 
from the second social research survey.  A related question was then developed:- 
 
Question 3: Does the user perception around the difference types of MDMA reflect what is 
found chemically? 
 
The third question answers the question around the purity of the different forms with the 
analysis of the street level drugs by the analytical technique of GC-MS. There is little to no 
data published on the relative purity of MDMA in the powdered form, and the reported quality 
of Ecstasy tablets has a reportedly wide range (EMCDDA, 2013). The last question looks to 
address what is found chemically in these drugs, and at what purity and whether this 
correlates to the users perceptions around these drugs. 
 
Finally, the impact of the growth and decline in Mephedrone use is also considered. 
 
Question 4: What impact has the emergence of Mephedrone had on the popularity 
and prevalence of Ecstasy and MDMA? 
 
The final question compares the relative popularity of the drugs in question, in comparison to 
the seizure data. The seizure data provides a picture only of what has been found, yet from 
user based surveys it is apparent that there are people who take controlled substances 
without ever getting caught (Mixmag, 2013; Homeoffice, 2013).  The second survey was 
developed to study whether there was a definitive difference in user perception and 
preference of the drugs, looking specifically at Ecstasy, MDMA and Mephedrone. The data 
collected is then compared to the other user based surveys, as well as to the seizure data 
collected and can be used to identify whether what is being seized accurately reflects what 
people report to be taking and like taking.  
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Chapter 3 Social Research Surveys on Drugs 
3.1 Introduction 
 
The first element of the research focused on the sociological aspects of the drug Ecstasy, 
exploring its changing position within the social consciousness and its popularity as a party 
drug. This was achieved through the use of two online surveys; Survey A that was focused on 
discovering the general public’s knowledge of recreational drugs and Survey B that looked at 
which drugs people report to haven taken. 
 
Survey A: Knowledge and Awareness  
Survey A was broken down into 3 sections; the first was used to gain an understanding of the 
participant’s baseline knowledge of recreational drugs; the second investigated the 
participants’ trust in information sources and the third section sought to understand 
participant’s perceptions about the importance of drug awareness.  
 
Survey B: Popularity and Prevalence  
Survey B asked the participants to recount their own experiences with selected substances. It 
was separated into 4 sections on; drug use, experience, preference and a discussion around 
drug use. Survey B was designed to explore which substances people have taken and their 
reasons behind those choices. A thorough breakdown of the questions for both surveys can 
be found in section 3.5.3. 
 
The survey data provides a sociological context that will then be compared to the analytical 
and trend data of the other two elements in this research. This was done to see if there was 
an association between what people report they like taking and what is actually being seized 
on the streets of Cambridge.  
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3.2 Context of the social surveys  
The research questions that are explored in this part of the project examine; (1) how the use 
of the terms Ecstasy and MDMA have changed and (2) the impact the emergence of the new 
psychoactive substances (NPS) has had on the reported level of use of MDMA. As has 
already been stated the terms Ecstasy and MDMA have been used interchangeably, yet can 
relate to different products (Smith, Moore and Measham, 2009; Turner et al. 2014). The 
sociological research method of surveys was chosen to investigate the general public’s 
understanding of the two terms and to identify whether the information the public knows 
accurately represents the academic understanding of the terms. Is there a consistency in the 
public’s knowledge surrounding Ecstasy?  
 
The second aim of the research questions was to investigate the level of drug usage and 
reasons behind preference, and so the second survey was developed. Two major national 
surveys influenced this work, primarily the ‘Crime Survey for England and Wales’ (CSEW) 
(ONS, 2013) and the ‘Global Drug Survey’ (GDS) run in collaboration with the magazine 
MIXMAG (2013), both of which are critically analysed in section 3.3. Survey B was developed 
for this project to qualitatively explore the personal experience of the participant.  
 
3.3 Critical analysis of research method  
 
3.3.1 Survey Theory 
 
A survey is a system that can be used for the collection of information, to detect patterns of 
relationships between variables from a number of case studies (Bryman, 2012; Sue and Ritter, 
2012). They can use quantitative methods, qualitative methods or a mixture of both, and the 
data can be collected in the form of either self-completion questionnaires or as structured 
interviews (De Vaus, 2001).  For the purpose of this chapter the focus is given to self-
completion questionnaires and the use of mixed method questions, as this was the method 
that was chosen.  
 
Self-completion questionnaires can be implemented as either paper-based or online. The 
model chosen for this research was the use of internet based surveys. The benefits of using 
an online model over the conventional paper-based are that online surveys are comparatively 
cheaper and are not as resource intensive, meaning that they are more environmentally 
friendly and sustainable (Sue and Ritter, 2012). Another benefit of the online model is that 
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they are faster and more efficient in delivering the questionnaire, making the data collection 
and data entry easier.  By being produced on the internet, online questionnaires become 
available to a broad spectrum of possible respondents (ibid.).  
 
There are disadvantages to using the online model one of which is the reliance on software, 
errors in the programming and loss of data can occurs. However when using an online model 
this issue can be mitigated by thoroughly backing up all data (Sue and Ritter, 2012). A second 
disadvantage with the online model is the validity of the user responses. How does the 
researcher know that the participant is who they claim to be? In a study into the comparisons 
of the responses between paper-based and computer based surveys specific to the topics of 
alcohol; tobacco and drugs, it was found that the computerised method yielded similar 
outcomes to the traditional methods and is therefore a justified method of collecting this sort of 
data (Hallfors et al., 2000).  
 
There are two main limitations that can be used to criticize the application of surveys in 
investigating sensitive topics, such as the topic of drugs and drugs use: the stigmatisation 
associated with certain social behaviours and the lack of accessibility to the target sample 
(Caetano, 2001).The first limitation is based on the principle of social desirability bias, with the 
participants being reluctant to admit to stigmatizing behaviours, such as taking drugs or 
drinking alcohol (Caetano, 2001).  Marquis, Marquis and Polich (1986, p.386), investigated the 
response bias and reliability of six sensitive research areas; including the topics of alcohol 
consumption, drug use and embarrassing medical conditions and concluded that as whole 
across all topics considered the respondents ‘did not withhold or underreport sensitive 
personal information’. It was also found that the results were similar to those found for non-
sensitive topics, and that variation in the reliability of data may have been due to the survey 
design (ibid.).  The impact of social desirability bias in relation to its application to this study is 
discussed further in section 3.4. 
 
The second limitation, the lack of accessibility, depends on sampling method and participant 
choice. For example, with general population surveys such as the Crime Survey for England 
and Wales (ONS, 2013), the focus is on a cross section of society as opposed to focusing on 
the specific group of drug users. However this sampling methodology employed may not 
reflect an accurate picture of the drug using community, a factor that is critically assessed in 
the following section.   
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3.3.2 Critical Analysis of Comparative National Drug Surveys  
 
This section evaluates the contributions and methodologies of two of the most prevalent and 
consistent social drug surveys in the UK, which were used in the development of this project. 
The survey methodologies are critically examined in regards to the implications they make on 
the estimation of the size of the drug using community. The two surveys are used as point of 
comparison throughout the analysis of second research survey.  
 
An overview of the Crime Survey for England and Wales (CSEW) 
  
Formerly known as the British Crime Survey (BCS), the CSEW is an interview based 
victimisation survey, covering the public’s perception of a number of crimes (ONS, 2013). First 
conducted in 1982, the methodology and crime types included within this survey have 
remained comparably consistent over the years (ONS, 2013). Initially it was run every two 
years until 2001 when it changed to an annual collection. From 2012, its name changed from 
the BCS to the CSEW when it ceased to include data for Scotland (ONS, 2013). The Scottish 
Government had commissioned a tailor made victimisation survey the Scottish Crime and 
Victimisation Survey (SCVS) in 2004 (The Scottish Government, 2013).  
 
The main aim of the CSEW is to provide trends analyses for the crime types and the 
population it covers; this includes but is not limited to drug usage (ONS, 2013). It does not 
claim to provide an absolute level of crime occurring in England and Wales, what it does 
provide is an estimate of the national levels of the crimes covered in the survey (ONS, 2013). 
One benefit of data provided by the CSEW report is that it reflects crimes that are not reported 
to or by the police. The data is also unaffected by changes in reporting practices of the police 
or by the levels of police reporting (ONS, 2013). In the case of drug use this can be compared 
to the recorded seizure levels. The size of the drug market is also estimated by the UNODC 
and the EMCDDA and relies on the official reported seizure levels (UNODC, 2013; EMCDDA, 
2013), which are discussed in Chapter 5.  
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An overview of the Global Drugs Survey (GDS) 
 
The Global Drug Survey (GDS) is an independently run survey assessing drug preferences. It 
claims to provide ‘qualitative and quantitative, non-judgmental, informative and confidential 
drug surveys’ (GDS, 2013). It began as a feature in the dance magazine Mixmag in 1999, 
which was run annually and founded by Dr Adam Winstock. The Mixmag drug survey was 
originally limited to responses from subscribers and readers of the magazine, who had a 
vested interest in the research subject (Mixmag, 2011). 
 
In 2012 a secondary media partner joined the GDS, in the form of The Guardian newspaper 
(Global Drug Survey, 2013). The survey was rebranded as the Global Drug Survey. With the 
rebranding also came the globalisation, the survey was now being hosted online and more 
readily accessible to the world. However in disseminating their findings they separate by 
country, with the United Kingdom and the United States being the largest contributors to the 
2013 survey (Global Drug Survey, 2013). It is the responses to the 2013 survey that will be 
used to compare to data collected for this research.  
 
Comparison of the methodologies employed by the CSEW and the GDS 
 
The following comparison of the CSEW and the GDS is founded on their question formats, the 
method of survey delivery and the sampling procedures.  Though there have been a number 
of studies that have investigated the use of Ecstasy (Gross et al., 2002; Hammersley et al., 
1999; Handy, Pates and Barrowcliff, 1998; McCambridge et al. 2005; Ogeil, Rajaratnam and 
Broadbear, 2013; Sherlock and Conner, 1999; Solowij et al., 1992), the CSEW and the GDS 
are two of the most consistent surveys that study the changing trends in drug usage in 
England and Wales, and Britain respectively. However each survey uses a different 
methodology to collect the data; the CSEW uses the face-to-face interview method (ONS, 
2013), whereas the GDS uses structured self-complete questionnaires (Global Drug Survey, 
2013).  
 
The CSEW is reviewed annually to reflect emerging issues, yet the wording of the questions 
has remained constant. The process employed is reliant on a core sample representative of 
the population households in England and Wales. In 2013 this related to 35,000 households 
being identified as possible candidates (ONS, 2013).  Households are identified by the use of 
the Postcode Address File (PAF) method (ONS, 2013). The interviewers then determine if the 
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chosen households are eligible, properties deemed ineligible include uninhabited houses or 
second homes. Also ineligible are group residences such as halls of residences. The 
ramifications of this are considered in the section on limitations of drug survey research.  
 
Once the households are chosen an adult resident is chosen at random to participate in the 
survey (ONS, 2013). The data is generated in face-to-face interviews that employs the use of 
computer assisted personal interviewing (CAPI), where responses are recorded by the 
interviewer using digital tablet (ONS, 2013).  Self-completion modules were introduced in 1996 
and are used for topic areas deemed sensitive or likely to make the participant uncomfortable, 
such as the questions on drug use (ONS, 2013). For these modules the participants would be 
required to complete the questions on the interviewer’s tablet. The limitation of this 
methodology is the risk of introducing social desirability bias as the participant is answering 
questions in the presence of the interviewer. Although bias has been detected in the use of all 
modes of survey (Glynn and Park, 1997), it has been shown to be more pronounced in 
interviewer led ones (Ipsos Mori, 2012). 
 
The GDS by comparison conducts its survey anonymously online. It employs the use of initial 
drug use screening questions before tailoring subsequent questions based on the participants 
recent self-reported drug use. As with the CSEW, the GDS is reviewed annually to reflect 
changes, yet it states that 65% of the questions are re-used to permit the monitoring of the 
changes in the drug trends over time (Global Drug Survey, 2013). 
 
The GDS relies on the self-nomination of participants, unlike the CSEW that uses direct 
recruitment and participant selection (Global Drug Survey, 2013).  To recruit participants the 
GDS has employed a number of measures that were also adopted for this research.  As 
stated in the previous section the GDS has a number of media partners, including Mixmag and 
the Guardian newspaper (ibid.). The GDS also relies increasingly on promotion through social 
media to attract a more diverse sample group that were also utilized to promote the surveys 
for this research. 
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3.3.3 Limitations of Surveys on Drug use 
 
The first limitation identified for both surveys relates to the sampling methodologies. This can 
be analysed when comparing the nature of each of the methods to the general population. 
Figure 3.1 displays a visual representation of the general population of Britain, signified by the 
blue circle. Within the population there is a subsection, the drug using population, signified 
here as the red circle. 
 
 
Figure 3.1:  Visual representation of general population and drug using population 
Although the total population of the UK is known, with the estimate for the population of 
England and Wales in mid-2013 being 57 million people (ONS, 2014) what is unknown is the 
exact size of the red circle, the drug using population.  Both surveys use different methods to 
try an estimate the size of this group. The CSEW method of participant selection and 
recruitment seeks to ‘reflect the profile of the general population’ (ONS, 2013, p.8). This is 
represent by Figure 3.2, whereby the survey seeks a cross-section of the general population, 
including participants from both the non-drug using and drug using sections of society. 
 
 
Figure 3.2: Visual representation of the CSEW sampling methodology 
Non-using population Drug using population 
Non using population 
Drug using population 
Non-drug using respondents 
Drug using respondents 
Total Population 
Total Population 
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The limitation of this method is an assumption of homogeneity of the drug using population, 
that the random sampling used by the CSEW will garner a representational selection from the 
drug using community. However there is also the issue that this method does not include 
responses from halls of residence (i.e. students), young adults living in shared 
accommodation or from the homeless community. Therefore in not acknowledging or 
representing these groups in the CSEW could have a negative impact the proportional levels 
being reported from the drug using population and reflect an under reporting of drug use.  The 
demographic analysis of the CSEW is assessed further in comparison to findings from this 
survey in section 4.2.1. 
 
The method for the CSEW can be compared to the participant selection method of the GDS, 
which claims to be a cross-sectional survey (Global Drug Survey, 2013).  As the GDS is self-
nominating and employs screening procedures to eliminate any non-drug using respondents, 
the sample represents only from within the drug using population, as represented in Figure 
3.3.  
 
 
Figure 3.3: Visual representation of the GDS sampling methdology 
The limitation of the GDS methodology is that fails to consider the relative size of the drug 
using population in relation to the non-using population. One question is how big a proportion 
of the drug using population does the GDS represent? The restriction of using the different 
approaches to estimate the relative size of the drug using population can be examined by 
comparing the findings. For example the number of people reporting to have taken Ecstasy in 
the last year for the CSEW in 2013 was 1.3% (Home Office, 2013), which works out at 278 
people, when using the unweighted base (n = 21359).  These results can then be compared to 
the GDS that found that 67% of respondents claimed to have taken Ecstasy, which works out 
to 5159 of its participants (n = 7700).   
Drug using population Non-using population 
Drug using respondents 
Total Population 
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Figure 3.4: Estimated levels of Ecstasy use as reported in the CSEW for 2013 (Home Office, 
2013) 
 
 
 
Figure 3.5: Estimated levels of Ecstasy use as reported in the GDS (2013) 
 
Figures 3.4 and 3.5 show the proportion of respondents who report to have taken Ecstasy 
compared to the unweighted base of participants.  Both figures reflect the representations of 
sample selection as shown in figures 3.2 and 3.3, but also highlight the disparity in the levels 
of drug use being recorded. On the one hand Ecstasy use is relative low, with less 2% of the 
total population reporting to have ever taken it. Yet when the sample is focused on the drug 
using population it increases to 67%. The population of England and Wales estimated mid-
2013 was 57 million people (ONS, 2014). If the data is extrapolated from the two surveys 
discussed the population of Ecstasy user’s ranges from 741,000 users based on the reports 
from the CSEW up to 3,819,000 for the GDS. However the authors of GDS do take into 
consideration that their data is representative of only the sample group (Global Drug Survey, 
2013) and that their findings should not be extrapolated to general populations.   
 
The CSEW is however held as the standard for assessing drug use in England and Wales, 
with the Prime Minister David Cameron recently using these statistics to support the claim that 
drug use is on the decrease (Wintour, 2014).  The reliability of the data to support this claim is 
debatable, as the issue of introducing respondent bias needs to be considered.  
Ecstasy user Non Ecstasy user
Ecstasy user Non Ecstasy user
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There are two possible forms of bias that can impact the data collected in both methodologies. 
The first is social desirability bias, when the participant provides the answers they believe the 
researcher wants to have (Bryman, 2012). The GDS attempts to address bias through the use 
of an online format, where no contact is required between the participant and the researcher 
(Global Drug Survey, 2013), which is an added benefit as the participant may be embarrassed 
or uncomfortable discussing the topic of drug use when confronted by a stranger in a face-to 
face interview.  
 
However as the CSEW uses a face-to face interview, the researchers behind the CSEW 
acknowledge the risk of bias and have tried to mitigate it by including the self-report modules 
method, described in section 3.3.2 (ONS, 2013). Yet there would still be the social pressure of 
completing the survey in front of the interviewer (Glynn and Park, 1997; Ipsos Mori, 2012), 
with the added pressure that the interviewer is reporting on behalf of a governmental 
organisation. Social desirability bias may come in to effect when examining the CSEW method 
of collection as the topic that is being examined is not only potentially seen as a social taboo 
but is also a criminal act, which the participant is effectively admitting to a government official.  
 
The second form of bias that may be present is recall bias, where participants have forgotten 
not only when they have taken a substances but also what substances they may have taken 
(Hassan, 2006). This can be observed in the types of questions asked. Both the CSEW and 
the GDS uses fixed response questions (ONS, 2013; Global Drug Survey, 2013), which does 
not give as much scope to assess the reasons and decision making processes behind which 
drugs the participants choose to take or why.  There are criticism about how and when the 
data is collected. Both surveys ask about historic drug use over set periods, asking 
participants about substances they have ever taken, substances taken in the last year and 
within the last month. The issue with asking these questions is the risk of introducing recall 
bias, if a participant cannot pinpoint exactly when they last took a particular substance. This 
would lead to inconsistent reporting, however this can be caught with asking about any historic 
drug use in the ‘ever taken’ question. Yet as the GDS does not recorded who responds year to 
year and the CSEW randomly chooses households it is impossible to state categorically that 
yearly trends are truly comparable.  
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The final issue is that drug use especially that of recreational drugs such as Ecstasy and 
MDMA powder, is not a static state. There is evidence to suggest use of these substances is 
transient and subject to specific usage trajectories as shown in the work by Smirnov et al. 
(2013), which examined the usages trends of young adult populations in Australia. The 
authors found that the self-reporting of high level MDMA use peaked at six months after initial 
use had started, with a sharp decline in use between the six and twelve month period in young 
adults.   
 
3.4 Counteracting Social Desirability Bias in Social Surveys  
 
Due to the nature of the research area it is important to address the possibility of encountering 
social desirability bias when dealing with sensitive subject matter (Bryman, 2012; Glynn and 
Park, 1997; Krumpal, 2011; Marquis, Marquis and Polich; 1986, Wheeler, 2013) where the 
topic being investigated may have negative social connotations. This is compounded with the 
study of drugs, as the behaviour being investigated is also illegal. Though it is not illegal to 
have taken controlled substances, it is illegal to have possession of them (MoDA c.38, 1971).  
 
One way that this research tried to mitigate the impact of social desirability bias was to host 
the survey completely on the internet with no interaction between the researcher and the 
participant, aside from the initial recruitment to complete the survey. The use of self-
administered questionnaires, such as the web based method, has proven to yield better 
accuracy when reporting on sensitive subjects. Tourangaeu and Yan (2007, p.864) report in a 
review of studies on sensitive topics: 
 
‘A higher proportion of respondents reported illicit drug use when the questions were self-
administered than when they were administered by an interviewer.’ 
 
The complete anonymity that web based method provides promotes a greater sense of 
honesty from the participant when completing the surveys.  Yet there are disadvantages to 
this method in that all information provided was taken as verbatim, all information provided 
was taken to accurately represent the views of the participant at the time of completion with no 
follow up with participants after. The surveys also included qualitative questions that allowed 
the participants to further explain their reasoning behind certain answers.  
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3.5 Survey Development (Methodology) 
 
3.5.1 Ethical Approval 
 
Prior to the development of the surveys ethical approval was sought from Anglia Ruskin 
University and was granted in October 2012.  
 
Consent 
 
To ensure that the highest ethical standards were met the participants were asked for their 
consent for both surveys. A clear explanation of how the consent process worked with these 
surveys was included before the start of each surveys. As all data was collected through a 
third party (GoogleTM), no information on the participants was given to the researcher aside 
from that provided within the survey.  It also meant that once submitted participants could not 
request to withdraw their responses. This was explained at the beginning and end of both 
surveys, a copy of the consent information is included in Appendix III. 
 
 
3.5.2 Survey Variables 
 
Demographics of other surveys 
 
The demographic variables for this survey were chosen in consideration of what had been 
used in previous surveys mentioned. The CSEW uses a number of demographic variables to 
evaluate its participants, the first set of variables is based the geographical location, where the 
participants are based. The second set of variables is on the household structure, family 
structure and income of the participant. The final set of variables is specific to the individual; 
age, gender, ethnicity, marital status, employment status; occupation, alcohol consumption, 
nightclub visits and pub/ bar visits.  The survey has a total of 11 variables by which the data is 
grouped and analysed (ONS, 2013). The GDS also uses a number of demographic variables 
to differentiate their data sets. The variables used by the GDS are; gender, age, income, 
geographical location (limited to country), sexual orientation, musical preference and other 
recreational activities (Global Drug Survey, 2013). After considering the approaches of the two 
different surveys, it was decided that due to the anticipated sample size for surveys A and B, 
the number of variables would be limited. The two variables that were chosen were gender 
and age, which could also be compared to historic studies on Ecstasy use as discussed in 
section 2.7.2.   
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Gender 
 
Gender was chosen as it is the most fundamental difference in the population; it easily 
separates the data set into two comparable groups. An initial aim was to gain equal weighting 
of both male and female participants as the distribution of the UK population in 2013 was 1.03 
females to males (ONS, 2014b). The CSEW achieve a ratio of 45% males to 55% females, 
compared to the GDS who managed a 69.7% to 30.3%, male to female ratio. The initial aim 
was to recruit an equal amount of each gender to represent the distribution of the UK 
Population, yet analysis of previous self-nominating studies (Section 2.7.2) suggested that 
males were more likely to respond.  
 
Age 
 
The age grouping was more difficult to define, specifically at which age the cut off points 
should be. Due to ethical restrictions of using research with children, the lower age limit was 
set to 18 years of age. However due to the anonymity of the data collection method, the age of 
the participants is taken as stated. No upper age limit was set however the final age band was 
set at 60+. The age ranges were as follows; 
 
Band 1: 18-21 
Band 2: 22-29 
Band 3: 30-39 
Band 4: 40-49 
Band 5: 50-59 
Band 6: 60+ 
 
The 1st and 2nd bands used in this research are the groups most likely to be experiencing the 
current changes in the recreational drug market, and as indicated most likely to be taking 
Ecstasy now (Gross et al., 2002; Hammersley et al., 1999; Handy, Pates and Barrowcliff, 
1998; McCambridge et al. 2005; Ogeil, Rajaratnam and Broadbear, 2013; Sherlock and 
Conner, 1999; Solowij et al., 1992). The 3rd and 4th bands represent the participants who 
would have experienced the original popularity of Ecstasy and the rave movement of the late 
1980s and 90s. The final two bands represented the generations who experienced the initial 
introduction of the drug laws of the 1970s. The CSEW uses participants between the ages of 
16 to 59, whereas the GDS also spans 18 to 60+.  
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3.5.3 The Questions 
 
Once the variables had been decided, the survey questions were developed to address the 
research questions.  
 
Questions for Survey A: Knowledge and Awareness 
 
The questions for Survey A are divided into the following sections; 
 
Section 1: Knowledge of Street Drugs (Questions 1 to 4) 
 
The questions in section 1 were devised to gather the base line knowledge of the participants, 
with a focus on the substances of interest to this project but also the most common 
substances in Britain. It was included to not only identify what people know but also if there 
are any gaps in the public’s knowledge that need to be addressed, specifically concerning the 
terms Ecstasy and MDMA.  
 
Section 2: Information sources (Questions 5 to 8) 
 
The second section sought to establish who the trusted information sources are, who the 
public trust to gain information and how the data collected from this survey influence the 
dissemination of new drug information.  
 
Section 3: Drug Awareness (Questions 9 to 12) 
 
The last section addresses the concept of awareness of drugs in society. Do the participants 
feel that it is an important issue? Section 3 allowed for the participants to explain their own 
views on this topic. 
 
A complete rationale for each of the questions included in Survey A can be found in Table 3.1
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Table 3.1: Questions for Survey A: Knowledge and Awareness  
 Question Type Answers Rationale 
1 
Which of the following drugs 
have you heard of? 
Multiple 
Choice 
Amphetamine, Cannabis, 
Cocaine, Crack, Ecstasy, 
Heroin, Ketamine, LSD, 
MDMA powder, 
Mephedrone, Piperazines, 
2CB, None 
 
The first question established a basic level of knowledge of 
recreational drugs that are controlled in Britain. It lists 12 
controlled drugs, including ones that are well established as 
well as the newer synthetic drugs such as Mephedrone and 
Piperazines (UNODC, 2013 p.62). The drugs were chosen 
based on their inclusion in the other social surveys mentioned 
earlier, as well as drugs that are of specific interest to this 
project, i.e. Ecstasy and the alternate term MDMA. 
 
The drugs will be ranked by the number of people who had 
heard of them, with the drugs of interest being compared as to 
how often they are identified. This question will set the 
foundation of whether MDMA as a term is as well-known as 
Ecstasy in the public consciousness. 
 
2 
Which Class do you think 
each drug belongs to? 
Single  
Choice 
Same drugs as above 
 
Class A, Class B, Class C 
and Do not know 
This question tested whether the general public understands 
the classification system and can accurately place the selected 
substances into the correct class; it goes towards proving the 
level of knowledge about drugs in British society, based on the 
MoDA 1971. It will be analysed in two ways; firstly by how 
many people get the classification right for each drug, and 
secondly by what the majority of people classify each drug as.  
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 Question Type Answers Rationale 
3 
Which of the following names 
do you associated with; 
Cannabis, Ketamine, Ecstasy 
and Mephedrone? 
Multiple 
Choice 
 
Cannabis: Bubble, Charlie, 
Dope, Grass, Green, Hash, 
Mandy, Pot, Skunk, Weed, 
Not heard of and other  
 
Ketamine: Bubble, Charlie, 
Dust, Green, K, Mandy, 
Skunk, Special K, Not heard 
and other 
 
Ecstasy: Adam, Bubble, 
Charlie, Crystal, E, Green, 
Mandy, MDMA, Skunk, 
XTC, Not heard and Other 
 
Mephedrone: 4-MMC, 
Bubble, Charlie, Green, 
Mandy, Meow-Meow, 
Skunk, White Magic, Not 
Heard and Other 
 
 
This question looked at the recognition and association of 
names and colloquial terms used to describe four chosen 
drugs. The drugs chosen represent the two that are of interest 
to the rest of the study, Ecstasy and Mephedrone. The other 
two were used to deflect attention so as to not introduce bias 
by introducing to much focus on Ecstasy.  Cannabis was 
chosen due to the fact that it is the most widely abused drug 
not only in Britain, but globally (UNODC, 2013) and Ketamine 
due to its media presence at the time. 
 
For each drug a number of known terms was included as well 
as a set list of terms that were used in each question. The set 
list included terms that describe the other drugs in the question 
and one for an unrelated drug. The terms that were chosen 
were taken from TalktoFrank (2013), a national government 
website that lists the known colloquial terms associated with 
each drug. 
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 Question Type Answers Rationale 
4a 
How prevalent do you think 
drugs are in modern British 
society? 
Likert 
Scale 
1 (Low) to 5 (High) 
 
This question asked about perception; how the participant gaged 
the level of prevalence of drugs in society. The answers provided 
by the people who rank it lower can then be compared to those 
who rank it higher. Did the people who rank it higher feel more or 
less informed on the drugs in question than those who would rank 
it as low? This can be tested by comparing the answers from the 
rest of question 4. 
 
4b 
How informed do you feel 
about the health risks caused 
by drugs? 
Likert 
Scale 
1 (Low) to 5 (High) 
 
What this question examined was the general perception of the 
health risks around drugs. Did the participants feel informed on this 
topic? Part of this project was identifying what the participants 
know, but also where there is a lack of knowledge. A lack of 
knowledge or the misunderstanding concerning drugs is a main 
issue this research hopes to address. Health risks are a key factor; 
if the general public feel uninformed about possible risks it could 
endanger the users. 
 
4c-g 
How informed do you feel 
about the effects of; 
Cannabis, Ketamine, 
Ecstasy, MDMA Powder and 
Mephedrone 
Likert 
Scale 
1 (Low) to 5 (High) 
 
Questions 4c to 4g examined the specific awareness of five of the 
drugs discussed in earlier questions. For this question Ecstasy and 
MDMA were separated and represent individual products, so they 
could be compared. The point of these questions was the 
comparison, though their individual values may give insight about 
each of the specific drugs. For example due to its prevalence it is 
anticipated that cannabis would score highly in the 
awareness/informed factor whereas Mephedrone being a new drug 
would score low. It again builds on the findings from the earlier 
questions on how well MDMA has infiltrated the public 
consciousness.  
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 Question  Type Answers Rationale 
5 
Have you ever received any 
education in regards to drugs 
and drug abuse? 
Single Choice  Yes or No 
 
 
A yes or no answer, it can be used to separate the participants who 
have had education and those who haven’t and then compare to their 
answers for question 4.  
 
 
6 
Where would you go if you 
were looking for information 
about drugs? 
a) For yourself 
b) For someone else 
Multiple 
Choice 
Teacher/School 
Friends 
Family 
GP/Doc 
Internet 
Drugs Forum 
Local drug service 
Drugs Helpline 
Government website 
Television 
Other Media 
(Newspapers) 
 
 
 
 
 
 
This question was divided into two sections, to compare whether 
people would use different information sources for themselves versus 
if looking for someone else. For example someone might look at a 
drugs forum if they wanted to find out what the effects of a drug are 
and contact a helpline if they suspect that a friend has a drug issue. 
 
It will also provide the most popular sources of information from these 
11 options. The results can be then compared to the results from 
question 7, which asked participants to rank the information sources 
on how trustworthy they are.  
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  Type Answers Rationale 
7 
Who do you trust for your 
information? 
Likert  
Scale 
1 (Do Not Trust) 
to 5 (Most) 
 
Divided into 6 parts, the participant is asked to rank each option on a scale 
with 1 being ‘Do not trust’ and 5 being ‘most trustworthy.  
 
The information sources chosen represent different perspectives in the field 
of drugs information:  
1) Government - they represent the law makers and stakeholders in the 
dissuasion of public drug use. They have a very clear agenda when it 
comes to drugs as set out in the MoDA 1971. 
2) Independent Scientist - to differentiate them from those who may be 
included as governmental sources; the example of Professor David 
Nutt is included as he is the most identifiable figure in this category.  
3) The Media - most vocal on this topic but how much do the public trust 
the information they report?  
4) Known User – a person who has experience but not an legitimate 
information source 
5) Doctor/GP – medical professionals whose primary concern is the health 
of the patient 
6) Internet – most easily accessible anonymous endless resource of 
information 
 
It can also be compared to question 6, is the most popular source also the 
most trusted, and if it’s not why is it the most popular? 
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 Question Type Answers Rationale 
8 
If you were considering taking 
a substance for the first time, 
or had recently taken a 
substance, who would you feel 
most comfortable discussing 
this with? 
Single 
Choice 
Teacher/School 
Friends 
Family 
GP/Doc 
Internet 
Local drug service 
Drugs Helpline 
Talk to FRANK 
A Known user 
Other 
 
With this question the idea of use was introduced, up to this 
point personal drug use had not been asked. This question 
hypothetically asks who the participant would be comfortable 
discussing drug use with.  
 
As it is still a sensitive subject this would give insight into how 
drugs education can develop, for example if people are only 
happy to talk to friends, how can open and honest dialogue 
about personal drug use be established? It is also a review of 
the services available, if people aren’t comfortable or don’t 
trust them what can be advised to change this. 
 
It was a single choice option, which meant the participants 
could choose only one option however the other option was 
included so as to not limit the responses.  
 
9 
Do you think it is important to 
be aware of drugs? 
Single 
Choice 
Yes or No 
 
A simple yes or no question that was elaborated on with the 
responses to questions 10 and 11. It emphasised whether the 
participant believes it is important to be aware of drugs.  
 
Again the participants were limited to the options of either yes 
or no to get a decisive opinion, the participant may not have 
ever considered this question before taking part in the survey 
and so the question primes them for the response for the next 
question. 
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 Question Type Answers Rationale 
10 
If you responded yes to 
question 9, what are you 
reasons? 
Paragraph 
Text  
Open Answer 
 
These questions were set as a paragraph answer so that the 
participants could write as much or as little on the subject as 
they liked. Based on the previous questions that will have 
made them think about what drugs in society mean to them 
these questions allows them to articulate their own feelings on 
the subject, if they so wished. It was a voluntary question, 
unlike the previous 9, which required an answer to complete 
the survey these were left optional. 
 
These questions are likely to contain the most content and so 
will not be quantitatively analysed but qualitatively. Key words 
and phrases will be looked for and the will be visualised using 
info graphic software, such as Wordles or Word bubbles. This 
software finds the most commonly occurring words in a set of 
text and makes an image to represent the prevalence of each 
word allowing for thematic analysis.  
 
11 
If you responded no to 
question 9, what are you 
reasons? 
12 
Do you think more should be 
done to educate people about 
drugs 
Single Choice Yes or No 
 
The last question was also yes or no, which required the 
participant to choose only one option. It established whether 
the participants believe enough is being done to educate on 
the topic of drugs. If they do not think there is enough what 
recommendations can this research make to improve this and 
impact policy?  
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Questions for Survey B: Popularity and Prevalence 
 
The questions for Survey B are divided into the following sections; 
 
Section 1: Drug Use (Questions 1 to 3) – sets out to establish the level of drug use of the 
participants over a set period. These questions are comparable to the questions found in both 
the CSEW and the GDS, and will give an indication of current drug use trends. 
 
Section 2: Experience (Questions 4 to10) – compares the drugs against each other. These 
questions look at the subjective experiences of the users to give an indication of what 
influences the participant’s decisions when choosing to use the selected substances. 
 
Section 3: Preference (Questions 11 to 17) – elaborates on the previous section, the 3rd 
section seeks to establish if there is a definable preference when selecting recreational drugs, 
and whether the internet is a source of supply.  
 
Section 4: Discussing Drug Use (Question 18 to 26) – these questions were developed to 
assess the openness and honesty of the participants, when it came to discussing their own 
drug use. These questions attempt to measure the impact of social desirability bias, and to 
see if there is a difference in discussing drug use between the age groups.  
 
 
A complete rationale for each of the questions included in Survey B can be found in Table 3.2. 
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Table 3.2: Questions for Survey B: Popularity and Prevalence Survey  
  Question Type Answers Rationale 
1 -3 
From the following list 
please check any 
substances that you 
have; 
1) Ever taken 
2) Taken in the last 
year 
3) Taken in the last 
month 
Multiple 
Choice 
Amphetamine, 
Cannabis, Cocaine, 
Crack, Ecstasy, Heroin, 
Ketamine, LSD, MDMA 
powder, Mephedrone, 
Piperazines, 2CB, 
Alcohol, Tobacco, BZP, 
Methamphetamine, 
Magic Mushrooms, 
Methylone, Naphryone, 
Other 
  
These questions are in the check box format, allowing the participant to 
choose multiple substances as and when they are applicable for each of 
the three questions. For example a participant may have tried cannabis in 
their lifetime but not within the last month or the last year. This question 
was based on the findings of the CSEW, the GDS and also from findings on 
the EMCDDA website for drug prevalence (Home Office 2013, Mixmag, 
2013, EMCCDA 2013). 
 
The answer choices available included are; the 12 drugs included in the 
first survey plus 7 new substances and the option for the participant to list 
their own. Alcohol and tobacco were included to give perspective on 
general acceptable drug use, which is examined further in question 24. 
BZP is the most prevalent form of piperazine and may give an indication of 
awareness of specific piperazine type drugs as opposed to using the 
blanket term. Methamphetamine and magic mushrooms were included 
because they are found in the other comparable surveys on drug use, and 
methylone and naphryone were included because there was a focus on 
their usage by the Home office at the time of question development (Home 
Office, 2013). 
 
The analysis of these questions will be looking at the significance of the 
number of reported usage for each substance, which can then be 
compared to each time frame.  
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  Question Type Answers Rationale 
4 
How would you rate your 
physical experience on 
the following 
substances? 
Single 
choice  
Substances; Cocaine, 
Ecstasy pills, MDMA 
powder, Mephedrone, 
Ketamine, Piperazine     
 
Options; Negative, 
Indistinct, Positive, Not 
Taken 
  
This question asked the participants to describe their physical experience 
felt on the selected drugs. The drugs chosen for this and the subsequent 
questions are; cocaine, Ecstasy pills, MDMA Powder, Mephedrone, 
ketamine and piperazine.  The descriptive options used for each drug was 
in four categories; positive, indistinct, negative and not taken. This question 
provides an insight into the user’s perspective on these chemicals, but also 
allows for comparison between substances. 
 
The significance of each of  the answers for each drug can be compared, 
and then cross compared  between each substance, for example is the 
physical experience for cocaine significantly more negative than that 
reported for Ecstasy. The substances can also be ranked by the number of 
positive experiences and again by negative experiences 
 
5 
How would you rate your 
emotional experience on 
the following 
substances? 
Single 
choice 
Substances; Cocaine, 
Ecstasy pills, MDMA 
powder, Mephedrone, 
Ketamine, Piperazine      
 
Options; Negative, 
Indistinct, Positive, Not 
Taken 
 
This question was laid out exactly the same as the previous question, 
however this time it was the emotional response that was examined. Due to 
the fact that MDMA has empathogenic properties this question compares 
the perspectives of the users have around pills and powders but also with 
Mephedrone and piperazine. Do these compounds also have a positive 
emotional response? 
 
 
As with Question 4 the significance of the responses can be compared for 
each drug individually and they in comparison to the other substances. 
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 Question Type Answers Rationale 
6 
Have you or do you 
know someone who has 
ever had a bad 
experience on any of the 
following substances? 
Single 
Choice 
Substances; Cocaine, 
Ecstasy pills, MDMA 
powder, Mephedrone, 
Ketamine, Piperazine       
 
Options; Yes- Myself, 
Yes- Someone else, 
No 
  
This question used the same drugs as questions 4 and 5, with the 
responses changed to; Yes-myself, Yes- Someone else and No. For this 
particular question the participant could only pick one response for each of 
the substances.  It is inclusive for those people who may not have ever 
tried the substances themselves but know people who have. It establishes 
which of the substances has the highest level of bad/negative experiences 
associated with it. 
 
This question is a tally that can then be compared to the more qualitative 
questions that follow. 
 
7 
Has your personal 
experience changed 
your drug use of the 
following? 
Single 
Choice 
Substances; Cocaine, 
Ecstasy pills, MDMA 
powder, Mephedrone, 
Ketamine, Piperazine       
 
Options; Yes, No, Not 
Taken 
 
This is a statement question, where the participant can state whether their 
personal experience has changed their own drug usage. The options again 
use the same compounds as the previous three questions with the 
responses now changed to; Yes, No and Not Taken. The question is an 
open one about usage, as the participants usage may have gone up after a 
positive personal experience of down after a negative one. This question is 
asking for the evaluation of the change. It is in the subsequent question that 
the participant is asked to quantify that change. The significance of the 
responses can be compared for each drug individually and then in 
comparison to the other substances. 
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 Question Type Answers Rationale 
8 
Has your knowledge of 
another person's bad 
experience changed 
your drug use of the 
following?  
Single 
Choice 
 
Substances; Cocaine, 
Ecstasy pills, MDMA 
powder, Mephedrone, 
Ketamine, Piperazine       
 
Options; Yes, No, Not 
Taken 
 
In the same format as the previous section, this time it is the bad 
experiences that are being evaluated, to see the impact of external factors 
cause a changes in behaviour. Again the significance of the responses can 
be compared for each drug individually and they in comparison to the other 
substances. 
9 
 
If you answered Yes to 
either question 7 or 8, 
How has your usage 
changed? 
 
Paragraph 
Text 
 
Open 
 
 
 
Both of these questions were open answer, which allowed the participant to 
write as much or as little as they choose. The purpose was for them to 
quantify the changes stated in their answers to either question 7 or 8, on 
whether their experiences had changed their behaviour. This question was 
an optional one as opposed to compulsory and so participants could 
continue the survey without needing to respond.  Similar to the questions at 
the end of the first survey these questions will give an insight into the 
participant’s opinions on this topic and will be analysed in the same way. 
Through thematic analysis and the identification of the most commonly 
occurring words and phrases to give an indication as to whether there is a 
positive or negative change.   
 
  
  
 
10 
If you answered No to 
either question 7 or 8, 
Why didn't your usage 
change? 
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 Question Type Answers Rationale 
11a 
If given the choice 
between Ecstasy Pills 
and MDMA powder 
which would you 
choose? 
Single 
Choice 
Ecstasy Pill, MDMA 
Powder or Neither 
  
 
 
Questions 11a to 14a asked the participant to choose between two 
compounds, to establish whether there was a preference. This is a main 
focus for this research, to observe whether the NPS compounds are more 
popular than MDMA. It also examines whether powders are more popular 
than pills with regards to Ecstasy, as suggested in the GDS (Global Drug 
Survey, 2013). Each of the question formats was in the multiple choice form 
with an option for each of the compounds as well as a neither option, this 
allowed for the answers to be ranked against each other. 
 
  
  
  
12a 
If given the choice 
between MDMA powder 
and Mephedrone which 
would you choose? 
MDMA Powder, 
Mephedrone or Neither 
13a 
If given the choice 
between MDMA powder 
and Piperazines which 
would you choose?  
MDMA Powder, 
Piperazine or Neither 
14a 
If given the choice 
between MDMA powder 
and Ketamine which 
would you choose? * 
MDMA Powder, 
Ketamine or Neither 
11b -
14b 
 
What are your reasons 
for your choice? 
Paragraph 
Text 
Open 
 
Each of the above questions was followed by a text answer question where 
they are asked to explain their choice, as with the other open answer 
options this was a voluntary response where the participant could write as 
much or as little as they choose.  
 
They were analysed by the same method as described for previous open 
response questions. 
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 Question Type Answers Rationale 
15 
Please Rank the 
following substances in 
order of your personal 
preference 
Scale 
Substances; Cocaine, 
Ecstasy pills, MDMA 
powder, Mephedrone, 
Ketamine, Piperazine       
 
Options;  1- least to 5 
most 
  
This question asks the participants to directly compare the same 
compounds as used in the above questions. The participants were asked to 
rank the compounds on a scale of 1 to 5, with 1 being the least and 5 being 
the most preferable. The results were assessed by comparing the results of 
the participants who reported to have taken the substances and those who 
had not. 
 
16 
Have you ever bought a 
substance over the 
internet?  
Single 
choice 
Yes or No 
  
There have been reports that more users are buying their product over the 
internet (Martin, 2014). This question evaluated to what extent that was true 
and was related back to the other questions in this section. 
 
17 
Have you ever tried a 
substance without knowing 
exactly what you were 
taking?  
Single 
choice 
Yes or No 
  
This was a yes or no question, and examined the trust drug users have in 
what they are taking. This question will also add to the profile generated. 
For example who are more likely to try a substance men or women? 
 
 
18 
 What do you believe it 
was? 
Multiple 
Choice 
Cocaine, MDMA Powder, 
Mephedrone, Ketamine, 
Piperazine and Other 
 
This question is only relevant to the participants who responded yes to the 
previous question, and the responses for each drug can be tallied and then 
compared. The options for this question were; cocaine, MDMA powder, 
Mephedrone, ketamine, piperazine and Other. The last option is to allow for 
substances not considered in this project.   
 
 
  
  
80 
 
 
 Question Type Answers Rationale 
19 
Do you ever talk about 
your own drug use? 
Single 
choice 
Yes, No or N/A 
 
This question assessed the participants’ honesty when responding to the 
questionnaire, whether drug use is something that is talked about? There 
was also the option to put N/A or not applicable due to the fact that some 
participants may have never taken any of the substances mentioned and 
therefore would not be able to talk about their own experiences. 
 
20 
Have you ever 
discussed your drug use 
with any of the 
following? 
Multiple 
choice 
Friends, Family, 
Online, Drugs 
Councillor, Drugs 
Helpline, Frank or 
Other research group 
 
Building on the previous question, this question asked who the participants 
did talk to about their own drug use with. The options ranged from friends, 
family, professionals to other research groups. Who did the participants feel 
comfortable to talk to about their drug use with? This can then be compared 
to the responses from Survey A to see if there is a correlation. 
 
21 
Who do you feel you can 
be honest about your 
drug use with? 
Text Open 
 
An open answer text response allowed the participants to elaborate on the 
previous question, if a previous answer was not included it also assessed 
whether people were confident to talk about their own drug use or whether 
it is still a closed subject.    
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 Question Type Answers Rationale 
22 
Do you think some drugs 
are more acceptable than 
others? 
Single 
choice 
Yes or No 
  
A yes or no question, it examined the participants own perception of the 
acceptability of drugs. This was then expanded in questions 23 and 24, 
which asked for an example for both an acceptable but also an 
unacceptable drug.  
These responses can be correlated back to earlier ones, for example are 
the participants more likely to view drugs as acceptable if they have tried 
them? 
 
23 
Can you give an example 
of a drug you think is 
acceptable 
Text Open 
 
These open answer questions asked the participant to give an example of 
which drugs they believed were acceptable if any and which are seen as 
unacceptable.  It can be assessed to see if there was difference in who 
believed which substances are acceptable. 24 
Can you give an example 
of a drug you think is 
unacceptable 
25 
If given a choice between 
something you have 
taken before and 
something completely 
new which would you 
choose? 
Single 
choice 
Something Taken 
Before or Something 
New 
  
The last questions sought to study the phenomenon of NPS, assessing the 
likelihood that someone would be willing to ‘try something new’. Can the 
factors that would lead to this be found in the responses given in question 
26?  
 
26 
What is your reason for 
your answer to question 
26? 
Text Open 
  
The participant were able to provide a reasons for their choice to the 
previous question, again this question was voluntary but may provide an 
insight into how NPS infiltrate the established recreational drug market. 
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3.5.4 Survey Development 
 
The software 
 
For the purpose of this research the software that was chosen to host the social surveys is 
produced by Google, the reasons for which are discussed below. 
 
Google documents are an add-on of the Google+ package that is freely available with a 
Google email address (Google, n.d.). The package provides online hosted software similar to 
Microsoft’s Office, including the function to develop online surveys. The surveys can be 
managed and stored through the email address associated with the G+ account (Google, 
n.d.). The features available include straight forward set up and manipulation of a range of 
question types. The major benefit of this program is that it inputs the response to the survey 
directly into an excel type spread sheet that can then be exported in to a range of formats for 
data analysis. It also runs its own simple visualisation of the data as the survey is being run, 
thus giving early indication of the likely outcomes from each question. Other software 
packages were available, including SurveyMonkey.  However it was the features mentioned 
above, as well as its usability, which led to the choice of using Google software to develop, run 
and manage the two online surveys (Google, n.d.).   For this research a specific email account 
was set up. The benefit of the email account being that it provided an anonymous point of 
contact if participants required further information. A G-mail account was chosen as it enabled 
the use of the other Google based programmes. 
 
The Email address used was: - AngliaRuskinDrugSurveys@Gmail.com  
 
Making the Survey 
 
Once the questions were finalised, they were inputted into the Google Documents form. In 
addition to the questions, page breaks and paragraph boxes were added as and when it was 
deemed appropriate, to separate questions into relevant sections and to provide additional 
information where necessary.  It was also possible to edit each question at any point and 
move the order by clicking the question box and shifting it up and down depending on what 
was needed. 
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When all the questions had been set up suitably, both Survey A and Survey B were launched. 
A soft launch began in December 2012, with the survey sent to small selection of Anglia 
Ruskin University students, where the author is based, to analyse usability before being 
officially launched in January 2013. The survey was run 12 months, no additional funding was 
provided or used as an inducement for participation or survey promotion. The surveys were 
officially taken offline on the 2nd of January 2014.  
 
3.5.5 Sampling  
 
Method 
 
A number of factors were considered when developing the methodology for participant 
sampling; firstly who were the target group, what would be the most effective way to reach 
them to ensure participation and how to guarantee anonymity of the participants due to the 
sensitivity of the topic.  A convenience sampling method was employed (Sue and Ritter, 
2012), with the only limiting factors being that of age, restricted to participants who are over 
the age of 18. This meant that anyone who wished to complete the surveys only had to have 
access to the internet and the links to the surveys. To generate interest and recruit 
participants a number of resources were used as detailed with the use of social media playing 
a vital role in the gathering of participants. 
 
Sample Size 
 
A number of factors were considered when deciding on a given sample size, first was the 
absolute size of the sample, opposed to the relative (Bryman, 2012). Although a larger sample 
is desirable, it cannot ‘guarantee precision’ (ibid. p.198), however it is more likely to increase 
precision, as the sample size increase the likelihood of sampling error decreases. It should be 
noted that though Bryman uses the term ‘precision’ what is actually required is a greater level 
of accuracy. Where precision relates to how close the responses are together compared to 
how accurately they represent the true views of the participants. Conversely Fowler (1993 
p.34) observed that it is not customary for survey researchers to be able to ‘specify in advance 
a desired level of precision’. The scope of this project is unlikely to generate the sample sizes 
comparable to those of either the CSEW or the GDS, as it did not have the same budget or 
resources namely the use of media partnership as found with the GDS. However the 
comparable surveys from section 2.7 had a range of participant sizes from 100 to over 4000. 
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Social Media Recruitment 
 
Facebook  
The most prevalent social media website used by contemporary society (Pew Research 
Center, 2014), it is a vast resource with numerous applications for social research. For the 
purpose of this research a group page was utilized, where links to the surveys are stored that 
were shared by the general public. 
 
Twitter  
Twitter is a micro-blog site that allows users to post 140 character statements that can be 
seen by their followers or by the general public with the addition of relevant hash-tags (Twitter, 
2015). The hash-tag function creates a conversation type scenario, where users who are 
tweeting on the same topic can be found. The benefit of Twitter is that there are numerous 
celebrities and accounts that have over a thousand followers, which retweet if approached. 
This research made use of retweets and targeted online personalities to spread the research 
to the general public. Also due to the fact that twitter is web-based the participant was taken 
straight to the surveys when they clicked on the link. Over the course of the twitter campaign 
there were a number of significant retweets; one by Dr Christian Jessen a noted doctor, TV 
personality and host of ‘Ecstasy trial: Live’. A second was from the team at the Global Drug 
Survey. 
 
Email Lists 
Within Anglia Ruskin University there are student email lists that were employed to garner 
interest in the research at a local level.  
 
QR Code  
A visualisation of the links was generated in the form of QR codes, which enabled anyone with 
a smart phone to take a photo of the code that automatically opened the survey in their phone 
browser. The codes were generated by a free online site (http://www.qr-code-generator.com/). 
They were also printed and included in documents, such as poster presentations. The QR 
codes are displayed in Figures 3.6. 
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Figure 3.6: The QR codes used to distribute online Surveys A and B 
3.5.6 Survey Analysis 
 
Due to the nature of the data collection, through the use of the Google documents, all 
responses were automatically loaded into a spread sheet that was downloaded and put into a 
number of statistical software packages, including SSPS and Nvivo.  Each survey was 
analysed separately using a variety of methods depending of the data type collected. As the 
surveys used a mixture of both quantitative and qualitative questions the analysis was tailored 
to each question. The statistical tests that have been used varied by the type and level of 
responses generated from the surveys, whether parametric or non-parametric tests were 
required. The majority of the data collected was non-parametric as the questions were 
nominal in nature and so the Chi squared test (χ2) was applied throughout. The chi squared is 
a non-parametric inferential statistical test that can be applied to frequency data. It is used to 
test if the differences between the observed and the expected frequencies are due to chance 
or something other than sample error (Mehta and Patel, 2012). 
 
Two forms of the χ2 test were used throughout the analysis of the surveys, one-way and two-
way chi squared.  The one-way test was used when the frequencies observed are assigned to 
a single set of categories, for example when testing the difference in response between 
genders. The two-way test was used when the responses were assigned according to two 
categories or variables, for example when assessing the difference between the numbers of 
people who had taken Ecstasy compared to the number who had taken MDMA, producing a 
two-dimensional frequency/contingency table. The Chi squared test is only valid if each cell in 
the table has a minimum count of 5. When the count was below 5 a number of exact tests 
could be applied to test the data, the Fishers Exact or the Monte Carlo Exact to provide a valid 
χ2 statistic (Ibid.).  A worked example of the chi squared tests and other statistical tests used 
throughout can be found in Appendix V. 
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3.5.7 Critical analysis of chosen survey method 
 
The method that is outlined in the previous sections was used to complete the recruitment and 
data collection for this part of the research. As assessed in section 3.3 there were a number of 
limitations that were identified in the existing drug use surveys. The following section critically 
examines the strengths and weaknesses relating specifically to this research.  
 
The first main difference between this survey and the Global Drug Survey was the decision to 
not include exclusionary questions. Viewpoints were accepted from both self-reported users 
and non-users, this enabled a comparative ratio which is not represented in the global drug 
survey, which only looks at drug users. A second strength of this research method was the 
recruitment method utilized, which attracted participants from within the age range identified 
by previous studies to most likely be engaging in the behaviour that was being examined, 
namely the use of Ecstasy/MDMA. There were no additional exclusionary criteria set nor 
specific groups targeted beyond participants over the age of 18 and with access to the 
internet. The use of the internet as the collection medium and the anonymity obtained from 
using this method is also a strength, as validity studies have shown that the use of self-
administered questionnaires, such as the web based method, has proven to yield better 
accuracy when reporting on sensitive subjects (Tourangaeu and Yan, 2007).  With the 
anonymity that the web based methods provide a greater sense of honesty is promoted from 
the participant when completing the surveys.  The use of the google+ software was also a 
benefit as although data was collected anonymously it only accepted complete survey 
responses and recorded time and date information which enabled internal verification of the 
data by the researcher to ensure validity.  
 
There were with any survey a number of limitations that applied, one key disadvantage to this 
method was that all information provided must be taken verbatim, and it is assumed that the 
findings accurately represents the views of the participant at the time of completion often with 
no possibility of follow up with the participants after.  There is the further issue that although 
voluntary self-nomination does result in access to the target group – drug users, it has been 
found that self-nominating participants’ responses differ from non-respondents, under what is 
known as the volunteer effect (Friedman & Wyatt, 1997, McCambridge et al. 2005).  As people 
responding to the survey will already have an interest in the topic, being able to extrapolate 
from the data is limited only to the participant group. This is not necessarily a negative as the 
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second survey examines specifically the users perceptive of the drugs Ecstasy and MDMA 
and their experience for the purposes of comparison with the other projects and so non drug 
users’ perception would not be suitable for this. Another weakness of the chosen methodology 
which was also highlighted in the critical analysis of other surveys is they often do not include 
participants who are homeless, this was however not considered to be an issue given that the 
focus was on the drug Ecstasy/MDMA which is considered to be non-addictive and 
recreational. Therefore the lack of representation by this group in this research was 
considered minor. 
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Chapter 4 Results for Social Research Surveys 
 
The following chapter has been divided into two sections, the first discusses the results for the 
first social research survey on knowledge and awareness of the drugs/terms of interest to this 
research. The second section discusses the results of the second research survey on use and 
preference. 
 
The purpose of the first survey discussed in Section 4.1 was to explore the baseline 
knowledge of the two terms Ecstasy and MDMA and compare how the public identifies them.  
Though the two terms have been used synonymously in the past there is evidence that they 
are being used to describe different products (Smith, Moore and Measham, 2009; Turner et 
al., 2014).  The results from this survey will establish whether the terms Ecstasy and MDMA 
can still be considered to be the same. There is also an evaluation of who/what are 
considered to be the best sources of information and what this means with regards to drugs 
education and clarifying drugs information.   
 
Section 4.2 analyses the results from the second social survey where participants were asked 
about prior drug use and their own perceptions about selected substances. The discussion of 
these results focuses on the use of Ecstasy, MDMA powder and Mephedrone from the point of 
view of the people who have used these substances. The results will identify any preferences 
the users may have and their reasons behind their choice. This can then be compared to the 
findings from the analytical chapter to see whether perception matches the reality in regards to 
quality and purity of products being seized versus what users believe.  
 
The analysis of quantitative data from both surveys made use of the statistical analysis 
software package SPSS (Version 20. IBM, 2011), whereas the analysis of qualitative data was 
aided by the software NVivo (Version 10. QRS International Pty Ltd, 2012).  
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4.1 Results for Survey A: Knowledge and Awareness  
 
4.1.1 Demographic Analysis for Survey A 
 
The first section of this results chapter evaluates the demographic break down of the 
participants who responded to the first social research survey. As stated in section 3.5.2 of the 
social research methodology chapter, the two variables examined were gender and age. The 
total number of valid responses received by this survey was 440.  
 
Gender 
 
Although the gender ratio of the UK in 2013 was 1.03 females to males (ONS, 2014b), this 
ratio was not achieved in this survey. The proportion of female to male participants is 
displayed in Figure 4.1.1.   
 
 
Figure 4.1.1: Proportion of female and male participants for Survey A: Knowledge and 
Awareness (n = 440) 
 
The participants for this survey were predominantly female, with a ratio of 1.70 females to 
males. This is unusual when compared to the findings from section 2.7.2, which found drug 
use surveys have historically had more male respondents (Gross et al., 2002; Hammersley et 
al., 1999; Handy, Pates and Barrowcliff, 1998; McCambridge et al. 2005; Ogeil, Rajaratnam 
and Broadbear, 2013; Sherlock and Conner, 1999; Solowij et al., 1992). The Global Drug 
Survey for example had an almost opposite gender response with 70% of the 2013 survey 
respondents reported to be male (Mixmag, 2013).  One survey that does report a more 
37%
63%
Male Female
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balanced proportion of females is the CSEW, which achieved 45% to 55% males to females in 
the 2013 survey. 
 
With regards to the social research survey employed as part of this doctoral research there 
was no intentional selection or preference for gender when sampling for the survey. One 
explanation of the difference in the proportion of genders may be the result of the location in 
which the research and researcher is based. Anglia Ruskin University in Cambridge has a 
student ratio of 62% female population and 60.5% female staff (Anglia Ruskin University, 
2013), which may have impacted on the unique outcome of a more female dominated survey.  
 
Age 
 
As with the variable of gender there was no preference required for the age of participants to 
complete this survey, with the only exception being that participants were required to be over 
18 as specified in the ethical approval.  Though the age requirement was stated on the 
participant information sheet (in Appendix III), the data was collected anonymously and age 
was taken as given. The percentages achieved for the age demographics is shown in Figure 
4.1.2. 
 
 
 
Figure 4.1.2: Proportion of participant in each age band for Survey A: Knowledge and 
Awareness (n = 440) 
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The responses to the question of age do not show an equal distribution, which may be due to 
the data collection and sampling method chosen, namely the use of an online survey and the 
use of social media as a recruitment tool. According to estimates by the Pew Research group 
(2015) 90% of 18-29 year olds used some form of social networking sites in 2013, compared 
to 78% for 30 – 49 year olds, 65% for 50 – 64 year olds and 46% for people over 65. As social 
media was the main recruitment tool the impact of this is reflected in the final outcome, with 
the majority of the respondents falling within the two youngest age groups.  The results above 
are also consistent with the findings from section 2.7 on the age profile of respondents to 
previous drug use surveys with the majority of participants being under 30. These findings 
could suggest that there is more interest in discussing drugs from the younger population. 
 
The data was also tested to see whether the gender ratios within each age band were 
comparable, to check that one age bad was not solely male or female. Across all the age 
ranges the gender divide was weighted towards female participants, but the proportion of 
males to females did not significantly vary band to band.  The significance was tested using a 
two-way chi squared test that returned χ2 value of 3.924 with a P value of 0.577, which 
exceeds the critical significance value of 0.05 (95% confidence level) and is therefore not 
significant. All further significance tests were applied at a 95% confidence level.    
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4.1.2 Questions 1 to 4 - Awareness of Drugs in Society  
 
Question 1: Which of the following drugs have you heard of? 
 
The first question asked the participants whether they had heard of a selection of 12 specific 
recreational drugs that are controlled in the UK. The lists included drugs that are well 
established such as heroin and cocaine as well as the newer synthetic drugs, the piperazines 
and Mephedrone. The aim of this question was to explore whether the term MDMA powder is 
as well-known as Ecstasy. It also highlights how well other comparable drugs; namely 
ketamine, Mephedrone and the piperazines are recognised by the public.  Figure 4.1.3 
displays the percentage of people who reported to have heard of each substance compared to 
the percentage who had not.  
 
Figure 4.1.3: Percentage of the responses for each drug listed in Question 1 (shown as a 
percent against total responses n = 440)
 
The figure above shows that there is difference of 20.4% between the participants who 
reported to have heard of Ecstasy compared to MDMA.  This suggests that despite the fact 
that the main chemical component of Ecstasy is considered to be MDMA, less people are 
aware of the existence of the term MDMA than that of the colloquial brand name. The 
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difference between the numbers of people who had head of Ecstasy versus those who had 
heard of MDMA was tested using a two-way chi square, which returned a χ2 value of 89.92 
and a P value of <0.001. Therefore a significant difference was observed between the number 
who had heard of Ecstasy and those who had heard of MDMA, with no participant reporting to 
have heard of MDMA but not Ecstasy. 
 
Demographic analysis of Question 1: Which drugs have you heard of? 
 
The first analysis examined the difference between which substances the two genders 
reported to have heard of. The results are shown in Figure 4.1.4. 
 
Figure 4.1.4: Percentage of participants having heard of each drug by gender (male n = 163, 
female n = 277) 
 
Of the responses to this question a significant difference in reporting by gender was observed 
for only four of the drugs, when tested using the two way chi-squared test of significance. 
These were: amphetamine, MDMA, piperazines and 2CB. The table of the chi square test 
statistics for all 12 substances is located in Appendix IVa Table 4.1.ii. There was no significant 
difference observed between the genders reporting to have heard of Ecstasy, with 100% of 
the male participants reporting to have heard the term.  
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The difference between who reported to have heard of the terms Ecstasy and MDMA can be 
further examined by looking at the difference in the reporting between age groups, shown in 
Figure 4.1.5.  
 
 
Figure 4.1.5: Percentage of participants reporting to have heard of Ecstasy and MDMA by age 
group (18-21 n = 177, 22-29 n = 128, 30-39 n = 57, 40-49 n = 39, 50-59 n = 19 and 60+ n = 
20)  
 
The graph above shows that for each age group, MDMA is the less known term. The 
difference between the level of reporting between the age groups for both Ecstasy and MDMA 
was tested using a two way chi-squared test. There was no significant difference observed 
between the age groups and whether they reported to have heard of the term Ecstasy (χ2 = 
3.125, P = 0.691).  However for the term MDMA a significant difference was observed, with a 
χ2 value of 20.380 and a P value of 0.02. The data suggests that the older population are less 
aware of the use of the term MDMA compared to that of Ecstasy. The above findings show 
that  not only there is a difference between the number of people reporting to have heard of 
Ecstasy compared to MDMA but also a difference between who is reporting to have heard of 
them. Across all variables there was no significant difference in the awareness of Ecstasy. Yet 
there was a difference between the genders and the age groups in terms of who had heard of 
MDMA, with males and the participants under 50 reporting a higher level of awareness.  There 
was also a significant difference in the number of participants reporting to have heard of 
Ecstasy but not MDMA. This finding is the first to support the hypothesis from the first 
research question, that Ecstasy and MDMA are not considered to be the same, as there is a 
significant difference in who has heard of each term. 
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Question 2: Which Class do you think each drug belongs to? 
 
The second question in the survey asked the participants on their knowledge of the legal 
classification system used within the UK to control the chosen substances and whether they 
could accurately place the selected substances into the correct class. This question was 
included to see whether the participants could identify that MDMA is the same classification as 
‘Ecstasy’.   
 
A brief description of the classification system was included before the question. The 
description stated that; the drugs considered the most harmful are Class A, the drugs 
considered to be of lesser harm are Class C with drugs in the middle being Class B. An option 
for ‘Do Not Know’ was also included to allow participants to indicate if they had no knowledge 
of the classification of a specific drug.   
 
The results in Table 4.1.1 show the percentage of respondents who correctly classified each 
of the drugs alongside the results for what the majority of responses believed the classification 
to be. A full break down of responses for each of the 12 drugs can be found in the Appendix 
IVa table 4.1.iv. 
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Table 4.1.1: Response to Question 2 compared to the correct classifications for each 
substance (*Amphetamine is classified as Class B, unless prepared for injection (MoDA 1971)) 
Drug 
Correct 
Classification 
 (As of Jan 2014) 
Percentage of 
participants who chose 
the correct 
classification  
Most Frequent Response 
(Percentage) 
Heroin A 94.1% Majority Correctly Identified 
Cocaine A 88.2% Majority Correctly Identified 
Crack A 86.1% Majority Correctly Identified 
Ecstasy A 68.4% Majority Correctly Identified 
LSD A 61.8% Majority Correctly Identified 
Cannabis B 57.5% Majority Correctly Identified 
MDMA A 47.5% Majority Correctly Identified 
Amphetamine B* 35.7% 
A 
(40%) 
Mephedrone B 26.6% 
Don't Know 
(39.8%) 
Ketamine C 21.4% 
B 
(32.7%) 
Piperazines C 8.6% 
Don't Know 
(77.5%) 
2CB A 3.2% 
Don't Know 
(72.7%) 
 
For seven out of the twelve drugs the majority of participants were able to correctly identify the 
classifications. When it came to the responses for Mephedrone, piperazines and 2CB the 
majority reported that they ‘Did not know’, this can be correlated to the findings from Question 
1 where for piperazines and 2CB the majority had not heard of them.  The case of 
Mephedrone is important as although the majority of participants report to have heard of it 
(72.3%) nearly 40% did not know the correct classification. This may be due to the fact that it 
is a relatively new recreational drug, as mentioned in section 2.6, it has only been controlled 
since 2010 and emerged under the banner of ‘legal highs’ (Alexandrescu, 2014; Measham et 
al., 2010; MoDA 1971, Amendment 1207, 2010).  
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A second point is the difference that occurred was with the responses for amphetamine, 
where the majority of participants placed it in Class A, which was considered as incorrect by 
this research.  Amphetamine has a dual classification based on its preparation, whereby 
amphetamine is classified as a Class B unless it is prepared for injection in which case it is 
Class A (MoDA, 1971). An explanation for the response choice by the participants could be 
because amphetamine is an analogue of methamphetamine and other ATS drugs that are 
classified as Class A and so there may be a common association of these substances and 
level of harm.  A further point of interest from these results relates to the responses for 
ketamine, which as of April 2014 was reclassified as a Class B (MoDA, 1971 amendment 
order 2014 no. 1106). This was the most frequent response by the participants, however at 
the time that the survey was run it was still classified as a Class C and so was counted as an 
incorrect identification.  
 
The scope of the participants’ knowledge of the classification system was also assessed. Out 
of the 440 participants who responded to this survey only 4 (0.9%) were able to correctly 
identify the class of all twelve substances, this increased to 27.7% participants for the seven 
substances that were correctly identified by the majority.    
 
Significance of results for Question 2: Which Class do you think each drug belongs to?   
 
The variation between the levels of responses for each classification for each drug was 
assessed using a one way chi squared test in Appendix IVa Table 4.1.v.  The results of the chi 
squared tests found that for all drugs a significant difference was observed and that none of 
the responses for any drug were evenly distributed between the classification choices.  
 
The one way chi squared test was also applied to test whether there is a significant difference 
between the levels of participants who got the classification correct and those who chose any 
other option (in Appendix IVa Table 4.1.vi.). For the drugs; cannabis, cocaine, crack, Ecstasy, 
heroin and LSD significantly more people were able correctly identify the classification of 
these substances. For ketamine, Mephedrone, piperazines and 2CB there were significantly 
more participants who were unable to identify the correct classification, which may relate to 
the relative obscurity of these compounds compared to the more established street drugs.  
 
MDMA was the only substance that did not have a significant difference between the number 
of participants who correctly identified and those who did not. Though the majority of 
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participants did pick the correct classification (47.5%), when the three incorrect options were 
grouped together no significant difference was observed.  The difference in the results 
between Ecstasy and MDMA for this question were also compared. As Ecstasy had a 
significant difference and MDMA did not this suggests that there is a difference in how the 
participants perceive these two terms. This was further assessed using the two demographic 
variables. 
 
Demographic analysis of Question 2: Which Class do you think each drug belongs to?   
 
In the analysis of question 2 using the two variables of gender and age, a variation of the two 
way chi squared test was required.  A full break down of the statistical tests for all the drugs is 
shown in Appendix IVa Table 4.1.vii.  For three of the substances: cocaine, crack and heroin, 
there was no significant difference observed for either the variable of gender or age. By 
comparison the responses for amphetamine, cannabis and MDMA has a significant difference 
for both variables.  The other substance displayed a significant difference in the reporting of 
only one variable, with the responses for Ecstasy, ketamine and LSD reporting a difference by 
the age groups and the responses for Mephedrone, piperazines and 2CB showing a 
difference between the genders. These results also show the disparity in the knowledge 
across the range of substances examined, with the reporting on heroin and cocaine appearing 
to be the only consistency.     
 
Comparison of Results for Ecstasy against MDMA 
 
As the focus of this doctoral research is on how the terms Ecstasy and MDMA are perceived 
the following section compares the responses for these two results.  This was achieved by 
cross tabulating the responses given for the two options. The cross tabulation looked at how 
many of the respondents answered which classification option for Ecstasy against what they 
chose for MDMA, the results are in Table 4.1.2.   
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Table 4.1.2: Cross-tabulation of the responses for Ecstasy against MDMA for Question 2 
  
 Q2 MDMA 
Total 
Ecstasy Class A Class B Class C 
Do Not 
Know 
 Q2 
Ecstasy 
Class A 
186 48 10 57 301 
42.3% 10.9% 2.3% 13.0% 68.4% 
Class B 
18 34 10 24 86 
4.1% 7.7% 2.3% 5.5% 19.5% 
Class C 
3 6 5 10 24 
0.7% 1.4% 1.1% 2.3% 5.5% 
Do Not 
Know 
2 1 0 26 29 
0.5% 0.2% 0.0% 5.9% 6.6% 
Total MDMA 
209 89 25 117 440 
47.5% 20.2% 5.7% 26.6% 100.0% 
 
 To test whether there is a difference between participants who were able to identify both 
terms correctly and those who were unable to identify them a one-way chi squared was 
applied to the above results.  The test returned a χ2 value of 78.066 and a P value <0.001, 
which is a significant difference between the people who identified both correctly and those 
who did not, with significantly more in the latter category. When the results were assessed 
using the demographic variables, shown in Appendix IVa Table 4.1.viii and Table 4.1.ix, there 
is a significant difference observed between the responses by the genders and by the age 
groups. Though only the 30-39 age groups had more participants who got the classification of 
both terms correct than incorrect.  
 
The results from question 2 support the hypothesis that the majority of participants were not 
aware that Ecstasy and MDMA are classified as the same, suggesting that the participants are 
not associating the two terms thus supporting the idea that these two terms now have 
separate identities. The implications of these findings suggests that the lack of association 
may be impacting on the reported level of use and the education around these two terms. If a 
participant is asked whether they have taken ‘Ecstasy’ but think they have only taken MDMA 
this could lead to underreporting of use, something that is explored further in Survey B. The 
concept of separate identities for these two terms is further explored in the following question 
on association of drugs with colloquial names.   
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Question 3: Which of the following names do you associate with: - 
Cannabis, Ketamine, Ecstasy and Mephedrone? 
 
Question 3 looked at the recognition and association of names and colloquial terms used to 
describe four chosen drugs. For each drug a selected number of known or associated terms 
were included, as well as names that are specifically associated with other substances. These 
were taken from the website TalktoFrank (2013) and are listed in Table 3.1. 
 
Some drugs have a multitude of names associated with them, while others have fewer more 
specific terms. Not all terms included in this question were relevant to the drugs that were 
being asked about. Part of the purpose of this research was in identifying whether there is 
misidentification of the names. Misidentification or a lack of understanding regarding colloquial 
terms can have implications to the user if they are not sure what it is they are using. It can also 
have an effect on the reporting of use if participants do not associate the colloquial name 
given to the substance they are using and the terms used by researchers. Five deliberate 
decoy terms were also included. These are described in Table 4.1.3, which gives the decoy 
name and the substance it is supposedly associated with according to TalktoFrank (2013). 
 
Table 4.1.3: List of decoy terms used in Question 3 
Term Associated Substance 
Bubble Mephedrone 
Charlie Cocaine 
Green Ketamine 
Mandy Ecstasy 
Skunk Cannabis 
 
Although the term green is referenced by TalktoFrank as an alternative for ketamine and was 
intended as a decoy in the other three questions, the level of participant identification of 
‘green’ as an alternative for cannabis meant that it was included in the recognised list, this is in 
spite of the fact that it is not a recognized alternate name for cannabis on TalktoFrank (2013), 
Erowid (n.d.) or Drugscope (2015). In responding to this question the participants were able to 
choose as many of the terms they believed were relevant to the four drugs. Table 4.1.4 shows 
the percentage response for each of the drugs and the relevant terms.  
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Table 4.1.4: Percentage of respondent identification of terms associated with specific 
substances in Question 3 
Cannabis Ketamine Ecstasy Mephedrone 
Weed 97% K 74% E 91% 
Meow-Meow 56% 
Pot 93% 
Special K 59% 
MDMA 44% 
Grass 90% XTC 37% 
4MMC 12% 
Green 64% 
Dust 4% 
Mandy 21% 
Hash 86% Crystal 6% Bubble 9% 
Dope 85% 
Green 1% Adam 5% White Magic 8% 
Skunk 80% 
 
The responses show that the alternative names for cannabis resulted in the highest level of 
recognition, with the highest being weed and the lowest green. Both ketamine and 
Mephedrone had low association with all but one of the key terms. In regards to the 
identification of the alternative names for Ecstasy, the responses were variable. The other side 
of this question looked at how often the terms are misidentified, whether people are using the 
colloquial terms consistently for the substance. Table 4.1.5 shows the percentage response 
for incorrect identification of the decoy terms. 
 
Table 4.1.5: Percentage of incorrect identification by participants to Question 3 
  Cannabis Ketamine Ecstasy Mephedrone 
Bubble 2% 3% 1% n/a 
Charlie 8% 1% 1% 0 
Green n/a n/a 0 0 
Mandy 7% 0 n/a 2% 
Skunk n/a 1% 1% 0 
 
The overall misidentification was low, with cannabis having the most misidentification of terms. 
The use of the term green, which was originally included as decoy name related to the 
substance ketamine, was included in the chosen terms for cannabis as it received over 64% 
identification.  The majority of the terms received less than 5% of the participants 
misidentifying these terms. Participants were also able to provide their own alternatives. The 
level of response for voluntary terms suggested were 42 for cannabis, 38 for ketamine, 22 for 
Ecstasy and 45 for Mephedrone. Of the times when the alternative option was deployed some 
used it to identify only knowing the name provided at the start of the question, the rest of the 
names provided can be found in Table 4.1.6.  
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Table 4.1.6: List of alternative names as provided by participants (*n = number of times 
mentioned independently by different participants) to Question 3 
Drug Alternatives Given 
Cannabis 
Blow, Blunts, Brown, Bud*3, Chang, Cheese, Draw*2, Ganja*6, 
Henry, Jungle, Lots of others*3, Marijuana*3, Mary Jane*6, MJ, 
Resin, Smoke, Sput, SweetLeaf, THC, The Devils Lettuce, The 
good thing, Tweeb, Wacky Baccy*2, Zoot 
Ketamine Horse Tranq, Horsey, Katy, Ket*8, Kit Kat, Regretamine, Wonk  
Ecstasy 
Disco Biscuits, Eccies, Fliers, Love Drug, MD*2, Molly*3, 
MumandDad, Pills*4, Pukka, Tabs, Speed*2, Whizzers 
Mephedrone 
Chine White, Dolly, Drone*2, Ember, MCat*2, Meph, Meth, MKat*4, 
Plant food, Speed 
 
Cannabis had the most alternative names suggested by the participants, with 3 participants 
merely stating that there were lots/loads of other names. Ketamine had the least amount of 
alternative names and the highest number of people stating they knew no other names beside 
ketamine.  
The use of the term Speed was used multiple times, not only as an alternative for Ecstasy but 
also for Mephedrone. Speed is a term reportedly associated with the drug amphetamine 
(TalktoFrank, 2013) however there is also evidence to suggest it is being used for 
methamphetamine (Erowid, 2013). This suggests that the term ‘Speed’ is being used as a 
generalised descriptor for any stimulating substance.  There is also the association identified 
between the use of the term Ecstasy and the form in which the drug is found, i.e. tabs or pills. 
This finding supports the hypothesis that the term Ecstasy is connotative of the form rather 
than the chemical composition. With regards to the drug Mephedrone the number of 
alternatives can relate to any number of the Cathinone derivatives, for example MCAT or 
MKat is used to describe the drug methcathinone.   
 
Variable analysis on the results for Question 3: Which of the following names do you 
associate with: - Cannabis, Ketamine, Ecstasy and Mephedrone? 
 
The level of association of the drugs with their alternate names was assessed using the two 
demographic variables to see whether there was a difference in the names each gender and 
the different age ranges associated with the terms. The difference was assessed using the 
chi-squared test, the full table of results is located in Appendix IVa Table 4.1.x. 
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Of the six terms that were chosen as alternatives to Ecstasy, half returned a significant 
difference in the responses between the genders. A significant difference was observed for 
the terms; ‘Mandy’, ‘MDMA’ and ‘XTC’, with all three being identified more by male 
participants than female.  This was also the case for the term 4-MMC, in relation to 
Mephedrone. Significantly more male participants identified 4-MMC as an alternate name than 
females. This is of interest as 4-MMC is the abbreviation of chemical name 4-
methylmethcathinone and is similar to MDMA, which is the abbreviation of 3, 4-
methylenedioxymethamphetamine the chemical associated with Ecstasy. What these results 
suggest is a difference in the level of knowledge and awareness between the two genders 
concerning these two drugs. The differences between the genders will be explored further in 
the second survey, when the participants were asked about their own drug use.  The 
difference may be due to females not using or coming into contact with these substances, 
something that was suggested in the section 2.7, which found that the majority of previous 
drug use survey participants were male.   
 
The association of the terms can also be explored by applying the variable of the different age 
groups.  Again a chi squared test was applied, the results for this are shown in Appendix IVa 
Table 4.1.xi. The results of the chi-squared test against the age variable shows two of the 
terms for Ecstasy and Mephedrone had a significant difference in the level of responses 
between the different age groups.  For Ecstasy the difference was observed for the terms 
‘Mandy’ and MDMA, for Mephedrone the difference was observed for Meow-Meow and White 
magic. The results showed that for Mandy, Meow-Meow and White Magic the names were 
less likely to be identified by participants from the bands 30 to 39 and older.  
 
The term MDMA, which is the focus of this research, showed a different trend when compared 
by the variable of age. When the results were analysed, the band that identified the highest 
level of association between the terms Ecstasy and MDMA was the 40 - 49 band with 62% 
association. The 18 – 21 and the 30 – 39 both reported 40% of participants associating the 
two terms, while 22 – 29 was slightly higher at 49%. The two oldest age groups examined in 
this research showed the lowest association with the 50 – 59 obtaining 26% and 60+ obtaining 
30%. Overall only 44% of the participants who responded to this survey associated the term 
MDMA with Ecstasy, which is a significant difference when tested using one-way chi (χ2 = 
6.145, P = 0.015). These results support the argument made throughout this research, that 
the terms Ecstasy and MDMA are no longer synonymous. The results from this and previous 
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questions prove that there is a division in what the participants understand Ecstasy and 
MDMA to be. 
 
Question 4 – Multipart scale questions on perception 
 
The next set of questions examined the participant’s perceptions of the substances and asked 
them to assess their own level of knowledge using a Likert scale. The analysis of these 
questions gives insight not only into the public’s views on the prevalence and health risks of 
drugs but about how informed they feel about the selected substance, and how each drug 
compares to the others.  
 
Question 4a: How prevalent do you think drugs are in modern British 
society? 
 
Question 4a asked the participants to think about the prevalence of drugs in modern British 
society. The range of answers was based on a Likert scale from 1 to 5, whereby a response of 
1 indicated that the participants thought the prevalence of drugs was low and 5 representing a 
high level of prevalence. Figure 4.1.6 displays a histogram showing the distribution of the 
responses to this question, while a summary of the descriptive statistics of mean mode and 
median for each of the dependant variable groups is shown in Table 4.1.7.  
 
 
Figure 4.1.6: Frequency distribution for total responses to Q4a – the prevalence of drugs in 
British society 
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Table 4.1.7: Descriptive statistics per variable for the responses to Questions 4a – Prevalence 
of Drugs 
 
Total Male Female 18-21 22-29 30-39 40-49 50-59 60+ 
Mean 3.80 3.85 3.77 3.72 3.91 3.91 3.64 3.68 3.40 
Mode 4 4 4 4 4 4 4 4 3 
Median 4 4 4 4 4 4 3 4 3 
n 440 163 277 177 128 57 39 19 20 
 
The majority of respondents ranked the prevalence of drugs in society towards the higher end 
of the scale, with an overall mean of 3.80. The mode was 4 across all the variable groups, with 
the exception of the 60+ age group. This suggests that the majority of the participants thought 
that drugs were quite prevalent in society. The difference between the responses given for this 
question from the total group were assessed using a one-way chi squared. This test gave a χ2 
value of 263.091 and a P value of <0.001, which is significant at critical level of 0.05.   
 
To test whether there was a difference between how the genders responded to this question a 
two-way chi squared was employed. As there were some counts that were less than five the 
Monte Carlo Exact was also applied and returned a χ2value of 7.620 and a P value of 0.105. 
As the P value is greater than the critical level of 0.05 there was no difference in how the 
genders responded on the prevalence of drugs. A second two-way chi squared using the 
Monte Carlo Exact test was employed to test the difference between the responses from the 
different age groups. This returned a χ2 value of 37.945 and a P value of 0.002, which is below 
the critical level and is therefore significant. The difference occurs between how the 60+ 
perceived the prevalence of drugs and the other age groups. Though use of the ranking of the 
scale could be considered quite broad and open to how each participant determines what they 
consider high. Yet it appears that the majority of participants did believe that drugs are 
prevalent in British society. The implications of this can be further explored by the analysis into 
the qualitative questions later in the chapter.   
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Question 4b: How informed do you feel about the health risks caused by 
drugs? 
 
Question 4b looked at how informed the participant felt about the general of health risks 
associated with drug use. Figure 4.1.7 displays the distribution of the results using the same 
Likert scale as question 4a, with 1 being low and 5 being highly informed. A summary of the 
descriptive statistics for each of the dependant variables is shown in Table 4.1.8 
 
 
Figure 4.1.7: Frequency distribution for the total responses to Q4b – the awareness of the 
risks of drugs 
 
Table 4.1.8: Descriptive statistics for question 4b – Health Risks caused by drugs 
 
Total Male Female 18-21 22-29 30-39 40-49 50-59 60+ 
Mean 3.97 4.06 3.91 3.88 3.61 3.72 3.51 3.53 3.65 
Mode 4 4 4 4 4 4 3 4 3.5 
Median 5 5 5 4 3 4 3 4 5 
n 440 163 277 177 128 57 39 19 20 
 
As with question 4a, the majority of the participants responded towards the higher end of the 
scale. The descriptive statistics are fairly unanimous, with 6 out of the 8 variable groups 
having a mode of 4, and the overall median being 5 the highest possible response on the 
scale. The responses given for this question from the total group were assessed using a one-
way chi squared to assess whether there was a significant difference between the responses 
across the scale. The test returned a χ2 value of 128.909 and a P value of <0.001, which is 
significant at the critical level of 0.05.   
11
57
105
137
130
0
20
40
60
80
100
120
140
160
1 2 3 4 5
F
re
qu
en
cy
 o
f P
ar
tic
ip
an
ts
 R
es
po
ns
es
How informed participants felt about health risks of drugs 
(1 = low, 5 = high)
 107 
 
 
The results for Question 4b showed that no significant difference was observed between how 
the genders (χ2 = 4.647, P =0.311) or the different age groups (χ2 = 27.546, P = 0.086), ranked 
their own level of information on the health risks of drugs. The results suggest that the 
participants felt informed of the health risks of drugs. One question that could be asked would 
be whether the information they possessed was accurate? Though not specifically evaluated 
by this survey an estimate could be made based on the responses to the prior knowledge 
based questions and by later questions, which assessed the information sources participants 
use to find information on drugs.   
 
Question 4c to 4g: How informed do you feel about the effects of: -   
4c) Cannabis, 4d) Ketamine, 4e) Ecstasy, 4f) MDMA Powder and 4g) 
Mephedrone 
 
Questions 4c to 4g examined the specific awareness of five of the drugs discussed in earlier 
questions. In this question Ecstasy and MDMA were separated and represented as individual 
terms, this was done so that a comparison between how the two terms are perceived could be 
achieved. The analysis of these questions gives insight not only into the public’s views on how 
informed they feel about the effects of each substance, but how their knowledge of the drugs 
compares.  The participants were asked to rank how informed they felt about each of the 
substances on the same Likert scale used in the previous questions. A summary of the 
descriptive statistical values of mean, mode and median for each of the substances are shown 
in Table 4.1.9.  
 
Table 4.1.9: Descriptive statistics for questions 4c to 4g – Effects of Drugs 
 Total 
4C  
Cannabis 
4D  
Ketamine 
4E 
Ecstasy 
4F  
MDMA 
4G 
 Mephedrone 
Mean 3.97 2.60 3.58 2.69 2.12 
Median 4 2 4 2 2 
Mode 5 2 4 1 1 
 
From the mean values shown in the table above, the substances can be ranked by how 
informed the participants felt about them. The rank order is as follows:  cannabis, Ecstasy, 
MDMA, ketamine and finally Mephedrone. The distributional analysis for each question was 
plotted onto individual histograms for each of the drugs and is displayed below in Figure 4.1.8.  
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Figure 4.1.8 Histograms for responses to questions 4c to 4g – How informed does the 
participant feel about the effects (1 = low to 5 = high)   
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Results for Question 4c - Cannabis 
 
In Figure 4.1.8 the histogram from the responses to question 4c - cannabis displays a 
negatively skewed distribution, with more participants reporting at the higher end of the scale. 
A one-way chi squared was applied to test the significance between the levels of responses, 
which returned a χ2 value of 214.091 with a P value of <0.001. Therefore there is a significant 
difference between the numbers of participants who chose each option on the scale, with the 
majority of participants choosing the highest possible choice. The participants clearly felt that 
they very informed on the effects of cannabis. There was no observed difference in how either 
gender (χ2 = 4.633, P = 0.311) or the different age groups (χ2 = 15.746, P = 0.657) rated how 
informed they felt about the effects of cannabis.   
 
Results for Question 4d - Ketamine  
 
The results for the responses on ketamine (Figure 4.1.8 4d) displayed a positive skew and in 
comparison to the results for cannabis the distribution for ketamine was more evenly spread. 
A one-way chi squared was applied to test the significance between the levels of response 
across the scale, which was significant (χ2 = 41.000, P = <0.001). The distribution was skewed 
towards the lower end of the scale with the majority of participants reporting to feel lowly 
informed on ketamine.  When a two-way chi squared was applied, there is a significant 
difference in how the genders ranked how informed they felt about ketamine, with males 
reporting to feel more informed than females (χ2 = 13.769, P = 0.008), however no significant 
difference is observed between the age groups (χ2 = 21.266, P = 0.368). 
 
Results for Question 4e - Ecstasy  
 
The distribution of the results for Ecstasy shown in Figure 4.1.8 4e display a negative skew, 
which when tested using a one-way chi squared returned a significant difference between the 
responses (χ2 = 87.682, P value = <0.001). The majority of participants choose the higher end 
of the scale. No significant difference was observed in how the two variables, gender (χ2 = 
5.500, P = 0.240) or age group (χ2 = 21.350, P = 0.320) responded to this question. The 
response for Ecstasy will be considered in more detail when compared to the results for 
MDMA at the end of this section.  
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Results for Question 4f - MDMA 
 
The histogram for the results for MDMA was positively skewed towards the lower end of the 
scale, with the participants’ responses to this question appear to be more evenly spread 
across the range of responses. However when tested using a one-way chi squared, a 
significant difference was observed (χ2 = 36.733, P = <0.001).  There was also a significant 
difference in how the genders, with the male participants rating their knowledge of the effects 
higher than the females (χ2 = 28.492, P = <0.001). A significant difference was also found 
between the results for the age groups (χ2 = 33.891, P = 0.018).There was a difference 
between the younger age groups and the older, though the overall mean was only 2.69, at the 
lower end of the scale. MDMA is the only substance that has so far had a significant difference 
between both variable groups. The differences in how the participants responded to Ecstasy 
compared to MDMA is examined in more detail further in the section. 
 
Results for Question 4g – Mephedrone 
 
A significant amount of participants rated their knowledge of the effects of Mephedrone as the 
lowest possible option on the scale, supporting the findings from previous question that 
mephedrone is still relatively unknown. A one-way chi squared was applied to test the 
significance between the levels of responses across the scale. The test returned a χ2 value of 
214.659 with a P value of <0.001, which is significant. There was also a significant difference 
in how the genders ranked how informed they felt about Mephedrone, with males rating their 
knowledge higher than females (χ2 = 11.525, P = 0.021), yet no significant difference was 
observed between how the age groups rated their knowledge of the effects of Mephedrone (χ2 
= 17.126, P = 0.609). 
 
Comparison of results for Questions 4c to 4g 
 
All of the substances returned a significant difference between the levels of responses for their 
individual questions. However the distributions of the responses varied between the 
substances. None of the histograms exhibited normal distribution for an expected population; 
both cannabis and Ecstasy exhibit negatively skewed distributions with the peaks towards the 
upper end of the scale. Ketamine, MDMA and Mephedrone exhibited positively skewed 
distributions with the peaks towards the lower end of the scale. This means that for cannabis 
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and Ecstasy the majority of participants rated their knowledge of the effects of these drugs 
highly compared to their knowledge on MDMA, ketamine or Mephedrone, which they rated at 
the lower end of the scale.   
 
The mode values denote the most frequent value chosen by the participants. For cannabis the 
modal value was the highest possible available at 5 on the scale given. Ecstasy also attained 
a high modal value with a mode of 4. Ketamine however attained a modal value of 2 and both 
MDMA and Mephedrone gained the lowest possible value of 1.  
 
When examining the difference in the responses between the two independent variables of 
gender and age the statistical analysis determined that for Ketamine, MDMA and Mephedrone 
there was a significant difference in how the genders ranked their perceived level of 
information, with the male participants consistently rating themselves higher in knowledge 
than the females. The only substance that received a significant difference in rating from the 
age groups was MDMA, which is consistent with the findings from the previous questions as it 
appears that the older age bands are less aware of the term. 
 
The Comparison of results for Question 4e Ecstasy and 4f MDMA 
 
Table 4.1.10: Cross tabulation of results for Question 4e (Ecstasy) against 4f (MDMA) 
  
 Responses for  MDMA 
Total 
1 2 3 4 5 
Responses 
for Ecstasy 
1 17 0 0 2 0 19 
2 40 32 2 1 0 75 
3 38 23 29 7 0 97 
4 29 25 20 52 3 129 
5 12 9 12 17 70 120 
Total 136 89 63 79 73 440 
 
Table 4.1.10 displays the cross-tabulation of results for question 4e - Ecstasy against question 
4f - MDMA. The significance between the responses given for Ecstasy and MDMA can be 
compared using a two-way chi squared with the application of the Monte Carlo Exact test. This 
returns a χ2 value of 315.441 and a P value of <0.001. The relevance of this finding is 
important when trying to establish how the public perceives these two terms. The fact that 
there is a significant difference in how informed the participants feel about two terms, both of 
which are used to describe the same product suggests that these two terms do have separate 
identities. This data can be further summarised by the number of participants who feel more 
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informed about Ecstasy and those that feel more informed about MDMA. This was calculated 
by taking the point difference between the two scored values, whereby a negative value 
suggests the participant feels more informed on MDMA and a positive value suggests feeling 
more informed on Ecstasy, this is summarised in Table 4.1.11. 
 
Table 4.1.11: Summary of difference in participant’s scores for Question 4  
Difference Between Score Frequency 
Percent 
(%) 
Higher for  Ecstasy 225 51.1 
Same for both 200 45.5 
Higher for MDMA 15 3.4 
 
A one-way chi squared test on the above data provides a χ2 value of 179.29 and a P value of 
<0.001, which is significant at a critical significance level of 0.05. This suggests significantly 
more participants felt more informed about the term Ecstasy than MDMA. Yet again 
supporting the idea that these two terms must be considered as separate terms.    
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Comparative analysis for Questions 1 to 4 
 
Up to this point in the chapter each section has summarised the individual findings from each 
of the first four questions, the following section will look at the differences between the 
participants’ responses between the questions.  
 
Cross tabulation of Question 1 responses against Question 2 
 
The first cross tabulation computed compares the results from the participants who had heard 
of Ecstasy and those who had not to what each group classified both Ecstasy and MDMA as 
in the Question 2, shown in Table 4.1.12. 
 
Table 4.1.12: Responses for Question 1 - Ecstasy against question 2 Ecstasy and MDMA  
Q1  
Ecstasy 
Q2 
 Drug Classifications  
Q2 Ecstasy Q2 MDMA 
Frequency Percent (%) Frequency Percent (%) 
Group 1: 
Have 
Heard  
(n = 434) 
Class A 298 69 207 48 
Class B 85 20 87 20 
Class C 23 5 25 6 
Do Not Know 28 6 115 26 
Group 2: 
Had Not 
Heard 
(n = 6)  
Class A 3 50 2 33 
Class B 1 17 2 33 
Class C 1 17 0 0 
Do Not Know 1 17 2 33 
 
The table above demonstrates that the majority of the participants who reported to have heard 
of Ecstasy (Group 1) were able to correctly identify its classification. The difference between 
the participants who choose Class A compared to those who choose any other option was 
tested using a one way chi squared that returned a χ2 value of 60.47 and a P value of <0.001, 
which is significant. Of the participants who reported to have not heard of Ecstasy (Group 2), 
half chose the correct response with the remaining three responses spread across the other 
three options.  This suggests that the classification status of Ecstasy is well known, and that it 
is perceived to belong with the more harmful drugs. This can be compared to the results for 
MDMA. 
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When it came to identifying the classification for MDMA the majority of participants in Group 1 
chose the correct classification out of the four options. However over a quarter of participants 
chose the ‘Do not know’ option. The difference between the participants who got the question 
correct compared to those who did not was tested using a one way chi squared that returned 
a χ2 value of 0.92 and a P value of 0.359, which is not significant at a critical significant level of 
0.05.  There was no significant difference in the number of participants who did identify the 
correct classification and those who did not, despite the fact the majority were able to classify 
Ecstasy correctly.  A second cross tabulation was completed with the responses from 
participants who had and had not heard of MDMA, the results are displayed in Table 4.1.13. 
 
Table 4.1.13: Cross tabulation results for Question 1 - MDMA against Question 2 Ecstasy and 
MDMA  
Q1   
MDMA 
Q2 Drug 
Classifications  
Q2 Ecstasy Q2 MDMA 
Frequency Percent (%) Frequency Percent (%) 
Group 3: 
Have 
Heard  
(n = 344) 
Class A 241 70 183 53 
Class B 67 19 76 22 
Class C 16 5 21 6 
Do Not Know 20 6 64 19 
Group 4: 
Had Not 
Heard  
(n = 96) 
Class A 60 63 26 27 
Class B 19 20 13 14 
Class C 8 8 4 4 
Do Not Know 9 9 53 55 
 
The table above shows that of participants who reported to have heard of MDMA (Group 3), 
the majority correctly identified the classification of Ecstasy. The difference between the 
number of participants who choose the correct classification was compared to the number of 
participants who choose any of the other three options was tested using a one way chi 
squared that returned a χ2 value 391.19 and  a P value of <0.001.  Of the participants who 
reported to have not heard of MDMA (Group 4), the majority also correctly classified Ecstasy. 
The difference was tested using a one way chi square, which gave a χ2 value of 75.08 and a P 
value of <0.001. The results for Ecstasy show that within both group 3 and 4 the majority were 
able to identify the correct classification. However this was not the case for the term MDMA.  
 
Of the participants that reported to have heard of MDMA the majority did choose the correct 
classification of class A. The difference between the numbers of participants who chose each 
of the four options was tested using a one way chi square that returned a χ2 value of 165.33 
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and a P value of <0.001 which is significant. Yet when number of participants who choose the 
classification correct is compared to those who did not using a one way chi squared there is 
no significance as the test returns a χ2 value of 1.41 and a P value of 0.258. This means that 
there was no significant difference between the number of participants who correctly identified 
MDMA and those that could not within the group that reported to have heard of MDMA. Within 
the group who reported to have not heard of MDMA the majority chose the ‘Did not know’ 
option. When the significance between the four options was tested using a one way chi 
squared it returned a χ2 value of 56.92 and a P value of <0.001, so the participants who had 
not heard of MDMA could not identify its classification.  
 
Although MDMA is classified the same as Ecstasy and is considered the same thing under the 
law, there was no significant difference between the number of people who could correctly 
classify MDMA and those who didn’t within the group who had heard of it. Thus supporting the 
hypothesis that MDMA and Ecstasy are not known as the same thing. A final cross tabulation 
in this section analysed the number of participants who got the classification correct for each 
term compared to whether they had heard of the terms.  The cross tabulation is shown in 
Table 4.1.14, with the percentage calculated against the number of responses per group.  
 
Table 4.1.14:  Cross tabulation of Q1 against Q2, grouped by who had heard of Ecstasy, 
Ecstasy and MDMA and heard of neither substance  
Question 1 Q2 Ecstasy Class A Q2 MDMA Class A Both Correct 
Heard of Ecstasy  
n=434 
Heard of MDMA 
n=344 
241 183 164 
70% 53% 47.6% 
Not Heard of  
MDMA 
n=90 
57 24 20 
63.3% 26.6% 22.2% 
Not Heard of Either Term 
(n = 6) 
3 2 2 
50% 33.3% 33.3% 
 
Less than half of all participants correctly identified both as being Class A, this is despite both 
terms being used to describe the same controlled substance. The inconsistency in responses 
between the two substances within the first two questions lends support to the main 
hypothesis of this research, that the two terminologies for this substance are not clearly 
understood to be the same thing. This can be further evaluated by correlating the responses 
from these questions with that of Question 3 which asked participants about the association of 
the two terms. 
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Cross tabulation of Question 1 responses against Question 3 
 
A cross tabulation was computed comparing the results from question 1 on which drugs 
participants had heard of to the responses they gave to Question 3 on association of terms. 
The responses were divided in the same manner as the cross tabulation in Table 4.1.15. The 
first group were those who had heard of both terms, the second those who had just heard of 
Ecstasy and the last those that had heard of neither. The responses for these groups were 
then separated into those who equated the term MDMA with Ecstasy and those who did not. 
The results of this comparison are shown in Table 4.1.15.  
 
Table 4.1.15: Question 1 responses compared against responses to Question 3 
Question 1:  
Which drugs have you heard of? 
Question 3: Which terms do you associate 
with Ecstasy 
Ecstasy = MDMA Ecstasy ≠ MDMA 
Heard of Ecstasy 
(n = 434) 
Heard of MDMA 
(n= 344) 
175 169 
51% 49% 
Not Heard of MDMA 
(n= 90) 
15 75 
16.7% 83.3% 
Not heard of either 
(n= 6) 
2 4 
33.3% 66.7% 
 
 
These results show a big difference in the awareness of MDMA as being another name for 
Ecstasy. The responses by the group who had heard of both terms were compared using a 
one way chi squared that returned a χ2 value of 0.1 and a P value of 0.777. This is not 
significant at the critical significance level of 0.05, which means there is no significant 
difference between the participants who did associate the two terms and those who did not. 
Less than half the participant group associated the two terms, which suggests that the 
participants must consider the two terms to represent different things. This may relate to the 
emergence of two separate products. The analysis of the section of the survey has shown that 
though majority of the participants claim to have heard of both substances, over half do not 
associate the two as being synonymous. This raises the question - what are the perceived 
differences?  This question cannot be directly answered based solely on the results from the 
questions in survey A, however will be addressed within the discussion of the whole project.  
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4.1.3 Questions 5 to 8 – Education and Information sources  
  
The next section of the survey asked the participants about their drugs education, where they 
look for information about drugs and how much they trust various sources of information on 
the topic.   
 
Question 5: Have you ever received any education in regards to drugs or 
drug abuse? 
 
The first question in this section asked whether the participants had received any education 
regarding drugs. Within the current national curriculum, set out by the Department of 
Education, drugs education is integrated into the module of PSHE (Personal Social Health and 
Economic education) and is seen as ‘an entitlement for every pupil and is supported by 
Section 351, of the Education Act 1996’ (Department of Education and Skills, 2004 p. 13). The 
focus on drugs education was renewed under the Government’s Drug strategy 2010 
(HMGovernment, 2010) to aid in the prevention of drug use. The aim of the drugs educational 
programme provided in the UK is: 
 
‘…to provide opportunities for pupils to develop their knowledge, skills, attitudes and 
understanding about drugs and appreciate the benefits of a healthy lifestyle, relating this to 
their own and others’ actions.’ 
(Department of Education and Skills, 2004 p. 18) 
 
As this survey is examining the participants knowledge and awareness drugs it was important 
to assess whether the participant group had received drugs education, to see whether this had 
an impact on how they answered the questions. The responses to this question were given as 
either a yes or no, with the summary of the results shown in Figure 4.1.9.    
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Figure 4.1.9: Total Responses for whether participants received any education in drugs (n = 
440) 
 
The above chart shows that there were significantly more participants who reported to have 
received some form of drugs education than not. A similar ratio was seen when comparing the 
male and female subgroups, with 74% of males and 79% of females who reported having 
received some education on drugs, with no significant difference between the gender 
responses observed (χ2 = 1.487, P = 0.223).The main difference that is observed occurs when 
examining the differences in the responses between the age groups as shown in Figure 
4.1.10. 
 
 
77%
23%
Yes No
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Figure 4.1.10: Responses to Question 5 separated by age group  
 
 
The above figure shows the decreasing level of reported drugs education as the participant’s 
age increases, with only 20% of the participants in the 60+ age group reporting to have 
received any drugs education. The significance was tested using a two way chi square. The χ2 
value returned was 101.443 and a P value of <0.001, which is significant and therefore proves 
a difference between the level of participants reporting to have received drugs education in the 
different age bands. 
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The differences between the age groups may be explained by looking at the time frame in 
which each group would have been at school and considering that the legislation regarding 
drugs has changed over the period of time when each groups schooling would have occurred. 
Table 4.1.16 shows the years that each of the age groups would have been 16, the current 
year at which all children in education should have received drugs education.  
 
Table 4.1.16: Years when each age group would have been in education (given age in 2013)  
Group Year when 16 years old 
18-21 2008-2011 
22-29 2000-2007 
30-39 1990-1999 
40-49 1980-1989 
50-59 1970-1979 
60+ Pre -1969  
 
Given that drugs education became an ‘entitlement’ in 1996 it is likely that the majority of the 
participants from the 30 to 39 group and younger would have received some form of drugs 
education, which is illustrated in Figure 4.1.14. One reason why the 50 to 59 groups reported 
higher affirmation of drugs education could be due to the fact that the time period when they 
would have been in education coincides with when the legislation of illicit compounds first 
came into effect, with the introduction of the Misuse of Drugs Act in 1971. Although the 
participants reported to have received some form of education the extent of that education 
may be questionable. Fletcher, Bonell and Sorhaindo (2010) found that secondary school 
children reported minimal education on the topic of drugs, and that the level of education 
varied widely between institutions. However in the modern day formal education is just one 
route to education, with the advent of the internet the general public has the ability to seek out 
information from a range of sources. To assess the impact of the participants previous drugs 
education on their responses cross tabulations against the questions from the first section was 
computed.  
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Analysis of responses for Question 5 compared to Question 1: which drugs have you 
heard of? 
 
The first analysis examined the impact of whether the participant had any drugs education on 
their reported awareness of the substances selected for this survey using a cross tabulation. 
The significance was calculated using a two way chi square test, the results of the chi squared 
test are shown in Appendix IVa Table 4.1.xii. When examining the results of the two way chi 
squared tests between, the participants who had education and those who had not and which 
drugs they had heard of, there was no significant difference between the groups reporting to 
have heard of amphetamine, cannabis, cocaine, crack, heroin, Ecstasy or ketamine.  Yet there 
was a significant difference between the educated group and the non-educated groups for the 
drugs; LSD, MDMA, Mephedrone, Piperazine and 2CB. This may relate to the difference 
observed in awareness of these substances between the age groups, as some of these 
substances were not known before the start of this millennium and so could not have been 
taught to older generations.  
 
Analysis of responses for Question 5 against Question 2: Classification of Drugs 
 
This analysis used a cross tabulation to examine whether reporting to have a drugs education 
had an impact on whether the participants could correctly identify the classifications of the 
substances. Again the results were tested with a two way chi square, with the results grouped 
by whether the participants choose the correct class and by those who did not. The results are 
shown in Appendix IVa Table 4.1.xiii. The results from these chi square tests show that there 
was no significant difference between the number of correct responses by the educated group 
and the uneducated group across all of the substances. This suggests that drugs education 
had no impact on whether participants could correctly classify these controlled substances.  
 
Analysis of responses for Question 5 against Question 3: Alternate Names 
 
The next analysis examined whether drugs education had an impact on the number of 
participants who correctly identified MDMA as an alternative term for Ecstasy. The 
significance was tested using a two way chi square that returned a χ2 value of 0.115 and a P 
value of 0.734, which is not significant. This suggests that within the participant group, 
previous drugs education was not a factor that impacted whether a person associated the two 
terms.   
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Analysis of responses for Question 5 against Question 4: How Informed does the 
participant feel? 
 
 The final analysis in this section examined the impact drugs education had on how the 
participants responded to the different parts of Question 4. The significance between the 
educated and the uneducated responses was calculated using a two way chi square with the 
results summarised in Appendix IVa Table 4.1.xiv. The results from the chi square tests show 
that there was no significant difference between the educated and the uneducated groups in 
how they rated how informed they felt on the topics of health risks, or the effects of cannabis, 
ketamine, Ecstasy, MDMA and Mephedrone. There was however, a significant difference 
between the educated and uneducated groups on how prevalent they believed drugs are in 
British society, with the educated group reporting a higher level of prevalence over the 
uneducated group. This finding might suggest that education makes people more aware of the 
topic of drugs. Whether the participants felt it was important to be aware of drugs is analysed 
in the qualitative responses to questions 10 and 11.  
 
Regarding the responses to first four questions, it does not appear that having drugs 
education had any significant effect on how the participants responded as there was no 
significant difference between how the educated and the non-educated response rated their 
own awareness of the effects of the chosen drugs, the educated group did rate the prevalence 
of drugs higher suggesting education made them more aware of drugs in society.   
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Question 6: Where would you go if you were looking for information about 
drugs?  
 
The next question in the survey asked about the participant’s information seeking choices, 
with regards to drugs.  It was divided into two parts; the first part of the question asked the 
participants about where they would go when searching for information about drugs for 
themselves, the second part of the question asked where the participant would look for 
information when looking for a friend or relative.  The options that the participants were given 
to choose from span a range of possible sources that provide drugs information. Some of the 
choices offered provide information on an individual yet objective basis depending what the 
person seeking information was looking for, examples of these types of information sources 
were the Doctors, Drugs hotlines and Local Drug Services. These were considered the 
objective information sources as they should provide information based on facts opposed to 
personal opinion. Other options represented a subjective view of drugs, the participant’s 
friends and family whose information would be dependent on the personal experience of these 
two groups.  The final sources included provide broader, less direct sources of information, 
such as the internet and different forms of media. For this question the participants were 
asked to choose from a number of options on where they would look for information for either 
themselves (6a) or for someone else (6b). They could choose as many of the options as they 
wanted. The total for each option is shown as a percentage against total number of 
participants in Figure 4.1.11 
 
 
Figure 4.1.11: Percentage of responses for each option to Question 6 – where would you look 
for information for yourself (6a) or someone else (6b) (n = 440) 
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The most frequently chosen answer for Question 6 was the internet, which is anticipated given 
73% of adults accessed the internet every day in 2013 (ONS, 2013). It is interesting to note 
that the user based forums come above the government website, doctors or drugs helplines 
as the place where more people would go for information. The reason that teachers came in 
last may be due to the age limit, that of over 18 and therefore out of secondary education 
given for this survey, had the survey been provided to school children the results may have 
been different. The only difference between the responses to 6a and 6b is observed with the 
drugs helpline, which was chosen more frequently than government website or doctors by 
participants when looking for someone else.   
 
The results were also assessed by separating the response by the demographic variables, the 
results for question 6a -gender are in Appendix VIa Figure 4.1.i. The difference between the 
responses of two genders shows no significance when tested using the two way chi squared 
for every option except ‘Drugs Forum’ (χ2 = 13.941, P = <0.001) with significantly more male 
participants choose this option. This may reflect that males are more likely to engage with 
discussions around drug use, as was highlighted in the review of previous drug use surveys in 
section 2.7. 
 
The difference between the responses by the two genders was also tested for question 6b – 
someone else (Appendix VIa Figure 4.1.ii), this question also showed no significance when 
tested using the two way chi squared for every option except ‘Drugs Forum’ (χ2 = 6.469, P = 
0.011) and Drugs Helpline (χ2 = 13.799, P = <0.001), with more males again choosing the 
option of drugs forum, however for this question significantly more females reported they 
would use a drugs helpline.  
 
Across all of the age groups the top choice in both 6a and 6b was the internet, with the main 
differences occurring in the second and third most frequent choices, as shown in Appendix Via 
Table 4.1.n.  For 6a all but the two highest age groups choose the friends option as the 
second most popular choice when looking for information for themselves, however the 50-59 
and the 60+ age groups both choose more reputable sources of information, namely the 
Drugs Hotlines or their Doctors respectively. With the third most popular choice, two out of the 
six groups choose the option of drug forums, with the rest selecting the governmental website. 
The older age groups put more trust in the ‘objective’ sources compared to the younger that 
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rated ‘subjective’ sources, the trust each group has in different information sources is further 
explored in question 7.  
 
The results between the ages for 6b question displayed more variety between the second and 
third choices made by the different age groups. With the younger two groups reporting the 
same choices as question 6a, groups 30 - 39 and above differ not only in their response given 
in this question but also between their response to the previous question.  The 30 – 39 group 
choose the government website as the second most frequent response, changing from friends 
for the previous question. The response shift from subjective source to objective, yet for the 
60+ group the change is the opposite from GP in question 6a to friends in 6b.   The main 
difference in the responses between question 6a and 6b appear to occur between the different 
age groups, with the younger generations consistently picking the subjective sources and the 
older generations picking the more objective ones.  This can be tested my examining how 
much each group trusts a variety of information sources, as examined in the next question.  
 
Question 7: Who do you trust for your information? 
 
The next question included in the survey looked at who the participants trusted to provide 
accurate information on drugs.  This question also used a Likert scale from 1 to 5, with 1 
representing low level of trust in the information source and 5 representing highly trusted. The 
participants were presented with six possible sources of information; the government, an 
independent scientist (i.e. Prof Nutt), the media, a known user, a Doctor/GP and the internet. 
They were asked to rank each of the options individually, as opposed to in comparison to the 
other options. The results of these questions can be compared to provide insight into who the 
public trust to provide accurate drugs information. The histograms for each option are 
displayed in Figure 4.1.12. 
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Figure 4.1.12: Histogram of results for Question 7a to 7f - Who do you trust for information (1-
Low Trust, 5 - High Trust) 
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Question 7a: The Government 
 
The UK Government are the foundation for legislation, policy and education on drugs. They 
produce numerous reports and reviews including CSEW. This question examined the public 
perception of this institution to provide accurate information on the topic of drugs, the results 
displayed in Figure 4.1.12 7a displays a distribution that is not normal and exhibits a negative 
skewness. The significance between the frequencies for each option was assessed using a 
one-way chi square test that returned a χ2 value of 63.750 and a P value of <0.001. The 
results for this question are further compared with the other options later in the section.  
 
Question 7b:  Independent Scientist (i.e. Professor Nutt)? 
 
The next source that was put before the participants was that of independent scientist. The 
example given was that of Professor David Nutt; the well-known and outspoken ex-
governmental adviser who set up his own independent drugs review committee the 
Independent Scientific Committee on Drugs (ISCD, 2013). Independent scientists and 
researchers are information sources without direct governmental involvement, the use of the 
word independent was specifically chosen for this reason. The results for question 7b also do 
not display normal distribution and a negative skewness. Though there was less division 
between participants rating this question. The significance between the frequencies for each 
option was assessed using a one-way chi square test that returned a χ2 value of 528.727 and 
a P value of <0.001. 
 
Results for Question 7c: Who do you trust for your information - The Media? 
 
The third choice was that of the media, a general term used to describe the technologies used 
to communicate to the general public. This could be in the form of television broadcasts, 
newspapers or other products used to convey information. This information source has the 
broadest reach when it comes to providing information and reiterating information from other 
sources. Unlike the previous two histograms, the histogram for this question displays a 
positive skewness, with more participants choosing the lower end of the scale. The 
significance between the frequencies for each option was assessed using a one-way chi 
square test that returned a χ2 value of 154.818 and a P value of <0.001.  
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Results for Question 7d:  Who do you trust for your information - A Known User? 
 
The fourth option was that of a known user, the people who report to take the substances in 
question. They can provide information through a variety of methods, including direct 
conversation and through the use of drugs forums mentioned in question 6. This information 
source can relay subjective information based on personal experience opposed to objective 
research. The histogram for this question displays the closest to a normal distribution, though 
it exhibits negative skewness. The significance between the frequencies for each option was 
assessed using a one-way chi square test that returned a χ2 value of 144.523 and a P value of 
<0.001.   
 
Results for Question 7e: Who do you trust for your information - A Doctor/GP? 
 
The fifth option that was given was that of doctor or GP, the health and medical experts. As 
the illicit substances discussed in this survey are psychologically and physiologically active, 
creating effects within the body, it is reasonable to assume that medical professionals 
should/would be able to provide information about these substances. This histogram for 7e 
displays a distribution similar to the one seen for the independent scientist, with little spread of 
the responses between the points and a negative skew. The significance between the 
frequencies for each option was assessed using a one-way chi square test that returned a χ2 
value of 209.886 and a P value of <0.001. 
 
 
Results for Question 7f: Who do you trust for your information - The Internet? 
 
The final option that was presented to the participants was that of the internet. As a source of 
information the internet encompasses all the information provided by the previous five options 
plus any other possible source of digital information, and it was also the more popular choice 
in question 6: Where would you go if you were looking for information about drugs? However 
question 7 was concerned with the reporting of accurate information, which could impact on 
how this option was perceived as both verified and unverified information is available side by 
side. The histogram from 7f also does not display a normal distribution, with the results 
skewed towards the upper end of the scale and the curve is steeper than expected for normal 
distribution. The significance between the frequencies for each option was assessed using a 
one-way chi square test that returned a χ2 value of 321.818 and a P value of <0.001.  
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The following section compares the results for all of the options to provide insight into how 
each source ranks in comparison to the others, with some discussion on the possible reasons 
behind this.    
 
Comparative analysis of questions 7a to 7f 
 
The aim of question 7 was to establish who the public trust as a source of accurate 
information on drugs. Up to this point the questions have been analysed individually, the 
following section compares the descriptive statistics, which provides a ranked scale of the 
trustworthiness of the sources according to the participant’s perceptions. Table 4.1.17 shows 
the descriptive statistics for each of the six options of question 7. 
 
Table 4.1.17: The descriptive statistics for Question 7a to 7f: Who do you trust for your 
information? 
 
7a 
Government 
7b 
Scientist 
7c 
Media 
7d 
User 
7e 
Doctor 
7f 
Internet 
Mean 2.86 3.68 1.93 2.90 3.79 3.16 
Mode 4 4 2 3 4 3 
Median 3 4 2 3 4 3 
 
When looking at the descriptive statistics in the table above the rank order as determined by 
the mean values is as follows; doctor, scientist, the internet, a known user, the Government 
and the media. It is unexpected that a known user ranked higher than that of the Government 
when using the mean values. When examining the shapes of the histograms, the government 
seemed to split opinion more than any other of the options, with almost equal weighting 
between the 2, 3 and 4 options. Before discussing the relevance of these results first the 
impact of the demographic analysis must be considered. Was there a difference in how the 
genders and the age groups ranked these information sources? 
 
Demographic analysis of questions 7a to 7f 
 
The next analysis examines the impact of comparing the response by the variables of gender 
and age.  Firstly a two-way chi squared was applied to test whether there was a significant 
difference in how the different genders responded to each of the information sources, Table 
4.1.18 displays the mean value for each gender as well as the test statistics and the 
significance.  
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Table 4.1.18: Analysis of Question 7a to 7f by the variable of gender 
Question Male Mean 
Female 
Mean 
χ2 Value P Value Significant 
7a: The 
Government 
2.67 2.97 10.29 0.036 Yes 
7b: Scientist 3.79 3.61 9.862 0.043 Yes 
7c: Media 1.81 2.00 6.896 0.093 No 
7d: User 2.99 2.84 6.061 0.195 No 
7e: Doctor 3.69 3.86 6.185 0.193 No 
7f: Internet 3.25 3.11 4.505 0.341 No 
 
Only two out of the six information sources reported a significant difference in how the 
genders responded. These were the options of the Government and the independent scientist. 
The mean values show that the female group rated the government higher than the male 
group, while the male group ranked independent scientists higher than the females. The 
analysis was repeated using the variable of the different age groups, the mean values for each 
group are displayed in Appendix VIa Table 4.1.xvi. 
 
There is variation of the mean values for the ‘known users’ option, with a clear difference 
between how the younger age groups and the two oldest age groups ranked this information 
source.  This finding suggests that younger participants trust a known user more than the 
older. The younger age groups 18 to 49 also appear to rank a known user above that of the 
Government as a trusted information source. The results shown for doctor however are less 
clearly defined. Two of the age groups, the 40 to 49 and the 60+ rank the doctor significantly 
lower than the other age groups. The mean values given for the option of doctor can be 
compared by looking at the ranking in comparison to the option of scientist. A doctor was the 
highest ranked when looking at the results of the mean value from the total population, 
however there is deviation between the age groups on where it is ranked.  For the age groups 
18 to 21, 22 to 29, 30 to 39 and 50 to 59 the option of doctor has the highest mean value, for 
the other groups it comes in second behind a known scientist. The difference between the 
responses per age group was compared using a two way chi squared test, the results are 
shown in Appendix VIa Table 4.1.xvii. 
 
Only two out of the six options returned a significant difference between how the age groups 
responded. There was a significant difference in how the age groups ranked the option of a 
known user (χ2 = 32.559, P = 0.020)  and a doctor (χ2 = 34.333, P = 0.007), with the younger 
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groups rating the known users significantly higher than the older groups, with the reverse 
observed for the option of doctor.  
 
There are three points that can be drawn from the results to question 7, which are relevant 
when considering the responses to question 6: where would go if you were looking for 
information about drugs?  The first points that can be drawn is that the role of a doctor in 
providing accurate information is ranked as the highest out of the information sources the 
participants were asked about. Yet when this is considered alongside the fact that only 22.3% 
reported that they would seek information for themselves about drugs, and 25% reported that 
they would seek information for someone else about drugs from a doctor this suggests that 
there is a disconnect in how people seek information about this subject. The participants trust 
the information doctors provide but would not necessarily ask for it.  
 
The second point of comparison concerns the role the government plays in drugs education. 
In questions 6a and 6b the governmental websites received 27.3% of participants reporting to 
use them to find information about drugs for themselves and 29.3% for someone else, yet the 
government was ranked second to last out of the information sources asked about. It also 
received a mean value of 2.86 that is just on the lower end of the scale. However the 
government did receive a mode of 4 and when examining the distributions of the histograms, 
the government seemed to split opinion more than any other of the options, with almost equal 
weighting between the 2, 3 and 4 options. What this shows is that though people are using the 
governmental websites as sources of information, the level to which they trust the information 
provided is variable. This may be an issue considering that the government and the 
information they provide is the basis for formal drugs education, and so if people do not trust 
the source of the formal education they may seek information from unverified sources, which 
could be harmful if the information is inaccurate. This links with the final point on the role of the 
internet.  The internet was the categorical first choice for almost all participants, with 90% 
stating they would use it to find out information for themselves and 86.1% stating they would 
use it to find information for someone else. However as with the Government, the perception 
of the trusted accuracy this information source was in the middle of the scale, with a mean 
value of 3.16. This suggests that while most people will look for information on the internet, 
there is perhaps more contemplation on whether the information there is accurate or not.   
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Question 8: If you were considering taking a substance for the first time, or 
had recently taken a substance, who would you feel most comfortable 
discussing this with? 
 
Question 8 posed a hypothetical situation to the participant. This question asked who the 
participants felt most comfortable discussing drug use with.  The same options that were 
presented in question 6 were given with the additional option of adding their own suggestions 
through the use of the ‘other’ option. For this question the participant was limited to only 
choosing one of the options, compared to previous options that allowed for multiple choices.  
 
 
Figure 4.1.13: Results for Question 8 – who would you discuss your drug use with? (n = 440) 
 
The majority of participants choose the friend option for this question, similarly to the results 
for question 6.  However of the 440 participants only 4.3% who choose to utilize the other 
option the responses ranged from answers; ‘n/a’, no-one, nobody, and other comments along 
the lines of ‘I would never try them’. One participant stated they would ‘consult the appropriate 
literature’. Very few people stated that they would feel comfortable discussing their first time 
drug use with a GP or doctor, despite the findings from the previous two questions that 
showed that the participants believed doctors to be the best source of accurate information.   
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4.1.4 Questions 9 to 12 – Importance of drug awareness  
  
The last section of questions asked the participant’s whether they thought drug awareness is 
important. It also allowed for the participants to elaborate on their reasons behind their answer 
in the form of two open questions, which permitted them to write as much or as little as they 
desired on the subject. 
 
Question 9: Do you think it is important to be aware of drugs? 
 
The first question in this section asked the participant about their own attitude towards drugs, 
did they think it was important to be aware of drugs. Due to the direct nature of this question 
only the options of yes or no were presented to the participants to choose from. The 
participant was then able to expand and comment on their choice in the open question format 
of questions 10 and 11. In response to whether the participants believe it is important to be 
aware of drugs the response was definite, with 99% of all participants responding with the yes 
category. This finding suggests that information on drugs is seen as important, the reasons 
behind the importance attached to drug awareness are discussed in the next question.   
 
Question 10: If you responded ‘Yes’ to question 9, what are you reasons? 
(Why do you think it is important to be aware of drugs?) 
 
This question, along with the juxtaposition of question 11: If you responded ‘No’ to question 9, 
were set to allow the participants to express their own opinions in as many words as they 
choose too. Based on the previous questions, which aimed to have made them think about 
what drugs in society meant to them. The two qualitative questions allowed them to articulate 
their own feelings on the subject if they so wished. They were voluntary question, unlike the 
previous 9 that required an answer to complete the survey. 
 
Of the 440 responses to the survey only 40 of the participants declined to leave any answer to 
question 10. Four of the non-responses came from the participants who chose to answer No 
to question 9 and so answered question 11 instead. This meant that only 8% participants 
chose not to respond to this question, one of which responded in question 11 despite 
answering yes to question 9.The responses given by the participants ranged in length from a 
single sentence to multiple paragraphs. To analyses the key themes of the 400 responses, a 
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full copy of the answer transcript was entered into the online software Wordle (Feinberg, 2013) 
to create an image of the most prevalent words found in the text Figure 4.1.14. 
Figure 4.1.14: Worlde of the most prevalent words from participant responses to Q10 – Why 
do you think it is important to be aware of drugs?) 
 
The image above shows a clear graphical representation of the key words that the particpants 
used to answer this question, with the size of the word representing how often it was repeated 
in text, the bigger the word the more frequent its use. The most dominant term found was the 
word drugs.  Thematic analsysis was applied to interpret the main themes of the participants 
responses, through the use of NVivo software,  20 thematic words excluding the words like, I 
and  is  were identified.  These words were then grouped into 5 main themes in which the 
responses from the participants could be organized, though within the responses some 
participants touched on more than one theme. Figure 4.1.15 displays the frequency with which 
each theme appeared in the participants responses.  
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Figure 4.1.15: Frequency of responses relating to the five themes identified in response to 
question 10.  
 
The first and most dominant theme identified was ‘Informed Choice’.  In these responses 
information and being informed was the most important feature highlighted by the participants 
on being aware of drugs. Awareness was often linked to the making of choices and decisions 
around using the substances. The tone of these responses were not so much concerned with 
the reduction of or prevention of the consumption of the substances discussed in the survey, 
rather that the people exposed to them can make an informed choice based objective 
information, as shown in the following example:  
 
‘To allow people to make informed choices as to whether they participate in drug-
taking or not. As drugs are part of British culture whether you choose to take them or not, you 
will come in contact with people who are or have taken drugs and it’s important to be aware.’ 
Participant 244 
  
The responses that belonged within this theme were the most pro-choice of the responses, 
seeing drug use as an individual choice, which can only be helped by having the most 
information. This is in direct contrast to the responses from the second theme. The second 
thematic group focused on the ‘dangers’ or risks of drugs. Included into this theme were 
discussions on the physical, psychological, social or legal risks and harms that can be 
associated with drug use.  There was some overlap between responses based on informed 
choice and those focused on the harms as to be able to make an informed choice all 
information must be considered. There were also responses with strong anti-drug messages, 
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from the simple ‘drugs are bad’ and ‘they kill’ to more elaborate answers such as the following 
example: 
 
‘Because too many young people are not aware of the long term physical and mental 
consequences of short and long term drug taking. It's treated with such a lack of care and I 
believe that if more people could see the future effects of drug use, then they would think 
more carefully about taking drugs. Drugs are stupid and incredibly dangerous and I CANNOT 
understand why someone would consciously make the decision to put them into their system. 
So many young people die through carelessness and a lack of information - stay away from 
drugs and enjoy life in ways that won't kill you or damage your physical and mental health.’ 
Participant 426 
 
These responses were the most negative and had the strongest antidrug message, indicating 
that the participants believed in strict prohibition as highlighted in the response from 
participant 426.  The theme of prevention of using drugs linked with the responses from the 
third thematic group, which saw awareness of drugs as an important deterrent in reducing or 
preventing drug use.  This again overlapped with the informed choice option, however here 
the participants state that they believed more information would reduce the likelihood that 
someone would want to use illicit substances. There is also overlap with the comments made 
by the group that mentioned the dangers, as being aware of the dangers is also seen a 
deterrent as exemplified in the following example: 
 
‘Some do not understand the implications of taking drugs, and so enter into it not 
knowing the effects it could have. I think more awareness about drugs, the effects and the 
situations where they may be confronted with drugs (so may be able to avoid them) would 
help reduce the prevalence of drug abuse. I had no formal education about drugs (only 
learning bits in science) and have seen friends use gateway drugs, thinking they are harmless 
and unfortunately being led into using more hard drugs.’ 
Participant 149 
 
The fourth thematic group represents the altruistic responses, where the main benefit of drug 
awareness was seen as the ability to help others. This ‘help’ was either in being able to 
provide information, or to provide some form of physical help to people who are suffering the 
negative effects of drugs, as in the following example: 
 
‘Helping others by spotting the signs and getting them help. Understanding why 
people have taken them. Being able to get assistance if someone is in trouble from the effects 
of drugs. Being able to advise others of the harmful effects’ 
Participant 12 
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The final thematic group identified focused on the principle of prevalence. As drugs are seen a 
prevalent in society, which was demonstrated in the response to previous questions, it is 
therefore necessary to be aware of them. This was most eloquently described by participant 
43, which is illustrated in the following example: 
 
‘They are everywhere, and whatever surrounds us we must surely appreciate as 
being part of human life. Even for those who do not branch into drug use, surely one must 
wonder what life is like on the other side of humanity, in the wild darkness where the fleeting 
glimpses of the hedonists and existentialists fly by. One must be aware of how humanity lives, 
for we are together in this mess. And drugs are a part of human life, and have been for a long 
time, from coffee to alcohol to heroin.’ 
Participant 43 
 
Though five main themes were highlighted there was a significant amount of overlap, with 
most of the responses reflecting sentiments from more than one of the themes. Demographic 
analysis was applied to see whether any of the themes were particularly expounded by any 
group. Table 4.1.19 displays the frequency with which each theme appeared per demographic 
variable and the percentage it represents of that variable. 
 
Table 4.1.19: Demographic analysis of responses to question 10 by theme 
Themes Male Female 18 - 21 22 - 29 30 - 39 40 - 49 50 - 59 60+ 
Informed Choice 37% 32% 37% 34% 33% 33% 32% 15% 
Dangers 26% 26% 27% 31% 23% 10% 26% 25% 
Deterrent 4% 15% 13% 10% 7% 8% 11% 10% 
Help 8% 7% 3% 5% 12% 8% 11% 25% 
Prevalence 9% 6% 4% 7% 12% 10% 5% 10% 
n 163 277 177 128 57 39 19 20 
 
The data above shows that between the variables no theme is particularly dominant, with all 
groups proportionally being represented in each theme with a couple of exceptions.  The 40-
49 age group reported the least number of responses relating to the dangers of drug use. The 
60+ reported the least responses for informed choice, however were more altruistic with the 
highest proportion reporting offering help as the key aim.  
 
The response to question 10 were also analysed in correlation to whether the participant 
reported to have had education or not, the table is located in Appendix IVa Table 4.1.xvi. The 
results were tested using a two way chi squared and no significant difference was observed 
 138 
 
between how the participant who had received education and those had not responded to this 
question. However these responses were only from the participants who thought it was 
important to be aware of drugs, either to make an informed decision or to know what to avoid. 
The next question examines the responses of the participants who thought it was not 
important to be aware of drugs. 
  
Question 11: If you responded ‘No’ to question 9, what are you reasons? 
(Why do you think it is important to be aware of drugs?) 
 
Question 11 was an opportunity for the participants who chose the no option in question 9 to 
elaborate on the reason behind their choice. However some participants who chose the yes in 
the previous question also made use of this question to either expand or repeat their previous 
comments. There were a total of 19 responses to this question, only three of which were from 
the participants who chose the no option in question 9. The responses from these participants 
were as follows; 
 
 
‘They are no more dangerous than alcohol’ 
Participant 46 
 
‘Not ever going to take any, will avoid them the best I can, don't see a need to educate myself 
on something I'll never use.’ 
Participant 287 
 
‘If you aren't aware of drugs you probably aren't going to take them.’ 
Participant 313  
 
 
The last response is of particular interest as it contradicts the responses from the rest of the 
sample group, where being informed on the topic of drugs is seen as a positive, were 
forewarned is forearmed.   
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Comparison of results from Question 10 and 11 
 
As stated in the previous section some participants choose to respond in both the section for 
question 10 and 11. Of these responses some participants merely repeated their response. 
For the ones that provided a difference responses to each questions, their responses can be 
found in Table 4.1.20. The responses are of similar themes to the ones discussed earlier, with 
no participant changing the direction of their opinion between answers the two either 
questions 10 or 11, when providing a reason why they believed it was or was not important to 
be aware of drugs.  
 
 Table 4.1.20 Responses of participants who responded in both question 10 and 11 
Participant 
Number 
Response to Question 10  
Yes it is important to be aware of 
drugs 
Response to Question 11 
No it is not important to be aware of 
drugs 
4 
Because they are ever present in our 
city's...[sic] 
Because I have 2 small children who 
will eventually grow up and be placed 
in the same situation's that I was. 
123 informed choice for family and friends 
144 
You can prevent [sic] people around 
you by informing the consequences 
of using drugs. 
Protection of the family, friends and 
people around you. 
178 
one should know every possible 
outcome of drug use. ignorance 
leads to bad decisions. 
if someone wants to use drugs, they 
should know the ins and outs of it and 
then make an informed decision, 
therefore if something eventually goes 
wrong there is no one else to blame 
but yourself. 
228 
Awareness of the law 
Awareness of short term and long 
term use in order to take educated 
risks. 
Drug taking is a risk and it is important 
to understand the risks involved and 
why people choose to take these risks. 
246 
As a user it is important to be aware 
of the affects.[sic] 
In today’s society the majority of young 
adults use recreational drugs 
354 
I have worked as a Drug Education 
consultant in the past and know how 
much mis-information [sic] is out 
there. People need to be aware that 
we live in a drug taking 
culture/society: we go to the GP and 
expect to be prescribed something to 
enable us to feel better....So we 
need to build an awareness of the 
differences between medicines and 
drugs 
All medicines are drugs but not all 
driugs [sic] are medicines.  There are 
no medicines or drugs that are risk 
free. 
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Question 12: Do you think more should be done to educate people about 
drugs? 
 
As with question 9, Question 12 was looking for a direct yes or no response to whether the 
participants think more education is needed to support people. Again the response to this 
question was a categorical yes with 91% of participants stating that they think more is needed 
to educate people about drugs.  A one way chi squared was applied to test for significance, 
the test returned a chi square value of 301.13 and a P value of <0.001. This is significant at 
the critical significance level of 0.05.  
 
 
4.2 Results for Survey B: Popularity and Prevalence 
 
This section covers the results of the second social survey in this research. Unlike Survey A, 
the questions used in this survey asked the participants directly about past drug use, as well 
as their opinions and preferences of selected substances. There are four sections that cover 
questions on previous drug use, experience, choice and the participants’ honesty around 
discussing drug use. As Survey B asked more direct questions relating to drug use the 
number of participants was less than that of Survey A, with the total number of respondents 
for the second survey being 252, the margin of error was 7% at a confidence level of 95%. 
The number is suitable when compared to the size of sample from previous drug surveys that 
ranged from 100 to over 7000 participants (GDS, 2013; Gross et al., 2002; Hammersley et al., 
1999; Handy, Pates and Barrowcliff, 1998; McCambridge et al. 2005; Ogeil, Rajaratnam and 
Broadbear, 2013; Sherlock and Conner, 1999; Solowij et al., 1992).  Also, as the exact extent 
of the drug using community is unknown and unquantified, the results from this survey can 
provide a comparison to the larger cohorts collected by both the CSEW and the GDS.  The 
participants were also asked a number of qualitative questions on their drug use, which can 
provide insight into the individual user’s perspective. 
 
4.2.1 Demographic Variable Results for Survey B 
 
The second survey was run independently of Survey A and due to the anonymity of the survey 
method the responses from survey A cannot be directly correlated to those in survey B. 
However there is a similarity observed in the breakdown of the demographics collected.  
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 Gender 
 
The first variable that was collected was that of the participant’s gender. Similar to the 
findings from Survey A the division of the participant’s gender was weighted towards the 
female gender as shown in Figure 4.2.1. 
 
Figure 4.2.1: Proportion of male and female participants for Survey B: Popularity and 
Preference (n = 252) 
 
The gender ratio collected for this survey is comparable to that of Survey A, which achieved 
63% female participant population. The difference between the gender ratios of the two 
surveys was tested using a two-way chi squared that returned a χ2 value of 0.14 and a P value 
of 0.708, which is not significant at the critical significance level of 0.05. This means that even 
though the actual number of respondents for survey B was less than survey A, there was no 
significant difference in the gender ratio between the two surveys and so comparisons 
between the two may be drawn. Gender was not the only variable, as the age of the 
participants was also considered. 
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Age 
 
The second variable that was collected was that of the age of the participants, using the same 
groups that were used in Survey A.  The frequency (shown as a percentage) of each band is 
shown in Figure 4.2.2. 
 
Figure 4.2.2: Proportion of participants for each age band for Survey B:Populairty and 
Preference (n = 252) 
 
The results for this variable reflect a similar pattern to Survey A, suggesting that the 
distribution of the participants between the two surveys is again comparable. The difference 
between the proportion of age groups between Survey A and B was tested using a two-way 
chi squared that returned a χ2 value of 8.96 and a P value of 0.110, which is not significant at 
the critical significance level of 0.05. This means that there is no significance difference in the 
proportion of the age groups between the two surveys.  
 
The data was also tested to see whether the gender ratios within each age band were 
comparable to check that one age bad was not solely male or female, as was done with 
Survey A. Across all age ranges, except the 50 to 59 group the gender divide is weighted 
towards female participants but the proportion of males to females did not significantly vary 
band to band.  The significance was tested using a two way chi squared that returned a χ2 
value of 4.129with a P value of 0.552, which exceeds the critical significance value of 0.05 and 
is therefore not significant.   
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Comparison of demographics to CSEW 
The data collected in this research can be contrasted to the distribution reported on the 
participants groups collected for the CSEW. The proportion of participants that fell into the age 
bands specific to the CSEW as reported in 2013 are displayed Figure 4.2.3. 
 
 
Figure 4.2.3: Percentage ratios for the age groupings as designated by the CSEW (n = 21363) 
(Home Office, 2013) 
 
The above graph shows the weighting of participants for the CSEW is towards the upper age 
limit, with the majority of respondents being over the age of 35. Less than 20% of the 
participants fell into the age range indicative of Ecstasy use (20 to 29 years old), as indicated 
in section 2.7.2. This is a direct contrast to the findings from this survey in which 78% were 
under 30. The impact of this is examined in relation to the responses on drug use where the 
proportions from both surveys are compared. The specific demographic breakdown of the 
responses to the 2013 Global drug Survey have not been published, however for the 2012 
survey only 24.5% of participants were over the age of 34 (Winstock, 2012).   
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4.2.2 Previous Drug Use 
 
The first three questions in the survey asked the participants about their own drug use. These 
were based on the style of question that are found in both the CSEW (2013) and the GDS 
(2013). These questions were used to establish which participants had used which substance 
so they could be grouped together when analysing latter questions on specific substance use.   
 
Questions 1 to 3: From the following list please check any substances that 
you have; 1) Ever taken, 2) Taken in the Last Year, 3) Taken in the last 
Month 
 
For these questions the participants were asked to state which of the 19 chosen substances 
they had used within given time frames of stated in the questions. The significance of these 
results can be compared to the findings by both the CSEW (2013) and the GDS (2013), which 
use most, if not all of the substances selected in their own questions.  
 
Table 4.2.1 below, displays the total number of participants reporting to have taken each 
substance within each of the given time frames. These responses were taken as reported, 
though verified to ensure that no participants claimed to have taken a substance in the last 
year or month, which they had not reported in their response to the first question.  
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Table 4.2.1: Total results for Questions 1, 2 and 3 on select substance use 
  
Q1: Ever Q2: Last year Q3: Last Month 
Total Percent Total Percent Total Percent 
Alcohol 249 98.8% 239 94.8% 216 85.7% 
Tobacco 203 80.6% 153 60.7% 111 44.0% 
Cannabis 170 67.5% 98 38.9% 59 23.4% 
Ecstasy 84 33.3% 42 16.7% 12 4.8% 
Cocaine 76 30.2% 40 15.9% 23 9.1% 
MDMA 76 30.2% 48 19.0% 19 7.5% 
Mushrooms 59 23.4% 19 7.5% 2 0.8% 
Ketamine 52 20.6% 27 10.7% 8 3.2% 
Amphetamine 48 19.0% 18 7.1% 8 3.2% 
LSD 40 15.9% 14 5.6% 3 1.2% 
Mephedrone 37 14.7% 11 4.4% 1 0.4% 
2CB 19 7.5% 5 2.0% 1 0.4% 
Methamphetamine 14 5.6% 7 2.8% 5 2.0% 
Methylone 10 4.0% 2 0.8% 0 
Crack 9 3.6% 3 1.2% 0 
Heroin 9 3.6% 3 1.2% 1 0.4% 
BZP 6 2.4% 0 0 
Piperazines 6 2.4% 0 0 
Naphryone 0 0 0 
unweighted base (n) 252 
        
From the results it is evident that alcohol is the most prevalent drug with 98.4% of participants 
reporting to have ‘ever taken’ it, with tobacco coming in second with 80% of participants 
claiming to have ever used it. Unsurprisingly the most frequently reported illegal drug used by 
the participants was cannabis, with 67.2% claiming to have ever taken it.  This finding 
correlates with reports from the CSEW, which states that cannabis is the most used illicit drug 
in the UK (Home Office, 2013). A graphical representation of the difference between the 
percentages of all 19 substances is shown in Figure 4.2.4.  
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Figure 4.2.4: Reported use of select substances; ever, within the last year and within the last 
month (n = 252) 
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Comparative analysis of selected substances of interest from Questions 1 
to 3   
 
Further into the second survey the questions were limited to six select substances or group of 
substances; cocaine; Ecstasy; MDMA; ketamine; Mephedrone and the piperazines. Table 
4.2.2 shows the responses just for these compounds.  
 
Table 4.2.2: Comparison of six selected compounds assessed in Survey B (n = 252) 
Substance 
Used 
Cocaine Ecstasy MDMA Ketamine Mephedrone 
Piperazines 
(including 
BZP) 
Q1:Ever 30.2% 33.2% 30.2% 20.6% 14.6% 3.2% 
Q2:Last year 15.8% 16.6% 19% 10.7% 4.3% 0 
Q3:Last Month 9.1% 4.7% 7.5% 3.2% 0.4% 0 
 
There was an increase in the reported use of MDMA compared to Ecstasy in the last month 
and last year categories. Yet with the category of ‘ever taken’ Ecstasy had a greater 
percentage of reported use. These results are compared to the reports from both the CSEW 
(ONS, 2013) and GDS (Mixmag, 2013) in Table 4.2.3. The table also includes data for 
cannabis as a point of reference as it is reportedly the most used substance. In the data 
presented by the CSEW, two different sample sizes are recorded for the questions of ‘ever 
taken’ (21,501) and ‘taken in the last year’ (21,363), the data is reported as presented (Home 
Office, 2013). 
 
Table 4.2.3: Comparison of results between research survey, CSEW and the GDS for 2013  
Substance 
Survey B 2013 
(this research) 
CSEW 
2012/13 
Global Drug Survey 
2013 
Ever Last Year Ever Last Year Ever Last Year 
Cannabis 67.2% 38.7% 30% 6.4% 91.6% 78.8% 
Cocaine 30.2% 15.8% 8.8% 1.9% 59.9% 41.5% 
Ecstasy 33.2% 16.6% 8.3% 1.3% 64.3% 42.4% 
MDMA 30% 19% (not included as a separate 
option) 
71.8% 60.8% 
Ketamine 20.6% 10.7% 2.3% 0.4% 50.6% 31.5% 
Mephedrone 14.6% 4.3% 1.9% 0.5% 36.1% 13.8% 
n 252 Ever = 21501 
Last Year =21363 
7700 
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The results in the above table show a discrepancy in the reported levels of use for specific 
recreational substances. In the survey produced for this research, the proportion of 
participants reporting to have ever taken cocaine and Ecstasy is around a third, compared to 
just over 8% from the CSEW and 59.9% and 64% found in the GDS respectively. When 
focusing on the responses for Ecstasy and MDMA it is not possible to draw a comparison with 
the CSEW as only used the term Ecstasy is reported, with no distinction between the two. 
However this doctoral research and the GDS used both terms independently and both 
reported a greater level of use in the last year for MDMA over Ecstasy. The use of 
Mephedrone is reported to be the least ever taken and having the lowest reported usage for 
last year in both this research and the GDS and the second lowest usage in the CSEW, of the 
selected substances examined. 
 
The differences between the reported levels between these three surveys is evident when 
looking at the results for the drug cannabis. In the reports by the CSEW only 30% of the 
participants questioned in 2013 had ever taken cannabis (Home Office, 2013), compared to 
the 91.6% reported in the GDS (Mixmag, 2013) and the 67.2% in the survey conducted for this 
research.  The evidence presented here supports the earlier criticism made in section 3.3.3, 
that estimating drug-using populations is problematic and dependant on sampling 
methodology.  The range observed between the two surveys criticised here show the variation 
in data that can be collected. However the results from this survey, despite being a smaller 
sample set, had proportional responses closer to the GDS than that of the CSEW. This is 
most likely due to the demographic characteristics of the participants in this survey, with 78% 
of the participants from this survey in the age range highlighted in section 2.7 as when drug 
use is most likely to be reported.  
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Separating participants into ‘User’ and ‘Non-User’ group 
 
As no exclusionary questions were asked at the beginning of the research survey to exclude 
non-drug users the participants’ responses can be separated into two groups; the users and 
the non-users. The groups can be further subdivided by users of the selected substances of 
interest.  This survey sought to learn what the perceptions users had of taking Ecstasy, MDMA 
and Mephedrone. The non-users can provide a control group for comparisons as well as for 
providing further insight as to why these substances do not appeal to the non-users. The ‘total 
user’ group was defined as any participant who reported to have ever taken any substance 
other than alcohol or tobacco, this equates to 171 of the participants for this survey or 67.9% 
of the participant population. As this survey focused on six selected substances each 
substance had a user group of varying size, shown in Table 4.2.4. 
 
Table 4.2.4: Number of users reporting to have taken six selected substances 
Substance Cocaine Ecstasy MDMA Ketamine Mephedrone 
Piperazines 
(including 
BZP) 
Users 76 84 76 52 37 8 
 
Of the 252 participants registered, only four reported to have ever taken all six of the 
substances of interest. A further 21 reported to have taken cocaine, Ecstasy, MDMA, 
Mephedrone and ketamine. Two further participants reported to have taken all bar ketamine. 
Of the substances related to the rest of the thesis, an additional three participants reported to 
have taken Ecstasy, MDMA and Mephedrone and a further eight reported to have taken just 
Ecstasy and MDMA. As these numbers are quite small the ‘user’ group included users 
reporting to have taken at least one of the substances in question, as the questions later in the 
survey relate more to hypothetical scenarios and perceptions relating to the other substances.  
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Demographic analysis of Drug using groups  
 
The demographic variables were applied to the user groups determined whether a particular 
substance was preferred by one set over another. Firstly the questions were assessed by the 
gender of the participants, whether the user groups of the substances of interest were more 
male dominated as was suggested in previous studies. Figure 4.2.5 displays the percentage 
of male and female users who reported to have ever taken each of the five substances.  
 
 
Figure 4.2.5: Percentage of male and female participants reporting to have ‘Ever Taken’ each 
of the five substances (n: Cocaine = 76, Ecstasy = 84, Ketamine = 52, MDMA = 76 and Mephedrone = 37) 
 
The graph above shows that for cocaine, Ecstasy and MDMA the user group was more 
heavily female, whereas for ketamine and Mephedrone the user group was more male-
weighted. The piperazine user group was not included as it was 100% male. To test whether 
there was a significance difference between the number of males and females within each 
user group a one way chi squared test was applied, a table of the full test statistics is located 
in Appendix IVb Table 4.2.i. When tested using the one way chi squared, there was no 
significant difference observed between the genders for any of the five user groups. However, 
as the ratio between the genders was not evenly split, a two way chi squared was applied to 
test whether there was a difference between the genders who reported use of the substances 
and those who did not. The results for this are shown in Appendix IVb Table 4.2.ii.  
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The results showed that four out of the six substances did have a significant difference in the 
reported usage between the using and the non-using males and females. For the substances 
MDMA, ketamine, Mephedrone and the piperazines a significantly larger proportion of the 
male participants reported to have ever taken these substances.  So although there were 
more females reported in the using groups, there was a greater proportion of male users in 
relation to the male non-users. The tests were also applied to the questions of ‘Taken in last 
year’ and ‘Taken in the last month’,  with the results shown in Appendix IVb. The only 
responses that showed a significant difference were the responses to Ecstasy – last month, 
Ketamine – last year and Mephedrone – last year, all of which reported significantly more 
male participants. Although a greater proportion of the male participants reported to have 
taken these substances compared to the non-using population, the actual division of 
participants within the using groups was not significantly different between the two genders.  
 
The other variable that was assessed was the impact of age on the use of substances, which 
was assessed in two ways. Firstly by the number of participants from each age group that 
made up the user group, and secondly the percentage of each age group reported to have 
used the substances. Figure 4.2.6 displays the results for each user group responding to the 
question ‘Ever Taken’ separated into age group, shown as the actual number of participants.  
 
 
Figure 4.2.6: Reported use of substances ‘Ever Taken’ separated into age groups (by number) 
 
  
0
5
10
15
20
25
30
35
40
Cocaine Ecstasy Ketamine MDMA Mephedrone Piperazine
N
um
be
r 
of
 U
se
rs
18 to 21 22 to 29 30 to 39 40 to 49 50 to 59 60+
 152 
 
In all groups except piperazine the majority of the users responding to this survey fell into the 
first two age groups. However, as with the variable of gender, the participants were not equally 
distributed between the age groups, Figure 4.2.7 displays the results to question 1 as a 
proportion against the total for each age group. 
 
 
Figure 4.2.7: Reported use of substance separated into age group (by percentage calculated 
against size of age group)  
 
When the proportional size of users per age group is considered there is a difference in the 
most prevalent users. For both cocaine and Ecstasy the group with the highest proportion of 
users was the 30 to 39 age group. For ketamine, MDMA and the Mephedrone age group it is 
the 22 to 29 age group, piperazine was an anomaly with a high proportion for 40-49 and 50-59 
groups. This is due to the relatively low sample size for both these age groups and the low 
level of response to piperazine. The analysis of question 2 (taken in the last year) and 
question 3 (taken in the last month) with regards to the variable of age is located in Appendix 
IVb Figures 4.2.iii through to 4.2.vi. The implication of the difference in the gender and age 
group will be considered alongside the user and non-user group when analysing the rest of 
the survey.  
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4.2.3 Questions on the Participants Experience of the Substances  
 
The second section of this survey focused on the user experience of the six selected 
substances discussed previously. The questions sought to discover how the participants rated 
their physical and emotional experience of the substances. The differentiation in experiences 
was based on the fact that the chemical MDMA, the focus of this research, has well 
documented empathogenic as well as stimulant properties as discussed in section 2.3 (Curran 
and Travill, 1997; Downing, 1986; Freese, Miotto and Reback, 2002; Greer and Tolbert, 1986; 
Harris et al., 2002, Kirkpatrick et al., 2015; Peroutka et al., 1988; Sumnall, Cole and Jerome, 
2006; Vollenweider et al., 1998).  
 
Question 4: How would you rate your physical experience on the following 
substances? 
 
Question 4 sought to learn from the participant about their physical experience when taking 
the selected substances. The participants were presented with four options to answer this 
question: negative; indistinct; positive and ‘have not taken this substance’.  It was anticipated 
that the participants who indicated in the first three questions that they had not taken a 
substance would choose the ‘not taken’ option. The participants who did report to have taken 
the substance were asked to rate their subjective experience of the substance in question. 
The frequencies for each option, separated into the two sub-groups of users and non-users, 
shown in Table 4.2.5. 
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Table 4.2.5: Frequencies for each substance shown for user and non-user groups answering question 4 on Physical experience of selected drugs 
  
Substance 
Cocaine Ecstasy MDMA Ketamine Mephedrone Piperazines 
  User Non-User User User User Non-User User Non-User User Non-User User Non-User 
Effect 
Negative 9 0 5 0 5 0 13 2 11 0 3 2 
Indistinct 25 1 13 1 6 1 9 1 9 2 3 1 
Positive 42 5 64 1 65 2 29 1 15 1 1 0 
Have Not 
Taken 
0 169 2 166 0 173 1 196 2 212 1 241 
Total 76 175 84 168 76 176 52 200 37 215 8 244 
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The data in the previous table shows that despite claiming not to have taken a substance 
some of the non-users rated the physical experience and some of the user participants now 
state not to have taken the substances. As the survey has been taken at face value the 
change in the participants recording was noted but was not included in the further analysis of 
the question, and so the user group totals were adjusted to reflect only the participants 
responding consistently between question 1 and 4. 
 
Table 4.2.6 shows the results for question 4 as a percentage of each user group, with the 
percentage calculated by dividing each frequency by the total for the respective group. For 
example 76 participants reported to have taken Cocaine, 9 reported to have had a negative 
experience, the percentage represented is a proportion of the 76 participants as opposed to a 
percentage of the total participant population. In this analysis the responses of ‘Not Taken’ 
were not included. The difference between the responses for each substance was tested 
using a one way chi squared, the results displayed in the table below. 
 
Table 4.2.6: Percentage of user group responses and significance for question 4  
Substance Negative Indistinct Positive  χ2 Value P Value Significant 
Cocaine 
(n = 76) 
11.8% 32.9% 55.3% 21.62 <0.001 Yes 
Ecstasy 
(n = 82) 
6.1% 15.9% 78.0% 75.14 <0.001 Yes 
MDMA 
(n = 76) 
6.0% 7.9% 85.5% 93.40 <0.001 Yes 
Ketamine 
(n = 51) 
25.5% 17.6% 56.9% 13.18 0.0014 Yes 
Mephedrone 
(n = 35) 
31.4% 25.7% 42.9% 1.61 0.447 No 
Piperazine  
(n = 7) 
42.9% 42.9% 14.2% 1.15 0.563 No 
 
Across all of the selected drugs except the Piperazine group, the majority of the users 
reported that their physical experience of these drugs was positive. Though there is a range in 
the percentages for the positive ratings, from an 85.5% for MDMA to only 42.9% for 
Mephedrone. If the substances are ranked by the proportion of users who rated their 
experience as positive the order would be as follows; MDMA, Ecstasy, ketamine, cocaine, 
Mephedrone and lastly the piperazines.  
 
The indistinct category provides an interesting insight, as all of these drugs should provide 
some form of physiological response.  The proportional rank order according to those who 
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described their experience as indistinct (neither good nor bad) were; piperazines, cocaine, 
Mephedrone, ketamine, Ecstasy and lastly MDMA. Whether this suggests that the quality of 
these substances is more variably or that the expectations the participant had were not meet 
can only be speculated.  However it is clear that of these drugs, MDMA and Ecstasy have a 
comparably high positivity of physical experience attributed to their use.   
 
The results of the significance test show that four of the substances – cocaine, Ecstasy, 
MDMA and ketamine did display a significant difference between how the users rated their 
experience. However for Mephedrone and piperazine no significance was observed, this could 
reflect the relative effects of these substances or may be due to the small numbers of 
participants who reported taking them. This difference will be explored through the use of 
qualitative questions later in the chapter.  
 
The results for question 4 were also assessed based on the gender of the respondents, to see 
whether there was a difference in the experience between the male and female users. The 
results were tested using a two way chi squared, which returned no significant difference 
between how the genders responded to this question for any of the substance that were 
assessed. Piperazines were not included as the user group was completely male. The table of 
results for gender and the two way chi squared is located in Appendix IVb Table 4.2.iv. As the 
results for variable of age had many groups with no responses a reliable statistical comparison 
between the groups was not possible to determine whether there was a difference between 
how the age groups rated question 4.   
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Question 5: How would you rate your emotional experience on the 
following substances? 
 
Question 5 asked the participants to rank their ‘emotional’ experience of the selected 
substances. The choice of the word ‘emotional’ was perhaps not the most accurate description 
when it comes to describing the feelings experienced under the influence of these substances, 
however it was included because MDMA/Ecstasy belong to the empathogenic subclass 
(Curran and Travill, 1997; Downing, 1986; Freese, Miotto and Reback, 2002; Greer and 
Tolbert, 1986; Harris et al., 2002, Kirkpatrick et al., 2015; Peroutka et al., 1988; Sumnall, Cole 
and Jerome, 2006; Vollenweider et al., 1998) and Piperazines and Mephedrone are reportedly 
mimics or replacements for MDMA (Measham et al., 2010; Wood and Dargan, 2012). It also 
provides a contrast between what is felt physically under the influence of these substances 
and what is felt psychologically. The participant was presented with the same four options as 
the previous question to answer this question – negative; indistinct; positive and ‘have not 
taken this substance’. As with Question 4 the responses were divided into the two groups, 
which were indicated by the responses to Question 1. The frequencies for each option were 
separated into the two sub-groups and shown in Table 4.2.7.  
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Table 4.2.7: Frequencies for each substance shown as user and non-user groups for Question 5 on emotional experience  
  
Substanc
e 
Cocaine Ecstasy MDMA Ketamine Mephedrone Piperazines 
  User 
Non-
User 
User Non-User  User Non-User User 
Non-
User 
User Non-User User Non-User 
Effect 
Negative 8 0 4 0 3 0 14 3 9 0 2 0 
Indistinct 27 1 3 1 1 1 13 1 7 1 3 3 
Positive 41 5 75 1 72 2 24 0 19 1 2 0 
Have Not 
Taken 
0 169 2 166 0 173 1 196 2 213 1 241 
Total 76 175 84 168 76 176 52 200 37 215 8 244 
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The data in the table on the pervious page shows similar results to those for Question 4, with 
some participants who claimed not to have taken a substance rated the emotional experience 
and some of the user participants now state not to have taken the substances, with the same 
participants as Question 4. As the survey has been taken at face value any changes in the 
participants recording were again noted and the user group totals reflect this change. Table 
4.2.8 shows the frequencies from Table 4.2.7 as percentages of each substances user group. 
This analysis also did not include the responses of ‘Not Taken’. The difference between the 
responses for each substance was tested using a one way chi squared, the results displayed 
in the table below. 
 
Table 4.2.8: Percentages of users who rated each substance and the significance for question 
5 
Substance Negative Indistinct Positive 
Chi Square 
Value 
P Value Significant 
Cocaine 
(n = 76) 
10.5% 35.5% 54.0% 21.78 <0.001 Yes 
Ecstasy 
(n = 82) 
4.9% 3.6% 91.5% 124.21 <0.001 Yes 
MDMA 
(n = 76) 
4.0% 1.3% 94.7% 128.49 <0.001 Yes 
Ketamine 
(n = 51) 
27.4% 25.5% 47.1% 4.35 0.114 No 
Mephedrone 
(n = 35) 
25.7% 20.0% 54.3% 7.10 0.029 Yes 
Piperazine  
(n = 7) 
28.6% 42.8% 28.6% 0.29 0.869 No 
 
The results show that across all substances the majority of each user group rated the 
‘emotional experience’ of each substance as a positive one, again with the exception of the 
piperazine group. The size of the percentage differed between substances and so a rank 
order can be established. The order being: MDMA; Ecstasy; Mephedrone; cocaine; ketamine 
and lastly piperazines. 
 
The rank orders between the responses to questions 4 and 5 are almost identical across all 
three options with the exceptions of the results for ketamine and Mephedrone, which swap 
position in each option. Mephedrone is consistently ranked lower in the physical response, 
whereas ketamine ranked lower in the emotional. This will be due to the reported negative 
effects of these substance, which the participants discuss in their responses to the qualitative 
questions later in the section.   
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The results of the significance test shows that there is a difference in how the participants 
rated their emotional experience for cocaine, Ecstasy, MDMA and Mephedrone. Neither the 
piperazines nor ketamine displayed a significant difference in how the participants rated their 
emotional experience. This may be anticipated in the case of ketamine, which does not have 
the same effects as the other substances, as it is not a stimulant but a dissociative anaesthetic 
(Curran and Morgan, 2002). Again the reason for the non-significant result for piperazine may 
be due to the small sample size.  
 
The response to question 5 were also assessed by the variable of gender, to see whether 
there was a difference between the emotional experiences of the two genders. This was 
tested using a two way chi squared, which again returned no significant difference across any 
of the substances. The table of these results are located in Appendix IVb Table 4.2.v. As the 
results for variable of age had many groups with no responses a reliable statistical comparison 
between the groups was not possible to determine whether there was a difference between 
how the age groups rated this question. 
  
A cross tabulation of Question 4 against Question 5 for each of the substances was compiled 
to see if there were any major differences in the participants’ responses for physical and 
emotional experiences. The variability observed between responses was low across all 
substances.  These tables are located in Appendix IVb (Tables 4.2.vi to xi).  
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Question 6: Have you or do you know someone who has ever had a bad 
experience on any of the following substances? 
 
Carrying on the theme of the previous questions, this question asked about the participants 
bad experiences with the substances. Unlike the previous questions that were dependant on 
the participant having first-hand knowledge of the selected substances, this question allowed 
for the non-user group to answer based on their knowledge of someone else reporting to have 
had a bad experience with the substances. This question examines the user based 
experiences but also the reputations of the substances in question. Table 4.2.9 displays the 
frequency for each response and its percentage of the total participant group. 
 
Table 4.2.9: Frequency and percentage of responses to Question 6 (n =252) 
 
Cocaine Ecstasy MDMA Ketamine Mephedrone Piperazines 
Yes   
Myself 
11 15 9 23 15 2 
4.4% 6.0% 3.6% 9.1% 6.0% 0.8% 
Yes  
Someone else 
89 84 62 88 39 14 
35.3% 33.3% 24.6% 34.9% 15.5% 5.6% 
No 
152 153 181 141 198 236 
60.3% 60.7% 71.8% 56.0% 78.6% 93.7% 
 
 
The above table shows that the responses for ‘yes-myself’ are relatively low; with all 
substance reporting less than 10% of the participants, the highest being ketamine at 9.1%.  Of 
the responses to ‘Yes – Someone else’ cocaine, Ecstasy and ketamine reported similar levels 
at over a third of participants having heard of someone else having a bad experience. The 
findings for Mephedrone and piperazines correlate to the findings from Survey A as both these 
substances appear to be relatively unknown to the public. To further explore this question the 
results were separated into user and non-user groups to establish whether the users were 
more likely to have responded to the ‘Yes-someone else’ option. The first option of ‘Yes-
Myself’ should be exclusive to the user group. The results are shown in Table 4.2.10.
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Table 4.2.10: Question 6 User responses vs non-user responses to having or hearing of bad experiences with the substances 
 
Cocaine Ecstasy MDMA Ketamine Mephedrone Piperazines 
Users Non Users Non Users Non Users Non Users Non Users Non 
Yes - Myself 
11 0 15 0 9 0 20 3 14 1 1 1 
14.4% 0.0% 17.9% 0.0% 11.8% 0.0% 38.5% 1.5% 37.8% 0.5% 16.7% 0.4% 
Yes -  Someone else 
28 61 36 48 25 37 23 65 13 26 4 10 
36.8% 34.9% 42.9% 28.6% 32.9% 21.0% 44.2% 32.5% 35.1% 12.1% 66.7% 4.1% 
No 
38 115 33 120 42 139 9 132 10 188 1 235 
50% 65.1% 39.3% 71.4% 55.3% 79.0% 17.3% 66.0% 27.0% 87.4% 16.7% 95.5% 
Total 76 176 84 168 76 176 52 200 37 215 6 246 
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As mentioned previously the responses to this question can provide insight into the 
reputations of the substances in question. The reputations can be assessed by analysing the 
responses to the ‘Yes-Someone else’ option, as this option suggests a second-hand 
knowledge or association of this substance with negative reactions, which can be further 
assessed by identifying whether there is a difference between the user and non-user groups. 
Using the figures generated from Table 4.2.10 a bar graph of the proportional responses to 
Question 6 – Yes - Someone Else was generated and is shown as Figure 4.2.8. 
 
 
Figure 4.2.8: Proportional percentages for the response to Question 6 – ‘Yes-Someone else’ 
 
The data displayed in the chart above shows that across all substances the user group are 
proportionally larger.  The significance between the user and non-user group was tested using 
a two way chi squared, the results are shown in Table 4.2.11. 
 
Table 4.2.11: Significance test between users and non-user group when responding ‘Yes – 
someone else 
Substance χ2 Value P Value Significant 
Cocaine 0.11 0.740 No 
Ecstasy 5.14 0.023 Yes 
MDMA 4.03 0.045 Yes 
Ketamine 2.50 0.114 No 
Mephedrone 12.81 <0.001 Yes 
Piperazine  43.75 <0.001 Yes 
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The piperazines group of substances had the highest proportion of its user group reporting to 
know someone who had a bad experience; it also had the biggest difference in proportion 
between the user and non-user groups. This lends support to the theory of the relative 
anonymity of this substance outside drug using groups. 
 
The responses relating to Mephedrone were similar to those for piperazine showed a far 
greater proportion of users who knew of someone else having a bad experience compared to 
the non-user group. This was a significant difference when tested using the chi squared at the 
critical significance level of 0.05. This could again be due to the relative anonymity of this 
substance, as suggested in the results from Survey A.Ecstasy had the third highest response 
rate, for the user group having heard of someone else having a bad experience. MDMA on the 
other hand had the smallest proportion of users reporting knowing someone who had had bad 
experience.  The responses from non-users were closer with Ecstasy obtaining 29% and 
MDMA 21%.   
 
The responses to question 6 were also assessed using the variable of gender. The responses 
to ‘Yes-myself’ were compared using a two way chi square to see whether there was a 
difference between the genders in who reported having had a bad experience. Across all 
substances no significance was reported between the genders and bad experiences, the 
results are shown in Appendix IVb Table 4.2.xii.  The responses for ‘Yes – someone else’ 
were also compared to test whether there was a difference between how the genders in the 
users and non-users responded to this question, again tested using a two way chi squared. 
The results are shown in Table 4.2.12.  
 
Table 4.2.12: Gender responses to Question 6 ‘Yes-someone else’ and statistical significance 
using two way chi squared (critical significance level 0.05) 
Drug Gender User Non-user χ2 Value P Value Significant 
Cocaine 
Male 16 18 
6.21 0.013 Yes 
Female 12 43 
Ecstasy 
Male 18 13 
4.64 0.031 Yes 
Female 18 35 
MDMA 
Male 16 9 
3.63 0.057 No 
Female 9 28 
Ketamine 
Male 15 19 
9.28 0.002 Yes 
Female 8 46 
Mephedrone 
Male 8 8 
3.39 0.065 No 
Female 5 18 
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More male users reported to know someone who had had a bad experience using cocaine, 
compared to more females for the non-user group.  Ecstasy had the same number of each 
gender from the user group reporting to know someone who had had a bad experience, but 
significantly more females from the non-user group. Ketamine followed the same pattern as 
cocaine, with more male users reporting to know someone who had had a bad experience, 
compared to more female from the non-users.   
 
The results from question 6 support the hypothesis that there is a definite disparity in how the 
two terms, Ecstasy and MDMA are being perceived. MDMA reported less negative 
experiences in question 4 and 5 and less bad experiences in question 6 for the responses 
‘Yes – myself’ and ‘Yes – someone else’ compared to Ecstasy, despite both supposedly 
containing the same chemical. These findings further support the results from ‘Survey A: 
Knowledge and Awareness’, that these two terms represent two completely separate 
entities/products.   
 
Question 7:  Has your personal experience changed your drug use of the 
following? 
 
This question examined whether the participants experience of the selected substances had 
had an effect on changing the participant’s behaviour towards the selected substances as self-
reported. The participants were given the choices of Yes, No and Not Taken. The reasons 
behind the participant’s choice for both question 7 and question 8 were further explored with 
the qualitative open responses analysed in questions 9 and 10. The results for this question 
are shown in Table 4.2.13, which shows the overall percentages for each of the options per 
substance.  
 
Table 4.2.13: Responses for question 7 on changing behaviour on use of the substances 
shown as percentage of total population (n = 252) 
  Cocaine Ecstasy MDMA Ketamine Mephedrone Piperazines  
Yes 12.3% 11.9% 11.9% 11.9% 8.3% 2.4% 
No 20.2% 21.0% 19.4% 10.3% 7.1% 3.2% 
Not Taken  67.5% 67.1% 68.7% 77.8% 84.5% 94.4% 
 
The same number of participants reported changing their drug use based on personal 
experience for cocaine, Ecstasy, MDMA and ketamine, with around 12% of the total 
participant population reporting a change in their use of these substances. A one way chi 
squared was applied to test whether there was a significant difference between the responses 
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to Yes and No for each of the six substances. The responses to ‘Not Taken’ were not included 
as this indicated that this question was not applicable. The results of the chi square returned a 
significant difference for; Cocaine (χ2 = 4.88; P = 0.036), Ecstasy (χ2 = 6.37; P = 0.016) and 
MDMA (χ2 = 4.57; P = 0.043) all of which are significant at the critical significance level of 
0.05, with more participants stating their use had not changed.  The other three substances 
(ketamine, Mephedrone and piperazines) did not report a significant difference between the 
responses of Yes and No.  
 
However as this question was based on personal experience the responses should be 
considered in the context of the user groups. As the number of participants who reported to 
have used each substance varied between the selected substances, the proportion of users 
reporting to have changed their use will vary between substances.  
 
As was seen with previous questions some participants in the non-user group responded to 
this question, reporting to have changed their behaviour, shown in Table 4.2.13. As this was 
inconsistent with their responses to question 1 ‘ever taken’, these responses were not 
included in the user group analysis. There was also inconsistency within the using group, with 
some participants reporting to have not taken the substance. The user groups were adjusted 
to the same values as seen in questions 4 and 5. Table 4.2.14 displays the responses from 
the user group as a frequency and a percentage of each respective drug-using group. The 
significance was also tested using a one way chi square, with the results shown in the table.  
 
Table 4.2.14: User responses to Question 7: Has your experience changed your usage 
(percentage shown against total for user group) 
Substance Yes No χ2 value  P Value Significant 
Cocaine 
(n = 76) 
40.8% 59.2% 2.58 0.136 No 
Ecstasy 
(n = 82) 
36.6% 63.4% 5.90 0.020 Yes 
MDMA 
(n = 76) 
39.5% 60.5% 3.37 0.085 No 
Ketamine 
(n = 51) 
54.9% 45.1% 0.49 0.572 No 
Mephedrone 
(n = 35) 
60.0% 40.0% 1.40 0.312 No 
Piperazine  
(n = 7) 
71.4% 28.6% 1.29 0.446 No 
 
The responses of the user groups for cocaine, Ecstasy and MDMA indicate that the majority of 
participants had not changed their behaviour based on previous experience. When examining 
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the results from the chi squared the only substance that showed a significant difference 
between the numbers of responses for Yes and No was Ecstasy, with significantly more 
participants claiming not to have changed their behaviour. This is the first question where 
these two terms are showing similar levels of responses. The majority of responses from the 
user groups of ketamine, Mephedrone and piperazine all indicated that experience had 
changed their usage. Yet none of the chi square tests returned a significant difference. This 
might in part be due to the relatively small sample sizes for these substances. What this 
question failed to identify is how the usage changed, whether it had increased or decreased, 
which is something that will be addressed in the qualitative questions at the end of this 
section. The results were also tested using the variable of gender using a two way chi squared 
test, all of which returned no significant difference, are shown in Appendix IVb Table 4.2.xiii.  
 
Question 8: Has your knowledge of another person's bad experience 
changed your drug use of the following? 
 
Instead of asking whether the participants own experience had changed their usage, this 
question asked about the impact of the knowledge of another person’s bad experience with a 
substance affecting the participant’s usage.  Using the same options that were provided in 
question 7. However, whereas question 7 was dependent on previous use to establish a 
change, this question is interpreted based on knowledge of someone else’s experience. This 
could therefore affect both the user and non-user groups. Table 4.2.15 shows the results as a 
percentage of the total participant population. 
 
Table 4.2.15: Percentage of responses to Question 8 changing behaviour on use of the 
substances shown as percentage of total population (n = 252) 
  Cocaine Ecstasy MDMA Ketamine Mephedrone Piperazines  
Yes 7.5% 8.3% 5.6% 7.5% 8.7% 1.6% 
No 28.2% 29.0% 27.8% 12.7% 17.5% 6.3% 
Not Taken 64.3% 62.7% 66.7% 79.8% 73.8% 92.1% 
 
The results indicate that the knowledge of someone else’s bad experience is less likely to 
change a person’s usage of these substances, as all received less than 10% of the 
participants stating it would affect their usage. A one way chi squared was applied to test 
whether there was a significant difference between the responses to yes and no for each of 
the six substances. The responses to ‘Not Taken’ were not included as again this indicated 
that this question was not applicable. The results of the chi square are shown in Appendix IVb 
Table 4.2.xvi. 
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The results show that for cocaine; Ecstasy, MDMA, ketamine and piperazine there was a 
significant difference at the critical significance level of 0.05, with more participants stating that 
someone else’s bad experience had not changed their own usage.  For Mephedrone there 
was no significant difference. However as this question sought to discover whether the 
participants’ usage had changed based on knowledge rather than experience, the difference 
between the response from the user and non-user group is important, which is shown in Table 
4.2.16. There were more of the non-user group participants who choose options other than 
‘Not Taken’ in response to this question than in previous questions, there were also more  
participants from the user groups who chose the ‘Not Taken’ option in this question, for 
consistency these results were not considered in further analysis. 
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Table 4.2.16: Comparison of the results for Question 8 - Knowledge of a bad experience affecting participant usage separated by user and non-user 
status 
  
Cocaine Ecstasy MDMA Ketamine Mephedrone Piperazines 
Users Non Users Non Users Non Users Non Users Non Users Non 
Yes 
12 7 12 9 10 4 10 12 12 7 3 1 
15.8% 4.0% 14.3% 5.4% 13.2% 2.3% 19.2% 6.0% 32.4% 3.3% 42.9% 0.4% 
No 
62 9 69 4 63 7 37 7 22 10 4 12 
81.6% 5.1% 82.1% 2.4% 82.9% 4.0% 71.2% 3.5% 59.5% 4.7% 57.1% 4.9% 
Not Taken 
2 160 3 155 3 165 5 181 3 198 1 231 
2.6% 90.9% 3.6% 92.3% 3.9% 93.8% 9.6% 90.5% 8.1% 92.1% 14.3% 94.3% 
Total 76 176 84 168 76 176 52 200 37 215 7 245 
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The responses to this question is the first to provide an insight into which substances are 
affected by second hand knowledge of experience, as both user and non-user group 
participants indicated that this knowledge had changed their behaviour.  Ketamine had the 
most non-users reporting that knowledge of someone else’s experience had changed their 
behaviour, with the second highest being Ecstasy. Interestingly less than half the number of 
respondents from the non-MDMA using group reported a change in behaviour compared to 
the non-Ecstasy group.  Cocaine and Mephedrone received the same number of non-user 
responses and piperazine had the least, with only one non-user reporting a change.  The first 
analysis tested whether there was a significant difference in how the user groups responded 
to this question using a one way chi squared test, displayed in Appendix IVb Table 4.2.xvii.  
 
The results of the one way chi square test showed that for cocaine, Ecstasy, MDMA and 
ketamine significantly more  user group participants reported that their behaviour had not 
changed due to the knowledge of someone else’s bad experience.  For both Mephedrone and 
piperazines there was no significance observed between the responses of yes and no, in the 
case of piperazine it was an almost equal split between the two responses, due to the small 
sample size limited conclusions can be drawn from this finding.  The non-user group 
responses to this question were also assessed using a one way chi squared, the only group 
that returned a significant difference were the response for piperazine non-using group, with 
the full results located in Appendix IVb Table 4.2.xviii. The variable of gender was also 
assessed to see if there was a difference between how the male and females within both the 
user and the non-user groups responded to this question. The results of the two way chi 
squared for both groups are located in Appendix IVb Table 4.2.xix. No significant difference 
was observed between the response of the genders for either group or substances at a 95% 
confidence level. 
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Question 9: If you answered ‘Yes’ to either question 7 or 8, how has your 
usage changed? 
 
This question was the first of the open answer qualitative questions, which allowed the 
respondents the opportunity of expanding on their reasons for changing their drug taking 
behaviour. This was an optional question whereby participants could choose not to respond. 
Out of a possible 252 responses only 28.6% participants shared their experiences and 
opinions on this question. There was no significant difference in levels of responses between 
the two genders (χ2 =0.01; P =0.920) or the age groups (χ2 = 3.579; P = 0.611) to this 
question. This means that of the qualitative responses received are spread between these 
variables. 
 
The first stage of the analysis of these responses examined the direct reference to the 
substances discussed in the previous questions namely; cocaine, Ecstasy, MDMA, 
Mephedrone, ketamine and piperazines. The number of direct references to the substances 
varied, with the most mentioned substance being cocaine with 13. Ketamine and Mephedrone 
were each mentioned 10 times, these two substances also had the most negative comments 
in the discussion. Ecstasy and MDMA were mentioned only 5 and 7 times respectively.  
 
The second stage of analysis examined the themes that emerged from the respondent’s 
answers, not all the responses were negative, with 12.5% who choose to respond stating that 
their use of these substances was either positive or had increased. Three participants 
specifically stating that they enjoyed using MDMA.  There were also responses from 
participants that were in the non-drug using group who discuss the change in their behaviour 
in terms of avoiding the substances discussed, using examples of other people’s bad 
experiences with the substances as the reason for their own non using status. The most 
frequently referenced substances in these responses were ketamine and cocaine. Of the 
remaining responses 22% of participants responded merely stating that they had stopped 
taking drugs with no further elaboration. The rest revolved around three main themes; 
personal experiences, the negative effects and the fear or results of dependency and 
addiction. 
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The responses that dealt with experience either discussed the change in the context of a bad 
experience that had ‘put them off’ the experience or as a result of personal growth. The 
following statements are examples of how the users expressed their own interpretation of their 
change in usage. The gender and age group of each participant is also included. 
 
Example of personal experience impacting use: 
 
I stopped taking drugs 5 years ago. This decision was based on personal experience, 
a desire to pursue my career and becoming better educated about the impact they may have 
on my body. I guess generally 'growing up' also played a huge part on my decision to stop.’ 
Participant 180 [Female, 22 to 29]  
 
I know how much I need to have a good time without taking too much. Knowledge of a 
friend's health problems, particular with ketamine and Mephedrone, has stopped me taking 
these things, though I occasionally have a little ketamine. It has certainly made me more 
aware of the problems of over-use. Moderation is key. With the rest, the more experience you 
have with a drug the more will learn to know what to expect and to do to have a good night 
(and what not to do). Experience is the same as learning, and learning = change, hence 
experience will always change what you do (in an exponential manner, i.e. after a great deal 
of experience less change is seen, but I believe there is still change).’ 
Participant 213 [Male, 22 to 29] 
 
The first example provides an interesting insight into the transient nature of recreational drug 
use, that it is something that is a ‘stage’ that can be ‘grown out’ of. With regards to Ecstasy 
and MDMA this had been supported by work on the trajectories of young adults ecstasy use 
(Smirnov et al., 2013; von Sydow et al., 2002).  These studies support the statement made by 
participant 180, finding that ‘young people's Ecstasy use is relatively transient’ (Smirnov et al. 
2013, p.2670), often stopping without the need of intervention.  
 
The second example highlights the importance of education and self-awareness when it 
comes to recreational drug taking, themes that were touched upon in Survey A. The 
participant suggests experience is the best way to have a positive use of these substances, 
however this maybe dangerous given the uncontrolled nature of the illicit drug market where 
products do not necessarily contain what is believed to be in them.  
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The second theme that was mentioned by the participants was addiction, either the fear of 
becoming addicted or overcoming their addictions to change their behaviour. The following 
examples provide two statements by the participants on this theme. 
 
Example of participant’s responses to addiction 
 
‘I now have no desire to take these kinds of drugs. Whilst some give you temporary 
'ups' the coming down got worse as time went on. Which meant I wanted to take more. I never 
wanted to have an addiction.’ 
Participant 185 [Female, 22 to 29] 
 
Only tried e twice and bad experience both times- never tried since even though it 
was popular with friends. Took cocaine for about two years. To start recreationally, but after 
few months was taking it during day on occasions. Usage ended being continuously. Only 
stopped after scaring myself when I didn't think I would make it to the morning but this 
happened more than once before I seriously acted on it. Now been clean for 10 years.’ 
Participant 134 [Female, 30 to 39] 
 
Both examples touch on the two themes of addiction and negative experiences. The first 
demonstrates that there was the possibility for this participant to become addicted, and so 
they changed their behaviour to avoid it. The second participant was candid in her discussion 
not only of her own use but also how she overcame an addiction to cocaine. Though the 
participant reports addictive behaviour towards cocaine, they did not report the same 
experience for ‘e’, this may be due to the difference between cocaine and Ecstasy (MDMA), 
whereby the latter is generally described as non-addictive (Jansen, 1999; Peroutka, 1990). 
The final theme centred on the various negative effects that are attributed to the substances in 
question. These effects could further be separated into physically, psychologically and 
social/economically negative effects. More than one participant negatively referenced the 
relative expense of cocaine in relation to what is experienced. The following are a selection of 
participants’ comments on the variety of negative experiences of the substances in question.   
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Example of negative effects (both physiological, psychological and social) impact use 
 
 ‘Realising that emptying one's wallet at the end of a hard day merely to stuff all the 
notes back into the black hole of one's nostrils is utterly futile, for the meagre buzz it 
momentarily provides barely reconciles the daft mistakes one makes in being so confidently 
obnoxious the whole night. In that way, after experiencing cocaine a plethora of times, I 
handed myself no blame, for I am young, and that is what we do, and came to the conclusion 
that to spend a fortune on petty highs worth nothing more than a tuppence should not be 
indulged in until I become a millionaire, which, of course, if fate has ever taught me anything, 
will be never.’ 
Participant 22 [Male, 18 to 21] 
 
‘Drone - Found it to be very addictive with horrendous comedowns. Eventually there 
was no nice feeling coming from taking it so the thought of it now makes me sick.’  
 
MDMA: was fun for a while, but after regular use (once a week / 2 weeks for a year) the 
effects often led to anxiety. It's very rare for me to touch it now.  
 
Ketamine: was fun at first as there were no effects on the mind or body the following day. 
However after doing it for a while, began feeling like a space cadet for the next (if not several) 
days.’ 
Participant 63 [Male, 18 to 21] 
 
‘Basically I tried them, enjoyed them and then felt absolutely cripplingly awful for 
about a week afterwards. I do not feel the benefits outweigh the costs and I do not socialise 
with people who do that sort of thing anymore. With MDMA my mouth was so ulcerated all 
over I could not eat for days. I also know people who have spent a lot of money on cocaine 
and I feel it makes their personality change for the worse. I also felt quite indifferent when I 
tried it. I had a boyfriend who took Mephedrone behind my back and felt it was a childish thing 
to do. Also people who take hallucinogens disturb me as I believe they can cause long term 
damage.’ 
Participant 95 [Female, 22 to 29] 
 
 ‘I think Mephedrone is a very unpredictable substance. I would never take it again. 
My experience wasn't terrible - just lots of memory loss which made me realize how 
dangerous the drug could be, I felt very out of control.’ 
Participant 192 [Female, 22 to 29] 
The first example eloquently describes that participants experience with cocaine, commenting 
on the negative social and monetary effects he had experienced in a rather polemic fashion. 
Though the choice of language used is emotive two key points are highlighted; the social 
stigma from being ‘confidently obnoxious’, a psychological effect of the drug in question and 
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the cost benefit analysis and economic viability of supporting those choices. From the parting 
statement from this response it appears that for this participant at least it is the monetary 
effect that was the driving force behind his change. This is in contrast to the other three 
examples that all state that their change was driven by either the physical or the psychological 
impact of the negative effects. In the examples chosen all three mention either Mephedrone or 
MDMA, with each of them giving a specific effect that changed their usage.  The difference in 
perception between these drugs is further explored in questions 11 through to 14.   
 
Question 10: If you answered No to either question 7 or 8, why didn't your 
usage change? 
 
In converse to question 9 this question looked at why people reported to have not changed 
their usage. The responses to this question were divided between the participants who were 
reported users who continued to use the substances and the respondents whose usage had 
not changed as they had never used the substances in the first place. Again the format of the 
question was an optional open ended question allowing participants to respond however they 
liked. This question gained more responses than the previous with 93 of the participants 
responding. 
 
Of the participants responding to this question 29 reported that the reason they had chosen 
‘no’ was that they would not take nor had taken any of the substances mentioned in questions 
7 and 8. Two participants made direct references to the bad experiences of others that had 
impacted their own attitude, with one relaying a personal story observed of a friends actions 
under the influence of cocaine. 
 
One of the reasons given by the user group for choosing the ‘No’ option for either question 7 
or 8 was that the participants either had had no bad experiences or that they did not know 
anyone who had.  Other users further expanded and explored the impact of other people’s 
experiences on their own usage, below are examples of their responses. A key theme is a 
lack of validity given to others experiences compared to self-experience. 
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Examples of participants’ responses on the subjective nature of experience  
 
‘My usage had to be based upon my own opinion and amalgamation of information 
from my personal experiences. Someone else's opinion would not be valid as interpretations 
are different between various individuals. Also, the press, most doctors and politicians are 
judgemental and shake their finger disapprovingly at drug use when they have no experience 
apart from what has been communicated by moral panic media and other middle/upper class 
batty men who don't have a clue about working class leisure activities but feel that they should 
voice their opinions on them anyway because of the misinformed and biased perceptions.’ 
Participant 21 [Male, 22 to 29] 
 
This first example holds much politicised opinion on the discussion of drugs, though touching 
on the subjective nature of experience at the start it develops into a diatribe against the 
‘establishment’. The mention that doctors are ‘judgemental’ and ‘have no experience’ is 
important in that it conflicts with the findings from the first social survey that found that doctors 
were the most trusted to give accurate information.  Other responses focused more on the 
difference between self-experience and the reporting from other sources: 
 
‘The experiences of others are always laced in hyperbole to make the storyteller in 
question sound preposterously cool and unbeatable. I never trust humanity, not even myself; 
which can often be a problem.’ 
 
Participant 23 [Male, 18 to 21] 
 
‘Because the effect of drugs affects people very much on an individual basis [sic]. If I 
was inclined to use a drug that I had heard other people had not always had a possible 
experience with, I would just make sure I tried it in a small amount and also in a safe 
environment.’ 
Participant 56 [Female, 18 to 21] 
 
 
‘Some people are stupid. They don't examine the information behind what they're 
taking. They allow themselves to be put into situations where they blindly take whatever 
happens to drift along. I am an informed drug user. And whilst I do my best to inform others, 
it's not my responsibility to save everyone.’ 
Participant 62 [Male, 22 to 29] 
 
 ‘Other people's physical and emotional experiences cannot be described more 
accurately to me than I know my own; therefore using the experience I have with certain drugs 
would form my decisions about usage’ 
Participant 67 [Male 22 to 29]   
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Participant 62 is particularly dismissive of other drug users calling them stupid, while the other 
participants examine the experience of drug use as an individual experience, one that cannot 
easily be explained to someone outside that experience.  Another participant was quite frank 
about the fact that a bad experience is likely when experimenting with illicit substances:  
 
 ‘You will usually have at least one bad experience on most drugs if you push them 
hard, that doesn't sway me, it's all experience and there's too much to benefit from to hold one 
bad avoidable and totally my fault experience against’ 
Participant 215 [Male, 22 to 29] 
 
 
One participants comment was of specific interest as it touched upon the perceptions of 
quality around what is known as ‘Ecstasy’: 
 
‘I prefer to base my usage on what I know to be true. The notoriously impure 'Ecstasy' 
market often results in user's obtain cut MDMA and/or a drug that is not actually MDMA, but is 
labelled as so. As a result, they have a bad experience and attribute that to MDMA. When in 
fact it was a result of a combination or different drug entirely. Thus, when I take MDMA I 
ensure my product and base my usage on my own experiences.’ 
Participant 238 [Male, 18 to 21] 
 
The difference in perception between the qualities of the substances is further explored in the 
responses to question 11 to 14. Another key theme that emerged from the responses to this 
question was the importance of the environment in which people took these substances, the 
response below highlight the participants’ need to be in a ‘safe’ environment.    
 
 ‘I believe people's emotional or psychological state before they take the drug will 
influence their drug experience, and that is often why people have a bad time. I wouldn't have 
taken drugs if I was not feeling mentally sound beforehand.’  
Participant 187 [Female, 40 to 49] 
 
 ‘I have taken ecstasy sensibly - tested the pills before I took them and had a great 
experience using it. I will only ever take drugs from people I know and trust - not strangers - 
and I rarely do drugs. I do them at festivals or with a group of close friends, not on a night out. 
Due to this I have never had any bad experiences and so would not change my usage apart 
from with Mephedrone which I felt unsafe using. I wasn't afraid of overdosing, just of being 
vulnerable even though I was with friends.’  
Participant 192 [Female, 22 to 29] 
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 ‘The circumstances in which I took drugs were isolated to one occasion (a festival) 
where I was surrounded by a big group of friends who were all doing the same thing and with 
whom I felt very safe with. Therefore I think that feeling secure, being in the right moment and 
place and being with friends definitely effects the decision on whether to take drugs.’ 
Participant 227 [Male, 18 to 21] 
 
The concern of safety appears to be more dominant theme with females than males, as 3 of 
the 4 participants who mentioned safety in this this question were female. This total included 
participant 56 whose example also highlighted the individual nature of drug use. 
 
Only one participant answered that the legality of the substances in question impacted their 
usage, responding specifically about the piperazine class of substances. The legality of the 
substances and the subsequent recriminations did not appear to be a concern of the drug 
taking participants, nor was it given as a reasons as to why non-users would not try these 
substances compared to the known and reported negative effects. This raises a question 
which has been broadly discussed earlier in Chapter 2 and has become a focus of much 
media debate and was included in party manifestos before the governmental election. One 
question that needs to be addressed is that if the Misuse of Drugs Act does not stop users 
from using, but is also not a key reason for why people choose not to take substance anyway 
is it fulfilling its basic requirement? This question will be addressed further in the final 
discussion chapter.  
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Comparative analysis for questions on Experience 
 
Comparison between results for Questions 4 and 5 
 
As this thesis is examining the perceptions between Ecstasy, MDMA and Mephedrone, Table 
4.2.17 summarises the results of Questions 4 and 5. It shows the percentage of the user 
group responses for each of the experience options. Question 4 relating to physiological 
experience and Question 5 the emotional. 
 
Table 4.2.17: Comparison of Results for Questions 4 and 5 for Ecstasy, MDMA and 
Mephedrone 
Responses 
Ecstasy MDMA Mephedrone 
(n = 82) (n = 76) (n = 35) 
Q4: Q5: Q4: Q5: Q4: Q5: 
Physical Emotional Physical Emotional Physical Emotional 
Negative 6.10% 4.88% 6.58% 3.95% 31.43% 25.71% 
Indistinct 15.85% 3.66% 7.89% 1.32% 25.71% 20.00% 
Positive 78.05% 84.15% 85.53% 94.74% 42.86% 51.40% 
 
In all cases the percentage of the user population who reported positive experiences was 
larger for the emotional experience than the physical one, which is not unexpected as the 
chemical MDMA is an empathogen, and Mephedrone has been reported to be a substitute for 
MDMA (Harris et al. 2002; Measham et al. 2010; Wood and Dargan, 2012).  The results for 
Ecstasy and MDMA are comparable, with the only major difference being that 15.9% of 
participants reported indistinct physical experiences for Ecstasy, which is almost double that 
reported for MDMA. 
 
Though Mephedrone has been touted as an alternative for Ecstasy/MDMA the results 
reported are less consistent. The participants’ reported experiences of this drug varied greatly 
in both the physical and the emotional. Although the number of users who responded to this 
survey was 37, which is relatively small in comparison to other larger surveys the findings 
relate to not only what has been found in the literature (Green et al, 2014) but is also 
supported by personal communication the researcher has had with users of both substances 
outside of the surveys.  
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Comparison between user responses who choose negative for both Question 4 and 5 
and the self-reported bad experience in Question 6 
 
From the results collected from each question the negative user responses can be compared 
to see whether the users who reported negative experiences and those reporting ‘bad 
experiences’ are comparable. The data was collated for Ecstasy, MDMA and Mephedrone and 
is represented in Figure 4.2.9.  
 
 
Figure 4.2.9: Comparison of Negative user group responses for Questions 4, 5 and 6 
 
The above figure shows that in comparison, Ecstasy and MDMA display greater reported 
levels for bad experiences against what was reported for physical or emotional experience. 
This can be explained by the nature of the question, for example a participant may have used 
the substance on numerous occasions and found that they generally had a positive reaction. 
However out of those numerous occasions they may have had one or more bad experiences, 
as evidenced in the comment made by participant 215. Mephedrone by comparison has far 
greater levels of both bad experiences and negative physical and emotional experiences. The 
significance between the responses for questions 4, 5 and 6 for each of the three substances 
was tested using a one way chi square. The results of the chi square test of significance found 
that there was a significant difference for the results for Ecstasy (χ2 = 9.25; P = 0.010), 
however no significance was observed for the results for MDMA or Mephedrone.    
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Comparison of User group response to Question 7 versus Question 8  
 
A comparison of question 7 and question 8 provides further insight into the differences in the 
effect of personal experience and knowledge to change usage behaviours. Question 7 asked 
whether personal experience had changed usage whereas question 8 asked if knowledge of 
someone else’s bad experience changed usage, shown in Figure 4.2.10. 
 
 
Figure 4.2.10: Comparison of user group responses for Question 7 and Question 8 
  
Across all three substances the personal experience was more likely to be a factor in 
changing usage than knowledge of someone else’s bad experience, and this finding was 
supported by the statements provided in question 9 and 10. In all cases, bar Mephedrone in 
question 7, more participants reported having not changed usage. The reasons for this are 
reflected by the large percentage reporting bad experiences and negative effects, supported 
by the statements from the open ended questions 9 and 10. Mephedrone, as reported in 
section 2.6, has been touted as the new ‘replacement’ drug of choice for Ecstasy, however the 
responses so far indicate that this drug is seen as comparatively negative. The significance 
between the two questions for each substance was tested using a two way chi squared test. 
All three substances returned significant difference; Ecstasy (χ2 = 10.1; P = 0.003), MDMA (χ2 
= 12.6; P = <0.001), and Mephedrone (χ2 = 4.22; P = 0.04). This means that across all three 
drugs significantly more user participants reported that they had not changed their behaviour.   
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4.2.4 Questions on the participants choice of drugs 
 
This section of the survey asked the participants to choose between two substances, with the 
focus on Ecstasy and MDMA powder in comparison to ketamine, Mephedrone and 
piperazines. The participants were also given the option to choose neither. They were then 
asked to give the reason for their choice in an open text question. Each question is split into 
two parts; the first a quantitative analysis of the number of participants who choose each 
option, followed by the qualitative analysis of the reasons behind that choice.   
 
Question 11a: If given the choice between Ecstasy Pills and MDMA powder 
which would you choose? 
 
The first question in this section offered the participants the option of a choice between 
Ecstasy pills or MDMA powder. The difference between the two products was emphasised by 
including the form, either pills or powder. Figure 4.2.11 displays the breakdown of responses 
with the option of neither included, as has been previously highlighted a number of the 
participants had not and would not take these substances even hypothetically.  
 
 
Figure 4.2.11: Participants responses to the choice between Ecstasy Pills and MDMA Powder 
(n = 252) 
 
The majority of the participants choose the neither option, this was anticipated based on the 
responses to previous question and from the number of participants in the ‘non-user’ category.  
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Of the participants who did make a choice there is a clear preference for MDMA powder. The 
responses were further analysed by looking at the choices reported by the user and the non-
user groups, as shown in Table 4.2.18. 
 
Table 4.2.18: Results for Question 11a choice between Ecstasy pills and MDMA powder by 
user and non-user groups (n = 252) 
Choice User Non-User 
Neither 6% 52% 
Ecstasy Pills 6% 6% 
MDMA Powder 26% 5% 
 
The user group for this question included the participants who reported to have tried both and 
those who just used one. Of the participants who had tried both 83% chose MDMA powder 
over the other two options, this was matched by the participants who had just tried MDMA 
powder with 80% also choosing MDMA. Of the participants who had just tried Ecstasy most 
chose the neither option.   
 
The difference in the frequency of the choices made by the user group was tested using a one 
way chi square test, which included the neither option. The results of the chi squared test 
returned a χ2 value of 54.25 and a P value of <0.001, which is significant.  The significance of 
the non-user group choices were also tested using a one way chi square, however this time 
the neither option was excluded. The test returned a χ2 value of 0.14 and a P value of 0.842, 
which was not significant, therefore there was no difference in the choices between the two 
made by the non-user group.  The variable of gender was also tested to see whether there 
was a difference in preference between males and females, tested using a two way chi 
squared there was no significant difference observed with both genders reporting a preference 
for MDMA over Ecstasy Pills. The results of this test are located in Appendix IVb Table 4.2.xx. 
The results of this question showed that among the user group there was a unanimous 
preference for MDMA powder. This correlates with the findings from the Global Drug Survey, 
which reported that users are taking the powdered form over the tableted or pill form (Mixmag, 
2013). Whether this is a consumer driven choice or merely reflects what is available in the 
marketplace has yet to be established. The prevalence of the different types of 
Ecstasy/MDMA found on the street is investigated in Chapter 6 with the seizures found in 
Cambridge.  The second part of the question asked the participants for the reasons behind 
their choices.  
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Question 11b: Qualitative analysis of reason for choice  
 
The second part of this question asked the participants to record their reasons behind their 
choice from the previous question. Responses were recorded from participants who choose all 
three options and so the analysis in this section is divided between the participants who chose 
neither, the ones who chose Ecstasy pills and the ones who chose MDMA powder.  Overall 
79% of the participant population responded to this question. Of the participants who choose 
the neither option 67% choose to respond, for Ecstasy pills it was 97% and for MDMA powder 
94%. 
 
Reasons given for choosing the neither option 
 
The first group whose reasons were assessed were the participants who had chosen neither 
in the previous question. The most stated reason for their choice was that they did not take 
drugs or had no interest in taking them. One participant mentioned their illegal status, a further 
seven mentioned the health and mental health risks associated with them. The overall tone of 
the response reflected the perception of the substances in a negative way. However some of 
the responses given were in themselves contradictory, for example: 
 
‘Although never heard of MDMA I am fully aware of the effect that drugs have to your 
body! [Sic]’    
Participant 147 
 
‘I don't have an interest in taking either. If there was no 'neither' choice I would choose 
MDMA.’ 
Participant 170 
 
One participant did however state that the two were effectively the same thing and that there 
is a perception about the purity: 
 
‘They are ultimately the same thing. Just one is supposedly a little bit more pure than 
the other.’ 
Participant 226  
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Reasons given for choosing Ecstasy Pills 
 
The second group of responses that were analysed were the ones who choose Ecstasy pills 
over MDMA powder. There were number reasons the participants gave for choosing Ecstasy 
pills over MDMA powder, the foremost being that they felt more informed about Ecstasy and 
had more experience of it, yet as was highlighted by participant 226 they are the same 
chemical. This supports the hypothesis that the two terms are definitely perceived as being 
separate. Other justifications for the choice of Ecstasy was that the pills were easier to take,  
and that there was a preference over the method of ‘bombing’ or ‘sniffing’ as highlighted by 
the response from participant 164: 
 
‘I prefer ecstacy [sic], bombing MD is unpleasant’ 
Participant 164 
 
A number of participants made references to the method of ingestion, and a number also 
discussed this in terms of getting a dosage and knowledge of purity based on imprinted 
designs. 
 
‘Convenient dosage unit, stamps are often indicator of quality.’ 
 Participant 239 
This is interesting as it conflicts with the statements made by the participants who chose 
MDMA powder as will be shown in the next section.  Another statement that is contradicted by 
the responses from the MDMA choosing group was that: 
 
‘Media say they are less likely to be cut with other substances [sic]’ 
Participant 109 
 
This statement is of interest as it is in direct contradiction not only with what the participant 
who said they would choose MDMA powder over Ecstasy but also with the majority of media 
and academic perception as assessed in the section 2.5.  
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Reasons given for choosing MDMA powder 
 
The final responses assessed were the ones who stated that they would choose MDMA 
powder over Ecstasy. Within this group the majority of the participants gave the reason that 
they believed that the powder was purer than the pills, with some using the word ‘cleaner’. 
Some of the participants even indicated the perception in difference in purity between MDMA 
powder and Ecstasy Pills as shown in the examples below. 
 
‘A belief that the drug is more pure maybe. Less side effects experienced [sic].’ 
Participant 10 
 
‘Never used MDMA Powder but have been told by several people the effects are 
much more prominent when using MDMA Powder as opposed to Ecstasy Pills.’ 
Participant 20 
 
‘It’s more potent, ecstacy [sic] pills are on average only 30-40% MDMA’ 
Participant 21 
 
Some participants noted the reason behind their choice was that they believed that the pills 
were more likely to contain adulterants, a dissimilar belief to the participants in the Ecstasy 
choice group. There was also links to the method of delivery of the powders. Some 
participants reported that the powdered and crystal forms of the compound were easier to 
check. That powders were easier to use with home testing kits that can be purchased over the 
internet. Or the participant said they could be checked by sampling a small portion of the 
sample before consuming the whole amount. This is specifically mentioned by 4 participants:  
 
‘Pressed pills are more likely to be compounded with adulterants. Powder or 
crystalline MDMA is rarer – but worth it as one is more able to check what it is via the Marquis 
reagent and other diagnostic tools.’ 
Participant 62 
‘You never know what’s in the pill. You can however taste MDMA to check that what 
you’re buying is legit.’ 
Participant 63 
 
‘usually mdma [sic] as more user control - dab a  bit at a time to test strength and 
effect, with a pill that involves halving etc [sic] which is a hassle - however sometimes a pill 
form is better than powder e.g. high humidity - so I would take pills instead’ 
Participant 208 
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‘I know the effects of mdma [sic] on me, and the [sic] can tell about the quality of the 
product by looking at it - whereas you never really know what you're getting in a pill. Also it's 
much easier to take a little bit of mdma [sic] than a little bit of a pill!!’ 
Participant 210 
 
Some believed that the powder form was safer, however there is a definite difference in the 
perception and understanding between what is MDMA and what is Ecstasy as shown in the 
following response: 
 
‘I have heard it is one of the safest drugs if pure: so it would have to be from someone 
I trusted who knew wether [sic] it was cut with anything else. I wouldn't take ecstasy as 
someone I knew died from taking one.’ 
Participant 224 
 
Despite the person stating that they have heard MDMA is ‘one of the safest drugs’ they 
wouldn’t take Ecstasy as they knew someone who had died. This is a inconsistency as both 
are technically the same chemical however as Participant 238 makes the point that: 
 
‘Both are risky but powder is less likely to contain something dangerous (e.g. PMA)’ 
Participant 238 
 
The compound PMA  (para-Methoxyamphetamine) that the participant referenced is a 
substance of a similar chemical structure to MDMA, which has been used as an adulterant in 
Ecstasy pills and is believed to be  responsible for over 20 deaths in 2013 (Saner, 2013).  
 
What is clear from the responses to question 11b is that there is a persistent contradiction in 
the understanding of what Ecstasy and MDMA actually refer to. Even among the ‘user’ 
communities, they are perceived to be different things. The main difference being that one is 
perceived to be ‘purer’. As has been consistently stated throughout this document there has 
yet to be any evidence to support this claim, however this is addressed in Chapter 8 when 
both forms are assessed analytically to either prove or disprove this hypothesis.  
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Question 12a: If given the choice between MDMA powder and Mephedrone 
which would you choose? 
 
The second question offered the option between MDMA powder and Mephedrone. This 
question was asked as there was prevalence in both the media and academic literature in 
2013 when the survey was run that stated that Mephedrone had ‘replaced’ MDMA (BBC, 
2013; Measham et al., 2010). This research was interested in investigating this claim, as 
evidence suggested that the use of Mephedrone was dropping (GDS, 2013). Figure 4.2.12 
shows the proportion of participants who choose each option for this question. 
 
Figure 4.2.12: Participants responses to the choice between MDMA powder and Mephedrone 
(n = 252) 
 
The majority of the participants responded to this question again chose the neither option. 
However of the participants that did choose between the two substances there is a clear 
preference towards MDMA. The results were separated into the user and non-user groups to 
identify whether there is a preference between the two substances, shown in Table 4.2.19. 
 
Table 4.2.19: Responses to Question 12a choice between MDMA Powder and Mephedrone 
by user and non-user groups (n = 252) 
Choice User Non-User 
Neither 3.6% 59.1% 
MDMA Powder 27.0% 7.1% 
Mephedrone 1.2% 2.0% 
 
34%
3%
63%
MDMA
Mephedrone
Neither
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The difference between the choices made by the user group was tested using a one way chi 
square test, which included the neither option. The test returned a χ2 value of 96.75 and a P 
value of <0.001. The significance of the non-user group choices was also tested using a one 
way chi squared with the neither option excluded. The test returned a χ2 value of 7.35 and a P 
value of 0.012. Therefore for both groups there was a significant preference for MDMA 
powder.  The variable of gender was also tested to see whether there was a difference in 
preference between males and females, tested using a two way chi squared there was no 
significant difference observed, with both genders preferring MDMA powder. The results of 
this test are located in Appendix IVb Table 4.2.xx. There were 80 participants identified as the 
user group for this question, of the participants identified as having tried both 82% stated they 
would choose MDMA. Of the participants identified as having tried just Mephedrone half 
picked MDMA, the other half picked the neither option. Of the group which had only used 
MDMA 92% reported they would choose MDMA over the other two options. The reasons 
behind these choices are assessed in the responses given to question 12b. 
 
Question 12b: Qualitative analysis of reason for choice between MDMA 
and Mephedrone 
 
Again the responses to the second part of the question were recorded from participants who 
chose all three options and so the analysis in this section will be divided between the 
participants, who choose neither, the ones who choose MDMA Powder and those who choose 
Mephedrone. Overall there were 190 responses to this question, from the participants who 
choose the neither option, 66% choose to respond. For MDMA powder it was 92% and 100% 
gave a reason for choosing Mephedrone. 
 
Reasons given for choosing the ‘neither’ option 
 
The vast majority of the participants who choose the neither option to this question either 
repeated their previous comment from question 11, or stated ‘see above/11b’. These 
responses are from participants who have stated categorically that they have no desire in 
taking any of the substances.  Some however did mention that they had not heard of or did not 
know of the drug Mephedrone, while others referred to the negative reputation it has earned, 
as exemplified by the following participant extracts:       
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‘Heard awful stories about Mephedrone and would never sniff anything.’ 
Participant 121 
 
‘I've never taken MDMA and I don't like m-cat, it's a dirty drug’ 
Participant 197 
 
The reference to m-cat, a synonym for the drug Mephedrone, as a dirty drug was not only 
expressed by the participants who choose the neither option, it also was given as a reason 
behind the participants’ choice when choosing MDMA powder.  
 
Reasons given for choosing MDMA powder 
 
The reasons the participants gave for choosing MDMA powder over Mephedrone can be 
separated into five main themes. The first was a lack of awareness of what Mephedrone was 
in comparison to MDMA, as illustrated in the following example: 
 
‘I'm just not sure what mephredrone [sic] really is...’ 
Participant 217 
 
The second theme was the participants who had heard of both but stated that the lack of 
knowledge of the effects of Mephedrone, both short and long term was a deciding factor. What 
is interesting is that one participant points out the lack of research available on this substance 
compared to that of MDMA.  
 
‘More research to back effects’ (referring to MDMA) 
Participant 17 
 
‘Mephedrone seems to be 'newer' with less known about potential effects.’ 
Participant 241 
 
‘Mephedrone is dirty man. Also have very little knowledge of its long term effects. 
MDMA has been "road tested" for longer.’ 
Participant 216 
 
As with the comment highlighted from participant 197 in the previous section, the word dirty is 
again used to describe Mephedrone, this is in contrast to the responses in Question 11 that 
used the word clean to describe MDMA. The perception and reputation was the third theme 
identified as a reason behind the participant’s choice in choosing MDMA over Mephedrone.  
 191 
 
 
‘Never heard any good stories from Meow Meow [sic]’  
Participant 226 
 
‘I have heard bad things about the latter.’  
Participant 227 
 
‘Had MDMA powder before, heard Mephedrone isn't as good’  
Participant 14 
 
‘Heard a lot of bad things about Mephedrone’  
Participant 16 
The fourth theme identified however supports the negative reputation that Mephedrone has, 
with a number of the participants recounting their negative experiences of this substance. 
Whereas the participants who stated they would not try it because they had heard bad things 
these participants state in their own words their negative experience of this drug. 
 
‘Mephedrone does nothing but give the user a blinding headache and a prolonged 
insight into utter desolation: a futile drug by all means.’  
Participant 23 
 
 
‘Mephedrone is awful. I mean seriously, compulsive redosing [sic], it's a substituted 
cathinone, give me MDMA any day of the week. Once, and then I can't take it again because 
it's self-limiting like that.’ 
Participant 62 
 
 
‘Mephedrone is a horrible drug and more addictive than people think. I have taken 
mdma before so would know what to expect, I know I would enjoy it.’  
Participant 95 
 
The final theme to the responses focused not on the negatives of Mephedrone but on the 
perceived positives of MDMA, as with the responses seen for question 11, there were 
statements  made about MDMA’s that it was cleaner or ‘purer, with some claiming that it gave 
a better or preferred high.  
 
If Mephedrone has such a negative reputation and reportedly negative effects, as suggested 
by the responses above, it is interesting to note what the 8 participants who stated that they 
would choose it gave as reason for their choice. 
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34.7%
1.2%
64.1%
MDMA
Piperazine
Neither
Reasons for choosing Mephedrone 
 
Of the eight people that choose Mephedrone for this question only three had tried it before. 
The reasons that were given were that; it was cheaper, it gave a better experience and that it 
had less of an effect and put less strain on the body. The other five response were from the 
non-user group, the reasons that they gave were; ‘Friends had done it’, two stated that it ‘had 
less of an effect’, and lastly because it was not MDMA.   
 
Question 13a: If given the choice between MDMA powder and piperazines 
which would you choose?  
 
The third question in this section asked the participant to choose between MDMA powder and 
Piperazines. The term piperazines covers a broad range of substances that are derived from 
the compound piperazine, the most commonly encountered substances being BZP, TFMPP 
and mCPP.  These substances were introduced in early 2000’s as an alternative to Ecstasy 
and have often been sold in tablet form (Staack, 2007, Wood et al., 2007).    
 
Figure 4.2.13: Participants responses to the choice between MDMA and Piperazines (n = 252) 
 
Following on the trend from the previous two questions the majority of the users still choose 
the neither option. MDMA Powder also continues to appear to be the more popular option 
when a choice was made by the participants. When the results are separated by user and 
non-user group, as shown in Table 4.2.20.  
  
 193 
 
 
Table 4.2.20: Results for Question 13a choice between MDMA powder and Piperazines by 
user and non-user groups (n = 252) 
Choice User Non-User 
Neither 3.2% 61.1% 
MDMA Powder 27.0% 7.5% 
Piperazines 0.8% 0.4% 
 
The difference in choice by the user group was tested using a one way chi square test, which 
included the neither option. The test returned a χ2 value of 102.46 and a P value of <0.001. 
The significance of the non-user group choices was also tested using a one way chi square, 
excluding the neither option. The test returned a χ2 value of 14.46 and a P value of <0.001, 
which is significant. Therefore for both groups there was a significant preference for MDMA 
powder. The variable of gender was also tested to see whether there was a difference in 
preference between males and females, tested using a two way chi squared there was no 
significant difference observed, with both genders preferring MDMA powder. The results of 
this test are located in Appendix IVb Table 4.2.xx.    
 
The number of users who choose MDMA powder in this question is the same as for the 
previous question, when the choice was between MDMA and Mephedrone. Only three 
participants stated they would choose piperazines, two users and one non-user. There were 
78 participants identified as the user group for this question, of the participants identified as 
having tried both 100% chose MDMA. Of the participants identified as having tried just 
Piperazines half picked MDMA, the other half picked the neither option. The MDMA only group 
reported 87% would choose MDMA over the other two options. The reasons behind these 
choices are assessed in Question 13b.  
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Question 13b: Qualitative analysis of reason for choice between MDMA 
and Piperazines 
 
As the third in a series of very similar questions at this point in the qualitative question the 
responses for the choices made are repetitive of the previous two questions. However of the 
252 participants who had responses recorded for question 13, 74% participants wrote a 
response to this question. For the neither option the response rate was 65%, for MDMA the 
response rate was 91% and 2 out of the three participants who choose piperazines gave a 
reason.  
 
The responses from the ‘neither’ group of participants are reiterative of their responses to the 
previous questions, yet there is also a frequent mention of a lack of awareness of what 
piperazines are. This is also reflected in the responses from the MDMA choosing group, with 
64% of the responses stating the reason they had chosen MDMA was because they had not 
heard of or were aware of the effects of piperazines. One participant however gave an 
emphatic description of their opinion on how they felt about piperazines.  
 
‘Because all of the piperazines are like drugs Satan pulled out of Hell. No, a better 
analogy. They're like drugs Satan's been working on for a while [sic], every Sunday in his 
hobby room, perfecting them, making sure they’re just awful and just right and blend in with all 
the other insane drugs out there. Piperazine derivatives are Satan’s masterpiece.’ 
    Participant 62 
 
So although piperazines appear to be relatively unknown in comparison to the other drugs that 
have been assessed, they elicited one of the strongest comments. Of the participants who did 
choose piperazines over MDMA, one reason was that they mimicked the effects of Ecstasy; 
the other reason that was given was;  
 
Because I have never tried it, and what would be the use in living without trying 
everything at least once, or twice to make sure?  
Participant 23 
 
The last example is of particular interest when considering drug using behaviours, do the 
majority of people stick to what they know or are they after new experiences? This was touch 
upon in section 2.7.1 with Werse and Morgenstern’s (2012) ‘omnivores’  and ‘psychonaughts’ 
typologies and is  examined in question 25 of this survey, which asked participants to choose 
between something they had taken before and something new.  
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Question 14a: If given the choice between MDMA powder and Ketamine 
which would you choose?  
 
The final question in this series offered the option between MDMA powder and ketamine. This 
question was included as was reported in the context chapter, the use of ketamine was being 
stipulated as an alternative to Ecstasy or MDMA in a BBC documentary (BBC, 2013). This is 
despite the fact that the two drugs have different effects and belong to different classes of 
drug. MDMA is a part of the Amphetamine Type Stimulant (ATS) family of compounds with 
purported empathogenic effects (Harris et al., 2002), whereas ketamine is a dissociative 
anaesthetic (Curran and Morgan, 2000). The difference between the expected outcomes in 
taking these substances is further highlighted in the participants’ responses.   The results for 
this question are shown in Figure 4.2.14. 
 
Figure 4.2.14: Participants responses to the choice between MDMA Powder and Ketamine (n 
= 252) 
 
The number of participants who choose the ‘neither’ option are still in the majority for this 
question. Although MDMA powder still is the more preferred substance (28%) there is a 
marked increase in the number of participants who would choose the alternative ketamine 
(10%), compared to when the choice was against Mephedrone (3%) and piperazines (1.2%). 
The difference is apparent when comparing the of the user and non-user groups. The user 
group that chose MDMA powder is smaller than it was for the previous two questions, these 
results are shown in Table 4.2.21. 
 
 
28.3%
10.0%
62.2%
MDMA
Ketamine
Neither
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Table 4.2.21: Results for Question 14a choice between MDMA and ketamine by user and non-
user groups (n = 252) 
Choice User Non-User 
Neither 3.6 % 58% 
MDMA Powder 23% 6% 
Ketamine 7% 3.2% 
 
The significance of difference in the choices made by the user group was tested using a one 
way chi square test, which included the neither option. The test returned a χ2 value of 47.79 
and a P value of <0.001. The significance of the non-user group choices was also tested using 
a one way chi square, with the neither option excluded. The test returned a χ2 value of 1.64 
and a P value of 0.286, which was not significant. Therefore though there is a significant 
preference for MDMA by the user group, there was no significant difference between these 
two substances for the non-users. The variable of gender was also tested to see whether 
there was a difference in preference between males and females, tested using a two way chi 
squared there was no significant difference observed, with both genders preferring MDMA 
powder. The results of this test are located in Appendix IVb Table 4.2.xx. 
 
There were 83 participants identified as the user group for this question, of the participants 
identified as having tried both 64% chose MDMA, with 24% choosing ketamine. Of the 
participants identified as having tried just ketamine, 43% picked MDMA, and 43% picked 
ketamine. The MDMA only group reported 81% would choose MDMA, and 10% would choose 
ketamine. The reasons behind these choices are assessed in Question 14b.  
 
Question 14b: Qualitative analysis of reason for choice between MDMA 
and Ketamine 
 
As stated at the start of question 14, these two drugs provide a different set of experiences 
with one a stimulant and the other a dissociative. This was a theme that was highlighted in the 
response by participant 62 who discussed the relative properties of the two compounds: 
 
‘I don't see how either of these drugs are comparable. Would depend on how the 
mood took me. Ketamine is a dissassociatve psychedelic. MDMA is a stimulant entacto-
empathogen. As I said, would depend on the mood I was in. [sic]’ 
Participant 62 
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The response rate to this question was still high with 189 participants choosing to answer. The 
percentages for each option stood as 64% for neither, 93% for MDMA powder and 96% for 
ketamine. The neither responses were again reiterative of the previous three questions, that 
the participants had no interest in taking these substances and/or had not heard of them. 
 
Reasons given for choosing MDMA powder over Ketamine 
 
The reasons given for the choices with this question can be divided into two main factions, the 
people that have heard or experienced the negative effects of ketamine and those that 
preferred the experience of MDMA. Many of the participants commented on the fact that it 
depended on what kind of effect one was after when consuming a substance, however there 
was a distinct negative tone when describing taking ketamine. There was also a frequent 
reference to horses and horse tranquilizers, which is one of its legitimate uses, when providing 
an example of the negativities of ketamine. Of the participants who wrote about the negative 
effects of ketamine one participant described it as;   
 
‘If I were inclined to sit in dark corners on my own and fathom detestable fates for 
myself whilst wriggling uncontrollably and yet imagining myself to sit unfathomably still, then I 
would choose ketamine. But being the putrid waste of an evening that it is, I would chose 
MDMA every night, without question.’ 
 Participant 23 
 
A number of participants’ stated that they felt or perceived ketamine as a ‘dirty’ drug, a word 
that was also used to describe Mephedrone and used in contrast to the perception that MDMA 
is perceived as clean. There was an overriding preference for the effects of MDMA, over the 
other substances. The context for taking and the desired effect received by these substances 
was also consideration for a number of the participants. One participant stated that ketamine 
was not a social drug and another claiming to only to enjoy ketamine when mixing the two 
substances.  
 
‘Depends on context, (in some situations ketamine would be my preference) but 
ketamine is not a very social drug.’ 
Participant 213 
 
‘Only enjoy ketamine when having MDMA first, not on it’s own [sic]’ 
Participant 78 
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Reasons given for choosing Ketamine over MDMA Powder 
 
The reasons given for choosing ketamine over MDMA powder came down purely to a 
preference for the effects that ketamine provides, the fact that it was not a stimulant was the 
most prevalent factor stated. Though other reasons provided included; potential weight loss, 
its classification - the first time legality had been addressed as a consideration, and that the 
participant felt better the day after than when they took MDMA. Other reasons given were: 
 
‘As I have chronic sleeping problems, I think Ketamine. It would be nice to actually get 
a decent sleep!’ 
Participant 80 
 
‘You can't do too many stupid things when you're knocked out.’ 
Participant 223 
 
‘Ketamine but only because I haven't used it before and I've wanted too [sic]. The 
dissociative effect is interesting, but I'd probably prefer MDMA after I had tried ketamine’. 
Participant 237 
 
‘Ketamine is an experientially preferable choice for me, I have outgrown the shallow 
hedonism of MDMA and find it counterproductive, ketamine is a deep and powerful 
psychoactive’. 
      Participant 240 
 
The choice between ketamine and MDMA powder came down to a preference of the type of 
high the user was after.  This is in contrast to the comparisons drawn between MDMA powder, 
Mephedrone and piperazine, which related to how the compounds were perceived or previous 
negative experiences.   
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Question 15: Please rank the following substances in order of your 
personal preference 
 
The participants were next asked to rank the selected substances based on their personal 
preference on a scale. The scale was from one to five, with a score of one indicating low or no 
preference for the substance and five indicating the most preferred.  The format of the 
question enabled the participants to pick the same value for each of the substances if they 
choose. It also allowed them to not answer if they did not wish too, this is shown as a no 
answer in the table.  Table 4.2.22 displays the results and mean value for each substance are 
shown for the whole sample population. 
 
Table 4.2.22: Percentage of responses for each rank score for the selected substances (n = 
252) 
Rank       
  (1 = least, 5 = most)  
Substances (%) 
Cocaine Ecstasy MDMA Ketamine Mephedrone  Piperazines 
1 49.2 42.9 44.0 58. 62.3 72.2 
2 9.9 6.7 4.4 8.3 12.3 4.8 
3 10.3 9.5 8.7 9.1 6.3 4.4 
4 8.7 17.5 9.1 4.8 3.6 0.4 
5 10.3 10.7 21.8 4.8 2.0 1.2 
No Answer 11.5 12.7 11.9 13.1 13.5 17.1 
 
The modal value for all six substances is 1, as it was the most frequently chosen response 
from the participants; this is anticipated when considering the responses from the answers to 
the previous questions and the number of non-user participants. The significance between the 
responses was calculated using a one way chi square test, which returned a significant result 
for all six substances, shown in Appendix IVb Table 4.2.xxi.   
 
A mean value was obtained by adding the scores for each drug and dividing by 5, excluding 
the non-answers. The mean values were then used to compare the substances and a rank 
order established. The order of preference observed when all the participants’ responses are 
included is as follows from highest to lowest: MDMA (2.55), Ecstasy (2.36), cocaine (2.11), 
ketamine (1.8), Mephedrone (1.74) and piperazines (1.24). However as preference denotes 
usage of the substances the user groups responses may provide a different rank order. The 
mean values for the users groups were calculated using the groups generated by the 
responses from Question 1 less the participants who did not supply an answer.  The mean 
values for each substance shown for each user group is shown in Table 4.2.23.  
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Table 4.2.23: Mean values for Question 15 for each substance separated by user groups 
 Mean of responses to Question 15 
User Group Cocaine  Ecstasy MDMA Ketamine Mephedrone Piperazine 
Cocaine  3.30 3.33 3.79 2.18 1.53 1.13 
Ecstasy  2.96 3.68 3.91 2.25 1.59 1.10 
MDMA 2.69 3.51 4.31 2.23 1.64 1.10 
Ketamine 3.02 3.59 4.10 2.84 1.66 1.10 
Mephedrone 3.03 3.51 4.08 2.84 2.06 1.17 
Piperazine  2.50 3.50 4.00 3.38 2.88 1.57 
Overall Mean  2.92 3.52 4.03 2.62 1.89 1.20 
 
The rank order of the substances by preference by the user groups reflect the same order of 
preference as was shown with the total participant population, with the exception of the 
piperazine user group. The rank order according to the preference of the piperazine users 
was; MDMA, Ecstasy, Ketamine, Mephedrone, Cocaine and Piperazine. 
 
 In all cases MDMA was ranked as the most preferred substance supporting the findings from 
Questions 11 through 14. It is also observed that across all users groups and the total 
population there is a difference in the mean rank values obtained by MDMA and Ecstasy.  
This clearly supports the hypothesis that these two are considered to be separate products.  
Both Mephedrone and piperazines received low scores for preference, not only from the total 
population but from the participants reporting to have taken them, which is again consistent 
with the responses from previous questions. 
 
Question 16: Have you ever bought a substance over the internet? 
 
In recent years there have been reports that there has been an increase in the purchasing of 
substances, both illicit and uncontrolled over the internet (Martin, 2014). This question asked 
the participants whether they had ever bought a substance over the internet. This was to 
establish whether there has been a significant change in how people are obtaining their 
substances.  The percentage of the participants who reported to have bought a substance 
over the internet was only 13% out of the total population of participants for this survey. This 
figure increased to 19% when measured against the participants who reported to have taken 
any substance other than alcohol and tobacco in Question 1 (n = 172).  This can be compared 
to the findings from the GDS (2013) that found that 22.1% their participants reported to have 
bought a substance over the internet. This suggests that the use of the internet and the 
purchasing of substances online is not the most prevalent method used to obtain substances. 
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However Martin (2014) suggests that in the future this percentage may increase. This 
question was also assessed to see whether there was a difference between the genders on 
purchasing substances online, the two way chi squared test returned a χ2 value of 12.732 and 
a P value of <0.001. Significantly more males reported to have bought a substance over the 
internet compared to females. 
 
Question 17: Have you ever tried a substance without knowing exactly 
what you were taking? 
 
It is unlikely that a user of an illicit substance will know with 100% certainty that it is what they 
believe it is, without the use of advanced analytical testing. However this has not stopped the 
use of illicit substances. This question asked the participants whether there was ever a time 
when the participants felt they did not know what they were taking.  
 
The percentage of the participants who reported to ‘have tried a substance without knowing 
exactly what it was’ was 27%, out of the total population of participants for this survey. This 
figure increases to 40% when measured against the participants who reported to have taken 
any substance other than alcohol and tobacco in Question 1 (n = 172).  This means that 2 out 
of 5 of the participants who stated to have known that they used illicit substances had at some 
time taken something without knowing exactly what it was.  
 
This can be compared to the findings from the GDS (2013) that found that 11% of their 
participants reported to have taken a ‘mystery white powder’. The difference in levels reported 
between the two surveys may be due to the phrasing of the question. This survey asked 
whether the participants had ‘ever’ taken an unknown substance without specifying type, 
whereas the GDS asked specifically about powders and within a time frame of 12 months. The 
next question asked the participants what they believed the substance to be.    
 
This question was tested to see whether there was a difference between the genders when it 
came to taking an unknown substance. A two way chi squared test was applied and returned 
a χ2 value of 1.245 and a P value of 0.265, which is not significant at the critical significance 
level of 0.05. This shows that when it comes to taking unknown substances there was no 
differences in the gender responses on this behaviour.  
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Question 18: What did you believe it was?  
 
When asked what the participant believed the substance was that was mentioned in question 
17 they were able to choose from a selection of substances as well as contribute their own 
choices. Table 4.2.24 displays the most frequent choices provided by the participants, the total 
number of participants who responded to this question was 68, however participants could 
choose to reply with multiple substances and so percent is calculated against total number of 
responses. The list of the other substances that received only one or two mentions in this 
question is shown in Table 4.2.25. 
 
Table 4.2.24: Responses given when asked what the participant believed the substance was 
from Question 17 
 
Percent of responses 
 (n = 68) 
MDMA Powder 30.9% 
Cocaine 14.7% 
Ketamine 13.2% 
Ecstasy 11.8% 
Mephedrone 7.4% 
Speed/Amphetamine 5.9% 
Cannabis 2.9% 
Other 22.1% 
 
Table 4.2.25: List of other substances mentioned in Question 18 
Other Substances mentioned  Piperazines 
Antidepressants 
Opium 
DMT 
Poppers 
Nitrous Oxide 
BZP 
MXE/something similar to ketamine 
Benzo Fury 
MDAI 
MDPV 
 
There are assumptions that are made by the drug using community, on the identity of and 
purity perceptions around specific substances, which are based on subjective experience only.  
This survey had discovered some of the perceptions held around Ecstasy and MDMA, which 
will be tested through chemical analysis of seized street samples in Chapter 8. 
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4.2.5 Questions on the participants honesty when discussing 
drug use 
 
The last section of the survey dealt with how the participants discussed their own drug use, 
the perception around what is deemed an ‘acceptable’ drug and what is ‘unacceptable’ and 
addressed the question of choice between something taken before and trying something new.  
 
Question 19: Do you ever talk about your own drug use? 
 
The opening question to this section asked the participants whether they ever talked about 
their own drug use. They were given three options to choose from; yes, no and not applicable 
(N/A), Figure 4.2.15 shows the percentage of responses for each option from the total 
participant population.   
 
 
Figure 4.2.15: Responses to the question ‘Do you ever talk about your own drug use?’ (n = 
252) 
 
The majority of the participants reported that they had talked about their own drug use, with 
just over a third choosing the not applicable option. The difference between the options was 
tested using a one way chi square that returned a χ2 value of 94.57 and a P value of <0.001, 
which is significant. When the responses for the user group of participants is examined the 
percentage of participants that choose the yes option increased to 79%, the percentage for 
the no option remained the same as the total population at 8%. However 12% of participants 
who reported to have tried a substance other than alcohol or tobacco in Question 1 stated that 
it was not applicable to them at this stage in the survey.    
58%
8%
34%
Yes
No
N/A
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Question 20: Have you ever discussed your drug use with any of the 
following? 
 
Following on from the previous question the participants were asked who they discussed their 
drug use with. The participants were provided a number of different options from which they 
could choose as many that were applicable to them. The results are shown in Figure 4.2.16. 
 
 
 
Figure 4.2.16:  Percent of participant who gave each option as a response to Q20 - Have you 
ever discussed your drug use with any of the following? (n = 252)  
 
The most popular answer was the participant’s friends followed by family; these results reflect 
the similar findings from survey A. Question 6 of survey A asked the participants where they 
would look for drugs information, with the first choice being the internet, followed by their 
friends in second. The option of ‘Family’ came in 7th out of eleven options in question 6. 
Question 8 from survey A asked the participant who they would be most comfortable 
discussing drug use with, as with this question the most popular option was friends followed 
by; online, a known user and family as the fourth most popular option. In all three questions 
the options relating to governmental options such as helplines and TalktoFrank received low 
levels of responses. Only 1% of the participants reported to have ever used FRANK. This 
correlates to the findings on trust of information sources that placed the government at the 
lower end of the scale and the second to last out of the options provided in trust.  As people 
distrust the information providers and are obviously not using these sources to obtain their 
information this prompts the question, what is the best way to provide accurate and unbiased 
information on drugs to the public?   
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Question 21: Who do you feel you can be honest about your drug use 
with? 
 
This question took a slightly different approach to the discussion of drug use, introducing the 
concept of honesty. As was mentioned in Chapter 3, bias can be introduced into drug 
research surveys through the principal of social desirability (Caetano, 2001). An example of 
this would be when the participant is not honest about behaviours that may be deemed 
undesirable, like the use of controlled substances. This question asked the participant directly 
who they felt they could be honest with about their own drug use. It utilised the same options 
as the previous question, the participants could also provide their own answers through the 
other option button. The results are shown in Figure 4.2.17. 
 
 
Figure 4.2.17: Participant responses to who they can be honest with about drug use (n = 252) 
 
Again the most frequent response chosen by the participant was friends; however the second 
most popular response was anyone. Though it should be noted that some participants who 
choose to write ‘anyone’ did go on to provide caveats to this statements, such as ‘anyone but 
my mother’ or employer or other select family members. One participant stated they would be 
happy to talk to anyone who wasn’t going to prosecute them. The overall results suggest that 
the participants are willing to be honest about their drug use with a range of different people, 
indicating that it is perhaps no longer such a taboo subject as it once was. 
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Question 22: Do you think some drugs are more acceptable than others? 
 
In this question the participants were asked to consider their perceptions about the different 
drugs, specifically about whether they believed there to be a difference between the 
substances and whether there are any substances that they deem more acceptable than 
others.  The results are shown in Figure 4.2.18, for this question one participant’s response 
did not register so the sample number was adjusted to 251.  
 
 
Figure 4.2.18: Percentage of participant responses to question 24 on the acceptability of drugs 
(n = 251) 
 
The majority of participants did believe that some drugs are more acceptable than others, the 
significance was tested using a one way chi squared, which returned a χ2 value of 237.22 and 
a P value of <0.001.  The results were then compared between the responses for the non-
drug using group and the total drug using group using a two way chi squared to establish 
whether there was a difference between who thought some drugs were more acceptable. The 
test returned a χ2 value of 7.56 and a P value of 0.02, which is significant. More non drug 
users responded that they did not think some drugs were more acceptable than others 
compared to the drug using group. In the next two questions they were asked to provide an 
example of a drug they deemed acceptable and one that they deemed unacceptable.  
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Question 23: Can you give an example of a drug you think is acceptable? 
 
The participants were asked to give an example of any substance that they thought was 
acceptable. In this question they were able to provide as many examples as they liked, 
however the majority choose to respond with just one example. The most frequent responses 
are shown in Figure 4.2.19, again one participant’s response was not recorded so the sample 
population is 251. 
  
 
Figure 4.2.19: Responses give for an example of an ‘acceptable’ drug (n = 251) 
 
The most frequent drug that the participants mentioned was cannabis (54%). Only 10 % of the 
participants stated that they believed there were no acceptable drugs, compared to the 17% 
from the previous question. Analysis of the results of the responses given to this question 
based on the participants who choose no previously showed that the ones who did give an 
example gave responses for; alcohol, tobacco, caffeine, over the counter medicines (OTC 
painkillers) and prescription medicines.  
 
Other responses that occurred only once or twice included:  Morphine, Codeine, Herbal Legal 
Highs, Magic Mushrooms, Methadone, GHB, and Amphetamine, 2-CE, 2-CB and DMT. Most 
participants responses were single word answers, however a couple of the participants, 
provided a longer answer to this question as shown in examples below: 
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‘Anything that someone takes within their own home, that doesn't cause any other 
person, or government service any hassle - If that makes sense? Therefore, any drug that 
people may take within their own homes, that does not yield medical problems (e.g. 
ambulance needed) or require the police (e.g. a fight), or aggrieve any other people (e.g. me!). 
As I am no expert on drugs, I'm afraid I cannot give a specific example, but I think I've given 
wide criteria, that at least a few drugs may fit into.’ 
 Participant 80   
 
‘None really, but if you were to order them somehow, 'party drugs' like ecstasy would 
rank above drugs like heroin, just because of the impact they have on a person’s life’ 
 
Participant 179  
 
I think it is not about a certain drug but amounts. One small line of ketamine may be 
no different to one pint in a pub. 
Participant 209 
  
The recurring theme that the participants brought up was the impact these substances had on 
the user and on the wider society. There was a clear preference for substances that are 
perceived to cause less of an impact, such as ‘party drugs’, which was reflected in the 
responses overall for this question.  What this questions shows is that there is now a broad 
range of substances, some that are controlled under the highest classification, which are 
perceived to be acceptable.   
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Question 24: Can you give an example of a drug you think is unacceptable? 
 
In contrast to the previous question the participants were also asked to give an example of a 
drug that they believed was unacceptable. The results for this question are shown in Figure 
4.2.20. 
 
 
Figure 4.2.20: Responses give for an example of an ‘unacceptable’ drug (n = 251) 
 
The most common example given of an unacceptable drug was heroin (49%), with the second 
most being cocaine. However the participants mentioned both cocaine and crack, which 
obtained 13.1% and 10%, when considered individually. 11% of the participants thought all 
drugs were unacceptable, though some provided caveats such as prescription medicines. 
Conversely 5% thought no drugs were unacceptable with one participant stating;  
  
 ‘It's not the drug it's the context and whether or not it has a harmful effect on the 
individual and/or 'society'’ 
Participant 206 
 
Both Ecstasy and MDMA appear infrequently, with 3.2% and 2% of the participants 
mentioning them as an example of an unacceptable drug.  As with the acceptable drugs there 
were a number of substances that appeared only once or twice, these were;  nicotine and 
tobacco,  piperazine derivatives, caffeine, Spice/Synthetic cannabinoids, Krokodil, any 
hallucinogen, LSD, Mephedrone, any non-prescription drugs, anything injected,  Fentanyl and 
speed.  The list of drugs that are unacceptable was a broad as the one of acceptable drugs, 
though there was a distinct disapproval of opiates and injected substances.  
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Question 25: If given a choice between something you have taken before 
and something completely new which would you choose? 
 
The last part of the survey asked the participants a hypothetical choice between taking a 
substance that they had tried before and something new. They then provided a reason for 
their choice in question 26. The results for this question are shown in Figure 4.2.21. 
 
Figure 4.2.21: Responses for the choice between something new and something taken before 
(n = 251)  
 
The majority of the participants stated they would choose something taken before, the 
significance was tested used a one way chi square, which returned a χ2 value of 149.94 and a 
P value of <0.001 and is therefore significant. The participants were not offered a not 
applicable option, which may have affected the participants’ choices. However they were 
given the opportunity to provide a justification for their decision in question 26. 
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Question 26: What is your reason for your answer to question 25? 
 
The responses to this question were divided by how the participants responded in the 
previous question. Only 11% of participants stated that they would have chosen something 
new, if given this hypothetical option. The reasons given in answer to this question fall into two 
categories; the first and more prominent reason that was given by the participants was that the 
participants sought new experiences, with 9% of the population giving this as the reason. 
These participants could be considered specialist psychonaughts or omnivores under Werse 
and Morgenstern’s typologies of drug use (2012 p.228). The other 2% of the participants 
rationalised choosing something new as they had never taken anything to begin with.  
 
More participants choose to answer with the option of something taken before, however due to 
the survey design some stated they choose this as no other option was available and that the 
choice was ‘Not Applicable’ to themselves, with 15% of participants using this or other 
synonymous terms in their response. Of the final 74% of the participants a number of key 
words and themes emerged in the analysis of their responses. 
 
The most prominent theme to emerge was knowledge of the substance, with 38% of 
participants using the terms to describe their choice.  Knowing about the effects, past 
reactions, ‘knowing it won’t kill me’ being the most frequently occurring phrases related to 
these responses.  The use of ‘know’ as a key phrase also corresponds to a second key word 
‘experience’, which as was seen with the people who choose something new, was an 
important factor in the participant’s choice.  Whereas with  the participants who choose 
something new were looking for new experiences, the participants who choose something 
known were relying on their own past experiences, both positive and negative to make their 
decision. Other key words to emerge, which corresponded to similar answers given in 
question 10 and 11 of Survey A, were the themes of ‘risk’, ‘safety’ and ‘fear’. With the 
perception being that a known substance would be safer, less risk and that there was a fear of 
what the new substances could do if taken. The theme of trust, or rather a lack of trust of the 
newer substances was also evident.   
 
The responses to this question suggests that both sets of participants rely on experience to 
guide their actions, whether it is to go out an experience new things or relying on past 
experience knowing about effects and personal reactions to substances.   
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4.3 Key findings from social research surveys 
 
Ecstasy is not synonymous with MDMA 
 
The first key finding from the social research surveys was that there is a disassociation 
between the terms Ecstasy and MDMA.  This was highlighted throughout both surveys, with 
the two terms obtaining separate scores across the range of questions. The first question that 
identified this difference was Question 1 from Survey A which asked the participants which 
drugs they had heard of. It was found that the majority of the participants had heard of the 
term Ecstasy (99%), with 78.2% reporting to have heard of MDMA (Figure 4.1.3). This was 
proven to be a significant difference when tested with the two way chi square (χ2 = 89.92, P = 
<0.001). Ecstasy was the better known term and no participants reported to have heard of 
MDMA but not Ecstasy. 
 
The hypothesis that Ecstasy and MDMA are not synonymous was further supported with the 
findings from the second question, which found that 68% of the participants correctly identified 
the classification of Ecstasy, while only 48% correctly identified MDMA despite both being 
controlled under the same class (Table 4.1.1). The amount of people who were able to 
correctly identify both as being Class A was only 42%. This meant that of the total population 
58% were unable to correctly identify both of these terms, thus supporting the theory that the 
public has not formed a synonymous association between the two terms, despite both relating 
to the same chemical compound. This was further supported by the 13% who correctly 
identified Ecstasy but claimed that they ‘did not know’ what the classification of MDMA was 
(Table 4.1.2). 
 
Building on the concept of separate identities of the terms Ecstasy and MDMA in the social 
consciousness was the third question which asked the participant about colloquial name 
association of a number of drugs, again with the key focus on Ecstasy. In this question instead 
of having the two terms as separate items the term MDMA was included into the list of 
possible synonyms the participant could choose from for Ecstasy. This question reinforced the 
concept of two identities of the terms Ecstasy and MDMA as only 44% of the participants 
identified the latter as being an alternative name for the former (Table 4.1.4).  A further point of 
interest is the low association with the term Ecstasy and the term Crystal at only 6%. As the 
term Crystal relates to the form in which the compound is found, there appears to be a strong 
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association between Ecstasy and the pill/tableted form, whereas crystal has a greater 
association with the term MDMA. This is further supported by the alternative names suggested 
by the public, of which the terms tabs and pills were mentioned.  
 
The final question from the first survey that established the difference in perception between 
the two terms examined the participants’ perception of their own knowledge of these terms.  
Again the findings from this question supported the idea that there are two separate products 
that are being identified by the public, with Ecstasy obtaining a mode of 4 the second highest 
possible value on the scale whereas Ecstasy obtained a mode of 1, the lowest. The fact that 
the majority of people feel highly informed about Ecstasy but gave the lowest possible value 
for MDMA suggests that these are separate in the public perception. 
 
This theory was also supported by the results for the second research survey into the use of 
these substances, with the terms representing different forms as either Ecstasy pills or MDMA 
powder. Across the range of questions asked the two terms received different responses, 
supported by the qualitative responses that there was a definite perception that these two 
represent different and separate products on the recreational drug market.  
 
Ecstasy no longer is a catch all term for MDMA, there has been a clear separation in the 
identities of these two terms. What has also been highlighted is a lack of awareness or 
understanding of what MDMA actually represents and perhaps a lack of clear information. 
This is a problem when considering the results of the second survey, where MDMA use was 
more prevalent than Ecstasy and the contradicting responses from the survey participants 
around preference. The impact of information sources is the second key finding from these 
surveys. 
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Information sources which are used and the ones that are trusted are not 
necessarily the same 
 
There was a clear lack of information and understanding around not just Ecstasy and MDMA 
but also the other drugs that were also discussed. These surveys have examined who and 
what the main information sources are, as well as establishing which are the most trusted. 
From the first survey, Question 6 asked the participants where they would look for information 
about drugs. For both parts of this question the results were unanimous in the top three 
options, with the most popular answers being; the internet, friends and drug forums. The 
governmental sources were outside the top 3 choices, with doctors receiving less than a 
quarter of participants stating they would seek information from this source. This was in stark 
contrast to the results for question 7, which found that doctors were the source that elicited the 
highest level of trust, just a head of independent scientists. So although doctors were seen as 
the most trusted to provide accurate information the majority would not actively seek advice 
from them. One explanation of this contrasting reporting may be given by examining 
responses to the second survey, when asked about actual drug use one participant stated: 
 
‘the press, most doctors and politicians are judgemental and shake their finger 
disapprovingly at drug use when they have no experience’ 
Participant 21 [Survey B] 
 
The perceived bias of the sources to provide accurate information may be due to the 
politicised nature of the question, as the substances are controlled there is the perception that 
this may impact in the information that is provided. The response by participant 21 also 
summarises the findings from question 7, which found that the media and the government 
were not trusted by the majority to provide accurate information.  
 
In Question 8 of survey A, the participants were posed the hypothetical questions of who they 
would feel comfortable discussing their drug use with. The vast majority chose the option of 
friends, with the internet and a known user coming in second and third. This question was 
reworded and asked again in Survey B, this time asking participants who they had talked 
about their drug use with, the majority responded that they had discussed it with their friends 
(87%) this correlates to the findings from Survey A. The second highest option was that of 
family (46%) followed by online (14%) and other research (11%). The participants were then 
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asked who they could be honest about their drug use with, again the most popular response 
was their friends (54%), and the next most popular response at 14% was that the participants 
felt they could be honest with anyone.   
 
At the end of survey A the participants were asked whether they thought awareness of drugs 
was important.  The vast majority (99%) stated that they did believe it was important, with the 
main reason being that it is important to be aware to be able to make informed choices around 
drugs and to be aware of the potential risks. Yet when asked whether they believed enough is 
done to educate about drugs 91% stated that they did not think that there was.  
 
The different perceptions around Ecstasy pills, MDMA powder and 
Mephedrone 
 
The second survey explored in more detail the perceptions the participants had about these 
two forms of the same chemical and the new competition. Questions 4 and 5 asked the 
participants about their physical and emotion experiences with the substances and in both 
questions the majority of the participants’ from the ‘user’ group stated that their experiences 
were positive.  The proportion of participants who rated the physical experience of the 
substances as positive varied between substances; MDMA received the greatest proportion of 
positive responses at 86% of the user group population stating their experiences were 
positive. Ecstasy was the second highest at 78%; this is compared to only 43% who rated the 
physical experience of Mephedrone as positive.  
 
The proportion of participants who rated the emotional experience of MDMA as positive was 
greater than for the physical at 95%. This is logical as the purported effects of the chemical 
MDMA are empathogenic (Harris et al., 2002). However what is of interest are the perceived 
differences between Ecstasy and MDMA. Only 92% of the users rated Ecstasy as positive, 
what is interesting is not the size of the difference but the fact that there is a difference at all. 
Both supposedly contain the same chemical yet these results suggest that the users are 
having different experiences on these two forms of the same drug, which may indicate 
inconsistencies in the chemical composition that is found in the products on the street. As 
there are no publications on composition of crystal/powder MDMA, this is a question which is 
examined in the analytical section of this doctoral research. The results for Mephedrone were 
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again much lower with only 54% of user participants rating the emotional experience as 
positive. 
 
The participants were also asked whether they had ever had a bad experience or knew of 
someone who had ever had a bad experience with the substances. The responses for ‘Yes-
myself’ for all three substances was low with 3.6% having a bad experience with MDMA and 
6% reporting a bad experience for both Ecstasy and Mephedrone. However the response for 
‘Yes-someone else’ were far greater. A third of the participants knew of someone who had a 
bad experience with Ecstasy, a quarter knew of someone who had had a bad experience with 
MDMA and 16% knew of someone who had had a bad experience with Mephedrone. The last 
is a bigger proportion than the amount of participants who reported to have ever taken 
Mephedrone to this survey.  
 
The next questions from survey B dealt with how experience had affected the participant’s 
behaviour towards these substances. The first, question 7, asked whether the participants 
own experience had changed their usage. The results for the user responses for Ecstasy and 
MDMA were close at 36% and 40% respectively.  However over half of the users of 
Mephedrone (54%) stated that their own experience had changed their usage. The second 
question, question 8, asked whether knowledge of someone else’s bad experience had 
changed their own usage. This received less ‘yes’ results across all three substances, Ecstasy 
received 14.3%, MDMA received 13.2% and Mephedrone receiving 32.4% of its user group 
stating changing their behaviour based on someone else’s bad experience.  
 
The participants were asked to provide a justification for their choice in the previous questions. 
The main reasons that the participants gave for changing their usage were; the bad 
experiences, negative side effects and the fear of addiction. The key reasons the participants 
who stated their usage had not changed gave were based on; a lack of validity given to other 
people’s negative experiences or that the participants had had no negative experiences only 
positive ones.  Analysis of the individual drugs found that both Ecstasy and MDMA received 
more positive comments than negative, whereas Mephedrone received mostly negative 
comments. There was also a perception that MDMA was seen a ‘clean’ or ‘pure’ compared to 
both Ecstasy and Mephedrone, with the latter described as ‘dirty’.  
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The purity of MDMA was also a key theme that was established when the participants were 
asked to choose between the substances. There was an outright preference for MDMA 
powder stated by the participants over either Ecstasy pills or Mephedrone. The reasons for 
this were also assessed with open questions asking for a reason for each choice. Again 
MDMA powder had mostly positive responses relating to previous experiences of the 
participants, whereas Mephedrone had negative comments as well as a distinct lack of actual 
awareness of the properties and affects it has. When the participants were asked to rank the 
drugs by order of personal preference MDMA was ranked as the highest by the user and as 
the second highest by the non-user groups. Conversely, Ecstasy was ranked the highest by 
the non-users but was third behind cocaine for the user group. Mephedrone was second from 
last in the order by both the user and non-user groups. 
 
The findings from these questions, along with the results provided by the Global drug survey 
(2013) suggests that this new form of MDMA powder has supplanted Ecstasy and is now the 
preferred form of this drug. The main reason that this has occurred appears to be the 
perception that this new form is somewhat ‘purer’ than the tablet form, with one participant 
mentioning the ‘notoriously impure Ecstasy market’.    
 
What is yet unknown is the relative abundance of the alternative powder form in the market or 
whether there is any truth to the perception that it is purer. These two questions are examined 
and answered in the remainder of this thesis.   
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Chapter 5 Analysis of Trend and Seizures of Drugs 
5.1 Review of Organisations examining drug trend data 
 
The use of population surveys is just one method of estimating drug use, another is to 
examine the level of seizures. The second part of the research project examined the changes 
in the size and types of ‘Ecstasy’ seized. This chapter critically examines how global, 
European and the national markets are estimated, comparing the data provided by the United 
Nations and the European Monitoring Council on Drugs and Drug Addiction. This will then be 
compared to the findings in the next chapter from the analysis of the seizures in Cambridge. 
 
5.1.1 United Nations World Drug Report 
 
The controlled status of drugs in most of the countries of the world can be traced back to the 
United Nations Convention on Psychotropic Drugs in 1971 (United Nations, 1971). The 
convention was the foundation of what would become the British response to the issue of 
drugs, namely the introduction of the MoDA 1971. The United Nations Office on Drugs and 
Crime (UNODC) report on the global drug trends, releasing an annual report on the changes 
in trafficking and production. The World Drug Reports on two factors; firstly it reports on the 
relative use of the substances and secondly it tracks production, exportation and seizures. 
Figure 5.1 taken from the 2013 World Drug report, displays the global prevalence of use of the 
drug Ecstasy. It shows that the UK has amongst the highest prevalence of reported use of 
Ecstasy. 
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Figure 5.1: Estimated Global Ecstasy Use from the World Drug Report 2013 (UNODC, 2013) 
 
The term Ecstasy is used by the UNODC to describe ‘3, 4-Methylenedioxymethamphetamine 
(MDMA) and its analogues’ (UNODC, 2013 p. xvii). This description includes a wide range of 
potential substances, without the focus on just MDMA, when considering what the Ecstasy 
market is. Figure 5.1 demonstrates that Britain is one of the countries with the highest 
percentage of the population to have used this substance. This is supported by the responses 
given in Survey B question 1, which found that 33% of participants reported to have used 
Ecstasy and by the findings of the Global Drug Survey (2013) that reported 64% use of 
Ecstasy by participants.   
 
The second part of the World Drug Report is the assessment of the relative size of the drug 
markets. This is done by comparing the reported seizure levels of the controlled substances 
by member states.  As was mentioned in Chapter 2 section 2, in 2009 there was a crackdown 
in the production of the precursor safrole (UNODC, 2008). This led to an observed lack of 
availability of MDMA at a global level in the years proceeding, however some recovery was 
noted: 
‘Although many countries reported a continued low availability of MDMA in the 
“ecstasy” market in 2010 (often compensated by the increasing availability of new 
psychoactive substances), there are signs that the “ecstasy” market began to recover in the 
period 2010/2011’ 
(UNODC, 2012 p. 54) 
 220 
 
 
An overall view of global seizures is dependent on the reporting of member states. This is 
further complicated by the individual social and political situations as well as the way the 
information is recorded. However the UNODC does provide an overview report of the global 
seizure levels as shown in Figure 5.2. 
 
 
Figure 5.2: Global Seizure of Ecstasy-Type Substances as reported by the UNODC (2013) 
 
The global level of seizures of Ecstasy type substances peaked in 2007, with the major 
decline observed from 2008, with the aforementioned recovery observed from 2011 onwards. 
The size of the yearly Ecstasy seizures, as provided by the UNODC, is calculated by 
converting the assumed bulk tablet weights into the equivalent kilograms based on information 
available. Thus the estimation on the size of the Ecstasy market is based solely on the 
seizures of tablets, with no reference to alternate forms. This is also reflected in the reported 
seizure levels specific to the United Kingdom, which also only accounts for tablet seizures as 
shown in Figure 5.3.  
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Figure 5.3: Reported seizure levels of Ecstasy type substance from the United Kingdom 
(UNODC, 2003-2012) 
 
The seizures in the UK follow a similar trend to that observed at a global level; however the 
measure of the seizures is in number of tablets as opposed to an equivalent weight.  As the 
two are measured by different parameters a direct comparison is not possible, but a number of 
observations can be made.  Firstly in the UK the peak seizures occurred in 2006, followed by 
a sharp decline in 2007. This is compared to the peak of 2007 observed at a global level. The 
recovery also occurred a year earlier with reported seizures showing an increase in 2010. 
However the UNODC is just one of many organisations that tracks the trends around the ever 
changing drug markets, another that was assessed was the European Monitoring Council on 
Drugs and Drug Addiction, the EMCDDA.    
 
5.1.2 European Monitoring Council for Drugs and Drug Addiction 
(EMCDDA) 
 
The European Monitoring Council for Drugs and Drug Addiction (EMCDDA) monitors drug 
abuse within the European Union (EU), like the UNODC they are focused on identifying drug 
trends and providing advice to aid the development of drug policies. The EMCDDA collects 
data from each of the participatory countries within the EU and generates comparative reports 
(EMCDDA, 2013). The EMCDDA also reports on the estimated size of the ‘Ecstasy’ market 
based on the seizures of tablets, Figure 5.4 displays the comparison of the UK seizures to the 
findings from the EU. 
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Figure 5.4: Comparison of reported seizure levels between the UK and the EU (EMCDDA, 
2013) 
 
The data from the EMCDDA is only available up to 2010 as not all member states produce 
regular statistics on their seizure levels. As can be seen from Figure 5.4, the decline in the 
level of seizures across Europe follows the same trend observed in both the global market and 
within the UK, with a decline in the lead up to 2009. However in Europe the decline is not as 
immediate, as was observed in the UK and Global trends, instead occurring over a number of 
years from 2007.  
 
It is the findings from the World Drug Report, alongside EMCDDA reports that have impacted 
the perceived level of drug usage at the global, European and national stage. Yet both rely 
solely on the seizure of tablets to estimate the size of the ‘Ecstasy’ market. However as was 
shown in the responses to the questions in Survey B, more people are reporting to take an 
alternate form of MDMA, namely a powder or crystal product. This is further supported by the 
reports from the Global Drug Survey (2013).  As estimations are made just on the level of 
tablets that are being seized, not including alternate forms, which are reportedly more popular. 
This could mean that the actual size of the market for MDMA is significantly underestimated.  
 
This research sought to prove that the classification of what constitutes modern Ecstasy and 
MDMA consumption may be being undervalued by investigating to what extent the new crystal 
form of MDMA was being found on the streets. This was achieved by using a case example of 
examining the seizure levels found in the city of Cambridge, to establish what the prevalence 
of the different types of MDMA.    
0
5000
10000
15000
20000
25000
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
S
ei
zu
re
s 
in
 '0
00
s 
of
 T
ab
le
ts
Year
United Kingdom Europe
 223 
 
 
5.2 Seizure Data Collection Methodology  
 
5.2.1 Introduction 
 
Through a collaboration with Cambridge Police access was granted to the police record drug 
logbooks, with the help of a gatekeeper. From these log books data was collected from over a 
10 year period. It was then examined for any possible changes in type of Ecstasy/MDMA 
being seized but also what impact the NPS has on seizure levels of the more established 
drugs.   
 
 
5.2.2 Collaborations 
 
Anglia Ruskin University is working in collaboration with the Cambridgeshire Constabulary 
working out of the Parkside Police station, situated in the city of Cambridge. This collaboration 
has allowed for the collection of primary seizure data of the drugs being seized in the vicinity 
of Cambridge. As well as providing access to the drug log books Cambridge Police are also 
providing seized street samples for analysis that are discussed in Chapters 7 and 8.  
  
 
5.2.3 Data Collection Method from Drug Logbooks 
A systematic review of the police logbooks was conducted, examining the time period 
between 2003 up to 2013. The number of books varied per year as did the total number of 
reported seizures per year. Upon examination of the drug record log books a number of 
variables were considered and recorded. Firstly, only samples that had a confirmed identity 
were included in the study, to ensure the accuracy of the data being recoded. Second, the 
seizures were counted per case rather than by the number or weight of the samples in each 
seizures. This was because the relative offence, either possession or supply were not 
considered and it was just the type that was of interest. There were also some substances that 
were excluded from the study namely; cannabis in any form, cocaine in any form, and heroin 
as they were not of interest to this research.   
 
The final and most important variable was the type of sample recorded; this was the most 
subjective variable as the descriptions were dependant on the officer who logged the sample. 
There was a lack of uniformity in the recording of the description of substances; the 
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ramification of this is discussed later on in the results section. The layout of the information 
and the drug log books is shown as a diagram in Figure 5.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Layout of Cambridgeshire Police Seizure Logbook 
 
Before data collection began certain data protection protocols were stipulated by the 
gatekeeper in relation to what was permissible to be recorded. It was made clear that only 
certain information was permitted to be included in this research, due to the sensitive nature of 
the information recorded in the logbooks. As mentioned previously the nature of the offence, 
either possession or possession with intent to supply was not recorded, neither were any 
personal details about the suspect or the case the samples related to. The information was 
that accessible to be recorded for this research included descriptions of the seizures and the 
confirmation of seizures chemical identity.  To collect the data from the log books a form was 
generated, this was printed out and the data was collected and recorded by hand. For each 
seized sample the following was recorded; the confirmed substance identity and form as 
recorded. 
 
The data collected was analysed in two ways; firstly to establish the prevalence of the type of 
MDMA being seized in Cambridge, looking specifically at when the powder first began to 
emerge and whether it has gained greater prevalence than the traditional pills. It was also 
analysed to look the impact that the emergence of NPS had on drug market of Cambridge, 
with a focus specifically on the impact of Mephedrone, its prevalence and whether it has it 
managed to persist in the market.   
 
a) Case Number/ Suspects 
Details 
 
b) Details of Offence 
 
c) Description of seized Items 
d) Laboratory Reference 
Section 
e) Drug Confirmation and 
Weight 
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Chapter 6 Results of Seizure Data for Drugs 
6.1 Cambridge Seizures between 2003 and 2013 
 
The data that was collected for this project looked at seizures in the period between 2003 and 
2013 in the city of Cambridge. The data was collected to answer two questions; firstly what 
was the prevalence of the compound MDMA compared to competing compounds. Secondly in 
which form was MDMA the most prevalent. The data collected from the drug logbooks has 
been summarised in Table 6.1.  
 
Similar to the description used by the UNODC, the Cambridge police use the term ‘Ecstasy’ to 
cover any substance that contains MDMA or its analogues. This is because these substances 
are all classed under the same section of the MoDA 1971. Therefore when analysing the data 
the term ‘Ecstasy’ has been used consistently in this section when discussing either form. 
There were also some substances that occurred infrequently in the records, these were 
grouped together into their respective class of drugs, the piperazines and cathinone 
substances. There was also variability in which compounds appeared from these classes year 
to year. Table 6.2 shows the different compounds found in each year; separated into either the 
piperazines or the cathinones, as described in the record books. Some samples were 
recorded as containing mixtures of more than one compound; in this case each compound 
was recorded individually. 
 
.  
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Table 6.1: Number of cases confirmed to contain chosen substances seized by Cambridge Police 2003-2013  
 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Average Range Variance 
Ecstasy 
(MDMA) 
23 17 21 26 17 28 7 7 18 30 14 19 23 54 
Amphetamine 15 11 28 24 14 17 23 15 26 20 18 19 17 27 
Ketamine 0 1 2 5 14 20 24 9 11 9 5 9 20 55 
Piperazines 0 0 0 1 1 7 22 22 1 4 0 5 22 66 
Cathinones 0 0 0 0 0 0 2 21 4 4 9 4 21 38 
n 38 29 51 56 46 72 78 74 60 67 46 56 49 225 
 
Table 6.2: Individual compounds from the Piperazine and Cathinone classes as reported each year in the Cambridge drug log books 
 2006 2007 2008 2009 2010 2011 2012 2013 
Piperazines BZP Piperazine 
BZP 
‘Piperazines’ 
BZP 
‘Piperazines’ 
BZP 
TFMPP 
TFMPP TFMPP TFMPP 
Cathinones None None None 
Khat 
Mephedrone 
(4-MMC) 
Mephedrone 
(4-MMC) 
Naphryone 
Flephedrone 
Mephedrone 
(4-MMC) 
MEC 
Mephedrone 
(4-MMC) 
 
Mephedrone 
(4-MMC) 
Methylone 
MEC 
Cathinone 
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6.2 Analysis of the seizures of Ecstasy reported in Cambridge 
 
The level of seizures of confirmed samples of ‘Ecstasy’ recorded by Cambridge police is 
displayed Figure 6.1, this figure shows the changing trend over the time period.  
  
 
Figure 6.1: Number of seizures of Ecstasy (MDMA) as recorded by Cambridge Police between 
2003 and 2013 
 
A key observation from this data is what occurred between 2009 and 2010. As has already 
been stated there was a specific crackdown on the production of safrole in 2008, which led to 
a major decrease in the availability of MDMA (UNODC, 2008). The effect of this is observed in 
the seizures found in Cambridge the following year. However the levels of Ecstasy/MDMA 
began to increase again past 2010. This correlates with the findings reported at a global level 
by the UNODC (2013) as shown in section 5.1.1.  The relevance of the lack of availability of 
MDMA at this time becomes apparent when examining the emergence of the NPS into the 
British recreational market, looking specifically at what occurred in Cambridge.  
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6.3 The analysis of Ecstasy seizures in comparison to Amphetamine 
seizures 
 
From the data it was observed that amphetamine was present most consistently of the 
selected drugs reported over the time period examined as it had the lowest range and 
variance of the substances examined, as shown in Table 6.1.  In the time period examined, 
the seizures of amphetamine also did not show the same decline in availability as was 
observed for Ecstasy in 2009. A direct comparison between the seizure levels of these two 
compounds is shown in Figure 6.2. 
 
 
Figure 6.2: The number of seizures of Ecstasy/MDMA compared to Amphetamine as found in 
Cambridge (2003-2013) 
 
The data shows is that while there was a decline in the seizures of Ecstasy in the years 
2009/2010 as a result of the crackdown of safrole production, the level of amphetamine seized 
in Cambridge was unaffected.  The observed trend suggests that the level of seizures for 
amphetamine appears to increase over the time period examined.   
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6.4 Seizures of Ecstasy in comparison to newly emerging NPS 
 
This research not only sough to discover the prevalence of the drug Ecstasy, but also the 
substances that were considered to be ‘replacements’ or ‘competitor’ compounds, namely the 
piperazine compounds and the substituted cathinones such as Mephedrone and ketamine, 
which were assessed in Survey B. Figure 6.3, depicts the emergence of these compounds, in 
comparison to the seizure levels recorded for Ecstasy.  
 
 
Figure 6.3: Seizures of Ecstasy/MDMA compared to the newly emerging NPS as found in 
Cambridge (2003-2013) 
 
 
The compounds and their impact will be discussed briefly by order of their emergence in 
Cambridge. However the use of the word emergence is perhaps not entirely fitting. The 
increase in the prevalence of these substances in the seizure records can be identified to 
when each of the substances were controlled under new legislature.  
 
The earliest of the NPS substances that was recorded in the log books was ketamine, which 
was controlled by an amendment to the MoDA 1971 in 2006. However there were records of it 
being seized before this in Cambridge, with the first recorded seizure in 2004. There was a 
sharp increase in the number of seizures of this substance being recorded post 2006. The 
reported numbers of seizures then increased year on year until 2009 when something else 
entered the market. As ketamine was only controlled in 2006 there was no requirement to 
record seizures before this date, even though some were, the actual scale of seizures pre-
2006 is unquantifiable by this project as only confirmed samples were assessed.  
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Next to enter the Cambridge drug records were the piperazine class of substances in 2009. 
The first of these to be identified was BZP but was subsequently followed by a generalised 
term of ‘piperazines’ and then TFMPP as shown in Table 6.2. It is important to note that these 
compounds were relatively unknown as recreational drugs towards the middle of the 2000s, 
being sold like Ecstasy tablets (Staack, 2007, Wood et al., 2007). Again the ‘emergence’ of 
these compounds in the Cambridge market coincides with the legislation brought in to control 
them in 2009.  Until this point any discoveries and seizures of these compounds would have 
gone unreported as they were treated as an unknown/uncontrolled substance and not 
confirmed as controlled substances.  
 
The final group of substances that appeared in the Cambridge data were the cathinone 
derivatives.  As with the piperazines it is impossible to discover the prevalence or emergence 
of these compounds pre-legislation in 2010. However Table 6.2 gives an indication based on 
the types of cathinones reported. There is a substantial increase in the seizures of cathinones, 
mostly the compound Mephedrone in 2010. This was at the peak of its media hype that was 
discussed in section 2.6.3 (Alexandrescu, 2014).   
 
Post-2010 saw the re-emergence and increased prevalence of the seizures Ecstasy in 
Cambridge, which correlates with the findings reported by the UNODC (2013), who also noted 
a recovery to the market for this drug in the same time period (Section 5.1.1).  This can also 
be linked to the observed decline in the levels of both piperazine and cathinone groups of 
compounds. Both these groups of substances were introduced as alternatives to the Ecstasy 
group of substances. However the findings from Survey B suggests that given an option the 
preference is for MDMA over these compounds. This could explain why the sudden decline of 
cathinones and piperazines coincides with the re-emergence of Ecstasy/MDMA products. As 
Ecstasy became more available there was less of a need for these products.  
 
This finding indicates that certain NPS markets are driven by availability of compounds in 
question. However there is an argument to be made for consumer choice, specifically related 
to the Ecstasy market. This poses an interesting question; if the UNODC had not cracked 
down on the production of safrole, thus leading to the mass unavailability of arguably one of 
the most popular recreational drugs, would there have been the sudden explosion of NPS 
substances into the market to fill the MDMA void?  
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The answer to this question is most likely to be yes as there are still new NPS compounds 
entering the UK market (Home Office, 2014) despite the apparent re-emergence and 
availability of MDMA. However whether the drug Mephedrone would have become as 
prevalent could potentially be argued based on the user reports from survey B, and that its 
prevalence in the Cambridge market was so short lived. This raises a second question about 
how prevalent NPS products really are in relation to previous ‘traditional’ compounds.  Has 
there been anything to emerge in the last 5 years that can actively compete with 
Amphetamine, Ecstasy and Cocaine? The data collected for this research, both the seizure 
records and social responses would suggest not.  
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6.5 Comparison of the Type of Ecstasy seized 
 
To answer the second research question, whether tablets or pills were more prevalent, 
information was collected on the Cambridge seizures. This information was provided in the 
descriptive section in the log book. The descriptions were variable as there was no uniform 
description method and was solely dependent on the officer who was logging in the sample. 
However there was a clear distinction between the forms that were being reported. These 
types fell into two categories as either tablets or powders/crystals; the change in the 
prevalence of these two types is displayed in Table 6.3.   
 
Table 6.3: Ecstasy Seizures in Cambridge city between 2003 and 2013 by type 
  2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Tablet 
23 17 18 22 12 13 4 1 1 5 0 
100% 100% 86% 85% 71% 46% 57% 14% 5.50% 13% 0 
Powder/ 0 0 3 4 5 15 3 6 16 25 14 
Crystal 0 0 14% 15% 29% 54% 43% 86% 89% 87% 100% 
Unknown 
0 0 0 0 0 0 0 0 1 0 0 
0 0 0 0 0 0 0 0 5.50% 0 0 
n 23 17 21 26 17 28 7 7 18 30 14 
 
 
The data shows a clear and definite shift has occurred in the type of MDMA being found in 
Cambridge, visualised graphically in Figure 6.4. There is a distinct cross-over period observed 
between 2008 and 2010. There was one sample in 2011 for which a clear identification was 
not possible, this sample was not included in the figure below.  
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Figure 6.4: The changing trend of Ecstasy recorded by type as found in Cambridge (2003-
2013) 
 
The changing trend observed in the Cambridge seizure records correlates with the findings 
reported in a paper on the changing use of the terms Ecstasy and MDMA (Turner et al., 2014). 
The significance of the change in seizures of tabletted material over time was tested using a 
spearman’s rank correlation co-efficient. The test returned an r value of -0.898 and a P value 
of <0.001. Thus the change in seizures of the tablets form is a significant decline over the time 
period examined. Conversely the trend in seizures of the crystal samples was also tested 
using a Spearman’s rank correlation co-efficient, this returned an r value of 0.836 and a P 
value of 0.001. This shows that the increase in crystal samples was significant over the time 
period examined.    
 
The findings in this section has provide clear evidence that there is now effectively two 
‘products’ in the recreational drug market that both use MDMA (the chemical), as their key 
psychoactive ingredient. The issues that arise from this were highlighted in the social 
research, that the public and potentially the users not recognising the two as being one and 
the same. This is further compounded by the belief that one product, namely the powdered 
form is purer, a hypothesis that will be analysed in the subsequent analytical section.  
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The second issue that was discussed in the evaluation of the UNODC and the EMCDDA’s 
estimation of the Global and European markets is the reliance on tablet seizures to estimate 
the size of the market. Yet as can be seen in the data collected from Cambridge and 
supported by the users own statements in the qualitative questions from the social surveys, 
tablets are not the most dominant and prevalent form which is being used or seized. This 
means the actual size of the MDMA market is being under estimated and its impact 
understated.  
 
 
6.6 Key Findings from analysis of Seizure Data from Cambridge  
 
The seizure data collected from the Cambridge show that the availability of MDMA in the city 
was impacted by the sanctions by the UN in 2008, with less Ecstasy being found on the 
streets in 2009 and 2010. This also coincided with the emergence and identification of NPS’s 
entering the Cambridge drug market. However neither the piperazines nor the cathinones 
have had the same level of prevalence of MDMA, and any increase in seizures of these 
substances was short lived once MDMA returned to the market. What is also apparent is the 
definite shift away from tableted material to the form of powders and crystals, which as of 
2013 were the most prevalent form of MDMA being seized in Cambridge. These findings 
support the second social survey data in which the participants stated a categorical preference 
for the product identified as MDMA powder. With more powder available in Cambridge the 
fourth research question which sought to discover the relative purities of the two forms is 
answered in the next section, the chemical analysis of the seized samples.   
 
    
 
 
 
 
 
 
 
 
 
Chapter 7 Chemical Analysis of Street Drugs 
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In previous chapters there has been a critical examination of how social surveys on usage and 
seizure data have been used in other research before comparing this to the data procured in 
this research.  The following chapter discusses the method used to identify and quantify 
seized street samples of powder MDMA. This cannot be critically compared to previous data 
as there is no other study that has published comparable data. Therefore the following section 
will instead outline the approach taken in examining controlled substances, including an 
overview of the instrumentation that was employed in this research and why. 
 
7.1 Process of Identification  
 
Throughout this thesis it has been taken for granted that when discussing drugs, the 
substances are what they are believed to be. This is specific to the reports from the users of 
the substances they have taken. However how does a user know exactly what the substance 
they are taking is? As reported in Question 19 of Survey B 27% of the participants (n =252) 
reported to have tried something without knowing exactly what it was.  The truth is that without 
thorough chemical analysis no user can be 100% sure that the drug they are taking contains 
the substance they think it does.   
 
One way to determine what is in a sample is to send it for analytical testing.  This is provided 
through forensic science laboratories to the police forces in relation to criminal cases. As the 
substances of interest are controlled under the MoDA 1971, accurate identification is 
important to be able to correctly prosecute. However due to the criminal nature of the control 
status of the substances, users have no legitimate way to gain access to the analytical 
techniques required for thorough identification.  The seizures examined in the previous 
chapter had already gone through the identification in forensic laboratories to confirm the 
identities of the substances at the request of Cambridgeshire police.  
 
After samples have been seized by the police or border agency they are sent to be examined 
by forensic laboratories for identification, quantification and any other testing that can provide 
information to help with the case. A general overview of the procedure the samples undergo is 
shown in Figure 7.1.  
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Sample of seized material 
selected for testing 
Physical Description 
is recorded 
Bulk Samples  Trace Samples 
Initial Identification 
(Presumptive Tests) 
Confirmation 
(Instrumental 
Analysis) 
Quantification of 
compounds  
 
Figure 7.1: Flow Diagram of a generalised procedure for identifying street samples of drugs 
(Cole, 2003) 
 
Once submitted to the laboratory, the first stage of identification is sample selection; this 
determines what needs to be tested and in what quantities. The second stage is a thorough 
and accurate record of every pertinent detail of the physical description of the sample, 
including any details of the packaging. This stage is especially important for tablets that have 
unique identifying markers that can link batches to producers, this has occurred most recently 
in the case of the yellow UPS tablets connected to group located in the Netherlands (Power, 
2015). In a forensic context it is important to record an accurate starting weight of the sample 
before anything has been removed as then an accurate dosage amount can be calculated 
(Cole,2003). Any distinctive odours should also be noted as this can give a preliminary 
indication of what might be present (Cole, 2003).  
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The third step determines what course of action to follow, this is achieved by determining 
whether the sample is considered bulk or trace. Trace samples may include items that have 
been submitted that are believed to have minute amounts of a controlled substance, such as 
weighing scales and other paraphernalia (Cole, 2003). Bulk samples in relation to drugs are 
not necessarily significantly large quantities, as the analytical tests that will be described later 
on require milligram quantities for identification. Trace items are directly analysed by 
instrumental analysis (Cole, 2003).  When dealing with large numbers of bulk samples a quick 
and cost effective method of eliminating samples is required. There are a number of 
presumptive tests that can provide preliminary identifications of select substances. Once a 
sample has indicated that it may contain a controlled substance it can then be analysed by a 
variety of analytical techniques. The technique that was used in this research was Gas 
Chromatography – Mass Spectrometry (GC-MS), a technique that can be used for the 
confirmation and quantification of controlled substances.  
 
7.2 Acquisition of Samples 
 
As mentioned in the section 5.2.2, the Forensic Science and Chemistry Research Group 
(FSCRG) at Anglia Ruskin University have an on-going collaboration with the Cambridge 
police based at the Parkside Police station. This collaboration provides seized samples of illicit 
substances for analysis to support the research projects conducted by the academics and 
PhD researchers of Anglia Ruskin. To date the number of samples provided by the Cambridge 
police stands at a total of 80 samples, these samples are allocated unique identifying numbers 
from A1 to A80. However not all these samples were of relevance to this research project, the 
choice of sample inclusion and exclusion is explained in the following section. 
 
7.3 Sample Selection 
 
Over the course of the project there were three stages of sample selection. The first stage was 
the initial test group made up of 19 samples. The first nine samples were specifically chosen 
at Parkside in March 2013 by the researcher as potentially containing the compounds of 
interest. Of these samples; four were in the tablet form with the other five were crystalline or 
powdered samples. The next ten samples were chosen using a random number generator 
from the samples labelled A1 to A44. These samples had been previously collected and were 
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also being analysed as part of other projects within the FSCRG. It was through these other 
projects that a further nine samples containing the target compounds were identified and so 
included into this project to make a second stage of samples. 
 
The last stage of sample selection were samples collected from Parkside in February 2014. 
This stage included 20 samples, 2 tablets and the rest powders or crystals. This correlates to 
the findings from the seizure records as in the time period of sample collection 2012/2013 as 
only 13% of ‘Ecstasy’ samples seized in this year were in a tablet form. Samples A63, A70, 
A71, A72 and A73 were made up of a series of individually wrapped samples, with samples 
A63, A70 and A73 containing what are known in the drug using community as ‘bombs’ 
(Measham et al., 2010).  Each ‘bomb’ was separated to create individual samples bringing the 
total number of samples for the third stage to 28. Pictures of the different packaging types are 
included in Chapter 8. The total number of samples assessed was 56, however not all of these 
contained substances of interest. To identify samples of interest the identification process 
followed the same method outlined in Figure 7.1, with primary identification using presumptive 
tests and confirmation and quantification using analytical techniques.  
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7.4 Presumptive Tests 
 
The first stage of analysis was to determine if the samples could possibly contain the 
substances of interest. The quickest and most cost effective method was through the use of 
presumptive tests (UNODC, 2006). There are a series of presumptive tests specifically 
developed for the primary identification of illicit compounds, these tests can indicate whether a 
sample contains a specific group of compounds and can differentiate to some extent between 
compounds (O’Neal, Crouch and Fatah, 2000). All of the samples were subjected to the same 
presumptive tests, with the two tests chosen being the Marquis and the Mandelin tests. These 
two tests can identify and distinguish between amphetamine type stimulants and other 
psychoactive compounds (Johns, Wist and Najam, 1979; O’Neal, Crouch and Fatah, 2000; 
UNODC, 2006; Velapoldi and Wicks, 1974). The expected results for each tests is described 
in the following sections.  
 
Marquis Test 
 
There are a number of different ways of producing the Marquis Test reagent (O’Neal, Crouch 
and Fatah, 2000; UNODC, 2006).  The method followed to produce the reagent used in this 
project follows the method outlined by O’Neal, Crouch and Fatah (2000). The solution was 
made by the addition of 100mL of concentrated sulphuric acid to 5mL of 40% formaldehyde 
(formaldehyde: water v/v). The Marquis test can be used to differentiate between 
amphetamine and the ring-substituted substances such as MDMA, as shown in Table 7.1.  
 
Table 7.1: The positive colour reaction responses for Marquis Test as recorded in the 
literature 
Compound 
Velapoldi and 
Wicks (1974) 
Johns, Wist 
and Najam 
(1979) 
O’Neal, Crouch 
and Fatah (2000) 
UNODC (2006) 
Amphetamine 
Orange – 
Brown  
Orange – 
Brown  
Reddish Brown 
Orange – turn 
slowly to brown 
Methamphetamine 
Orange – 
Brown  
Orange – 
Brown  
Reddish Brown Orange – Brown  
MDA Purple Black Black 
Dark Blue – 
Black  
MDMA No Data 
Blue – Purple 
– Black 
No data 
Dark Blue – 
Black  
The Marquis test cannot be used to differentiate between amphetamine and 
methamphetamine nor between the methylenedioxy compounds, hence why it is only a 
presumptive test.  
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Mandelin Test 
 
The Mandelin test can differentiate to some degree between amphetamine and 
methamphetamine. However it cannot differentiate between the methylenedioxy compounds 
as shown in Table 7.2. There are a number of self-test kits available on the market that rely on 
the Mandelin test reagent as proof of MDxx compounds, most notably the EZtestkit (EZtestkit, 
2013). The Mandelin reagent was also produced in accordance to the method described by 
O’Neal, Crouch and Fatah (2000). To produce Mandelin reagent, 1.0g of ammonium vanadate 
was dissolved into 100mL of concentrated sulphuric acid. The varieties of colours which are 
produced when Mandelin reagent is added to the different compounds are due to oxidation of 
the vanadium ions in solution (ibid.).  
 
Table 7.2: The positive colour reaction responses for the Mandelin test as recorded in the 
literature 
Compound 
Velapoldi and Wicks 
(1974) 
Johns, Wist and 
Najam (1979) 
O’Neal, Crouch and 
Fatah (2000) 
Amphetamine Bluish green Green Bluish Green 
Methamphetamine Yellowish green Light Green Dark Yellowish Green 
MDA Purple – Black Red – Purple Bluish Black 
MDMA No Data 
Blue- Dark Purple – 
Black 
No Data 
 
Presumptive tests cannot be used as confirmation of a sample as there are number of factors 
that can impact how a presumptive test is interpreted. Firstly, colour is subjective, as 
demonstrated in the variation reported by the different papers published on what colour should 
be expected (Table 7.2). Therefore it is imperative that a known control is used at the same 
time as any unknown compound for a direct comparison (UNODC, 2006). There are also other 
factors that can affect the colour produced; the concentration of the compound and whether 
that drug is found as a salt or free base, whether there are any diluents, contaminants or dyes 
that could mask the colour change (O’Neal, Crouch and Fatah, 2000).  Therefore confirmation 
of the sample requires further analysis by chromatographic and mass spectrometric 
techniques. 
 
7.5 Chemical Analysis by Gas Chromatography- Mass 
Spectrometry (GC-MS) 
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The analytical technique that was employed in this research was GC-MS, which is a well-
documented technique that is used in the identification and quantification of controlled and 
seized samples. In section 2.5 previous studies were discussed that specifically examined the 
content of ecstasy samples, these studies all made use of GC-MS to identify their samples 
(Baggott et al., 2000; Cole et al., 2002; Milroy, Clark and Forrest, 1996; Ramsey et al., 2001; 
Renfroe, 1986; Sherlock et al., 1999; Tanner-Smith, 2006).  The technique has also been 
applied to chemical profiling, which provides further information on the potential synthesis 
routes, discussed in section 2.1.3 (Cole, 2003; Gimeno et al., 2002; Swist et al., 2005; van 
Deursen, Lock and Poortmen-van der Meer, 2006; Verweij, 1990).  
 
The advantages of using GC include; ‘the speed of analysis, high levels of resolution, ease of 
operation, excellent quantitative results and the moderate cost’ (McNair and Miller, 2009, 
p.156). The following section will provide a brief overview of how GC-MS works and how it 
was effectively applied to identify and quantify the compounds of interest to this research. 
 
7.5.1 Gas chromatography – Mass Spectrometry 
 
Gas Chromatography 
The basic principle of GC is that when a complex sample is introduced to the system, 
separation takes place (Carlin and Dean, 2013).  The complex sample in this research refers 
to samples that may contain more than one compound.  The components that make up a GC 
system are: carrier gas and flow control, a sampling device and a heated injection inlet/port, a 
column and oven, a detector and a data recording device. Figure 7.2 shows a simplified 
schematic of a basic GC system.  
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Figure 7.2: A basic schematic of a Gas Chromatographic system 
 
Sampling 
Firstly the sample is collected by the auto-sampler. The sample injection is controlled through 
an automatic sampling device with a micro-syringe to ensure the same amount is introduced 
onto the system with each injection (McNair and Miller, 2009).  The sample is then injected 
through the heated injection port, where it is vaporised and carried onto the column by the 
carrier gas.  
 
Mobile Phase 
An inert carrier gas, such as helium flows through the injection port and along the column. It is 
the mobile phase that carries the sample through the system. The flow rate of the mobile 
phase is controlled to ensure reproducibility between samples (McNair and Miller, 2009).   
 
Stationary Phase 
The column is comprised of a fused silica tube coated with a thin film of stationary phase 
material. The stationary phase varies dependant on the type of analysis that is required, for 
the compounds of interest to this research namely MDMA and Mephedrone, there are two 
types of stationary phase that are recommended. These are either a 5% diphenyl/ 95% 
dimethylsiloxane composite or 100% dimethylpolysiloxane (UNODC, 2006). The oven runs a 
selected temperature programme to aid separation (McNair and Miller, 2009).  As the sample 
passes along the column it partitions between the mobile phase and the stationary phase that 
causes the separation, illustrated in Figure 7.3.   
Auto-Sampler 
Column 
Data 
Recording 
Device 
(Computer) 
Injection port 
Oven  
Detector 
Gas 
Supply 
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Figure 7.3: Visual representation of the separation of compounds by GC 
 
Image A above illustrates two compounds entering the column, both compounds then partition 
into the stationary phase. One compound then partitions back into the mobile phase and is 
moved further along the column. As the column temperature increases the second compound 
also repartitions back into the mobile phase. The separated molecules then pass into the 
detector. The detector then registers the presence of compounds as an electrical signal that 
can be picked up by the data recording device that then produces a chromatogram for 
interpretation (Carlin and Dean, 2013; McNair and Miller, 2009).  Figure 7.4 displays an 
example of a chromatogram, how the data is presented for analysis. The example provided is 
a chromatogram that was generated for the analytical standard for MDMA.    
  
Figure 7.4: Exemplar chromatogram for MDMA Standard (RT 16.40 minutes) and the internal 
standard (RT 17.87 minutes) 
 
The above chromatogram is an example of the report generated from the detection of 
compounds that have been separated using GC. It can provide two sets of information on the 
sample being analysed. The first is the time at which the peak was first detected, this is known 
as the retention time (RT). The RT for compounds can be collected by running known 
standards of the compounds before trying to identify any unknown samples. The second is 
quantitation of the compound, this is determined by how big the electrical signal is that is 
detected. The chromatogram above shows two peaks, the first was recorded at the time of 
A B C D 
Abundance MDMA 
Internal 
Standard 
(Mins) 
 244 
 
 
16.40 minutes and is the peak for a known standard of MDMA. The second peak, at 17.87 
minutes was the Internal Standard (IS).  
 
An internal standard is a known compound which is used as a reference point to verify that the 
instrument is processing each sample to the same standard and is used to verify that there is 
reproducibility and consistency between samples (Carlin and Dean, 2013).  There are a 
number of qualities that determine a good internal standard that are; the IS must elute near 
the peaks of interest but not on top of any compounds of interest, as there must be clear 
resolution and separation between compound of interest and the IS as shown in Figure 7.3. 
The IS should also be chemically similar to the compounds of interest but should not interfere 
or react with any compounds analysed (McNair and Miller, 2009).The GC is just the first part 
of the analysis, once the sample has been separated on the column it then is passed into the 
MS, which completes the second stage of analysis.  
 
Mass spectrometry  
 
Mass spectrometry consists of ionisation source, mass analyser and the detector. In this 
research electron impact ionisation (EI) was used. The basic principle of EI is that the gaseous 
sample is bombarded with a stream of electrons to create ions that are then passed through a 
mass analyser and into the detector (Downard, 2004).   
 
Firstly the gaseous sample, which was separated by the GC, is introduced into the ion source 
to fragment the molecule within a vacuum. The ion source produces a stream of electrons. As 
gaseous molecules pass through the stream they collide with the electrons, which leads to 
ionisation that causes the molecules to gain a charge (Downard, 2004). If sufficient energy is 
conferred to the molecule during ionisation the molecule will fragment. Each primary product 
ion derived from the molecular ion will then also fragment into smaller ions (de Hoffmann and 
Stroobant, 2007). Once ionised the fragment ions are then accelerated into the mass 
analyser, in this research a quadrupole mass analyser (QMS) was used. A QMS separates 
the ions according to their mass-to-charge ratio (ibid.). The mass to charge ratio is indicated 
as m/z, where m represents the mass of the ion over z the charge. As most ions lose only one 
electron the charge is +1, which means the m/z value of the ion is often considered to be the 
mass (Shimadzu, 2015). Once the ions have been separated by the QMS they pass into the 
detector, which registers the ions in proportion to their abundance. The most abundant ion is 
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labelled the base ion, with all other ions represented as a proportion against the value of the 
base ion (de Hoffmann and Stroobant, 2007). The resulting data produces what is known as 
the mass spectrum for the molecule and is plotted as ion abundance versus the m/z. An 
example of a mass spectrum is shown in Figure 7.5. 
Figure 7.5: Exemplar Mass Spectrum for the compound MDMA (Base ion indicated on 
structure in red) 
 
The spectrum above shows the fragment ions that were recorded for a standard of MDMA. 
The heaviest ion recorded relates to the molecular ion (M.+), in the above spectrum this is the 
ion at m/z 193 the molecular weight of MDMA. The base ion (the most abundant ion) for 
MDMA is m/z 58, the other ions recorded are fragments of varying sizes.  The confirmation of 
the identity of a sample can be assessed in a number of ways. As this spectrum was collected 
from a sample made from a known analytical standard it is logical to state that it is a spectrum 
for that compound, the fragmentation pattern and the relative abundance of selected ions is 
unique to each molecule and thus provides a confirmed identity for the substance. However, if 
a sample is unknown there are also library databases, such as NIST (NIST, 2006), which are 
installed in the recording software. These databases provide a comparison to the collected 
spectra of known samples that can provide a preliminary identification, which can then be 
confirmed with a known standard once an identity is suspected.  
 
Another way in which the spectra can be analysed to provide identity is to look at the specific 
fragment ions, which can give an indication of the structure of the sample being analysed if 
there is not a known standard or a library match. This is sometimes the case in the field of 
drug analysis when assessing NPS compounds. As new unknown compounds are entering 
the market, the databases and analytical standards for comparison are not always readily 
available, so interpretation of spectra can give an indication of the functional groups and type 
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of compound present though further confirmation of elemental composition would require the 
use of NMR (Cole, 2003). For this research NMR was not required as known analytical 
standards were available and the comparable spectra were available in the library. 
 
Compounds can also be quantified using the mass spectrum, by using the abundance ratio of 
the base ion of unknown sample to the internal standard against different concentrations of 
the standard.  
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7.5.2 Choosing an appropriate method  
  
The use of a GC-MS to identify and quantify illicit compounds is widely used within the field of 
drug analysis.  There is a profusion of methods that have been used and are cited throughout 
the literature, which are specific to the analysis of MDMA using a GC-MS (Bonadio et al., 
2009; Gimeno et al., 2002; Swist et al., 2005; van Deursen, Lock and Poortmen-van der Meer, 
2006).  In 2006 the UNODC released its manual to be used by the national drug testing 
laboratories:   
 
 
‘Recommended Methods for the Identification and Analysis of Amphetamine, 
Methamphetamine and their ring-substituted analogues in seized materials’ 
 (ST/NAR/34)  
 
The document produced by the UNODC provides step by step instructions for tested and 
validated methods for the identification of compounds of interest to this project, and so was 
adopted as the method of choice for this research. However, at the time of completing the 
analysis in this research little had been published on the analysis of the compound 
Mephedrone, the second compound of interest in this research (Maheux, Copeland and 
Pollard, 2010; Santali et al., 2011).  Yet the methods that are reported are comparable to ones 
published for the analysis of MDMA. As Mephedrone and its analogue cathinones share 
structural similarities to the phenethylamine compounds that are covered in the UNODC 
manual the analysis was adapted to cover Mephedrone as well.  
 
Once the samples were identified through the presumptive tests they were then prepared, 
extracted, analysed and quantified using the validated method outlined by the UNODC (2006, 
p. 34-35).  
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7.5.3 Sample preparation 
 
The sample preparation method adopted from the UNODC report (2006), was scaled down, to 
reflect the level of material available. In the UNODC report it is suggested that 1000mg of 
active compound was to be made up into 1000mL of water, this was scaled to 10mg in 10mL, 
for cost and environmental purposes. The sample preparation method was employed for both 
the analytical standards and the unknown street samples.  
 
Preparation of the Internal Standard (IS)  
 
An internal standard is used as an internal reference controls for injection and instrument 
variability. The UNODC method suggests a number of possible internal standards; ‘n-
tetradecane, other n-alkanes, diphenylamine or any structurally similar ATS’ (2006, p.34). For 
this project the internal standard that was chosen was n-hexadecane. The concentration of the 
IS used in each sample at injection was 0.48mg/mL as this was within the same concentration 
range used for the samples. 
 
Preparation of Analytical Standards  
 
Before the street samples could be examined the method needed to be verified using 
analytical standards. This was done to collect the retention times and mass spectra for each 
compound so identification could take place. The analytical standards were made to a 
concentration of approximately 2mg/mL and made with deionised water. The standards were 
stored at below 5˚C; as the standards are stable under these conditions for up to one year 
(UNODC, 2006 p. 65). The analytical standards that were chosen were based on the 
possibility of encountering them in the street samples. The standards included were either 
analogue compounds such as MDMA and MDA or competitor compounds that are found in 
the same format, such as piperazines, which have been previously misidentified as ‘Ecstasy’ 
tablets (Staack, 2007, Wood et al., 2007).    
 
The list of 16 standards chosen in the research fell into 4 categories: amphetamine type 
stimulants, cathinone derivatives, piperazine derivatives and caffeine as shown in Table 7.2.3. 
Table 7.2.3: List of analytical standards  
Group Compound 
Amphetamine Type Stimulants 
(ATS) 
Amphetamine 
Methamphetamine 
3,4-Methylenedioxyamphetamine (MDA) 
 249 
 
 
3,4-Metheylenedioxymethamphetamine (MDMA) 
3,4-Metheylenedioxyethylamphetamine (MDEA) 
para-Methoxyamphetamine (PMA) 
para-Methoxymethamphetamine (PMMA) 
Cathinone Derivatives 
Methcathinone (MCat) 
4-Methylmethcathinone (4-MMC/Mephedrone) 
4-Methylethcathinone (4-MEC) 
3,4-Methylenedioxymethcatinone 
(MDMC/Methylone) 
Piperazine Derivatives 
3-Trifluoromethylphenylpiperazine (TFMPP) 
1-Benzylpiparazine (BZP) 
Adulterant Caffeine 
Internal Standard n-hexadecane 
 
 
Preparation of Street samples 
 
Firstly the samples were weighed, with the tabletted samples being homogenised into a 
powder before being weighed out. The same protocol that was used for the analytical 
standards was then applied to the preparation of the street samples, with samples made up to 
a concentration of about 2mg/mL in water, the exact weights for each sample are recorded in 
Appendix VI Tables 8.viii and 8.ix.  
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7.5.4 Extraction of samples  
 
Preparation of the samples for analysis required the compounds to be extracted, as directed in 
the method already mentioned (UNODC, 2006 p.65).  This is due to the compounds being 
dissolved in their salt form. To be extracted and analysed the samples needed to be converted 
to their base form, this was achieved through the process of liquid-liquid extraction (ibid.).   
 
An aliquot of the prepared sample solution was pipetted into a vial. The solution was then 
basified using concentrated ammonium hydroxide (NH4OH). The pH was checked using 
universal litmus paper, indicated by a colour change reaction in the paper. Once the sample 
had been basified, chloroform (CHCl3) was added to the vial, forming two layers. The sample 
was thoroughly mixed to ensure the maximum transfer of compound from the polar water layer 
to the non-polar chloroform layer. The sample was left to stand to allow the two layers to 
separate. Once the two layers were separated, the chloroform layer was removed. The 
chloroform layer was then passed through a layer of anhydrous sodium sulphite into a clean 
vial. The chloroform was filtered in this way to ensure that there is no transfer of any water that 
could damage the sensitivity of the GC-MS (UNODC, 2006 p.65). The final filtrate was then 
used for analysis and made up to a known concentration. This procedure was used for both 
the known standards and the street samples.  
 
To check that 100% of the sample was extracted by the method discussed above, an 
experiment was run to check the efficiency of the extraction. Firstly, a sample of analytical 
standard MDMA was extracted using the method above with the chloroform extract collected 
for analysis. A second and third round of chloroform was then applied to the original water 
solution, to check whether there was any remaining drug in the water sample. The second and 
third chloroform washes were processed in the same way as the initial extract. All three 
chloroform extracts were then analysed by the GC-MS to see whether any MDMA was 
detected in the second or third chloroform extract, however none was detected and so the 
extraction process had removed all the sample in the first extract as shown in Figure 7.6.  
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Figure 7.6: Chromatograms of multiple extractions of MDMA sample (1: first extraction, 2: 
second extraction, 3: third extraction) 
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7.5.5 Preparation of Calibration standards  
 
The use of calibration standards provides a range of concentrations that can be used to 
quantify unknown samples. To quantify the street samples in this research an 11 point 
calibration was generated for the two compounds of interest, MDMA and Mephedrone.   The 
samples were made up by the addition of a known volume of the extracted standard at a 
starting concentration of 2mg/mL in chloroform, a known volume of the IS solution at a starting 
concentration of 1.95mg/mL and made up to 100µl with chloroform to give the final 
concentrations used for analysis. The volumes required for each calibration point are shown in 
Table 7.2.4. 
 
Table 7.2.4: Volumes used to generate 11-point calibration of analytical standards (Starting 
concentration of Standard = 2mg/mL, concentration of IS = 1.95mg/mL)  
Calibration 
Point 
Analyte 
Solution  
 (mL) 
IS 
(mL) 
 Solvent 
(Chloroform) 
(mL) 
Final 
Volume 
(mL) 
Final 
Concentration of 
Analyte 
(mg/mL) 
1 0.0025 0.025 0.0725 0.100 0.05 
2 0.005 0.025 0.070 0.100 0.10 
3 0.010 0.025 0.065 0.100 0.20 
4 0.015 0.025 0.060 0.100 0.30 
5 0.020 0.025 0.055 0.100 0.40 
6 0.025 0.025 0.050 0.100 0.50 
7 0.030 0.025 0.045 0.100 0.60 
8 0.035 0.025 0.040 0.100 0.70 
9 0.040 0.025 0.035 0.100 0.80 
10 0.045 0.025 0.030 0.100 0.90 
11 0.050 0.025 0.025 0.100 1.00 
 
The starting concentration of the analytical standard was 2mg/mL, to prepare a calibration 
standard with the final concentration of 1mg/mL the following calculation was used. 
 
Calculation:  starting concentration x volume 1/ volume 2 = final concentration  
Example: 2 x 0.050/0.100 = 1mg/mL 
 
Where by 2 is the starting concentration, 0.050 represents the volume of millilitres taken from 
the original solution (Volume 1) and 0.100mL is the final volume of the sample (Volume 2). 
This gives the final concentration of 1mg/mL. However as the initial concentration of the 
extracted standard depended on the initial weight of the samples in solution, the final 
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concentrations varied depending on how close to 2mg/mL the starting solution was, the actual 
concentrations used are shown in the section 8.5. 
 
7.5.6 GC-MS Instrumental Method 
 
The instrumental analysis was performed using a PerkinElmer Clarus 500 GC-MS. The 
column employed was an Equity-5, which has cross-linked poly 5% diphenyl/95% 
dimethylsiloxane stationary phase. The column parameters were 30m length by 0.32mm 
internal diameter and a 0.5µm film thickness. This column is comparable to the one used by 
the UNODC but also in other research looking at these compounds (Bonadio et al., 2009; 
Gimeno et al., 2002; Maheux, Copeland and Pollard, 2010; Santali et al., 2011; Swist et al., 
2005).  
 
The oven temperature programme was set at; 100˚C for the first 4 minutes,  then ramped at a 
rate of 5˚C/min  until 200˚C, then 10˚C/min   to 270˚C, whereby it was held for a final 3 
minutes. The injection port temperature was set at 190˚C and the transfer line temperature 
was 280˚C. The injection volume used was 1µl with a split ratio (20:1); the helium carrier gas 
flow rate was set at a rate of 1.2mL/min. 
 
The Mass Spectrometer was tuned on electron impact ionisation (EI) operated at 70eV, with 
an ion source temperature of 230 ˚C. The samples were run in scan mode with a range of 35 
to 450 m/z.  
 
The data was collected and analysed using the compatible software TurboMassTM 
(PerkinElmer, 2006), the statistical analysis was also completed using SPSS. 
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Chapter 8 Results of the Chemical Analysis of Street 
Samples 
This chapter examines the results obtained for the chemical analysis of the seized street 
samples using GC-MS, using the method outlined in section 7.5. The whole process of 
identification, from sample selection to initial presumptive testing through to the final 
quantitation of the samples will be reported in this chapter.  
 
8.1 Descriptions of Samples 
 
Part of the research was looking at the differentiation between tableted and 
powdered/crystalline samples that were seized by Cambridge police. The final count of 
samples assessed for this part of the research was 56. A description of each sample, its 
weight and defining characteristics can be found Appendix VI Table 8.i to iii.  The samples 
were initially divided between tableted samples and powders or crystals. There were 11 
tablets and 45 powder/crystal samples.  
 
8.1.1 Visual depictions of different types of samples 
 
As the samples are separated into two groups, tablets and powders, the descriptions for each 
group have been written up separately. There were a total of 11 tablets that were tested as 
part of this project for which there are photographs of 7, with an image taken from above and 
from a side view. These are shown in Table 8.1. The four remaining samples that were 
included into this study had been used by a separate research project and so had been 
ground into a powder before an image was taken. The powder and crystal samples fell into 
two distinct categories some were white and the rest displayed a pale brown or tan hue. The 
size and shape of the crystals varied, from some that resembled fine powders to large distinct 
crystals. Table 8.2 provides an example of the range of the types of crystallised samples 
examined.  
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Table 8.1: Images of selected tablets samples  
Sample  Top view Side View Dimensions 
A4 
  
Unidentifiable imprint 
(possibly bulls head) -
poor quality imprint 
Diameter: 9mm 
Depth: 3mm 
A47 
  
Pale blue circular 
tablet 
Mickey mouse imprint 
on one side, 
Fantasia hat on other 
Diameter: 8mm 
Depth: 3mm 
A48 
  
Teal heart shaped 
tablet 
with gold flecks 
Height: 1cm 
Width: 8mm 
Depth: 3mm 
A49 
  
Pale red circular tablet 
Cupid design on one 
side 
Blank on other side 
Diameter: 8mm 
Depth: 4mm 
A50 
  
Dark orange circular 
tablet 
Armani design 
Blank on other side 
Diameter: 9mm 
Depth: 3mm 
A79b 
 
None available 
Red  circular tablet 
No Design, rough top 
and Bottom 
Diameter: 8mm 
Depth: 4mm  
A80 
  
White Circular Tablet 
Star Design, blank 
other side 
Diameter: 1cm 
Depth: 4.5mm 
Table 8.2: Types of Powder and Crystal samples  
Sample Type Image 
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A61 Fine White Powder 
 
A51 Distinct White Crystals 
 
A77 Fine Brown Powder 
 
A70a Small Brown Crystals 
 
Table 8.2: Types of Powder and Crystal samples (continued) 
Sample Description Image 
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A54 Medium Brown Crystals 
 
A75 Large Brown Crystals 
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8.1.2 Types of Packaging  
 
When the samples were obtained they were collected as either a subsample of a larger 
seizure and were repackaged into clean polythene bags, or when possible were acquired in 
the original packaging that they were seized with.  Most of the samples that came with the 
original packaging came in similar polythene bags to the ones that were used to repackage 
the bulk samples. Some samples needed to be placed in a second bag to prevent the risk of 
contamination between samples. There were a number of samples that were presented in the 
form of wraps and bombs. The images below depict the types of packaging found and to 
which samples the different packaging relates - Figures 8.1 to 8.7.  
 
 
Figure 8.1: Sample A65 with original seized packaging and secondary packaging 
 
 
Figure 8.2: Sample A65 original seized packaging  
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Figure 8.3: Sample A65 original packaging and secondary packaging side by side 
 
 
Figure 8.4: Sample A80 example of packaging used for tablets  
 
 
Figure 8.5: Sample A64 packaged ‘bomb’s that were separated into samples A64a to e 
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Figure 8.6: Sample A71, a wrap in original plastic bag (front and back view) 
 
 
 
Figure 8.7: Sample A79 that contained a pill and crystal material that was separated and 
repackaged as A79a and A79b. 
 
 
 
  
 261 
 
 
8.2 Presumptive Test Results 
 
The first stage of analysis used to distinguish between the samples was presumptive testing. 
This was employed to give early indications of whether the samples included the desired 
compounds. The samples were tested using the Marquis and Mandelin reagents as described 
in section 7.4. There were a total of 56 samples tested, the results that indicated a positive for 
both tests is shown in Table 8.3.  
 
Table 8.3: Results of the presumptive tests  
 Positive colour test for MDxx 
compounds 
Negative or no colour 
reaction 
Samples 
 A3, A4, A7, A9, A11, A27, 
A28, A37, A44, A48, A50, 
A53, A54, A55, A63, A64a–e 
(5), A69, A71, A72, A73a-c 
(3), A74, A76, A77, A79a, 
A80 
A12, A29, A30, A31, A32 
A35, A40, A41, A42, A45, 
A47, A49, A51, A52, A61, 
A65, A66, A67, A68,  
A70a-c (3), A75, A78, A79b 
Total  31 25 
 
The presumptive test stage of identification of the street samples indicated that, out of the 56 
samples tested with the Marquis and Mandelin reagents, 31 samples potentially contained an 
MDxx compound. Although the remaining samples gave a negative or non-reaction with the 
tests chosen they too were continued on for analytical identification as at time of analysis 
there was no published presumptive test for Mephedrone, the second compound that was 
being considered. The next stage of analysis was identification of the compounds using the 
GC-MS.  
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8.3 Primary Identification of Street Samples using GC-MS   
 
Before the street samples were analysed using the GC-MS for identification, known analytical 
standards were run to collect the retention times and mass spectra for a range of possible 
compounds that may be present. This was done to be able to correctly identify the compounds 
that may appear in the street samples and to verify which substances were not present using 
the methods of identification outlined in section 7.5. By using the chosen method on analytical 
known standards first, this provided a way of verifying that the method being used could 
identify the substances of interest shown in Figure 8.8.  
Figure 8.8: Chromatogram showing separated amphetamine and cathinone standards (A: 
amphetamine, B: methamphetamine, C: methcathinone, D: PMA, E: PMMA, F: Mephedrone, G: MDA, H: 4-
methylethylcathinone, I: MDMA, J: MDEA, IS: n-hexadecane, K: Methylone, L: Caffeine)  
 
The analytical data collected for the known standards used for identification including retention 
times can be found in Appendix VI Table 8.iv. This data was used to successfully identify the 
compounds in the 56 street samples. The samples were prepared in the manner as outlined in 
section 7.5, they were then analysed and the compounds present in each sample was 
identified. The focus of this research was on samples that contained the compounds MDMA or 
Mephedrone. Table 8.4 shows the samples that were confirmed as containing either of these 
two substances. It is these samples that were taken forward to the quantification stage. 
  
  
Abundance  
Time 
[A] 
[B] 
[C
] 
[D] 
[E] 
[F] 
[G
] 
[H] 
[I] 
[J] 
[IS] 
[K] 
[L] 
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Table 8.4: Samples that were identified as containing either MDMA or Mephedrone 
Samples identified as contained 
MDMA 
Samples identified as 
contained Mephedrone 
Samples that did not contain 
compounds of interest 
A3, A4, A7,  A9, A11, A27, A28, 
A37, A44, A48, A50, A53*, A54, 
A55, A63, A64a – e, A69, A71, 
A72, A73a – c*, A74*, A76*, 
A77, A79a, A80 
A12, A29, A40, A42, A51, 
A52*, A61 
A30, A31, A32, A35, A41, 
A45, A47, A49, A65, A66, 
A67, A68, A70a – c, A75, 
A78, A79b 
n = 31 n = 7 n = 18 
 
Samples marked with an * indicate more than one compound was detected in this sample; the 
other compounds that were detected and are shown in Table 8.5.  
 
Table 8.5: Samples that contained more than one compound 
Sample Primary compound Secondary compound/s 
A52 Mephedrone 4-Methylethcathinone (4-MEC) 
A53 MDMA Benzocaine 
A73a – c MDMA TFMPP and BZP 
A74 MDMA Methylone 
A76 MDMA Methylone 
 
Only 38 out of the 55 original samples contained compounds of interest to this research, the 
rest of the samples were therefore discarded after the initial identification stage. The individual 
identification of these samples can be found in Table 8.6.  The most frequent compound that 
was found was methylone, a derivative cathinone similar in structure to MDMA and 
Mephedrone. The samples containing methylone were not assessed further, as this 
compound was not one of the key compounds identified for this research. However the 
presence and relevance of this compound will be discussed in Chapter 9.  
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Table 8.6: Identification of samples that did not contain either MDMA or Mephedrone 
Sample Compounds Identified 
A30 Methylone 
A31 Ketamine 
A32 No Compound Detected 
A35 Caffeine 
A41 Benzocaine 
A45 Cocaine 
A47 TFMPP and Caffeine 
A49 Caffeine 
A65 Ketamine 
A66 Ketamine 
A67 Methylone 
A68 Methylone 
A70a – c Methylone 
A75 Methylone 
A78 TFMPP 
A79b PMA 
n 17 
 
A point of interest is the identifications of samples A79a and A79b, which were seized and 
received to the project together. As one was crystal and one a tablet they were separated into 
two samples for analysis. The crystals of sample A79a were identified as containing MDMA, 
while the tablet contained PMA (para-Methoxyamphetamine). PMA was mentioned in Chapter 
4.2, is a compound which has been sold under the guise of ecstasy tablets and caused a 
series of fatalities in the summer of 2013 (Saner, 2013).   
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Figure 8.9: Number of samples and the number of compounds detected (n = 55)  
   
There were very few samples that were identified as containing more than one psychoactive 
compound, the graph in Figure 8.9 shows that of the 55 samples only 8 samples contained 
more than one compound. However this only relates to compounds that can be extracted 
through the method and does not reflect any diluent compounds that would not appear using 
this method.  
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8.4 Calibration of standards for MDMA 
 
Once the street samples had been identified as containing MDMA, standards of MDMA at 
different concentrations were analysed to produce calibration results, the standards were 
made using the method described in section 7.5.4. A calibration is used to quantify the levels 
of MDMA found within the street samples.  The quantification of the samples will allow for the 
purity of the different forms of MDMA to be established.  
 
Calculating Concentrations of Calibration points 
 
Using the method described in section 7.5.4, an 11 point series of calibration samples were 
made. However the weight of the MDMA exceeded the desired 20mg and so an adjustment 
was calculated using the actual starting concentration of 2.044mg/mL. A further adjustment 
was taken into consideration as the original starting weight was in the salt form, which was 
converted through the extraction process to the free base form of the compound, shown in 
calculation 1. 
 
Calculation 1:- concentration converted from salt form to base form  
 
RMM of MDMA HCl. = 229.7 
RMM of MDMA = 193.24  
193.24/229.7 = 0.84 
 
Therefore the free base concentration = starting concentration x 0.84 
2.044*0.84 = 1.717 
 
Using the above adjustment the actual concentration of free base MDMA that was in the 
calibration points was calculated as shown in Appendix VI Table 8.iv. 
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Calibration Results using integrated peak area 
 
Once the calibration was completed the post-run analysis was accomplished using the 
TurboMassTM software (PerkinElmer, 2006). The peak area integration function was utilized to 
give peak area values for the MDMA peak. The value for MDMA was then divided by the 
internal standard to give the Peak Area Ratio (PAR), illustrated in Appendix VI Figure 8.i. This 
was repeated for each of the triplicated points per calibration point, with a mean calculated 
from the triplicate values. The mean and standard deviation of the triplicate values are shown 
in Table 8.7.  The individual triplicate values are reported in Appendix VI Table 8.v. 
 
Table 8.7: Calibration results table for MDMA standards 
Concentration of MDMA free base 
 (mg/mL) 
Instrumental Response (PAR) 
Mean response Standard Deviation 
0.043 0.027 0.010 
0.086 0.068 0.027 
0.172 0.185 0.025 
0.258 0.335 0.016 
0.343 0.492 0.008 
0.429 0.774 0.007 
0.515 1.100 0.097 
0.601 1.354 0.055 
0.687 1.584 0.078 
0.773 1.882 0.097 
0.858 2.085 0.021 
 
 
The mean values were plotted on a scatter graph to check for a linear response as well as 
producing a linear regression equation that can be used in the calculation of the 
concentrations of the street samples. Figure 8.10 displays the calibration graph using the full 
range of calibration points. 
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Figure 8.10: Calibration curve of the points calculated from the calibration standards (n = 3) 
 
For predictions made from a calibration curve to have low uncertainties the R2 values needs to 
be as close to 1 as possible, the closer to 1 the stronger the correlation between the variables. 
To be considered acceptable for linearity there can be 10% relative uncertainty, and so the R2 
value should be within 0.99 (Ellison, Barwick and Farrant, 2009). As can be seen in Figure 
8.10 the R2 value is 0.983, which is outside the limit for accepted linearity. However the 
linearity can be improved by excluding the lowest two calibration points to give the liner 
response seen in Figure 8.11 that produces an R2 value of 0.994. 
 
 
Figure 8.11: Adjusted scatter pot displaying linearity between concentration points 0.172 and 
0.858mg/mL 
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As removing the lowest two points provided the best linear response, this was the range that 
was used for the analysis of the street samples. Using the regression equation in the above 
figure, the calculation can be rearranged to provide the concentrations of the street samples.  
 
Validation of PAR Calibration Data 
 
To check whether the calibration data was valid to be used for the quantification of the street 
samples, a number of statistical tests were employed. To confirm the validity of the calibration 
data the normality of the residuals and a runs test was completed using SPSS (IBM, 2011). 
The normality of the residuals checks whether the residuals (the difference between the actual 
value for the dependant variable and the estimated value from the regression equation) are 
normally distributed. Table 8.8 displays the concentration, the value obtained from the 
instrumental response designated as actual Y, the estimated dependant variable as calculated 
using the regression equation (y=2.9145x-0.4133) is designated as estimated Y and the 
residual is the difference between the actual Y and the estimated value. 
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Table 8.8: Calculated Residuals for PAR results for MDMA  
Concentration  
(mg/mL) 
PAR Value 
(Actual Y) 
Estimated Y Residuals 
0.172 0.185 0.088 0.097 
0.258 0.335 0.339 -0.004 
0.343 0.492 0.586 -0.094 
0.429 0.774 0.837 -0.063 
0.515 1.1 1.088 0.012 
0.601 1.354 1.338 0.016 
0.687 1.584 1.589 -0.005 
0.773 1.882 1.840 0.042 
0.858 2.085 2.087 -0.002 
 
 
The residuals calculated were tested using the Shapiro-Wilk test for normality in SPSS (IBM, 
2011), with the null hypothesis stating that the distribution of the residuals is normal. The test 
returned a P value of 0.933. As this value exceeded the chosen significance level of 0.05 at a 
95% confidence level the null hypothesis is retained, which means the residuals were normally 
distributed. The Runs test checks whether the data generated has been produced at random, 
whether the points along the regression line are distributed randomly (Walpole, Meyer and 
Meyer, 1998). Again the test was performed on the residuals and run in SPSS (IBM, 2011).  
The null hypothesis states that the sequence of values for the residuals is random. The test 
returned a significance of 1.000, which was greater than the significance level of 0.05 (95% 
confidence level) and so the null hypothesis is retained and the data has been shown to be 
random.  These tests validate the data generated, allowing for it to be used to quantify the 
results for the street samples.  
 
However if there is an issue with co-elution, whereby to samples are detected at the same 
time in the chromatogram the PAR cannot be used to accurately quantify those samples. This 
was an issue that arose with samples A73a, b and c, which contained a mixture of both 
MDMA and TFMPP. Both MDMA and TFMPP had overlapping retention times (16.34 mins 
and16.39 mins respectively) and so in analysis their peaks merged meaning that the method 
discussed above could not be used to quantify these samples.  
This was addressed by using the mass spectra of that compounds, which can be used when 
chromatograms cannot. As both MDMA and TFMPP have distinct spectra as shown in Figure 
8.12, the quantification of MDMA in these samples was achievable using the method of 
extracted ion chromatogram (EIC) by using the relative abundance of the base ion m/z 58. 
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Figure 8.12: Mass spectra for MDMA and TFMPP  
Relative abundance 
Relative abundance 
m/z 
m/z 
MDMA 
TFMPP 
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Calibration of MDMA (using EIC) 
 
The quantification of the MDMA in samples A73a, b and c was not possible using the 
calibration already stated, however as the mass spectral data for MDMA and TFMPP are 
sufficiently different as shown in Figure 8.12, this allowed for quantitation from the spectra. 
The same data set that was used to produce the integrated peak area calibration was used for 
the mass spectral data analysis.  The EIC was calculated by using the abundance level of the 
base ion (most abundant fragment ion) instead of the PAR. The response from the base ion of 
the compound, in this case the ion with an m/z of 58 for MDMA, is divided by the base ion for 
the IS (m/z 57). This provides the ratio that can be used to plot a calibration. Table 8.9 
displays the mean values for the calculated EIC of MDMA divided by the IS. The individual 
triplicate values are reported in Appendix VI Table 8.vii. Figure 8.13 displays the calibration 
graph using the full range of calibration points. 
 
Table 8.9: Calibration data for MDMA using selected ions (m/z 58 for MDMA divided by m/z 57 
for the IS) 
 
 
 
Concentration of free base MDMA 
(mg/mL) 
Instrumental Response (PAR of m/z 58 / m/z 57) 
Mean Response Standard Deviation  
0.043 0.078 0.071 
0.086 0.115 0.022 
0.172 0.406 0.086 
0.258 0.737 0.112 
0.343 1.049 0.075 
0.429 2.022 0.112 
0.515 2.541 0.264 
0.601 3.572 0.101 
0.687 3.861 0.767 
0.773 4.743 0.223 
0.858 5.320 0.164 
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Figure 8.13: Calibration Graph using EIC data with standard deviation error bars plotted (n = 
3) 
 
As with the integrated peak area data from the total ion chromatogram shown in Figure 8.10 
the best linearity achieved between points 0.2 and 1.0 as shown in Figure 8.14. 
 
 
Figure 8.14: Calibration graph displaying linearity between concentration points 01.72 and 
0.858 mg/mL  
 
The regression equation from Figure 8.14 was used to calculate the concentrations of 
samples A73a, b and c as well as sample A53 to verify the accuracy of the two methods. 
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As the EIC method would be needed to quantify the mixed compound samples, it also 
required the same statistical analysis to check for validity. As with the PAR calibration graphs, 
the R2 value was 0.99, which is within the correct linear range for quantification (Ellison, 
Barwick and Farrant, 2009). To confirm the validity of the EIC calibration data, the normality of 
the residuals and a runs test was again completed using SPSS (IBM, 2011). The values for 
the EIC calibration data using the regression equation from Figure 8.12 and the calculated 
residuals is located in Appendix VI Table 8.viii. 
 
 
The residual data was again tested using the Shapiro-Wilk test, and generated a significance 
of 0.197, at a 95% confidence level. Again this value exceeds the stated significance The test 
statistics generated by SPSS for the Runs test on the EIC calibration residuals generates the 
same significance as the PAR calibration, with a significance value of 1.000.   The runs test 
again proves that the calibration data is randomly distributed. As both sets of statistical tests 
on the two methods for quantification generated the same level of significance, this suggests 
that either method is suitable for quantifying the street samples.    
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8.5 Calculating purity of MDMA street samples 
 
From the calibration data collected above, the concentrations and relative purities of the street 
samples containing MDMA were calculated. The samples were run in triplicate under the 
same method as the calibration standards. The concentrations of each sample and the 
instrumental response are reported in Appendix VI Tables 8.ix and 8.x. To calculate the 
relative purities of the samples a series of calculations were used, as shown in the example 
below using the data collected for sample A53.  
 
Example using values from PAR of total ion chromatogram 
The starting concentration for sample A53 was 0.67mg/mL (from Table 8.ix in Appendix VI) 
with an instrumental response of 0.928 (from Table 8.x in Appendix VI). These values can be 
used with the regression equation from Figure 8.10. 
 
Y=2.9145X-0.4133 
 
As Y, the instrumental response is known, the actual concentration of the sample can be 
established by rearranging the equation; 
 
X = (Y+0.4133) / 2.9145 
 
The values are then inputted into the equation to calculate the concentration of the sample 
 
X = (0.928+0.4133)/2.9145 = 0.460 
 
This shows that this sample contained 0.460mg/mL of MDMA free base, however this is 
different to the original concentration calculated based on the weight of the sample dissolved 
(0.670mg/mL). The relative purity of the sample was calculated by dividing the actual 
concentration by the initial sample to provide a percentage. 
 
(0.460/0.670) * 100 = 69% MDMA 
Table 8.10 lists the relative purities of the 29 samples that could be analysed using the PAR 
total ion chromatogram, as well as the form of the sample. 
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Table 8.10: Relative purities of street samples identified as MDMA (as a percentage of mass 
of sample represented as free base MDMA) 
Sample Type Relative Purity of MDMA 
A3 Tablet 39% 
A4 Tablet 17% 
A7 Tablet 46% 
A9 Tablet 39% 
A11 Tablet 45% 
A27 Crystal 42% 
A28 Crystal 58% 
A37 Crystal 52% 
A44 Crystal 52% 
A48 Tablet 33% 
A50 Tablet 37% 
A53 Crystal 69% 
A54 Crystal 70% 
A55 Crystal 77% 
A63 Crystal 75% 
A64a Crystal 87% 
A64b Crystal 73% 
A64c Crystal 85% 
A64d Crystal 72% 
A64e Crystal 65% 
A69 Crystal 70% 
A71 Crystal 51% 
A72 Crystal 73% 
A74 Crystal 78% 
A76 Crystal 79% 
A77 Crystal 76% 
A79a Crystal 61% 
A80 Tablet 34% 
 
 
 
 
  
 277 
 
 
As has been noted there were three samples (73a-c) for which using the PAR of the total ion 
chromatogram would not have given an accurate concentration due to the co-elution of a 
second compound so the EIC was used (Section 8.4). The same example of sample A53 has 
been used to illustrate that both methods are comparable.  
 
To calculate the concentration using the EIC the same initial concentration for A53 was 
0.670mg/mL. The instrumental response for A53 using EIC was 2.271 and the regression 
equation from Figure 8.14 was; Y = 7.5454X-1.1922.  The regression equation was 
rearranged in the same manner as before to give the calculation 
 
X= (2.271+1.1922)/7.5454 = 0.459 
 
This gave the same relative percentage as was calculated when using the PAR, which was a 
relative purity of 69%. These calculations were then used on samples A73a through c, as 
shown in Table 8.11.  
 
Table 8.11: Percentage of MDMA found in samples using EIC 
Sample Type Relative Purity of MDMA 
A73a Crystal 48% 
A73b Crystal 47% 
A73c Crystal 50% 
A53 Crystal 69% 
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8.6 Statistical analysis of significance of the results for MDMA 
 
To assess the significance of the results, a series of statistical tests were performed on the 
relative purity percentages of the street samples to examine whether there is a significant 
difference between the two sample types, namely the tablets and the powders. This was done 
to answer the research question of whether the purity of the newly emerged MDMA powders 
is greater than that of the tableted form as was suggested in the analysis of the social survey 
data of this research.  To answer the question; ‘does MDMA powder live up to its reputation?’ 
 
The statistical tests of mean, median, range and standard deviation were applied to the data 
the results for these tests are shown in Table 8.12.  
 
Table 8.12: Descriptive statistics for the MDMA street samples shown by type  
  n 
Mean 
(%) 
Median 
(%) 
Range 
(%) 
Standard Deviation 
(%) 
All 31 58 58 69 17.8 
Tablets 8 36 38 28 8.7 
Powders 23 66 70 45 13.3 
 
The results above show a difference between the mean values for the tablets and the 
powdered samples. This is also true for the median and range values. The mode values were 
not included in the Table as the powdered samples had 4 sets of duplicate percentages; 47%, 
52%, 70% and 73%. However the distribution of the samples percentage values was 
assessed through the use of the histogram displayed in Figure 8.15. 
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Figure 8.15: Distribution of the percentages of drug found for each type of sample 
 
As suggested by the descriptive statistics in Table 8.15, the histogram shows that the 
distribution of the powdered samples are towards the higher end of the percentage scale and 
the tablets the lower. All of the tableted samples fell beneath the average for all the samples 
combined. There is an area of overlap between the two sample types, with the lowest 
percentage powders being less than the highest tablets. The distribution of the tablets appears 
to be normally distributed about the mean, whereas the powder samples display bimodal 
distribution, which was anticipated as the data set contained multiple modes. As the data is 
not normally distributed, a non-parametric test is needed to test the significant difference 
between the two types of MDMA, and so a Mann-Whitney U test was performed, an example 
is located in Appendix V. The Mann-Whitney U test returned a Z value of -4.06 as this less 
than -1.96 there is a significant difference at the critical confidence level of 0.05 in the 
percentage of MDMA found in the two types. With the powder form being significantly higher 
purity than the tablets for the samples tested. However further examination was conducted to 
assess whether the samples for which an accurate weight was gathered contained an active 
dose. As the powders had a high percentage of MDMA and the tablets a lower one, the weight 
of the full samples should be taken in to consideration. The next section examines the impact 
the weight of the sample had on the dose. 
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8.7 Dosage Level of MDMA Street Samples 
 
Up to this point in this section the percentages have been calculated based on the weight of 
the sample analysed, approximately 20mg. Although the samples analysed represent the 
proportion of MDMA found within the sample, these calculations do not take into consideration 
whether the weight of the whole seizure represents an active dose. What is considered an 
active dose varies from source to source, it is also specific to the different individuals taking 
the substance, however for the purpose of this comparison an active dose is considered to be 
75mg, as stated by the EMCDDA (2015). 
 
To compare the dosage between the two types of sample, two factors were necessary. Firstly 
the proportional percentage from Tables 8.10 and 8.11, and secondly the known weight of the 
sample without any packaging. The weights of the samples varied and due to the relatively 
small amounts of the seized material it was not possible to separate all samples from their 
packaging to obtain a sample weight without risking significant loss of material and so a dose 
calculation is not possible for all samples. However of the samples that did have a sample 
weight, these were divided into two categories, bulk materials and bombs/individual doses. All 
tablets had a separate weight and so an accurate dosage level was obtained for all of the 
samples in this type, as shown in Table 8.13.  
 
Table 8.13: Level of active doses available in Tablet samples (active dose = 75mg (EMCDDA, 2015)) 
Sample Percentage 
Tablet 
Weight   
(mg) 
Weight of 
MDMA.HCl 
(mg) 
Active 
Dose 
Number of 
Doses  
A3 39% 310 121 Yes 1.6 
A4 17% 307 52 No 0.7 
A7 46% 266 122 Yes 1.6 
A9 39% 223 87 Yes 1.2 
A11 45% 291 131 Yes 1.7 
A48 33% 423 139 Yes 1.9 
A50 37% 316 117 Yes 1.6 
A80 34% 326 111 Yes 1.5 
 
Only one out of the eight tablets did not contain the threshold level of MDMA considered to be 
an active dose. The other seven tablets did however contain an active dose, with six of the 
tablets containing over 110mg of MDMA, which according to the dosage guidelines by the 
EMCDDA constitute a ‘large’ dose (EMCDDA, 2015). How did the dosage levels found in the 
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tableted Ecstasy compare to the crystalline MDMA powder? The results for the powdered 
samples for which an initial weight was known are shown below in Table 8.14.  
 
Table 8.14: Dosages available in powdered MDMA samples  
Type Samples Percentage 
Weight of 
sample  
(mg) 
Weight of 
MDMA.HCl 
(mg) 
Active 
Does 
Number of 
Dose  
Bulk 
powders 
A53 69% 629 434 Yes 5.8 
A54 70% 2189 1533 Yes 20.4 
Bombs/ 
Individual 
wraps 
A64a 87% 83 72 No <1.0 
A64b 73% 73 53 No 0.7 
A64c 85% 163 139 Yes 1.9 
A64d 72% 105 76 Yes 1.0 
A64e 65% 88 57 No 0.8 
A71 51% 75 38 No 0.5 
A72 73% 88 64 No 0.9 
A73a 47% 55 26 No 0.3 
A73b 47% 40 19 No 0.3 
A73c 49% 82 40 No 0.5 
 
The first point of comparison is the starting weight of the individual/bombs, whereas the tablets 
are set at specific weight by the manufacturer, bombs were found to be more variable in their 
weight. An example of this was observed with sample A64, which was seized as a pack of 5 
bombs. The lack of uniformity between the individual bomb weights and the homogeneity of 
the original product has impacted the individual dose level found in each of the bombs. In the 
case of A64 only 2 out of the 5 samples contained an active dose. However if the average 
percentage for sample A64 is taken as 76% when the weights are averaged to 102mg per 
sample, which provides an average dose of 79mg. It is important to consider whether the 
sample would be for single consumption by an individual or shared between multiple users. 
Personal communications on this subject suggests that an individual user may use between 3 
and 5 bombs to themselves over the course of an evening (Anon. pers. com. May 2014).  
The mean weight of MDMA hydrochloride across all individual bombs was 58%, which is 
below the threshold considered an active dose of 75mg.  As has been previously stated this 
data cannot be compared to national averages as this has not yet been established. Though 
the variable content of pills has been tracked there are no comparisons for bomb weights or 
samples of MDMA powders. Also samples A73a-c should be considered separately to the rest 
of the MDMA seizures found, as they contained the adulterants BZP and TFMPP, two 
compounds that are considered to be MDMA substitutes (Staack, 2007; Wood et al., 2007). 
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Though these samples did not contain the threshold amount of 75mg MDMA, which 
constitutes an active dose, the interaction between the compounds and the resulting 
psychoactive effects are as yet unreported in the academic literature. However on online 
forums discussing drug use there is the suggestion that the combination of these two classes 
of substances namely MDMA and substituted piperazines causes a greater negative 
‘comedown’ than when the substances are taken individually (Futura2012 on Bluelight.com, 
2012).   
   
Interestingly two single samples, A71 and A72 that were packaged in paper wraps did not 
contain an active dose. However it is unknown what the circumstances under which these 
samples were seized. One obvious difference was that they were packaged differently, in 
paper parcels as shown in Figure 8.16, compared to the ‘bomb’ packaging shown in Figure 
8.17, which is associated with the consumption of MDMA. One difficulty observed with the 
paper form of packaging was ensuring complete separation of the product from the paper; as 
the ‘bomb’ would be ingested whole (Measham et al., 2010). 
 
       
Figure 8.16: Image of A71 packaging  Figure 8.17: Image of A64d packaging  
8.8 Calibration of standards of Mephedrone (4-MMC) 
 
One of the research aims was to investigate what impact the new psychoactive substances 
have had on the use of MDMA. As has been previously reported throughout this document 
much has been made of the emergence and popularity of the drug ‘Mephedrone’. This 
research has sought to examine one possible reason for the difference, looking at the relative 
purity of these two substances. The known purities of seized Mephedrone, as with MDMA 
powder has been under reported. Following the same method as outlined in section 7.5, a 
calibration for Mephedrone was run and the 7 street samples that were identified in the initial 
analytical stages as containing Mephedrone were quantified.  
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The same concentration points that were used for the MDMA calibration were used for the 
Mephedrone calibration. Using the same volumes illustrated in section 7.5, an 11 point 
calibration was run in triplicate with a starting stock solution of 1.97mg/mL. 
 
The results displayed in Table 8.15 show the mean and standard deviation for each 
concentration of the integrated peak area of the TIC response for Mephedrone divided by the 
integrated peak area of the TIC response internal standard. The instrumental response 
reported in triplicate is located in Appendix VI Table 8.xii. 
 
Table 8.15: The mean of the Calibration results for Mephedrone standards 
Concentration 
 (mg/mL) 
Instrumental response 
Mean Response Standard Deviation  
0.049 0.011 0.003 
0.098 0.041 0.003 
0.197 0.112 0.027 
0.295 0.207 0.024 
0.393 0.330 0.013 
0.492 0.470 0.016 
0.590 0.633 0.010 
0.688 0.766 0.025 
0.786 0.908 0.024 
0.885 1.007 0.054 
0.983 1.132 0.016 
The linear regression is plotted on a scatter graph; Figure 8.18 displays the mean average 
value against the actual concentration. The Linear regression equation and the R2 value are 
displayed below.    
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Figure 8.18: Calibration graph for Mephedrone displaying standard deviation error bars (n = 3) 
 
The R2 value displayed on the above graph demonstrates that linearity has been achieved, 
with a value of 0.99, which is within 10% relative uncertainty (Ellison, Barwick and Farrant, 
2009). This means that the calibration can be used to calculate the unknown concentrations of 
the street samples.  
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Validation of Mephedrone Calibration Data 
 
The validity of the Mephedrone data was assessed in the same manner as that of the MDMA 
calibration data. As shown in Figure 8.16 the R2 value is within the linear range. The tests for 
the normality of the residuals and the runs test were also performed, using SPSS.  The 
residuals calculated from the Mephedrone data are located in Appendix VI.xiii. 
 
When the residual values were tested using the Shapiro-Wilk generated in SPSS the P value 
of 0.587 is given. As this value is greater than the chosen significance value of 0.05 the null 
hypothesis is retained and is therefore normally distributed. The data was then tested for 
randomness through the use of the Runs test, where a P value of 0.58 was obtained. As this 
value is greater than the significance level of 0.05 the null hypothesis is retained and the data 
is shown to be randomly distributed. The statistical tests prove that the data generated for the 
Mephedrone calibration is sufficiently valid to quantify the street samples identified as 
containing Mephedrone.   
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8.9 Quantification of Street Samples of Mephedrone 
Using the linear regression equation calculated from the calibration data above the relative 
purities for the seven Mephedrone samples were calculated, the results from the instrumental 
data are reported in Appendix VI Tables 8.xiv and 8.xv. The values calculated from the 
instrumental data were then compared to the original concentrations to provide the relative 
purity of the Mephedrone street samples, shown in Table 8.16.  
 
Table 8.16: Relative purity of Mephedrone found in seized street samples from Cambridge 
Sample 
Calculated concentration 
(mg/mL) 
Original sample concentration 
(mg/mL) 
Relative purity 
(%) 
A12 0.696 0.886 78% 
A29 0.966 1.473 66% 
A40 0.572 0.825 69% 
A42 0.589 0.795 74% 
A51 0.635 0.821 77% 
A52 0.340 0.677 50% 
A61 0.781 0.781 100% 
 
The percentage was calculated by dividing the instrumental response by the concentration 
calculated from the actual weighed value.  The mean of the Mephedrone samples was 74%. 
This will be compared to the values for both the Ecstasy Tablets and MDMA powders in the 
following section. As noted in previous sections sample A52 was a mix of both the 4-MMC 
compound found in Mephedrone and an analogue 4-MEC. The quantification suggests that 
the sample maybe equal parts of both compounds, however a calibration of the 4-MEC 
compound was not completed as it was not one of the compounds perceived to be relevant to 
this research. None of the other Mephedrone samples contained any other chemically active 
substances that would have been identified through this analytical method. The mean and 
median values for the Mephedrone samples returned the same value of 74%, with the range 
giving a value of 50%, the same as the lowest reported sample value. The sample that 
reported the lowest percentage of Mephedrone (4-MMC) was also the only sample to contain 
another compound, 4-MEC a structural homologue to Mephedrone. As with the MDMA 
samples that contained TFMPP, the effect of the combination of 4-MMC and 4-MEC on the 
user is unreported. 
8.10 Comparison of the purity of Ecstasy Tablets, MDMA powder and 
Mephedrone 
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One of the questions this research sought answers was whether there is a difference in the 
purities of the street level seizures of Ecstasy Tablets, MDMA powers and the newly emerged 
Mephedrone, and whether this difference reflects the relative popularity and usage that was 
examined in section 4.2 on the second research survey. 
 
Before this question can start to be answered a statistical comparison between the results 
discussed above is needed. As the data is not normally distributed a non-parametric test is 
required, as in section 8.6 a Mann-Whitney U test was used to test the difference between the 
results for Tablets, Powders and Mephedrone samples. The following analyses compare the 
mean results of all MDMA samples against the mean value for the Mephedrone samples, the 
mean value for just the powders in comparison to the Mephedrone samples and the mean of 
the tableted samples against Mephedrone. All of the tests were run using the SPSS Software 
to generate the results, the below sections contain a summary of the results.  
 
Mann-Whitney U test to determine whether there was a significance between all MDMA 
samples and the Mephedrone samples 
 
The first test compared both samples sets to determine whether there was a significant 
difference between the relative purities of the two substances. The test returned a z value of -
1.827, which is greater than -1.96 and so is not significant at the critical significance level of 
0.05. This shows that there is not a significant difference in the percentage purity between the 
samples of MDMA and Mephedrone that have been tested.  
 
However as the mean value of the tableted Ecstasy samples were significantly different the 
test was repeated to compare Mephedrone to the ‘Ecstasy’ Samples and the MDMA powder 
samples.  
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Mann-Whitney U test to determine whether there was a significance between powdered 
MDMA samples and the Mephedrone samples 
 
This test compared the MDMA powder sample with the Mephedrone samples to determine 
whether there was a significant difference between the relative purities of the two substances. 
The test returned a z value of -1.006, which is less than -1.96 and so is not significant at the 
critical significance level of 0.05. This shows that there was no significant difference in the 
percentage purity between the samples of MDMA powder and Mephedrone that have been 
tested.  
 
Mann-Whitney U test to determine whether there was a significance between Tableted 
MDMA samples and the Mephedrone samples 
 
The third test was compared the tableted Ecstasy sample with the Mephedrone samples to 
determine whether there was a significant difference between the relative purities of the two 
substances. The test returned a z value of -3.243, which is greater than -1.96 and is therefore 
significant at the critical significance level of 0.05. There is a significant difference between the 
tableted samples and the Mephedrone samples analysed.  The relevance of these tests are 
discussed in the following section. 
 
8.11 Summary of the results of the chemical analysis of Street sample 
 
The above sections detail the results for chemical analysis stage of this thesis. In starting this 
research a number of hypotheses were discussed as to what would be found when street level 
MDMA powder was to be analysed. As had been stated throughout this document very little 
has been published on its purity, or whether it was being adulterated and diluted. Though the 
last statement was not examined thoroughly as part of this research, the findings from the 
results of what was assessed allow for certain conclusions to be drawn. There were two 
questions that the chemical analysis of the street samples hoped to address, the first 
examined the difference in purity between the types of MDMA. The second looked at the 
difference in the purity between MDMA and Mephedrone.  
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Question 1 
H1: There will be a significant difference in the purity between the two forms of MDMA 
street samples  
 
H0: There is no significant difference between the reported purities of the different 
types of MDMA street samples 
 
The first hypothesis relates to the responses reported in the second research survey, taken 
from the responses to Question 11b: Describe the reasons for your preference between 
MDMA Powder and Ecstasy tablets, the majority of respondents mentioned purity as the major 
factor in their choice between the two MDMA products when the powder type was chosen. 
These results suggested that there was a perception of purity relating to the new powdered 
product. This perception was unsupported as there had been no publications to date on the 
relative purity of other forms of MDMA aside from tablets. 
 
The results of the chemical analysis of the street samples proved that there was a significant 
difference in the relative purity of MDMA being found between the two types. The powder 
samples had a greater average value of 66% MDMA compared to the 36% for the tablets. To 
contextualise these figures, consider a hypothetical 1g of each type of sample. Within the 1g 
of 66% MDMA powder there would be 660mg, the equivalence of just over 8 active doses of 
MDMA, using the dosage level of 75mg (EMCDDA, 2015). This is compared to the 360mg that 
would be in the tableted form, which would provide only 4.8 doses, it would seem that the 
powders are almost twice as pure as tablets. Though it would appear that the powders contain 
the greater quantity of MDMA, the dosage comparison in section 8.7 proved that this was not 
always the case when assessing street samples.  As a tablet is pressed into a set form there 
is a set level of MDMA but also a relatively set weight. All bar one of the tableted samples 
included in this project contained an active dose of MDMA, yet this was not the case when 
considering the seized ‘bombs’.  The number of tablets analysed within this project are at the 
higher end of tablet market when compared to the data by the EMCDDA for 2014. The sample 
size is also not large enough to determine whether this is true across the breadth of tablets 
available within the UK, this is due to the fact that in the data collected on the seizures of 
MDMA within Cambridge there were no recorded tablets seized for the year 2013 when the 
analysis was taking place as reported in Chapter 6. 
 
Question 2 
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H1: There will be a significant difference in the purity between the MDMA samples and 
the Mephedrone samples 
 
H0: There will be no significant difference in the purity between the MDMA samples and 
the Mephedrone street samples  
 
This hypothesis was assessed statistically in three ways; by comparing the purities of all 
MDMA samples to the Mephedrone samples, then be comparing each type of MDMA 
individually to the Mephedrone samples. As was shown with the Mann-Whitney U results for 
all MDMA samples versus Mephedrone samples there was not a significant difference 
between the average purities. However when type of samples was considered there was a 
difference found between Mephedrone and the Ecstasy tablets. To answer this question it 
should be considered in the context of the results from the other sections of this project, 
namely the seizure records and the social response from the surveys. When the seizure 
records are considered that looked at the relative abundance of the two types of MDMA 
available in Cambridge over the course of the research project it is clear that the comparison 
should be drawn between the powdered MDMA samples and the Mephedrone. As of 2010 the 
majority of MDMA samples being seized in Cambridge were powdered, with no tablets at all in 
2013. So if the comparison to just the powder samples are taken as the responses to the 
above hypothesis it is therefore the null hypothesis that is accepted. Between MDMA powder 
and Mephedrone there was no significant difference in purity observed. The ramifications of 
this statement with regards to popularity and the use of both substances are examined in 
detail in the discussion section. It will take into consideration the responses from the social 
survey as well as the trends established from the seizure data and the host of literature 
already discussed in previous sections.  
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Chapter 9 Discussion 
The discussion section of this thesis has been broken down into three sections, to answer the 
four research questions set at the start of the thesis. The first section discusses the changing 
identity of Ecstasy in modern Britain. The second correlates the findings around the two types 
of street drug, namely Ecstasy tablets and MDMA powders with regards to the seizure findings 
and the participant’s preference. The final part examines the impact of NPS substances, what 
can be learned from their emergence and their impact on Ecstasy use.  
 
9.1 What is in a Name?  
 
 
‘The changing social identity of the drug Ecstasy in 21st century Britain’ 
 
Throughout this research what has become apparent is the importance of names. The 
compound MDMA has, over the century since it was first patented, been recognised under a 
number of different chemical names. First mentioned under the title of ‘Methylsafrylamine’ in 
the German patent, it was later referred to as either ‘Safryl-methyl-amine’ or ‘1-(2-
methylaminpropyl)-3, 4-methylenedioxybenzol’ (Freudenmann, Öxler and Bernshreider-Reif, 
2007). The first widely accepted use of the term 3, 4-methylenedioxymethamphetamine can 
be attributed to the ‘Godfather of Ecstasy’ Alexander Shulgin, in his collaborative paper with 
David Nicholls on the effects of ingesting the substance published in 1968 (Shulgin and 
Nicholls, 1968). Even in this paper the authors point out that MDMA was also known as either 
‘N-methyl-3, 4-methylenedioxyphenylisoproylamine’ or 1-(3, 4-methylenedioxyphenyl)-2-
(methylamino)-propane.  Shulgin provides a clear explanation for the variety in the naming 
conventions applied to this substance; 
 
‘MDMA has a number of correct chemical names based on one portion or another of 
the chemical structure. With that defining portion named as the stem word, the full chemical 
name is apparent by the addition to this base fragment.’ 
(Shulgin, 1986, p. 291) 
Even today, though the most common chemical name attributed to the compound remains as 
3, 4-methylenedioxymethyamphetamine, current systematic naming conventions as set out by 
the International Union for Pure and Applied Chemistry (IUPAC) who determine the 
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nomenclature of chemicals, uses the name 1-(1,3-benzodioxol-5-yl)-n-methyl-2-propanaime. 
Although ‘MDMA’ is controlled under the MoDA 1971 in the amendment in 1977, its chemical 
name or any other affiliated terms are not mentioned.  It is instead captured in an all-
encompassing paragraph that covers any substituted phenethylamines. The passage that 
governs the control of this compound states; 
 
‘Any compound (not being methoxyphenamine or a compound for the time being 
specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-
alkylphenethylamine, a-methylphenethylamine, an N-alkyl-a-methylphenethylamine, a-
ethylphenethylamine, or an N-alkyl-a-ethylphenethylamine by substitution in the ring to any 
extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further 
substituted in the ring by one or more other univalent substituents.” 
 
(MoDA 1971 modification 1977, Paragraph 1) 
  
The use of the same encompassing terminology was also utilized in the control of the 
substituted cathinones (MoDA 1971, Amendment 1207, 2010).  However control has done 
little to stop the spread of these recreational substances, with the use of MDMA emerging as 
part of the first wave of what would be known as ‘designer drugs’ (UNODC, 2013). 
It was not the term MDMA that initially permeated the market or the social conscious, rather a 
catchy moniker attributed to an unknown dealer in the 1980s who labelled this drug ‘Ecstasy’ 
(Pilcher, 2008 p.24).  It was Ecstasy, sold as tablets, which became the third most used drug 
in the UK (Home Office, 2013; Karch, 2011; Sedghi, 2013), and with it the changing social 
phenomenon (Measham and Shiner, 2009; Rushkoff, 2001; Shapiro, 1999). Ecstasy was a 
status symbol, evocative of the style icons it plagiarised on the tablets themselves. However 
as shown in section 2.5, there was a decline not only in the use but the trust of the product 
available (Measham, 2004). As Ecstasy grew in popularity the content of the active compound 
MDMA began to decrease, with tablets being mixed with a range of substances (Cole et al., 
2002; Ramsey et al., 2001; Sherlock et al., 1999). Ecstasy lost its status symbol to become a 
cheap high, with tablets being sold for as little as a few pounds apiece (Binney, 2013).  
After the crackdown of the production of the key precursor material in 2008, which led to a 
global decline in the availability of the compound (UNODC, 2008a), a new form began to 
emerge. A 2009 paper noted the issue of the undocumented emergence of a new form of 
Ecstasy known as MDMA powder or crystal (Smith, Moore and Measham, 2009). This was 
also an issue highlighted in the 2009 ACMD report on MDMA under recommendation 5, which 
stated that more information was needed on alternate forms of this substance (ACMD, 2009).  
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This new form of an old compound appeared to have undergone a ‘rebranding’, with a new 
street name and a new reputation. Though MDMA was now being used as a term in its own 
right, there were no publications examining its emergence as separate name or how it related 
to what was described as Ecstasy until a paper published from this research examined how 
the use of these two terms, Ecstasy and MDMA has changed over the last decade (Turner et 
al., 2014).  
 
Using metadata analysis from a number of different sources, academic usage, media usage 
and public usage of both terms were examined. The first analysis looked at the usage of the 
terms Ecstasy and MDMA as key words in journal articles from the UK between 2004 and 
2013. The requirement of limiting to UK based authors was necessary as terminology can vary 
even between English speaking countries.  The results of the data analysis are shown in 
Figure 9.1. 
 
 
Figure 9.1: The frequency with which each word appears individually as a keyword found in 
journal articles from the UK in the academic databases Elsevier and Sage (Turner et a.l, 2014) 
 
A changed was observed in the use of these terms as key words in the journals and 
databases as shown in Figure 9.1. Pre-2007 the most frequent term was ‘Ecstasy’, however in 
2008 MDMA was more prevalent. This could relate to focus on MDMA at this time and 
crackdown by the UNODC on the production of MDMA, which can then be observed with the 
drop in usage in 2009 that relates to findings from the current research on the availability of 
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MDMA at this time, as shown in the seizure records of the Cambridge police reported in 
section 6.5, Figure 6.4. From 2010 onwards the use of MDMA starts to be used more 
frequently than Ecstasy. Therefore there has been a shift observed in the academic literature 
towards the use of the term MDMA over that of Ecstasy. This trend was then explored by 
examining the use of the terms by the BBC in their news stories. Using the same time period 
the number of times stories mentioned either terms was counted. The results from this count 
are shown in Figure 9.2. 
 
 
Figure 9.2: Number of news stories referencing Ecstasy and MDMA as reported by the BBC 
News Corporation (Turner et al., 2014) 
 
Again ‘Ecstasy’ is shown to be the most dominant term used up until 2008, when it was briefly 
overtaken by MDMA. Ecstasy remained the most dominant term, however the use of MDMA 
increased year on year until 2012 when it overtook the use of the term Ecstasy. This data 
supports the idea of a shift in usage, which was also found with the academic database 
results. This suggests that within the UK at least, MDMA is now the most common term that is 
being used. However the differentiation between what the two terms are actually describing 
required further definition, as both technically refer to the same compound.  
 
One issue noted with the media’s use of the term Ecstasy is in the imprecise application of the 
term. A recent example of this is in a recent case of ‘contaminated’ Ecstasy pills. In January 
2015 there were reports of dangerous Ecstasy pills that were responsible for a number of 
fatalities. The pink superman embossed tablets were described in the media as ‘rogue’ 
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Ecstasy pills (Sabin, 2015). These pills were found to contain the compound PMMA, there was 
no evidence to suggest that the pills contained MDMA, which would mean that these are not in 
fact ‘contaminated’ pills, but rather they were PMMA tablets labelled as ‘Ecstasy’. 
 
The final aspect covered in the paper looked at how the general public in the UK were using 
these terms. This was explored utilizing a function of the Google software ‘Google Trends’. 
This web based application records the frequency with which users search for terms, which 
can then be limited by location and time. The results for the use of the terms Ecstasy and 
MDMA over the same time period and limited to UK searches is shown in Figure 9.3. 
 
 
Figure 9.3: Frequency of searches for both search terms entered into Google Inc. (Turner et 
al., 2014) 
 
The results of the Google Trends search displayed a similar pattern that was observed with 
both the results from the academic and media searches. With Ecstasy being the most 
dominant term used until 2010 when MDMA starts to overtake the number of searchers for 
Ecstasy. There is also a similar cross over period between 2008 and 2010. The large peak 
observed at the start of 2013 relates to the broadcast of the Channel 4 show ‘Ecstasy drug 
trial Live’, which shone a spotlight on this substance and made use of both terms 
interchangeably (Channel 4, 2013).  The results found from the meta-data analysis highlighted 
a clear change in the use of the two terms. In the last five years there has been a shift away 
from using the term Ecstasy towards MDMA. The reason behind this could be due to the 
emergence of the new crystal form that was being found. This supports the idea that Ecstasy 
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and MDMA are now being viewed as separate products, each with its own social identity and 
reputation.   
 
This hypothesis was further explored through the use of the social research surveys. Analysis 
of the responses from both social research survey found that there is a distinct disassociation 
in the understanding of what the terms Ecstasy and MDMA represent.  This was highlighted 
throughout both surveys, with the two terms obtaining separate scores across the range of 
questions. The first question that identified this difference was the first question from Survey 
A, which asked the participants which drugs they had heard of. It was found that the majority 
of the participants had heard of the term Ecstasy (99%), with 78.2% reported to have heard of 
MDMA. This was proven to be a significant difference when tested with the two way chi 
square (χ2 = 89.92, P = <0.001). Ecstasy was the better known term, with no participants 
reporting to have heard of MDMA but not Ecstasy. 
 
The hypothesis that Ecstasy and MDMA are not synonymous was further supported with the 
findings from the second question from Survey A, which found that 68% of the participants 
correctly identified the classification of Ecstasy while only 48% correctly identified MDMA. This 
is despite both being controlled under the same paragraph in the legislation (MoDA1971 
modification 1977, Paragraph 1). The amount of people who were able to correctly identify 
both as being a Class A was only 42%, which meant that of the total population 58% were 
unable to correctly identify both of these terms. This supports the theory that the public has 
not formed a synonymous association between the two terms. The theory of separate 
identities is further reinforced by the 13% who correctly identified Ecstasy but claimed that 
they ‘did not know’ what MDMA’s classification was. 
 
Building on this concept of a separate identity of the terms Ecstasy and MDMA in the social 
consciousness was the third question which asked the participant about colloquial name 
association of a number of drugs, again with the key focus on Ecstasy. In this question instead 
of having the two terms as separate items the term MDMA was included into the list of 
possible synonyms the participant could choose from for Ecstasy. This question reinforced the 
concept of two identities of the terms Ecstasy and MDMA as only 44% of the participants 
identified the latter as being an alternative name for the former.  A further point of interest is 
the low association with the term Ecstasy and the term Crystal at only 6%. As the term Crystal 
relates to the form in which the compound is found, there appears to be a strong association 
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between Ecstasy and the pill/tableted form, whereas crystal has a greater association with the 
term MDMA. This is further supported by the alternative names suggested by the public, of 
which the form terms tabs and pills were mentioned.  
 
The final question from the first survey that established the difference in perception between 
the two terms examined the participants own perception of their knowledge of these terms.  
Again the findings from this question supported the idea that there are two separate products 
that are being identified by the public, as Ecstasy obtained a mode of 4 the second highest 
possible value on the scale whereas MDMA obtained a mode of 1, the lowest. The fact that 
the majority of people feel highly informed about Ecstasy but gave the lowest possible value 
for MDMA suggests that these are separate in the public perception. 
 
This theory was also supported by the results for the second research survey into use of these 
substances with the terms representing different forms, Ecstasy pills and MDMA powder. 
Across the range of questions asked on use the two received different responses, supported 
by the qualitative responses that there was a definite perception that these two represent 
different and separate products on the recreational drug market, with MDMA being reported to 
be ‘purer’.  
 
The results from the survey data not only supports the idea that MDMA and Ecstasy are now 
considered separate products, it also highlights a definite gap in the awareness and 
understanding of MDMA as a term and what it actually represents. The origin of this gap may 
be linked to the inconsistent reporting of these terms and this drug in general, not only by the 
media as already discussed but also by the organisations that publish information on these 
substances for educational purposes. Information sources was another aspect that was 
examined as a part of this research, and are discussed in the paper on the use of language 
(Turner et al., 2014). The inconsistency can be identified in the descriptions of Ecstasy used 
by the different organisations that report on this substance.  
The UNODC has been cited throughout this work and could be considered the pinnacle of 
organisations who report on drug use. In their annual publications The World Drug report, they 
state ‘Ecstasy is a subgroup of drugs which contains MDMA and its analogues’ (UNODC, 
2013 p.xvii). The UNODC do not distinguish between the street name and the chemical 
component.  
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This is also reflected in the use of Ecstasy by the EMCDDA it its annual reports, which 
considers the term ‘Ecstasy’ to be inclusive of the range of analogues potentially found in the 
street samples. There is however one discrepancy in how the EMCDDA report on this 
substance. As part of the EMCDDA’s web based information page they provide profiles of a 
number of substances which are stated as being ‘scientifically sound descriptions of drugs’ 
(EMCDDA, n.d.). Instead of there being a profile dedicated to the drug ‘Ecstasy’ there is in its 
place one for MDMA. On the profile page, the description is given as; 
 
 ‘A synthetic substance commonly known as Ecstasy, although the latter term has 
now been generalised to cover a wide range of other substances.’  
(EMCDDA, n.d.)  
 
Though acknowledging that Ecstasy is an umbrella term, the fact that the focus of the page is 
on the term MDMA is of interest, suggesting that in terms of educating on this subject the 
EMCDDA has shifted the focus onto the chemical rather than the brand or form in which it 
may be found. However both the UNODC and the EMCDDA are not UK-centric, and must use 
language and terms that are applicable to the widest possible audience. As part of the paper 
published, three UK based sources were examined on how they used these terms. These 
were the ACMD, the TalktoFrank webpage and the charity Drugscope (Turner et al., 2014).  
 
In 2009 the ACMD released its review into MDMA, not ‘Ecstasy’.  In the opening paragraph of 
the introduction the report states that the focus of the review was MDMA because it was the 
most commonly seized compound associated with the term Ecstasy being found in the UK 
(ACMD, 2009, p.9). Conversely the TalktoFrank website has stuck with the term Ecstasy as 
the chosen term, with the option for MDMA being redirected to the Ecstasy page (TalktoFrank 
n.d.). As a part of the profile a description of Ecstasy’s appearance is given as; 
 
‘Pure ecstasy is a powder made of white crystals, known to chemists as MDMA. 
Ecstasy is usually sold on the street as tablets, although it's getting more common to see it 
sold as powder and called by its chemical name, MDMA, or 'crystal'.’ 
(TalktoFrank n.d.) 
 
The importance of this statement is that the form in which the drug is found dictates the name 
that it is given; Ecstasy to tablets and MDMA to crystal or powder. Yet the description is 
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problematic as it suggests that the newer powdered form is ‘pure’, which to date, the relative 
purity has yet to be established or published. This message about purity is reiterated by the 
drugs educational charity DrugScope, whose own web based information portal states that;  
  
‘Ecstasy is an illegally manufactured drug that usually comes in tablet or capsule 
form. The chemical name of pure ecstasy is 3, 4-Methylenedioxymethamphetamine or MDMA 
for short’ 
(Drugscope, 2015) 
 
Both of these resources provide an explanation that could be misleading to the general public 
they are informing. The perception being promoted is that the term MDMA means “pure”. 
From a purely chemical sense this is true, as it is the abbreviation of the longer chemical 
name. However as the term MDMA has been used to effectively rebrand the new powdered 
and crystal form of the recreational drug found on the street, of which the relative purity is still 
unknown. The perception that MDMA is pure has permeated the social conscious, as shown 
in the responses to the second research survey. This is without any substantial evidence into 
the chemical composition of the powdered form having been published.  
 
The inconsistent and potentially inaccurate information provided by the sources examined 
may have an impact on how the public perceives this compound and the two names it is 
associated with. The second half of Survey A examined where people went for information 
and who they trusted to supply it. Question 6 asked the participants where they would look for 
information about drugs. For both parts of this question the results were unanimous in the top 
three options, the most popular answers being; the internet, friends and drug forums. The 
governmental sources were outside the top 3 choices and doctors received less than a quarter 
of participants citing them as a source they would use. This was in stark contrast to the results 
for question 7, which found that doctors were the source that elicited the highest level of trust, 
closely followed by independent scientists. These findings correlate with a recent poll by Ipsos 
Mori (Duffy, 2015) on which professions the public trusted to tell the truth. The most trusted 
profession as reported were doctors, followed by teachers and then scientists. The lowest 
ranking professions in the poll were journalists and politicians.  
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The outcome of this section of the research has proven that there is a definite difference not 
only in how the terms Ecstasy and MDMA are being used but also in how they are being 
perceived. They now represent different identities with regards to what is seen in the 
recreational drug market, something that has yet to be adopted by the media and the 
governmental organisations. This research has also highlighted the inconsistency in the 
reporting on this topic and discussed the relevant information sources in relation to how the 
public perceive the accuracy of the information they provide. The next section will examine the 
responses found in this research in the context of the second research question. So far the 
emergence and knowledge of the new form of MDMA has been established but not its 
prevalence or whether perception matches reality.  
 
9.2 Prevalence, Perception and Purity  
 
The previous section established that there has been a shift in the terms used to describe the 
compound MDMA, with the identification of terms referring to specific forms of the drug as it is 
found on the street. Ecstasy can be said to describe any illicit compound that is presented in a 
tabletted form that may or may not contain MDMA as the active component. Whereas the 
designation of MDMA has been introduced to cover the newly emerged powders and 
crystalline material, which has suffused the British recreational market. Prevalence of use was 
examined in two ways in this research, firstly by examining user based reports of substances 
(Section 4.2) and secondly by examining seizure records (Section 6.5). 
 
Prevalence  
In the 2012/13 edition of ‘Drug Misuse Declared’, which published the responses to the 
CSEW, it was noted that the proportion of participants reporting to have taken ‘Ecstasy’ was at 
its lowest since records began in 1996 (Home Office, 2013). Yet a number of criticisms of the 
methodology employed in this survey were highlighted in section 3.3, concerning issues of 
sampling and participant bias. As discovered in the review of pervious drug use surveys in 
section 2.7, the profile of an Ecstasy user was a male in his twenties (Gross et al., 2002; 
Hammersley et al., 1999; Handy, Pates and Barrowcliff, 1998; McCambridge et al. 2005; 
Ogeil, Rajaratnam and Broadbear, 2013; Sherlock and Conner, 1999; Solowij et al., 1992) yet 
this group is under represented in the CSEW survey as was shown in section 4.2.1.  In 
addition there is the issue of including only the term Ecstasy in the questions set for the 
CSEW.  
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As discussed there has been a change in the terminology to describe what is being used, as 
there are now two products with separate identities for the same compound.  As the results of 
the analysis of Social Survey A there was a distinct disassociation between what is 
understood about the two terms, therefore if participants are not identifying the drug they have 
taken as Ecstasy but rather as MDMA then the usage of this substance is not accurately being 
recorded by the CSEW.  
 
This is further supported when comparing how the Global Drug Survey has responded to the 
shift. Over the last 5 years the language used to describe the substance MDMA in this survey 
has changed. In 2010 participants were asked if they had tried Ecstasy or MDMA powder, with 
both answers being displayed as separate (Mixmag, 2010). In the 2011 survey the option 
Ecstasy (pills or powders) was deployed (Mixmag, 2011). However since 2012 the Global 
Drug Survey has just used the term MDMA, omitting the use of the term Ecstasy (Mixmag, 
2012). This change, alongside the methodology and rationale of the Global Drug Survey, also 
described in section 3.3, may explain why MDMA has remained one of the most popular 
substances recorded by the Global Drug Survey (2013).  
 
In the 2014 survey 45.2% of participants reporting to have taken MDMA (in any form), which 
was more than the number who reported to have taken a caffeinated drink (44.7%) (Sedghi, 
2014). The level reported by the GDS is a stark contrast to the 1.3% reported in the CSEW. 
This was also evident when compared to the findings from Survey B. The findings of this 
research show a distinct difference in the level of reported use between the three surveys as 
shown in Figure 9.4 
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Figure 9.4: Comparison of percentage of participant responses to substances taken in the last 
year 
 
There is difference observed between the percentage of participants reporting to have taken 
MDMA and Ecstasy in the last year from Survey B and what was reported by the CSEW.  
Proportionally the responses from Survey B reflect a similar pattern of use identified in the 
Global Drug Survey, though none of the substances are as prevalent. This again can be 
explained by the eliminatory questions employed by the Global Drug Survey to remove non-
drug users, something that was not applied to the findings of this research. In removing the 
responses from non-drug users the relative proportion of use cannot be contextualised to 
society as a whole.  
 
One clear point that can be drawn from the above findings is that the CSEW, in not utilizing or 
recognising the term MDMA as being separate to that of Ecstasy, is potentially missing a large 
proportion of the MDMA using community and so is under reporting the relative prevalence of 
the use of this substance. So to refer to the early statement made in section 2.3.3 , that 
Ecstasy use is at an all-time low is disingenuous.   
 
Under estimating the size and prevalence of the MDMA market is not just an issue that is 
apparent in survey based research. This research also examined how the market was 
assessed at a global, continental and national level through the use of seizure data analysis. 
In looking at how the UNODC, the EMCDDA and the UK government classify the size of the 
‘Ecstasy’ market it is apparent that there is the potential for underestimation of the market.  
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The level of ecstasy seizures and the prevalence of the market is calculated in relation to the 
number of tablets seized. This was logical when the tabletted form was the most dominant, 
however in reviewing the data collected from Cambridge police, reported in section 6.5, this no 
longer is the case. As of 2010 the most dominant from that was being found in Cambridge was 
reported to be powders.  The findings from the seizure records alongside the responses to 
Survey B clearly indicate that alternate forms of MDMA need to be considered to accurately 
estimate the size of the market. This is a change which has yet to occur within the way that 
governmental and international organisations report and record the seizures of this substance.  
 
 
  
 304 
 
 
Perception and preference  
The second research question that was posed at the start of this research wanted to examine 
how the perception of the types of Ecstasy and MDMA differed. The literature on this subject, 
reviewed in section 2.5, was conflicting with the scope of the survey information variable to 
when and where it was conducted (Hammersley et al., 1999; Handy, Pates and Barrowcliff, 
1998; Parrott, 2004; Peroutka et al., 1988; Solowij et al., 1992). The only consistent evaluation 
on the subject of the perception around Ecstasy specific to the UK was the Mixmag/Global 
Drug Survey, which reported on the user perception of the quality of the products they were 
using (Winstock et al., 2001). There has been very little qualitative research into the 
preference of specific substances, this has subsequently been addressed in this research.   
 
The analysis of responses from Survey A found that there was a definite difference in what the 
participants thought about the two terms Ecstasy and MDMA , while Survey B provided a 
qualitative context to the question by asking both user and non-users to compare their 
perceptions of the two types. Some of the most interesting points that arose from this survey 
came from the qualitative responses of the users, who provided erudite discourses on the 
topics discussed.  
 
The first point of interest was the user perspective on the physical and emotional effects 
experienced under the influence of ‘Ecstasy’ and MDMA powder. The effects of this chemical 
is well documented (Curran and Travill, 1997; Downing, 1986; Freese, Miotto and Reback, 
2002; Greer and Tolbert, 1986; Harris et al., 2002, Kirkpatrick et al., 2015; Peroutka et al., 
1988; Sumnall, Cole and Jerome, 2006; Vollenweider et al., 1998). However as discussed, 
there is a difficulty in measuring and quantifying the subjective effects (Sumnall, Cole and 
Jerome, 2006), which was also highlighted by the participants in their qualitative responses.  
In this research the participants were asked to rate their physical experience of the drugs, with 
both Ecstasy and MDMA being rated as significantly positive. What was interesting from this 
question was the number of users who ranked the terms as ‘indistinct’, with double the 
number of users stating that Ecstasy produced indistinct physical effects compared to that for 
MDMA. The participants were also asked to rate their emotional experience, again both rated 
significantly positive each achieving over 90% of the respective users rating the experience as 
positive. This follows the well documented evidence that MDMA as a compound is an 
empathogen that causes euphoria and a positive mental state (Harris et al., 2002).  
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When participants were asked whether they had ever had a ‘bad experience’ on the drugs, 6% 
responded ‘Yes’ for Ecstasy compared to 3.6% for MDMA. There were significantly more 
participants who did not report ever having a bad experience on this drug. The participants 
were next asked if they knew of someone else that had had a bad experience, relating to the 
reputation of the drug as opposed to purely first-hand experience. There was a significant 
difference between the participants reporting to know someone who had had a bad 
experience with Ecstasy (33.3%) compared to who had for MDMA (24.6%). For both 
substances significantly more users reported to have known someone with a bad experience 
than non-users.   However when asked about whether their own knowledge or the knowledge 
of someone else’s bad experience had changed their usage, the majority reported that neither, 
the knowledge of or their own first hand bad experience had had an effect in changing their 
behaviour.   
 
These questions lead into the first of the qualitative questions where participants provided 
detail responses for their reasons behind their choices. There were three themes that 
emerged from the ‘Yes’ responses;  with bad experiences, negative side effects and the risk 
and fear of dependence being highlighted as key factors. In this question both MDMA and 
Ecstasy were discussed in a negative context, though not to the extent of other substances 
included in the questions. Of the reasons given by the users who stated that their usage had 
not changed based on the knowledge of others experiences was summed up in the response 
by participant 23; 
 
‘The experiences of others are always laced in hyperbole to make the storyteller in 
question sound preposterously cool and unbeatable. I never trust humanity, not even myself; 
which can often be a problem.’ 
 
Participant 23 
 
This comment is consistent with the criticism of subjective user reports mentioned previously 
(Sumnall, Cole and Jerome, 2006). There was also a critical tone observed within some on the 
user based responses, with a few of the participants judging other drug users, stating that their 
negative experience are based on ignorance. However considering the criticisms this research 
has raised regarding the inconsistent information that is being distributed on these drugs, 
ignorance or lack of understanding is bound to emerge. Though some may try to self-educate 
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the mixed messages and inaccurate information available on this substance in particular may 
be dangerous as people are not sure of what it is they may be taking. Participant 238 
commented succinctly on the issue around what they noted as ‘the notoriously impure 
'Ecstasy' market’;  
 
‘I prefer to base my usage on what I know to be true. The notoriously impure 'Ecstasy' 
market often results in user's obtain cut MDMA and/or a drug that is not actually MDMA, but is 
labelled as so. As a result, they have a bad experience and attribute that to MDMA. When in 
fact it was a result of a combination or different drug entirely. Thus, when I take MDMA I 
ensure my product and base my usage on my own experiences.’ 
Participant 238 
 
This relates back to how the two terms are perceived, where ‘Ecstasy’ is connotative of the 
tablet form that may contain any number of substances that then get attributed to MDMA.  The 
final question that assed the differences between the perception of Ecstasy and MDMA 
powder provided the hypothetical choice between the two. In this question the significant 
choice was MDMA with 31.1% of the participants choosing it over Ecstasy (11.6%), the rest of 
the participants choose the neither option.  When asked the reason behind the choice there 
was one resounding reason given – MDMA powder was ‘purer’.   One participant stated that 
tablets were only ‘30-40%’ MDMA in content.  Whether this is the case or not is something 
discussed in detail section 9.3. The preference for MDMA was further reinforced in the 
findings from question 15, where the participants were asked to rank the drugs selected based 
on their own preference. The analysis of this question found that MDMA was not just the most 
preferred substance by both Ecstasy and MDMA users, of which there was overlap, but 
across all groups examined.  
 
One final noteworthy finding from social survey B was the impact of the gender ratio on the 
findings. As discussed, the profile generated from previous user surveys suggested that the 
Ecstasy user was male and in his twenties (Gross et al., 2002; Hammersley et al., 1999; 
Handy, Pates and Barrowcliff, 1998; McCambridge et al. 2005; Ogeil, Rajaratnam and 
Broadbear, 2013; Sherlock and Conner, 1999; Solowij et al., 1992). The surveys generated for 
this research both obtained gender ratios more dominant in female participants, which is 
unique. However when the gender ratio of the users was analysed there was no significant 
difference between the number of male and female who had ever used Ecstasy or MDMA. 
The only difference that was observed was within usage of Ecstasy in the last month.  The 
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difference in the perception and choices of the two genders was assessed throughout the 
analysis of the second survey (Section 4.2). The main finding being that there was no 
significant difference in how the genders perceived or reported their experiences. The majority 
of the users, whether male or female did fall within the same  age range as observed in 
previous surveys, specifically when examining the responses to the question of usage in the 
last year and last month,  as shown in Appendix IVb. 
 
A key finding from this research is the unequivocal preference for MDMA powder stated by the 
participants of this survey, which is supported by a perception that the product in the powder 
form is of better quality and higher purity. This could be the driving force behind the shift in 
type of MDMA being found on the street as shown in the seizures from Cambridge, with 
people actively choosing to buy crystal/powder over ‘unreliable’ tablets. However whether the 
perception is supported by reality is the focus of the final part of this section.  
 
The truth behind the perception of purity 
 
As has been stated in section 2.5.3, there is a host of published literature on the quality and 
prevalence of the Ecstasy tablet (Baggott et al., 2000; Cole et al., 2002; Milroy, Clark and 
Forrest, 1996; Ramsey et al., 2001; Refroe, 1986; Sherlock et al., 1999; Spruit, 2001; Tanner-
Smith, 2006), which supports the user perception highlighted by Participant 238 on the ‘the 
notoriously impure 'Ecstasy' market’.  There is however very little published or confirmative 
literature on the comparable purity of the powdered form of the street drug.  The only 
reference found to date is located in the footnotes of the EMCDDAs’ website page on the 
purity of selected drugs. The EMCDDA report that of the 487 samples examined, the average 
content of MDMA found in the crystal form was 81.1%. The median is given as 88% and the 
mode is 92% suggesting that it is indeed ‘purer’.  The number of samples of powder recorded 
by the ECMDDAs page is also more than four times as many tablets that were analysed, 
suggesting powders were more dominant and yet the focus of the page remains on tablets 
(EMCDDA, 2014).   
 
The truth of the perception of purity was tested by this research through the quantitative 
chemical analysis of seized samples from Cambridge. The results from the street samples 
proved that there was a significant difference in the relative purity of MDMA being found in the 
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two types, with the powders having a greater average value of MDMA at 66% compared to the 
36% that was found for the tablets. This finding correlates with the statement made by 
participant 21, who claimed Ecstasy tablets contained between ‘30-40%’.   
Though it appears that the powders contain the greater quantity of MDMA, the dosage 
comparison in section 8.7 proved that this was not always the case when assessing street 
samples. As a tablet is pressed it is in a set form, with a set level of MDMA but also a 
relatively set weight. All bar one of the tableted samples included in this project contained an 
active dose of MDMA. This correlates with the qualitative responses from the users who 
stated they would choose tablets over the powder form, who stated that the relative ease of 
administration and does control a key factor in their choice.  
However the relative dosage varied when considering the powder forms. Two types of seizure 
were assessed as a part of this project, bulk and individual ‘bombs’. Although all powders had 
a comparatively high purity, the weights registered for the individual ‘bombs recovered did not 
necessarily relate to what would be considered an ‘active’ dose.  The sample size is also not 
large enough to determine whether this is true across the breadth of tablets available within 
the UK, this is due to the fact that in the data collected on the seizures of MDMA within 
Cambridge there were no recorded tablets seized for the year 2013 when the analysis was 
taking place.  
The overall finding from the chemical analysis completed in this research supports the 
perception reported by the user groups from the second survey, that the powder form of 
MDMA is ‘purer’ when the relative percentage is taken into account.  One reason for the high 
purity of the products being found on the street may be related to the competitive market into 
which MDMA powder emerged. There is now a broader choice of substances to choose from 
than ever before, the impact of which is assessed in section 9.3.   
The aim of the second question of this research was to discover whether there was a 
difference in how the two forms are perceived but also whether this perception had any basis 
in fact. In reviewing the data collected it is apparent that Ecstasy has had an effective re-
branding, shaking off its reputation as an impure product and emerging under the new banner 
as MDMA powder. This new product also appears to live up to its reputation of being a ‘purer’ 
product when considering the relative purities of the samples examined in this project. 
However MDMA powder has only just entered the market and whether producers follow the 
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pattern of adulteration further down the line has yet to be seen. With such a saturated 
recreational drug markets, producers now have more competition. This is examined in the final 
aspect of this research, which summarises the impact NPS have had on the use of Ecstasy 
and MDMA.  
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9.3 The deal with Mephedrone  
 
As previously reported in Chapter 2 of this thesis, recent years has seen the emergence of 
numerous new psychoactive products entering the market under the banner of ‘Legal Highs’ 
(APPGDPR, 2013; EMCDDA and Europol, 2013; EMCDDA, 2011; UNODC, 2013b).  With 
some sources claiming these new compounds are replacing the use of conventional or 
traditional drugs (BBC, 2013; McElrath and Van Hout, 2011; Measham, Moore, Newcombe 
and Welch, 2010; Measham, Wood, Dargan and Moore, 2011). This final section of the thesis 
seeks to examine to what extent this statement was true.  This research has focused on the 
drug known as Mephedrone and the impact it has had on the use of Ecstasy/MDMA. 
 
It is difficult to establish when Mephedrone exactly emerged onto the recreational drug market 
before it became prevalent and before it was controlled under the MoDA 1971. This is due to 
the nature of recording practices of seizures, and issue that was also observed in the analysis 
of the seizure data at Cambridge. As substance can only be recorded once it has been 
identified and if it is not controlled it is unlikely to be recorded. It is believed that Mephedrone 
first emerged in the late 2000’s (Measham et al., 2010), but it was not until 2010 when it 
became a national ‘moral panic’ (Alexandrescu, 2014) that it was controlled under the MoDA 
1971, Amendment 1207 (2010). There was much speculation at the time as to whether 
Mephedrone would replace Ecstasy as the party drug of choice (BBC, 2013). This was the 
final question evaluated in this research. To answer this question a comparison between 
Mephedrone and MDMA in any form was assessed throughout the three projects.  
 
The comparison was first assessed in Survey A, which compared the participants’ awareness 
of the two substances. The first question examined whether people were aware of 
Mephedrone. The analysis of this question found that in comparison to Ecstasy that obtained 
98% of the participant population reporting to have heard of it, only 72% reported having 
heard of Mephedrone. This was high in comparison to other drugs asked in this question, 
namely the piperazines and 2CB that obtained 14% and 22% of participants reporting to have 
heard of them. One reason why such a large proportion reported to have heard of 
Mephedrone may relate to the media presence of this drug (Alexandrescu, 2014).  However 
though people reported to have heard of Mephedrone, the responses on the knowledge based 
questions in the rest of Survey A suggested that there was a lack of knowledge about what 
Mephedrone is and what it does beyond a name for new synthetic substance. 
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In the question that asked participants what classification Mephedrone belonged to, the 
majority of participants stated that they did not know (40%). Only 27% were able to correctly 
identify the substance as a Class B, compared to 69% that correctly identified the 
classification of ‘Ecstasy’ and the 48% that classified MDMA correctly. The low level of 
knowledge was also reflected in the response to the question on what other names the 
participants associated with the drug, 56% identified it with the name meow-meow, and 
variations thereof. Coincidentally, as was seen in the case of Ecstasy and MDMA, the 
abbreviation of the chemical name also had less recognition than the slang term. Only 12% of 
participant’s identifying the term 4-MMC, the abbreviation for 4-methylmethcathinone as being 
related to the drug. 
 
The lack of awareness and knowledge around this substance was further reinforced by the 
responses to the ranked question that asked participants to rate their knowledge of the effects 
of a selection of substances on a Likert scale, where 1 represented low and 5 represented 
high. The most frequent score that was selected by the participants for Mephedrone was the 
lowest possible on the scale. The overall mean reported for Mephedrone was 2.12, this was 
the lowest score given by the participants on their knowledge of the selected substances. This 
suggests that though people may have heard the term Mephedrone there remains a gap in the 
knowledge about this drug. A reason for this lack of knowledge is perhaps that the use of 
Mephedrone has not proliferated and it has not become as prevalent in the recreational drug 
market post control as was suggested it might when it first emerged (BBC, 2013; McElrath and 
Van Hout, 2011; Measham, Moore, Newcombe and Welch, 2010; Measham, Wood, Dargan 
and Moore, 2011).  
 
There are a number of possible explanations as to why Mephedrone may not have been as 
prevalent post control, though the published literatures suggests that the legislative control 
alone of new psychoactives has not shown to reduce use (Dargan et al., 2011; Wood et al., 
2011; Wood, Measham and Dargan, 2012).  Therefore there may be alternative reasons as to 
why this drug appears to not be as popular, with the responses to Survey B providing an 
insight through the qualitative and quantitative responses of the users.  
 
In Survey B only 37 participants reported to having ever tried Mephedrone, this equalled 15% 
of the total participant population. Only 4% reported to have used it within the last year, 
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relating to the period of 2012/13.  By comparison the Global Drug Survey for the same year 
recorded participant usage who had ever tried Mephedrone at 36%, and at 14% for having 
tried in the last year (Mixmag, 2013). These figures are significantly smaller than the level 
reported for Ecstasy or MDMA in either survey. As with the comparison between Ecstasy and 
MDMA that has previously been discussed, the user perception of Mephedrone was also 
assessed. What was reported was a negative reputation that Mephedrone has gained in the 
short time that it has been available.   
 
The first of the perception questions in Survey B asked users about the effects of 
Mephedrone. As reported in section 2.6.3 Mephedrone reportedly mimics the effects of MDMA 
and other ATS drugs (Coppola and Mandola, 2012; Measham et al., 2010; Winstock et al., 
2011a). The participants’ responses in these questions indicated that the physical and the 
emotional effects of both Ecstasy and MDMA were positive. Therefore if the effects of 
Mephedrone are designed to mimic MDMA the participant responses should also have been 
positive. This however was not what was reported, as the participants’ response to physical 
effects indicated that there was no significant difference between the numbers of participants 
who stated their experience was positive, negative or indistinct. There was significant 
difference in the responses reported for the emotional experience, with more participants 
reporting positive experiences over either of the other two options.   
 
The impact of the effects and the reputation of Mephedrone was also examined in questions 
6, 7 and 8. In question 6 the participants were asked whether they had or if they knew 
someone who had had a bad experience with the substance. 38% of the people who reported 
to have used Mephedrone stated that they had had a bad experience, this is compared to 
18% for Ecstasy and 12% for MDMA powder. Yet only 16% of all the participants reported to 
have known someone who had had a bad experience, compared to a third for Ecstasy and a 
quarter of participants reporting to know someone with a bad experience of MDMA powder. 
Significantly more participants from the user group were more likely to have known someone 
who had a bad experience of Mephedrone than a non-user. Question 7 asked whether the 
participant’s experience of the drug had changed their usage, 60% claimed it had changed 
their use of Mephedrone, compared to 37% for Ecstasy and 40% for MDMA. When asked 
whether someone else’s experience had changed their usage, 32% of users stated that it had 
compared to 14% for Ecstasy and 13% for MDMA powder. Mephedrone consistently reported 
more participants with a negative association with the drug than either Ecstasy or MDMA 
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powder as shown in Figure 9.5, which summarises the user group responses for Questions 4 
through to 8. 
 
 
Figure 9.5: Summary of User group responses for Questions 4 to 8 from Survey B (Ecstasy n 
= 86, MDMA Power n = 77, Mephedrone n = 37)  
 
The effects and users perceptions were elaborated on in the responses to questions 9 and 10. 
The participants were asked to provide qualitative answers about the changes to their usage 
or knowledge of others negative experiences. In the analysis of these questions Mephedrone 
was the second most mentioned substance by name, tied with ketamine.  The tone of the 
comments provided by the participants were very negative as shown in the following 
examples; 
 
‘Negative effects from Mephedrone resulted in no longer using. Don't think there's 
enough information regarding this drug available.’ 
Participant 20 
 
‘Drone – Found it to be very addictive with horrendous comedowns. Eventually there 
was no nice feeling coming from taking it so the thought of it now makes me sick.’ 
Participant 63 
 
I think Mephedrone is a very unpredictable substance. I would never take it again. My 
experience wasn’t terrible – just lots of memory loss which made me realize how dangerous 
the drug could be, I felt very out of control. 
Participant 192 
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The comments from the users indicated that the side effects were a key reason in why they 
had moved on from its use. Not a single participant referred to in the context of its control 
status or whether their use of the experience had changed based on the change in legislation, 
supporting the findings from published literature (Dargan et al., 2011; Wood et al., 2011; 
Wood, Measham and Dargan, 2012). One further insight into the prevalence of Mephedrone 
can be obtained from the results to question 12, which asked participants to choose between 
MDMA and Mephedrone and provide reasons for their choice.  When given the choice 
between these two comparable substances 34% chose MDMA while only 3% chose 
Mephedrone, with the rest choosing the neither option. In providing a reasons behind the 
choice, the majority of participants who chose MDMA stated the fact that there is less known 
about Mephedrone. That the participants had heard ‘bad things’ about its use and again 
reiterated the negative effects.  Of the few people that did choose Mephedrone, their reasons 
were that is was cheaper and less effective than the other choice.  
 
A review of the user response from all parts of the second survey suggest that though it was 
speculated that this drug was set to replace MDMA (BBC, 2013; McElrath and Van Hout, 
2011; Measham, Moore, Newcombe and Welch, 2010; Measham, Wood, Dargan and Moore, 
2011), this has been proven not to be the case. This is supported throughout by the numerous 
participants referencing negative side effects and a poor reputation for this substance.  
 
The lack of proliferation by Mephedrone into the recreational drug market was further reflected 
in the seizure data collected from Cambridge police. The analysis of the record books at 
Cambridge police station highlighted a number of trends, which correlated to the findings from 
the literature and the social research surveys. Firstly was the emergence of cathinone 
derivatives in Cambridge, Mephedrone was the first of a variety of substances that was 
recorded in the logbooks, with the first confirmed sample appearing in 2009. This correlates to 
the suspected time of emergence reported in the literature (Measham et al., 2010). There are 
limitations to this data however as the police only have to record substance that are controlled 
under the MoDA 1971, with substituted cathinones only being controlled in 2010. This therefor 
accounts for the observed trend in the Cambridge data that saw a spike in the seizures of 
Cathinones and Mephedrone in particular in 2010 shown in Figure 9.6, a revised copy of 
Figure 6.3 that shows the seizure of Cathinones and MDMA.  
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Figure 9.6: Seizures of Cathinones and Ecstasy recorded in Cambridge between 2003 and 
2013 
 
The seizure trend observed in Cambridge for cathinones is interesting as there was a spike in 
2010 when the blanket ban came into effect (MoDA, 1971 amendment 2010), with very few 
being found between 2011 and 2012. This trend also coincides with when there was a noted 
shortage of MDMA available, which has previously been discussed. There was a noted 
increase in 2013, which related to a number of seizures of the compound Methylone (3, 4-
methylenedioxymethcathinone). Methylone was also found in some of the samples that were 
tested as a part of the chemical analysis of the street samples. Interestingly the seized 
Methylone samples bore a visual similarity to the MDMA crystals rather than the samples that 
tested positive for other cathinones. The Methylone samples were light brown irregular shaped 
crystals, compared to the samples positive for Mephedrone that were all white or colourless as 
shown in Figure 9.7. 
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Figure 9.7: Visual comparison of Mephedrone sample with Methylone and MDMA. 
 
The use of Methylone was also documented in Survey B, with 10 participants (4%) claiming to 
have ever taken it and 2 participants stating they had taken it in the last year. However the use 
of Methylone was not considered in the development of the later survey questions and the 
records of its seizures were discovered after the majority of the data collection had been 
completed, and so the use of Methylone as an alternative was not examined as a part of this 
research.  
 
The question of what was prevalent has already been addressed with regards to the terms 
Ecstasy and MDMA. In answering that question the use of the Google Trends application 
provided an interesting insight into the search patterns of the UK public, with the data for 
Ecstasy and MDMA correlating to the pattern observed with the seizures in Cambridge. The 
use of Google trends was also applied to the term Mephedrone so examine its search history 
within the UK, as shown in Figure 9.8. 
 
 
Figure 9.8: Searches recorded for the term ‘Mephedrone’ by Google Trends in the UK 
between 2004 and 2013. 
 
As can be seen from the Google trends data there was a surge in the number of people who 
were searching google for the term Mephedrone. This in itself is perhaps not that radical 
bearing in mind the media presence of this term and the changes in legislation that were 
occurring at the same time (Alexandrescu, 2014). Yet the fact that the search history of the UK 
correlates almost exactly the pattern observed for the seizures of this substance in Cambridge 
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is significant. The use of this method of data collection and analysis has a number of potential 
advantages. It could potentially be used to track the prevalence and use of specific 
substances in a way that seizure and self-report survey data cannot. The data captured in this 
method is not subject to the many forms of bias encountered in survey methodologies nor is it 
hindered by changes in reporting practices. One disadvantage would be the variety of names 
and potential misspellings by the public in their searches, however google has an autocorrect 
feature that mitigates this issue. The use of Google Trend could also help predict which 
substances are emerging and track the ever evolving recreational drug market in real time.  
 
The final aspect that was examined was whether there was a difference in the relative purity of 
Mephedrone in comparison to MDMA in either form. The results from the street samples 
varied with the mean content of Mephedrone came out as 74%, with a range between 50 and 
100%. 
 
The fact that one sample returned a 100% purity, and that the purity of the samples examined 
was so high may be due to the methods of manufacture. Mephedrone, unlike MDMA, was not 
originally being manufactured in illicit clandestine factories but by corporations in China, which 
promised a high purity of product (Davidson, 2015). The samples of Mephedrone tested did 
not show a significant difference in the level of compound found in the samples compared to 
the MDMA samples. However the samples tested were from within a time frame close to when 
the original ban occurred, subsequent testing of later samples would be required to see 
whether the control had impacted the quality of this product. However in correlating the 
chemical data with the survey findings, the quality of the actual substance appears not to 
impact the preference when choosing between MDMA and Mephedrone, rather the actual 
experience of Mephedrone is reported to not be as positive.  
 
In answering the final research question, this project sought to answer was whether 
Ecstasy/MDMA had been replaced by the newly emerged Mephedrone. On review of the data 
collected from the various different sources the answer to this question appears to be no. 
Though there was a drop in the recorded seizures of MDMA, it appears to have recovered its 
prevalence post the 2009/10 dip. It was in this time when Mephedrone shot to prevalence as a 
short term alternative due to its availability. However the long term prevalence and popularity 
of Mephedrone appeared to have waned in comparison to MDMA.   
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Chapter 10 Conclusions, Recommendations and 
Limitations  
10.1 Conclusions 
 
To conclude this thesis, the findings will be considered in relation to the four questions 
outlined at the beginning of this document. The first question that was posed at the start of this 
research was:  
‘Has there been a change in what is meant by the terms ‘Ecstasy’ and MDMA, and 
how are they being used in relation of the recreational drug in modern UK society?’ 
 
This research has shown that there is a definite gap in what the public know and perceive 
about these two terms, which are supposed to be affiliated with the same compound. What 
has been found is that these two terms now represent separate products to the public, and 
that the terms are no longer considered to be synonymous. What is known about Ecstasy has 
not translated into what is known about MDMA. There has been inconsistent reporting by 
organisations responsible for the dissemination of information on this subject and this 
research has discovered that there is a lack of trust in the information sources who produce 
the information. Through the social research surveys it was revealed that there is also a desire 
for more drugs information to be provided. The analysis of the questions into the trust and 
searching for information provides a potential opportunity to discuss how to engage the public 
and who would be the most effective in reporting accurate information. The overall outcome of 
this element of the research is that now the term Ecstasy is connotative of the tablet form 
rather than the chemical composition. Whereas MDMA has a dual meaning; primarily it 
represents an abbreviation of the chemical while its second meaning represents the new form 
that has emerged, the crystal and powders.  It is important going forward that the new use of 
these terms is adopted and proliferated to aid in accurate dissemination of information. 
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The second question that this research sought to answer was: 
 
What are the differences in the types of Ecstasy being seized on the streets of 
Cambridge, and how does this relate to user preference? 
 
This question was answered by the research surveys, which established that there is a 
difference in perception around what the two terms Ecstasy and MDMA represent, and that 
there is a difference in how the two forms are perceived by the users themselves. There was 
also a unanimous preference described by the users for the new MDMA powder over that of 
the tabletted Ecstasy, with the perception that one was ‘purer’ than the other.  The preference 
for MDMA powder was also shown in the analysis of the seizure records, which found that as 
of 2011 the most prevalent form of MDMA being seized in Cambridge was either crystal or 
powder. Once the preference was identified, the perceptions about the quality of the products 
was tested using analytical chemistry on seized street samples. These results answered the 
third research question which asked: 
 
Does the user perception around the difference types reflect what is found 
chemically? 
 
This perception stated by the users in the responses to the second social research survey was 
supported by the findings from the chemical analysis of the street samples in Cambridge, 
which found that on average the powders contained a higher percentage of MDMA. However, 
the analysis of the street sample also found variability in the content and the relative dose 
forms of the drug. There were however limitations with the sample size and extrapolation to a 
wider population, which is discussed further in section 10.3. 
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The final question set out at the beginning of the research was: 
 
What impact has the emergence of Mephedrone had on the popularity and 
prevalence of Ecstasy and MDMA? 
 
The answer to this question was assessed throughout, in the results of both the social surveys 
and the seizure data. The results of the chemical analysis however showed no significant 
difference in the mean content of the street samples analysed as a part of this research. In the 
social surveys a number of key findings were observed, firstly that the participants felt that 
they were less aware of Mephedrone and its effects which suggests that this drug was still 
relatively obscure in 2013. The Second finding showed that those who did have first-hand 
knowledge/experience of Mephedrone consistently rated more negatively than that of 
Ecstasy/MDMA, with the word ‘dirty’  frequently used by the participants when describing 
Mephedrone. Lastly, when participants were given the hypothetical choice between the two 
substances there was a categorical preference for MDMA by both the user and non-user 
participants.  
 
Although it has been suggested that when Mephedrone was introduced it was being chosen 
over MDMA as the new party drug (BBC, 2013; McElrath and Van Hout, 2011; Measham, 
Moore, Newcombe and Welch, 2010; Measham, Wood, Dargan and Moore, 2011) this may 
not have been the case. On examining the evidence from this research it is plausible to 
suggest that Mephedrone only became popular as a response to the unavailability of MDMA 
caused by the UN crack down of safrole production (UNODC, 2008a), and once MDMA 
remerged into the market users switched back to the product they preferred.  The answer to 
the above question would therefore be, that Mephedrone has had very little effect on the use 
of MDMA. As Mephedrone has appeared and subsequently disappeared in relation to the 
disappearance and re-emergence of MDMA.   
 
Nevertheless the recreational drug market is ever evolving, with new products constantly 
being introduced and though this research has shown a popularity of MDMA in the future this 
may change.  If the quality of powders declines, as was seen with the tablets at the turn of the 
millennium, there may be a shift to a new ‘drug du jour’. 
  
 322 
 
 
10.2 Limitations  
 
There are a number of limitations that have affected this survey, which will be considered in 
relation to each project separately. However there are two main limitations that impacted all 
three aspects, namely timeframe and geographic location.  
 
All data collection relating to this project is a product of the time in which it was collected, as 
the recreational drug market is constantly evolving, the analysis is therefore retrospective. It is 
also limited by the geographic location, specifically the seizure and street samples that are 
representative only of Cambridge.  However the findings from this research have been 
compared to national and international data when available.  
 
When considering the limitations of the social surveys, many of them were highlighted in the 
critical analysis of other national surveys. It is incredibly difficult to accurately estimate the 
prevalence of use of a substance that is illicit and therefore covert in nature. There are 
methodological issues including representative sampling and participant bias, which impact 
any survey based studies.  And although this research did not obtain a significantly large 
participant group size, the results collected have provided new insight into this subject. 
 
The limitations of the seizure data relate to the recording practices, the records examined 
were not consistent in the descriptions of the samples being seized and were limited to 
identification only once a substance had been controlled. Without a control status there is no 
necessity to report. There may also be variation based on geographic location, however 
comparison to other locations was not available to the research at this time. The same 
limitations applied to the testing of the street samples, which were representative only of what 
was available in Cambridge at the time of the research. However as stated comparisons to 
published literature was completed when available.  
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10.3 Recommendations and Further Work 
 
Throughout the development and analysis of this project a series of recommendations 
emerged that could impact and influence current understanding and policy making.   
 
Recommendation One 
 
The first recommendation that can be made on the basis of the findings from this research 
revolves around the clarification and consistent use of the terminology around these 
substances.  A clear definition needs to be established concerning what is considered to be 
Ecstasy and what is now MDMA, the following are three examples of definitions that could be 
applied:-  
 
Ecstasy – A tablet or pill that is believed to contain the substance 3, 4-
Methylenedioxymethamphetamine but may in fact contain a range of substances. 
 
MDMA – (Colloquial) the term given to crystalline or powdered products believed to contain 
the compound 3, 4-Methylenedioxymethamphetamine 
 
MDMA – (Chemical) the abbreviation of the term 3, 4-Methylenedioxymethamphetamine 
 
Though these definitions may not be adopted, what is clear from this research is the need for 
corresponding organisations to all use the same language, and language that is consistent 
with what the public understand. 
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Recommendation Two  
 
The second recommendation that can be made from this research concerns the effectiveness 
of drugs education.  In this research the majority of participants reported to have had some 
form of drugs education, yet there was no difference in the level of accurate knowledge 
between the educated and non-educated groups. This is further supported by the work of 
Fletcher, Bonell and Sorhaindo (2010) who found that drugs education in secondary schools, 
though a requirement under the current curriculum was minimal and varied greatly between 
institutions. Although this research focused on one aspect of drug use, specifically the 
changing perceptions around the drug Ecstasy. What it has highlighted is that there is a 
definite gap in what the public knows about illicit substances, how these substances are now 
being perceived and that there is also a desire for better education on this subject.   
 
Through this research it became apparent that the traditional sources of information are either 
untrusted (i.e. the government) or underutilized (i.e. doctors). This can be attributed to the 
debate and controversy between experts, such as Professor Nutt, which has eroded 
confidence in governmental sources (Kasperson et al. 1988). This if further compounded by 
the conflicting information that is available on the internet, produced by factions with differing 
political agendas. 
 
Therefore a recommendation from this research would be to instead of merely educating on 
what drugs are, to include critical analysis of the information that is available. This could be 
achieved with greater engagement with the using community as well with support from 
academia, which would provide a more holistic knowledge base that can communicate 
effectively the true risks associated with specific substances.  
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Recommendation Three 
The third recommendation relates to re-evaluating the data collected from the social research 
surveys used to estimate drug use. Currently drug use is estimated from the reports to the 
CSEW, however this research has shown the inaccurate and conflicting data that is produced 
by social surveys, by comparing the CSEW, the Global Drug Survey as well as the data 
collected from this survey. There are a variety of alternative methods, as shown with seizure 
data and with the use of google trends that can and should be utilized to represent an 
accurate measure of the illicit market.  
 
Recommendation Four 
 
The final recommendation relates to the recording practices of the UK police forces and the 
British government. As with the use of terminology there is also the need for accurate and 
consistent reporting of the type and form of ‘Ecstasy’ that is being seized. As highlighted in 
this project the reliance on tablet seizures to estimate the size of this market is under 
estimating its size. Therefore there needs to be a change in what is recorded with tablets and 
powders being recorded separately.   
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Further Work 
As this research has covered a number of different disciplines there are a multitude of 
possible opportunities for further study. 
 
One aspect which could be explored further is an examination of the curriculum set out to 
provide drugs education. Who is responsible for providing it, where does this information come 
from and is it consistent across the country?  A clear understanding of what is currently being 
taught and what is available post-secondary education could further aid in the development of 
a better drugs education system suggested in recommendation two. This would provide 
support for the debate around changing drug policy. If what people actually know and believe 
about drugs it is better understood, harm reduction can be targeted to disambiguate 
misinformation on the topic. 
 
A second aspect which could also be explored could look at the diversity of drug use across 
the UK. This study was focused on the city of Cambridge, an affluent University town and so 
has a specific socioeconomic and social structure. The research could be developed to 
compare the differences in drug use reported in rural, urban and suburban communities. This 
could also then be compared to what is being seized in these areas to examine changing 
trends and also further develop the argument for whether the recreational drug market is 
consumer or product led. This could also be expanded to a continental or global comparison.  
 
A third area of expansion could investigate how new drugs spread across the country. With 
new substances emerging their popularity and prevalence could be tracked by combination of 
social surveys and comparison to official seized data. If a new substance is found in 
Cambridge for the first time it would be interesting to see where else it has been found and 
when, to track the emergence across the country. This could have two benefits, the first would 
be the possibility of modelling possible distribution routes, the second could again help with 
information sharing. If there were a pattern of emergence, information could be disseminated 
for the purposes of reducing possible harm.  
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Investigating the terminology used to describe Ecstasy 
Drugs and Alcohol Today, VOL. 14 NO. 4 2014, pp. 235-244 DOI 10.1108/DAT-07-2014-0029 
 
Introduction 
In their paper Smith, Moore and Measham (2009) outlined an issue in the undocumented 
emergence of a new form of Ecstasy known as MDMA powder or crystal. It was noted that this 
new form could have ramifications not only on under reporting of drug use but also inhibit the 
work of healthcare professionals working towards harm reduction. The authors comment that 
the general understanding of the difference between the two terms had yet to be established. 
Five years on and this is still the case with the relative prevalence and consistency of use of 
both terms, Ecstasy and MDMA, unknown. A considerable body of literature across a range of 
disciplines has been written about ‘Ecstasy’. However there has been no published articles 
which addresses the use of the nomenclature, Ecstasy and MDMA, or how these two terms 
are used.  This paper addresses the issue through the use of metadata analysis of a selection 
of resources; from governmental organizations, academic publications and web-based 
information sources to establish the use and consistency of both terms.  
 
In popular drug culture there is a unique and specific language which is associated with not 
only the substances themselves, but also how they are used and the societal context that 
surrounds them, for example their control status. For each individual compound and class of 
compounds there is a multitude of names and subsequent terminology or ‘slang’ with which 
they are associated. In regards to the terms ‘Ecstasy’ and MDMA, the term ‘Ecstasy’ is a 
colloquial generic brand name whereas the term MDMA is derived from the abbreviation of the 
chemical compound 3, 4-Methylenedioxymethamphetamine, the psychoactive compound 
which is found in Ecstasy. The diversity in terminology is not only limited to the language being 
used to describe the drugs but also to the groups and organisations who make use of this 
language when discussing drugs and drug use.  
 
One group who actively utilizes the language surrounding drug and drug use is the academic 
community who study these compounds from a host of different disciplines. These studies 
range from establishing what effect these chemicals have on the individual to the effect they 
have on society as a whole. In the context of this paper the academic literature has been 
evaluated through the preference of the keywords chosen by examining the use of either 
Ecstasy or MDMA as key words.  The second group who make use of the language are the 
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policy makers, governmental organisations and law enforcement agencies (e.g. the United 
Nations Office on Drugs and Crime), whose role it is to evaluate the literature produced by the 
academic community and then implement it into legislation and subsequently enforce it. The 
use of the two key terms, Ecstasy and MDMA, by these organisations has also been 
considered. The key organisation in the United Kingdom which oversees the evaluation of the 
academic output is the Advisory Council on the Misuse of Drugs (ACMD) whose own use of 
the two terms is evaluated. The dissemination of the academic and policy information is 
through a third group of sources who propagate the information about the substances. 
Included in this group are the healthcare professionals, educational programmes, the media 
and the internet/web-based resources whose purpose it is to provide information to the 
general public. It is the output of the last two groups which form the foundation of the 
comparison for this paper.   The last and final group who make use of the language are the 
general public who rely on the information provided by the other three groups. Their use of 
language has been evaluated through the analysis of google trends, software which tracks the 
use of search terms.  
 
What has yet to be established is whether there is cohesion in the language used by these 
different groups when it comes to reporting on and discussing Ecstasy and MDMA. Both terms 
have been used synonymously in the past. A thorough investigation of the literature will 
establish for the first time whether there has been a shift in the frequency with which the two 
terms are being used and if there has what implications this has with regards to the 
dissemination of accurate information.   
 
Why the names of drugs are important 
 
As with any taxonomy there are different classifications under which each substance may fall. 
The chemical MDMA is part of the Amphetamine-Type Stimulant (ATS) class of substances. 
This is due to its chemical structure and reported stimulating effects. MDMA’s other noted 
effects mean that it is also a part of a class of substances known as ‘empathogens’ (Harris et 
al., 2002).  
 
Illicit drugs do not generally have just one name. In addition to their chemical name they have 
a number of colloquial synonyms which differ not only by geographical location and also over 
time.  A number of issues can arise when there is a difference and/or overlap in names being 
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used. For example different names can be used for the same compound or the same name 
can be used for different compounds as is the case with the colloquial term ‘Speed’ which has 
been used to describe both amphetamine and methamphetamine as can be seen on the 
website Erowid (https://www.erowid.org). 
 
In the case of the MDMA, it is reported to have gained its infamous moniker, Ecstasy, from an 
anonymous American dealer in the early 1980s, when it started coming into prevalence in the 
recreational drug scene; 
 
‘Ecstasy was chosen for obvious reasons, because it would sell better than calling it 
Empathy. Empathy would be more appropriate but how many people know what that means?’ 
 (Pilcher, 2008 pg.24).  
 
Subsequently the term Ecstasy has followed the spread of this substance around the globe 
until it finally made its way to the British dance scene towards the late 1980s (Karch, 2011). 
Aided by clear branding stolen from other famous designs the ‘Ecstasy’ tablet became the 
third most used drug in Britain (ibid).  
 
Towards the end of the nineties and into the first decade of the new millennium the declining 
purity and quality of tablets found on the Ecstasy market led to an apparent decline in their 
use (Cole et al, 2001 and Smith, Moore & Measham, 2009). This is supported by seizure 
levels reported; primarily at a national level by the ACMD (2009), at European level as 
reported by the European Monitoring Council for Drugs and Drug Addiction (EMCDDA) (2004 
- 2013), and lastly at a global level as reported by the United Nations Office on Drugs and 
Crime (UNODC) in their annual World Drug Reports (2004 - 2013). The decline in the use of 
Ecstasy tablets could have been a reason for the shift or ‘rebranding’ of the product back to 
the chemical designation MDMA. The extent of this change will be assessed through the 
analysis of the use of both terms throughout this paper. 
 
An analysis of the use of language in publications by the UNODC & EMCDDA 
 
An analysis was completed to determine the frequency with which the two terms Ecstasy and 
MDMA have been used within the annual reports from the EMCDDA and the UNODC. These 
were chosen because these are the two major organisations that report and assess the impact 
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of drugs on society at a global and continental level. The UNODC annually compiles data on 
global drug trends, trafficking, and reported usage which forms the basis of their World Drug 
Report. 
 
The UNODC’s definition of the term Ecstasy states that; ‘Ecstasy is a subgroup of drugs which 
contains MDMA and its analogues’ (UNODC, 2013). This infers that the compound MDMA is 
not to be considered to be directly synonymous with the term Ecstasy, but rather ‘Ecstasy’ is 
used as an all encapsulating term for any of the ring-substituted phenethylamines.   
 
The EMCDDA also produce annual reports on the prevalence and use of drugs available in a 
multitude of languages as pdf documents found on their website. They have two published 
definitions of Ecstasy.  The first description that they use can be found in the annual reports 
which states: 
 
 ‘Ecstasy refers to synthetic substances that are chemically related to 
amphetamines…The best-known member of the Ecstasy group of drugs is 3, 
4-methylenedioxy-methamphetamine (MDMA), but other analogues are also 
sometimes found in Ecstasy tablet’ 
 (EMCDDA, 2013, pg51). 
 
The definitions used by both the UNODC and the EMCDDA employ the term ‘Ecstasy’ as an 
umbrella term to cover a range of analogous substances. However there is a slight deviation 
in what definition is used when it comes to the second definition which can be found on the 
drug profile pages published on the EMCDDA homepage. As part of the EMCDDA’s web 
based information page they provide profiles of a number of substances which are stated as 
being ‘scientifically sound descriptions of drugs’ (http://www.emcdda.europa.eu/drug-
profiles/mdma). Instead of there being a profile dedicated to the drug ‘Ecstasy’ there is in its 
place one for MDMA. On the profile page, the description is given as ‘a synthetic substance 
commonly known as Ecstasy, although the latter term has now been generalised to cover a 
wide range of other substances’ (ibid). The page also states that the most prevalent form the 
drug is found in is white tablets yet also notes other forms of powders and capsules are found 
but less commonly. Although both definitions given by the EMCDDA refer to Ecstasy as an 
encapsulating term for a range of substances there is an apparent change in focus from the 
term Ecstasy to the term MDMA. This change in focus for the drug profile is of key importance 
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since it suggests that there has been a change in use of these two terms with the use of 
MDMA being more prominent.   
 
This idea was further explored by analysing the frequency with which the two terms, Ecstasy 
and MDMA have been used by both organisations over a ten year period within their annual 
reports shown in Figure 1. 
 
 
Figure. 1: The frequency of the terms Ecstasy and MDMA used in the annual reports 
produced by the UNODC World Drug Report and the EMCDDA Annual drug monitoring report. 
 
The data shown in Figure 1 indicates the change over time in the frequency of each term 
found in the annual reports from both organisations. The frequency was calculated by 
recording the number of incidences with which both search terms occurred throughout the 
documents using the Nvivo software. This was then converted to a percentage by dividing the 
frequency of each term by the total number of times Ecstasy and MDMA appeared within each 
set of documents, with each set of documents considered as individual data sets. The total 
number of occurrences is 2189 for the UNODC reports and 868 for the EMCDDA reports. 
 
Up to 2013, there is a clear preference for the term Ecstasy being used by both organisations. 
This is not unexpected when considering their official descriptions and use of Ecstasy to 
represent more than merely MDMA in terms of seizures, usage and trafficking.   
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One point of interest is the marked decline in the use of the term Ecstasy in the 2009 
EMCDDA report and then in 2010 UNODC report. This can be correlated to the lack of 
availability of MDMA found globally at this time. This deficit was due to the increase focus on 
the control of safrole which is one of the main precursors for the manufacture of MDMA 
(UNODC, 2008 available at http://www.unodc.org/unodc/en/frontpage/cambodia-tackles-
safrole-oil-production.html).  
 
Though Ecstasy is the more prevalent term used by the UNODC the frequency with which it is 
found per report has declined over the last decade. Meanwhile the use of the term MDMA has 
remained consistent in the World Drug Report. The focus of the EMCDDA’s report has varied 
depending on the prevalence of the drugs found in Europe year on year. As both sets of 
reports reflect changes in overall drug trends different drugs have become the focus 
dependant on their relative prevalence and the political focus. The relevance of this data 
becomes apparent when it is compared to the use of the terms in academic literature and by 
the web based information sources.  
 
An Academic Perspective  
 
The study of drugs is of interest to a variety of parties and disciplines and it is important when 
looking at these substances to differentiate between research on the pure compound and 
what it is found on the street.  A literature search was conducted on two databases of 
academic journals relating specifically to the study of drugs (Elsevier – 
https://www.elsevier.com/advanced-search and Sage - http://onlne.sagepub.com/). These 
databases were chosen as both make use of similar online search parameters for their 
archives which proved advantageous when compiling comparable data. Other databases were 
investigated but did not contain the same level of discriminative search parameters for the 
purpose of comparison, namely not being able to limit the data by location. Through the use of 
databases and restricted search terms a count was conducted of the number of times 
Ecstasy, MDMA and both terms together were used in the keywords of journal articles. 
 
The keywords are one of the most important factors when searching for and evaluating 
academic literature. In choosing a key word the author is focusing what the impact and 
relevance of the article is about into a limited number of words. In choosing to examine the 
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use of Ecstasy and MDMA as key words it filters the journals and articles that mention these 
specific terms without them being the focus of the article in question. Figure 2 illustrates the 
change over time in the use of the two terms, comparing when they have both been used as 
keywords and when they have been used separately. Figure 3 shows the difference between 
when each term has been used individually as a keyword alone. 
 
 
Figure 2:- The frequency of the terms appearing as keywords, together and individually in 
journal articles from the UK in the academic databases Elsevier & Sage 
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Figure 3:- The frequency with which each word appears individually as a keyword found in 
journal articles from the UK in the academic databases Elsevier & Sage 
Figure 2 shows that there was a marked increase in journals which used both terms as key 
words in 2006; the impact of this is evident in the policy making of the United Kingdom as 
demonstrated in the correspondences between the Science and Technology Committee 
(STC) and ACMD. The response published by the ACMD to the STC report states that; 
 
‘In view of the high-profile nature of the drug and its apparent widespread usage 
amongst certain groups, it is surprising and disappointing that the ACMD has never 
chosen to review the evidence for ecstasy’s Class A status…We recommend the 
ACMD carries out an urgent review of the classification of ecstasy.’ 
 (Rawlins, 2006 pg12) 
 
The recommendation was accepted and the ACMD went on to publish their review in 2009. 
They acknowledged that MDMA was the most prevalent compound found in Ecstasy. When 
examining the prevalence of the language used in the review report the authors use the term 
MDMA 1.5 times more often than that of Ecstasy. This relates to the findings displayed in 
Figure 3, when the individual use of both terms is considered, as in 2008 the term MDMA is 
recorded as being used as a keyword more frequently than Ecstasy for the first time.  
 
After the increase in use of the term in 2008, the frequency of the use of the term MDMA falls 
in 2009. This reflects the findings shown earlier in Figure 1, from the UNODC and the 
EMCDDA Reports, reflecting the lack of MDMA available globally at this time. However, post 
2011 the most prevalent term being used as a keyword in the journals and databases 
examined is MDMA. There has also been an apparent decline in the number of journals that 
used both terms as key words as shown in Figure 2. 
 
The findings from this study suggest that that MDMA has replaced the term Ecstasy in the 
academic vocabulary. This also supports the idea that there may have been a shift in type of 
Ecstasy being found on the street as suggested by Smith, Moore and Measham (2009). 
However these findings are contradictory to the conclusions found in Figure 1, which 
described the usage by both the UNODC and the EMCDDA which maintained the use of the 
term Ecstasy.  The difference between the two can be attributed to the necessity for the global 
organisations to reflect the use of the term in its broadest sense. 
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The review of the academic literature could be considered reductionist as it merely reflects the 
literature from the UK; however this data is further supported by the analysis of the media, 
online information sources and search terms stored by Google. To further explore whether 
there has been a definitive shift in the use of the two terms in the UK a third database was 
assessed. This was explored by examining the response by the British media, with a specific 
examination of news stories published by the BBCnews archive.  
 
Ecstasy, MDMA and the Media 
To examine the impact and change of language in the media the frequency with which each 
term appears in the news stories reported on the BBC news website 
(www.bbc.co.uk/search/news) was selected as an example to compare to the other sources. 
The BBC website was chosen due to the similarity in the search function of its archive to that 
of the journal databases. With the same search parameters being employed allowing for 
comparable data the findings are shown in Figure 4. 
 
 
Figure 4: Number of news stories referencing Ecstasy and MDMA as reported by the BBC 
News Corporation  
 
As with the findings from the academic literature search the data above shows that there has 
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There is the same drop in use of the term Ecstasy in 2008 with further usage mirroring the 
findings reported above.   However the term MDMA has increased year on year, until finally 
surpassing the term Ecstasy in 2012, to become the more frequently used term in the 
subsequent year. This data supports the dominance of the term MDMA over Ecstasy, as 
found with the academic database results. This suggests that within the UK at least, MDMA is 
the term that is being used. However the differentiation between the two terms requires further 
defining as technically they both refer to the same compound. To examine how a 
differentiation could be achieved the way both terms are used by a number of web-based 
information sources has been considered. 
 
Web based Information sources 
 
The lack of consistency in the description of Ecstasy could be an issue for a number of 
individuals and organizations, including healthcare professionals, drugs educators and law 
enforcement organisations. This role becomes difficult when the information provided is 
inconsistent, not only between the political and academic sources, but also when it is at odds 
with the vast array of internet and web based sources. 
 
One of the most respected independent online sources of drug information is the website 
Erowid. Similar to the pages found on the EMCDDA’s website, Erowid works with academics, 
medical experts and user based experiences to provide individual pages devoted to 
psychoactive substances. Parallels can be drawn between Erowid’s page and the EMCDDA’s, 
as both choose to use the term MDMA as the focus, with Erowid providing the following 
description;  
  
 
‘MDMA is one of the most popular recreational psychoactive, most commonly sold in the form 
of "ecstasy" tablets’ 
(http://www.erowid.org/chemicals/mdma/mdma.shtml) 
 
Though its vaults provide a vast abundance of information on all things drugs related, Erowid 
is not considered to be an official drugs educational resource, nor is it specific to the British 
drug culture, yet a distinction is made by mentioning the form, namely ecstasy being tableted. 
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This could perhaps be the route to differentiation, whereby Ecstasy refers to tableted form and 
MDMA crystalline. This can be examined further by looking at other web based resources. 
 
In 2003 the UK government launched the ‘Talk to Frank’ campaign as a ‘standardised 
educational drugs prevention messages’ programme (Smith, Moore & Measham, 2009, 
pg.16). As with the EMCDDA, the web-based service provides individualised profiles on the 
most common recreational drugs found in the UK. However, unlike the profile on the 
EMCDDA’s website TalktoFrank has stuck with the term Ecstasy as the chosen term, with the 
option for MDMA being redirected to the Ecstasy page 
(http://www.talktofrank.com/drug/ecstasy). As a part of the profile a description of Ecstasy’s 
appearance is given as; 
 
‘Pure ecstasy is a powder made of white crystals, known to chemists as MDMA. Ecstasy is 
usually sold on the street as tablets, although it's getting more common to see it sold as 
powder and called by its chemical name, MDMA, or 'crystal'.’ 
(http://www.talktofrank.com/drug/ecstasy) 
 
Again the form in which the drug is found dictates the name which it is given, Ecstasy to 
tablets, MDMA to crystal or powdered. Yet the description may cause concern as it suggests 
that the newer powdered form is ‘pure’ without the relative purity having been established. If 
the communication from ‘standardised educational message’ is that MDMA powder is pure 
this could mislead users and inhibit harm reduction initiatives. This message is reiterated by 
the drugs educational charity DrugScope, whose own web based information portal states 
that;  
 
 ‘Ecstasy is an illegally manufactured drug that usually comes in tablet or capsule form. The 
chemical name of pure ecstasy is 3, 4 Methylenedioxymethamphetamine or MDMA for short’ 
(http://www.drugscope.org.uk/resources/drugsearch/drugsearchpages/ecstasy.) 
 
Both of these resources provide an explanation that is misleading. With the emergence of 
these two terms, the perception being promoted is that the term MDMA means “pure”. From 
the purely chemical sense this is true as it is the abbreviation of the longer chemical name. 
However the term MDMA has been used to effectively rebrand the new powdered and crystal 
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form of this recreational drug. A distinction needs to be made between what is understood as 
the pure chemical and this new product on the street.  
 
A final information source that provides evidence in the shift in the use of these two terms is 
the search engine Google. In 2006, the internet giant launched a series of applications, one of 
which was its ‘Trends’ application (http://www.google.com/trends/), a system which records 
the frequency with which users search for terms which can then be limited by location and 
time. To further support the changing of use of these two terms is the data collected from this 
application displayed in Figure 5.  
 
 
Figure 5: Frequency of searches for both search terms entered into Google Inc.  
 
The data shows the search trends within the UK and reflects a similar pattern to the ones 
shown in both Figures 3 and 4.  Similar to the findings from both the academic and media 
searches, it is seen that the term Ecstasy is the most prevalent term being used until 2010 
when MDMA began to overtake and become to more dominant term. This supports the notion 
that not only have the academic community moved away from the use of Ecstasy to describe 
this recreational drug but so have the general public within the UK.  
 
This data shown in figure 5 could also reflect the change in use and prevalence of the different 
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the ‘Global Drug Survey’ run in collaboration with the magazine Mixmag (Mixmag 2010 – 
2012). The survey asks its participants which drugs they have tried. Over the last 5 years, the 
language they have used to describe the substance MDMA has shifted, in 2010 participants 
were asked if they had tried Ecstasy or MDMA powder, with both answers being displayed as 
separate. In 2011 the option Ecstasy (pills or powders) was deployed. However since 2012 
the Global Drug Survey has just used the term MDMA, omitting the use of the term Ecstasy 
(Globaldrugsurvey.com, Mixmag 2010, 2011, 2012). This change reflects the findings from the 
other sectors examined; that the change in language reflects a change in the type of drug 
being found and used, moving away from tablets towards the powders.  
 
Conclusion 
 
This paper has examined the different sources and groups concerned with the dissemination 
of information concerning illicit drugs. What has been shown is a distinct change in the 
prevalence of use of the term ‘MDMA’. It now being used to describe what was once known as 
‘Ecstasy’ in the UK. However this shift in use has not been universal or consistent, as has 
been shown with the analysis of both the UNODC and the EMCDDA who both still exhibit a 
preference for the term ‘Ecstasy’,   
 
The persistence in the use of ‘Ecstasy’ as the main term used in the annual reports produced 
by both organizations can be explained due to its encapsulating nature; in this regard it is not 
a direct synonym for MDMA but rather a descriptive for a group/class of substances – the ring-
substituted phenethylamines. The use may also be explained in the persistent association with 
the form in which these substances are found, namely as tablets. Both sets of annual reports 
state that the most prevalent form is that of the ‘Ecstasy’ pill; however this is not necessarily 
now the case in the UK. 
 
Recent years have seen the emergence of a new form of powdered and crystalline drug which 
is sold as ‘MDMA’ (Smith, Moore & Measham 2009).  There is very little information available 
to date on the current prevalence of powdered MDMA compared to the tablets, or the relative 
purity of this new product.  Yet the data suggests that the emergence of this new form may be 
a reason for the change in the use of these two terms. Whilst the term Ecstasy signifies the 
tablet form, MDMA has come to signify the powdered or crystalline. This change in the 
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language may not only reflect the different types now being found but the prevalence of use of 
each type.  
 
Another factor that may have impacted not only the shift in terminology but changed the 
method of substance delivery is the reputation that Ecstasy pills have subsequently gained. 
Long since the ‘heyday’ of the eighties and nineties the declining purity of ecstasy tablets is 
well documented (Cole et al, 2001, Parrott, 2004, Smith, Moore & Measham, 2009,). The 
decline in purity led to a decline in the popularity and trust in Ecstasy tablets. This precipitated 
a change in the way that Ecstasy was being sold. Ecstasy is now an imprecise term where 
once it related to the branding of MDMA pills. It is now associated with a cheap and poor 
quality product (Smith, Moore & Measham, 2009) whilst a new product, MDMA powder, has 
emerged in its place with a reputation for purity.  
 
So why is clarification of the terms necessary? There are a number of stakeholders to whom 
accurate consistent information is vital. There is much discussion around the need for harm 
reduction and evidence-led policy when it comes to the discussion around what to do about 
drug use. The most important issue is to make sure that every party is using the same 
terminology when describing the same problem, for example if the UNODC claim Ecstasy use 
is on the decline, a statement based on tablet seizures and yet the Global Drug Survey and 
other organizations state that MDMA use is on the increase, what are policy makers, law 
enforcement and the health professionals to use? Admittedly the social reaction in the UK is 
different to that of the rest of the global population, as the UK is reportedly the largest market 
for the new psychoactive substances (NPS) in Europe (UNODC, 2013). However it is 
important to understand the different terms people use when selling products and using them 
to be able to provide the right information.  
 
There is a need for a consistent use of language and a universal description of illicit 
substances is important when identifying issues within the recreational drug market at local, 
regional, national and, indeed, international levels. Is Ecstasy use on the decline or has there 
just been a shift to using MDMA powders? From a health perspective, when someone claims 
to have taken Ecstasy, are they talking about a pill or a powder? Is there a reason differentiate 
between the two? The answer has to be an emphatic “yes”, especially from a harm reduction 
perspective as there is very little information regarding the relative purity of the new powdered 
MDMA, what it actually contains, and at what concentrations?  
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There has been a change in the use of language to describe Ecstasy. This change may reflect 
more than just what people are saying and may actually provide an insight into the change in 
the type and form of MDMA being used. It may also provide important information for 
healthcare professionals, educators and law enforcement professionals. 
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FORREST CONFERENCE 25-26 June 2013 
 
Abstract Submission Form 
 
If you wish to submit an abstract for this meeting, please email this form to 
forrest2013@anglia.ac.uk no later than Friday 26th April 2013. 
 
Please indicate on the form whether you wish to present a 15-minute talk or a poster. Advice 
for preparing talks and posters can be found on our website www.anglia.ac.uk/FORREST2013 
 
Poster or talk?  
Talk 
Title:  
Ecstasy:- An Evolution of a Party Drug 
 
Authors:  
Alexandra Turner 
 
Academic address:  
Mel 210, Melish-Clark Building, Anglia Ruskin University, Cambridge Campus, CB1 1PT 
 
Email address: Alexandra.Turner@anglia.ac.uk 
 
Abstract (Max 250 words):  
 
This talk will examine the journey taken by one of the most interesting illicit drugs, the evolution of 
Ecstasy. From humble beginnings as an intermediate chemical in the development of a lifesaving 
medicine, 3, 4-methylenedioxymethamphetamine’s (MDMA) true potential as a psychoactive substance 
would not be discovered until 75 years after its discovery. It was not until pioneering chemist Dr Alexander 
Shulgin published his first paper in 1978 on the effects of this substance that its properties were known. 
From Shulgin this compound found its way into the developing psychedelic therapeutic movement of the 
late 70’s, early 80’s, whereby it was reportedly successful in the treatment of a number of psychotic 
disorders. Alongside the lofty ideals of the psychologists behind the psychedelic therapy, MDMA had 
found its way into the general population. MDMA quickly became a part of the American recreational drug 
scene, where it received its trademark name, ‘Ecstasy’ from an anonymous dealer.  Ecstasy use spread 
outward from the United States; following the growing dance movement it eventually found its way onto 
British Shores. DJ’s coming from the party island of Ibiza brought back a new sound and a new product. 
However once a product had become established unscrupulous producers became greedy, and the 
quality of the product available began to decline, allowing for the introduction of new synthetic chemicals 
to replace Ecstasy as the drug du jour of the party scene. Nevertheless the later part of the 00’s has seen 
resurgence in the appearance of the chemical MDMA in a new form. 
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Fig.1The mean MDMA content of ecstasy tablets analysed by the Forensic Science Service in the United 
Kingdom between 1991 and 2001 ( data  taken from Cole,  J et al, 2002. The content of ecstasy tablets: 
implications for the study of their long-term effects. Addiction, 97, pg1531-1536)
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Introducing a New Product
MDMA Powder/ Crystal
Global Drug Survey 2013
 60.8 admitted taking MDMA Crystal
 40.2 took in tableted form
 
Slide 13 
Brand awareness
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(Crazy for Party drugs, BBC 2013)
Do people take what's available or is there ‘brand’ 
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Appendix III:  Participant Information Sheet for Social Surveys 
Opening Statement 
The purpose of this piece of research is to investigate the awareness the general public has 
regarding drugs, drug names and the information sources available. It is necessary for the 
purposes of this research that you are either a national or a resident of Great Britain as we are 
only looking at British legislation and society. 
 
We also ask that you be at least 18 years old to participate in this research. 
 
About the research  
 
This research is a project of two parts, firstly to investigate the current state of the public 
knowledge and awareness of drugs; it will be looking at information sources and the 
perceptions around the accuracy of the information available. The second part is an analysis 
of which drugs people admit to taking and examining whether there is a preference for specific 
drugs. This is then to be related to seizure data collected from collaborating police stations to 
see whether there is a correlation between what people like and levels found on the street. 
This research will give an insight into links between user preference and street drug seizure 
trends. 
 
Consent 
 
By ticking the box at the beginning of the survey and filling out and submitting your responses 
you are authorising the author of the survey to use the information you provide for the 
purposes of this research. At no point will any personal information be required past a general 
location, age and gender. The researcher will not contact you directly about your responses 
and no information will be stored that will enable the researcher or third parties to identify 
participants. Due to the nature of the data collection you will be unable to withdraw your 
responses once you have clicked on the final submission button at the end of the survey. 
However if you close the webpage at any point before submitting your responses they will not 
be stored. 
 
If you wish to contact the researcher please e-mail: 
 
AngliaRuskinDrugSurvey@Gmail.com 
 
There will be a link at the end of this survey, once you have completed it that will take you to 
the adjoining survey on drug use and preference. You do not have to fill the second survey if 
you filled the first survey. 
 
Concluding Statement 
 
Thank you for completing the survey your responses have now been recorded. 
 
Due to the nature of the data collection you will be unable to withdraw your responses at this 
point, however all responses are recorded anonymously. 
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Appendix IVa: Additional Material for Chapter 4.1 
Table 4.1.i: Responses to Question 1 (n = 440) 
Drug Frequency Percent response  
Amphetamine 405 94.1% 
Cannabis 434 98.6% 
Cocaine 427 98.4% 
Crack 435 97.1% 
Ecstasy 433 98.6% 
Heroin 414 98.7% 
Ketamine 431 92.1% 
LSD 434 98.0% 
MDMA 344 78.2% 
Mephedrone 318 72.3% 
Piperazines 96 21.8% 
2CB 62 14.1% 
 
Table 4.1.ii: Responses for Question 1 separated by the variable Gender, including 
significance tests. 
Substance 
Male Responses 
(n=163) 
Female Response 
(n=277) χ2 P value Significant 
Heard Not Heard Not 
Amphetamine 160 3 254 23 7.709* 0.005 Yes 
Cannabis 162 1 272 5 1.083* 0.420 No 
Cocaine 162 1 271 6 1.580* 0.267 No 
Crack 160 3 267 10 1.121* 0.290 No 
Ecstasy 163 0 271 6 3.579* 0.089 No 
Heroin 161 2 274 3 0.019* 1.000 No 
Ketamine 154 9 251 26 2.093 0.148 No 
LSD 161 2 270 7 0.866* 0.495 No 
MDMA 138 25 206 71 6.375 0.012 Yes 
Mephedrone 125 38 193 84 2.518 0.113 No 
Piperazine 40 123 22 155 23.352 <0.001 Yes 
2CB 58 105 38 239 28.758 <0.001 Yes 
[* indicates the application of the Fishers Exact test; used when expected frequencies are <5] 
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Table 4.1.iii: Significance test for the variable Age on the responses to Question 1 
Substance χ2 P value Significant 
Amphetamine 6.528 0.182 No 
Cannabis 1.660 0.918 No 
Cocaine 0.998 1.000 No 
Crack 7.368 0.102 No 
Ecstasy 2.564 0.707 No 
Heroin 2.443 0.734 No 
Ketamine 9.347 0.061 No 
LSD 1.349 0.927 No 
MDMA 20.380 0.001 Yes 
Mephedrone 8.671 0.123 No 
Piperazine 6.911 0.220 No 
2CB 1.121 0.952 No 
 
Table 4.1.iv: Responses to Question 2 shown as frequency and percentage against total 
population (n = 440) 
Drug   Class A Class B Class C Don't Know 
Amphetamine 
Frequency 176 157 27 80 
(%) 40.0 35.7 6.1 18.2 
Cannabis 
Frequency 33 253 135 19 
(%) 7.5 57.5 30.7 4.3 
Cocaine 
Frequency 388 31 5 16 
(%) 88.2 7.0 1.1 3.6 
Crack 
Frequency 379 29 7 25 
(%) 86.1 6.6 1.6 5.7 
Ecstasy 
Frequency 301 86 24 29 
(%) 68.4 19.5 5.5 6.6 
Heroin 
Frequency 414 9 2 15 
(%) 94.1 2.0 0.5 3.4 
Ketamine 
Frequency 128 144 94 74 
(%) 29.1 32.7 21.4 16.8 
LSD 
Frequency 272 112 23 33 
(%) 61.8 25.5 5.2 7.5 
MDMA 
Frequency 209 89 25 117 
(%) 47.5 20.2 5.7 26.6 
Mephedrone 
Frequency 80 117 68 175 
(%) 18.2 26.6 15.5 39.8 
Piperazine 
Frequency 14 47 38 341 
(%) 3.2 10.7 8.6 77.5 
2CB 
Frequency 52 43 25 320 
(%) 11.8 9.8 5.7 72.7 
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Table 4.1.v: Chi-Squared Test statistics of independence between responses for each of the 
substance in Question 2  
Drug χ2 P Value Significant 
Amphetamine 130.491 <0.001 Yes 
Cannabis 320.764 <0.001 Yes 
Cocaine 939.873 <0.001 Yes 
Crack 879.600 <0.001 Yes 
Ecstasy 463.764 <0.001 Yes 
Heroin 1120.964 <0.001 Yes 
Ketamine 27.564 <0.001 Yes 
LSD 361.327 <0.001 Yes 
MDMA 159.236 <0.001 Yes 
Mephedrone 63.073 <0.001 Yes 
Piperazines 652.091 <0.001 Yes 
2CB 537.982 <0.001 Yes 
 
  
 373 
 
 
Table 4.1.vi: Chi-Squared Test statistics of independence between correct and incorrect 
responses to question 2.  
Drug 
Correct 
Responses 
Incorrect 
Responses 
χ2 P Value Significant 
Amphetamine 157 283 35.52 <0.001 Yes 
Cannabis 253 187 9.60 0.0019 Yes 
Cocaine 388 52 255.06 <0.001 Yes 
Crack 379 61 228.38 <0.001 Yes 
Ecstasy 301 139 58.92 <0.001 Yes 
Heroin 414 26 340.38 <0.001 Yes 
Ketamine 94 346 143.18 <0.001 Yes 
LSD 272 168 24.12 <0.001 Yes 
MDMA 209 231 1.10 0.317 No 
Mephedrone 117 323 95.52 <0.001 Yes 
Piperazines 38 402 299.48 <0.001 Yes 
2CB 52 388 255.06 <0.001 Yes 
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Table 4.1.vii: Chi-Squared Test statistics of the variables of age and gender applied to 
Question 2 
Substance Variable 
Chi 
Squared 
P value Exact Significant 
Amphetamine 1) Gender 
2) Age 
9.106 
31.245 
0.028 
0.011 
χ2 
MC 
Yes 
Yes 
Cannabis 1) Gender 
2) Age 
22.602 
24.646 
<0.001 
0.048 
χ2 
MC 
Yes 
Yes 
Cocaine 1) Gender 
2) Age 
6.732 
14.389 
0.075 
0.339 
MC 
MC 
No 
No 
Crack 1) Gender 
2) Age 
5.533 
17.579 
0.150 
0.186 
MC 
MC 
No 
No 
Ecstasy 1) Gender 
2) Age 
0.345 
54.825 
0.951 
<0.001 
χ2 
MC 
No 
Yes 
Heroin 1) Gender 
2) Age 
2.237 
18.297 
0.548 
0.145 
MC 
MC 
No 
No 
Ketamine 1) Gender 
2) Age 
4.085 
28.010 
0.252 
0.023 
χ2 
MC 
No 
Yes 
LSD 
 
1) Gender 
2) Age 
4.494 
30.566 
0.213 
0.007 
χ2 
MC 
No 
Yes 
MDMA 1) Gender 
2) Age 
18.548 
50.232 
<0.001 
<0.001 
χ2 
MC 
Yes 
Yes 
Mephedrone 1) Gender 
2) Age 
10.169 
23.794 
0.017 
0.070 
χ2 
MC 
Yes 
No 
Piperazine 1) Gender 
2) Age 
10.612 
17.334 
0.014 
0.223 
χ2 
MC 
Yes 
No 
2CB 1) Gender 
2) Age 
15.997 
10.553 
0.001 
0.764 
χ2 
MC 
Yes 
No 
 
Table 4.1.viii: Gender responses that correctly identified the classifications of Ecstasy and 
MDMA 
Gender Both Correct Both Not correct χ2 P value 
Male 87 163 
13.1 <0.001 
Female 99 178 
  
Table 4.1.ix: Age Responses that correctly identified the classifications of Ecstasy and MDMA 
Age Both Correct Both Not correct χ2 P value 
18-21 71 106 
18.7 0.002 
22-29 61 67 
30-39 30 27 
40-49 17 22 
50-59 2 17 
60+ 5 20 
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Table 4.1.x: Two-way chi squared analysis of the alternate names for select substance by 
gender 
Substance Name χ2  P value Significant 
Cannabis 
Dope 0.359 0.549 No 
Grass 1.430 0.232 No 
Green 5.290 0.021 Yes 
Hash 0.035 0.852 No 
Pot 1.177 0.278 No 
Skunk 2.934 0.087 No 
Weed 0.209 0.647 No 
Ketamine 
Dust 1.946 0.166 No 
Green 1.777 0.299 No 
K 4.327 0.038 Yes 
Special K 4.600 0.032 Yes 
Ecstasy 
Adam 1.057 0.304 No 
Crystal <0.001 0.999 No 
E 0.561 0.454 No 
Mandy 6.008 0.014 Yes 
MDMA 3.862 0.049 Yes 
XTC 8.657 0.003 Yes 
Mephedrone 
4MMC 7.887 0.005 Yes 
Bubble 2.062 0.151 No 
Meow-Meow 2.617 0.106 No 
White Magic 0.359 0.549 No 
 
Table 4.1.xi: Chi Squared test of significance for the variable of Age applied to the results of 
Question 3 
Substance Name χ2 P value Test Significant 
Cannabis 
Dope 4.062 0.545 MC No 
Grass 10.187 0.064 MC No 
Green 55.653 <0.001 χ2 Yes 
Hash 2.478 0.782 MC No 
Pot 0.834 0.968 MC No 
Skunk 11.389 0.027 MC Yes 
Weed 5.866 0.198 MC No 
Ketamine 
Dust 1.778 0.843 MC No 
Green 2.110 1.000 MC No 
K 5.471 0.334 MC No 
Special K 6.714 0.243 χ2 No 
Ecstasy 
Adam 4.310 0.445 MC No 
Crystal 6.769 0.186 MC No 
E 7.032 0.155 MC No 
Mandy 14.607 0.007 MC Yes 
MDMA 11.677 0.039 χ2 Yes 
XTC 7.039 0.218 χ2 No 
Mephedrone 
4MMC 1.889 0.886 MC No 
Bubble 2.701 0.725 MC No 
Meow-Meow 17.297 0.004 χ2 Yes 
White Magic 9.678 0.055 MC Yes 
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Table 4.1.xii: The results of the two way chi square test on the cross tabulation of question 1 
against whether participants had drugs education  
Substance Test χ2 P Value Significant 
Amphetamine X2 0.217 0.641 No 
Cannabis FE 0.352 0.626 No 
Cocaine FE 0.316 0.696 No 
Crack FE 3.970 0.086 No 
Ecstasy FE 0.352 0.626 No 
Heroin FE 0.803 0.594 No 
Ketamine FE 1.452 0.228 No 
LSD FE 5.407 0.035 Yes 
MDMA X2 4.489 0.034 Yes 
Mephedrone X2 6.015 0.014 Yes 
Piperazine X2 7.847 0.005 Yes 
2CB X2 7.106 0.008 Yes 
 
Table 4.1.xiii: The results of the two way chi square test on the cross tabulation of question 2 
against whether participants had drugs education  
Substance χ2 P Value Significant 
Amphetamine 1.75 0.186 No 
Cannabis 0.29 0.590 No 
Cocaine 0.46 0.498 No 
Crack 0.49 0.484 No 
Ecstasy 0.57 0.450 No 
Heroin 0.89 0.345 No 
Ketamine 0.00 1.000 No 
LSD 0.05 0.823 No 
MDMA 1.52 0.217 No 
Mephedrone 2.26 0.133 No 
Piperazine 0.53 0.467 No 
2CB 1.91 0.167 No 
 
Table 4.1.xiv: The results of the two way chi square test on the cross tabulation of question 4 
against whether participants had drugs education  
Question 4 Test χ2 P Value Significant 
a) Prevalence of 
Drugs 
MC 21.287 <0.001 Yes 
b) Health Risks MC 7.468 0.118 No 
c) Cannabis MC 5.107 0.270 No 
d) Ketamine χ2 2.906 0.574 No 
e) Ecstasy MC 8.064 0.089 No 
f) MDMA χ2 7.014 0.135 No 
g) Mephedrone χ2 7.805 0.099 No 
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Figure 4.1.i: Results for Question 6a separated by the variable of gender (female n= 277, male 
n=163) 
 
 
Figure 4.1.ii: Question 6b responses separated by the variable of gender (female n= 277, 
male n=163) 
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Table 4.1.xv. Top three choices to questions 6a (themselves) and 6b (someone else) by age 
group 
  
  
6a) Themselves 6b) Someone else 
1st 2nd 3rd 1st  2nd 3rd  
Overall Internet Friends 
Drugs 
Forum 
Internet Friends 
Drugs 
Forum 
18-21 Internet Friends 
Drugs 
Forum 
Internet Friends 
Drugs 
Forum 
22-29 Internet Friends 
Government 
Website 
Internet Friends 
Drugs 
Forum 
30-39 Internet Friends 
Drugs 
Forum 
Internet 
Government 
Website 
Drugs 
Forum and 
Drugs 
Helpline 
40-49 Internet Friends 
Government 
Website 
Internet 
Drugs 
Helpline  
Friends and 
Government 
Website 
50-59 
 
 
 
Internet 
Drugs 
Helpline  
Government 
Website  
and 
GP/Doctor 
Internet 
Drugs 
Helpline  
Government 
website 
60+ Internet GP/Doctor 
Government 
Website  
and Hotline 
Internet 
Friends and 
Drugs 
Helpline 
Government 
Website 
and Local 
Drug 
Service 
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Table 4.1.xvi: Mean values for each of the options in Question 7 by the variable of Age 
Question 
Mean Values For Age groups 
18-21 22-29 30-39 40-49 50-59 60-69 
7a: The Government 2.84 2.89 2.82 2.72 3.37 2.6 
7b: Scientist 3.54 2.81 3.67 3.74 3.74 3.85 
7c: Media 1.91 2.01 1.98 1.77 1.89 1.85 
7d: User 2.99 3.02 2.91 2.92 2.11 2.00 
7e: Doctor 3.97 3.7 3.72 3.56 3.95 3.3 
7f: Internet 3.12 3.26 3.14 3.05 3.26 3.15 
 
Table 4.1.xvii: Results for Questions 7a to 7f for the Chi Squared test when applied using the 
variable of age 
Question χ2 Value P Value Significant 
7a: The Government 18.043 0.557 No 
7b: Scientist 21.908 0.282 No 
7c: Media 9.188 0.850 No 
7d: User 32.559 0.020 Yes 
7e: Doctor 34.333 0.007 Yes 
7f: Internet 17.211 0.584 No 
 
 
Table 4.1.xviii: The frequency of occurrence for the  
Word Frequency of occurrences  
People 205 
Know 163 
Effects 140 
Aware 130 
Taking 89 
Informed 84 
Important 81 
Risks 64 
Healthy 56 
Help 38 
Consequences 36 
Knowledge 35 
Decision 31 
Awareness 29 
Information 28 
Danger 25 
Decisions 24 
Harm 20 
Dangerous 19 
Choices 17 
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Table 4.1.xix: Response to Question 10 by theme compared to whether participants reported 
to have had drugs education  
Themes 
Q5: Education 
χ2 P value Significant Yes 
(n = 338) 
No 
(n =102) 
Informed Choice 
118 32 
0.04 0.842 No 
35% 31% 
Dangers 
93 22 
0.26 0.61 No 
28% 22% 
Deterrent 
34 13 
1.48 0.224 No 
10% 13% 
Help 
24 8 
0.36 0.548 No 
7% 8% 
Prevalence 
21 9 
1.64 0.2 No 
6% 9% 
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Appendix IVb: Additional Material for Chapter 4.2 
Table 4.2.i: Reported use for selected substances to the question of Ever taken by the 
different genders with the user group 
Substance χ2  P Value Significant 
Cocaine 2.58 0.136 No 
Ecstasy 0.76 0.446 No 
MDMA 0.08 0.887 No 
Ketamine 0.05 0.887 No 
Mephedrone 2.19 0.189 No 
 
Table 4.2.ii: Reported use for selected substances to the question of Ever taken by the 
different genders with the user group compared to non-user group  
Substance χ2  P Value Significant 
Cocaine 0.243 0.622 No 
Ecstasy 2.422 0.120 No 
MDMA 4.775 0.029 Yes 
Ketamine 4.992 0.025 Yes 
Mephedrone 10.263 0.001 Yes 
Piperazines 4.651 0.031 Yes 
 
 
 
Figure 4.2.i: Percentage of male and female participants reporting to have ‘Taken in the Last 
year’ each of the five substances (n: Cocaine = 76, Ecstasy = 84, Ketamine = 52, MDMA = 76 
and Mephedrone = 37) 
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Figure 4.2.ii: Percentage of male and female participants reporting to have ‘Taken in the Last 
Month’ each of the five substances (n: Cocaine = 76, Ecstasy = 84, Ketamine = 52, MDMA = 
76 and Mephedrone = 37) 
 
 
Table 4.2.iii: Reported use for selected substances to the questions of taken in the last year 
and last month by the different genders with the user group compared to non-user group  
Substance χ2 P Value Significant 
Cocaine 
Last Year 0.857 0.356 No 
Last Month 0.004 0.947 No 
Ecstasy 
Last Year 1.773 0.183 No 
Last Month 7.093 0.012 Yes 
MDMA 
Last Year 0.692 0.405 No 
Last Month 0.684 0.408 No 
Ketamine 
Last Year 5.509 0.019 Yes 
Last Month 0.462 0.489 No 
Mephedrone 
Last Year 5.694 0.025 Yes 
Last Month No responses 
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Figure 4.2.iii: Reported use of substance ‘Taken Last Year’ separated into age group 
(percentage calculated against size of age group)  
 
 
 
Figure 4.2.iv: Reported use of substance ‘Taken Last Year’ separated into age group  
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Figure 4.2.v: Reported use of substance ‘Taken Last Month’ separated into age group 
(percentage calculated against size of age group)  
 
 
Figure 4.2.vi: Reported use of substance ‘Taken Last Month’ separated into age group  
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Table 4.2.iv: Gender responses to Question 4 and statistical significance using two way chi 
squared (critical significance level 0.05) 
Drug Gender Negative Indistinct Positive χ2 P Value Significant 
Cocaine 
Male 2 9 20 
1.264 0.531 No 
Female 7 16 22 
Ecstasy 
Male 1 6 29 
0.416 0.812 No 
Female 4 7 35 
MDMA 
Male 0 3 34 
0.850 0.079 No 
Female 5 3 31 
Ketamine 
Male 7 4 16 
3.325 0.189 No 
Female 6 5 13 
Mephedrone 
Male 4 7 10 
2.300 0.316 No 
Female 7 2 5 
 
Table 4.2.v: Gender responses to Question 5 and statistical significance using two way chi 
squared (critical significance level 0.05) 
Drug Gender Negative Indistinct Positive χ2 P Value Significant 
Cocaine 
Male 1 11 19 
1.964 0.374 No 
Female 7 16 22 
Ecstasy 
Male 0 2 28 
1.361 0.506 No 
Female 4 1 41 
MDMA 
Male 0 0 37 
1.348 0.510 No 
Female 3 1 35 
Ketamine 
Male 6 5 16 
3.48 0.175 No 
Female 8 8 8 
Mephedrone 
Male 4 4 13 
0.694 0.707 No 
Female 5 3 6 
  
Table 4.2.vi: Cross tabulation of responses between Questions 4 and 5 for Cocaine  
 
Q4 Cocaine - Physical 
Total 
Negative Indistinct Positive Not Taken 
Q5 Cocaine 
- Emotional 
Negative 4 3 2 0 9 
Indistinct 3 18 5 0 26 
Positive 1 8 39 0 48 
Not Taken 0 0 0 169 169 
Total 8 29 46 169 252 
 
Table 4.2.vii: Cross tabulation of responses between Questions 4 and 5 for Ecstasy  
 
Q4 Ecstasy - Physical 
Total 
Negative Indistinct Positive Not Taken 
Q5 Ecstasy 
- Emotional 
Negative 2 1 2 0 5 
Indistinct 2 2 9 0 13 
Positive 0 1 59 0 60 
Not Taken 0 0 0 168 168 
Total 4 4 70 168 246 
 
Table 4.2.viii: Cross tabulation of responses between Questions 4 and 5 for MDMA 
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Q4 MDMA - Physical 
Total 
Negative Indistinct Positive Not Taken 
Q5 MDMA - 
Emotional 
Negative 2 1 2 0 5 
Indistinct 0 1 6 0 7 
Positive 1 0 66 0 67 
Not Taken 0 0 0 173 173 
Total 3 2 74 173 252 
 
Table 4.2.ix: Cross tabulation of responses between Questions 4 and 5 for Mephedrone 
 
Q4 Mephedrone - Physical 
Total 
Negative Indistinct Positive Not Taken 
Q5 
Mephedrone - 
Emotional 
Negative 8 0 3 0 11 
Indistinct 0 6 4 1 11 
Positive 1 2 13 1 17 
Not Taken 0 0 0 213 213 
Total 9 8 20 215 252 
 
Table 4.2.x: Cross tabulation of responses between Questions 4 and 5 for Ketamine 
 
Q4 Ketamine - Physical 
Total 
Negative Indistinct Positive Not Taken 
Q5 
Ketamine - 
Emotional 
Negative 12 1 2 0 15 
Indistinct 0 10 0 0 10 
Positive 5 3 22 0 30 
Not Taken 0 0 0 197 197 
Total 17 14 24 197 252 
 
Table 4.2.xi: Cross tabulation of responses between Questions 4 and 5 for Piperazines  
 
Q4 Piperazine - Physical 
Total 
Negative Indistinct Positive Not Taken 
Q5 
Piperazine - 
Emotional 
Negative 1 4 0 0 5 
Indistinct 1 2 1 0 4 
Positive 0 0 1 0 1 
Not Taken 0 0 0 242 242 
Total 2 6 2 242 252 
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Table 4.2.xii: Gender responses to Question 6 ‘Yes-Myself’ and statistical significance using 
two way chi squared (critical significance level 0.05) 
Drug Gender 
Yes - 
Myself 
Other χ2 P Value Significant 
Cocaine 
Male 4 27 
0.596 0.440 No 
Female 7 28 
Ecstasy 
Male 8 30 
0.483 0.487 No 
Female 7 39 
MDMA 
Male 5 32 
0.193 0.660 No 
Female 4 35 
Ketamine 
Male 9 18 
0.624 0.429 No 
Female 11 14 
Mephedrone 
Male 7 16 
1.416 0.234 No 
Female 7 7 
  
Table 4.2.xiii: Gender responses to Question 6 ‘Yes-someone else’ and statistical significance 
using two way chi squared (critical significance level 0.05) 
Drug Gender User Non-user χ2 P Value Significant 
Cocaine 
Male 16 18 
6.21 0.013 Yes 
Female 12 43 
Ecstasy 
Male 18 13 
4.64 0.031 Yes 
Female 18 35 
MDMA 
Male 16 9 
3.63 0.057 No 
Female 9 28 
Ketamine 
Male 15 19 
9.28 0.002 Yes 
Female 8 46 
Mephedrone 
Male 8 8 
3.39 0.065 Yes 
Female 5 18 
 
Table 4.2.xiv: Gender responses to Question 7 and statistical significance using two way chi 
squared (critical significance level 0.05) 
Drug Gender User Non-user χ2 P Value Significant 
Cocaine 
Male 15 16 
1.251 0.263 No 
Female 16 29 
Ecstasy 
Male 12 24 
0.293 0.588 No 
Female 18 28 
MDMA 
Male 16 21 
0.429 0.512 No 
Female 14 25 
Ketamine 
Male 12 12 
0.01 0.920 No 
Female 13 11 
Mephedrone 
Male 10 11 
3.353 0.067 No 
Female 11 3 
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Table 4.2.xv: Chi squared test results for significance between yes and no responses to 
question 8 
Substance χ2 value P Value Significant 
Cocaine 30.04 <0.001 Yes 
Ecstasy 28.77 <0.001 Yes 
MDMA 37.33 <0.001 Yes 
Ketamine 7.33 0.007 Yes 
Mephedrone 3.314 0.069 No 
Piperazines  7.2 0.007 Yes 
 
Table 4.2.xvi: Chi squared test results for non-user response to question 8 
Substance χ2 P Value Significant 
Cocaine 0.25 0.807 No 
Ecstasy 1.92 0.265 No 
MDMA 0.82 0.548 No 
Ketamine 1.32 0.359 No 
Mephedrone 0.53 0.624 No 
Piperazines 9.31 0.005 Yes 
 
Table 4.2.xvii: User responses to Question 8: Has knowledge of someone else bad 
experience changed your usage 
Substance χ2 Value P Value Significant 
Cocaine 
(n = 74) 
33.78 <0.001 Yes 
Ecstasy 
(n = 81) 
40.11 <0.001 Yes 
MDMA 
(n = 73) 
38.48 <0.001 Yes 
Ketamine 
(n = 47) 
15.51 <0.001 Yes 
Mephedrone 
(n = 34) 
2.94 0.123 No 
Piperazine 
(n = 7) 
0.14 1 No 
 
 
Table 4.2.xviii: Gender responses to Question 8 – User group and statistical significance using 
two way chi squared (critical significance level 0.05) 
Drug Gender Yes No χ2 P Value Significant 
Cocaine 
Male 4 25 
0.206 0.649 No 
Female 8 37 
Ecstasy 
Male 4 31 
0.56 0.454 No 
Female 8 38 
MDMA 
Male 3 32 
1.495 0.221 No 
Female 7 31 
Ketamine 
Male 6 19 
0.017 0.896 No 
Female 4 18 
Mephedrone 
Male 5 15 
1.292 0.256 No 
Female 7 7 
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Table 4.2.xix: Gender responses to Question 8 – Non-user group and statistical significance 
using two way chi squared (critical significance level 0.05) 
Drug Gender Yes No χ2 P Value Significant 
Cocaine 
Male 2 5 
0.327 0.567 No 
Female 5 4 
Ecstasy 
Male 4 1 
0.002 0.964 No 
Female 5 3 
MDMA 
Male 2 2 
0.004 0.949 No 
Female 2 5 
Ketamine 
Male 1 2 
0.265 0.607 No 
Female 11 5 
Mephedrone 
Male 2 2 
0.029 0.864 No 
Female 5 8 
 
Table 4.2.xx: Gender responses to Question 11 to 14 statistical significance using two way chi 
squared (critical significance level 0.05) 
Drug Gender Ecstasy MDMA χ2 P Value Significant 
Q11 
Male 11 37 
0.722 0.379 No 
Female 18 41 
 
Drug Gender MDMA Mephedrone χ2 P Value Significant 
Q12 
Male 42 4 
0.094 0.759 No 
Female 44 4 
 
Drug Gender MDMA Piperazine χ2 P Value Significant 
Q13 
Male 41 1 
0.014 0.905 No 
Female 46 2 
 
Drug Gender MDMA Ketamine χ2 P Value Significant 
Q14 
Male 31 14 
1.13 0.288 No 
Female 40 11 
 
Table 4.2.xxi: Chi squared test for difference between responses to question 15: preference  
  
Substances 
Cocaine Ecstasy MDMA Ketamine Mephedrone  Piperazines 
χ2 176.93 125.32 136.42 320.16 377.69 590.02 
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Significance  Yes Yes Yes Yes Yes Yes 
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Appendix V: Statistical Tests Used for Hypothesis Testing  
Chi Squared Test 
 
Example of one-way chi squared test 
 
The following example demonstrates how the one chi squared test was applied to the 
following survey data using the example from the first question, whether participants had 
heard of Ecstasy. 
 
Equation 
 
χ2 = ∑
(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑−𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑)2
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑
 
 
Table 5.i: Example of One way chi square contingency table  
Response Observed 
Value 
Expected O – E ( O – E)2 ( O – E)2 /E 
Heard 434 220 +214 45796 208.16 
Not Heard 6 220 -214 45796 208.16 
Total 440 440   416.32 
 
χ2 = 416.32  
P = <0.001 
 
Using the above calculation the χ2 value obtained for this question came back as 416.32 with 
a P value of <0.001, which is significant at the critical significance level of 0.05 ( 95% 
confidence level).  
 
Example of two-way chi squared test 
 
The following example demonstrates how the two chi squared test was applied to the survey 
data.  Using another example from the first question, whether participants had heard of MDMA 
this time including the variable of gender, the numbers in the brackets indicate the expected 
values for each variable. 
 
Table 5.ii: Example of a 2 x 2 contingency table for the results from Question 1  
Heard of MDMA Male Female Total 
Yes 138  
(127.44) 
206 
(216.56) 
344 
 
No 25  
(35.56) 
71 
(60.44) 
96 
 
Total 163 
 
277 
 
440 
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The above information can be inputted into the same equation as for the one way chi square   
 
Table 5.iii: Example of two way chi squared calculation table 
Response Observed 
Value 
Expected O – E ( O – E)2 ( O – E)2 /E 
Male Heard 138 127.44 10.56 111.51 0.88 
Male Not 
Heard 
25 35.56 -10.56 111.51 3.14 
Female Heard 206 216.56 -10.56 111.51 0.51 
Female Not 
Heard 
71 60.44 10.56 111.51 1.85 
Total 440 440   6.37 
 
χ2 = 6.37  
P = 0.012 
 
Using the above calculation the χ2 value obtained for this question came back as 6.37 with a P 
value of 0.012, which is significant at the critical significance level of 0.05 (95% confidence 
level). Though the data can be assessed manually, this project used the statistical analysis 
software SPSS to conduct the statistical tests. 
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Mann Whitney U 
The following example demonstrates how the Mann-Whitney U test was applied to the findings 
from the analytical chapter, using the data for MDMA powders and tablets. 
 
Equation 1 
 
𝑈 =  𝑛𝑎𝑛𝑏 + 
𝑛𝑎(𝑛𝑎 + 1)
2
− 𝑇𝐴 
 
𝑛𝑎 = number of samples from group a (23) 
𝑛𝑏 = number of samples from group b (8) 
𝑇𝐴 = sum of ranks from larger group (458) 
 
 
Table 5.iv: Rank scores for Analytical data 
Powder 
% 
Rank a 
Tablet 
% 
Rank b 
42 7 17 1 
58 16 33 2 
52 14.5 34 3 
52 14.5 37 4 
69 19 39 5.5 
70 20.5 39 5.5 
77 27 45 8 
75 25 46 9 
87 31 
  
73 23.5 
  
85 30 
  
72 22 
  
65 18 
  
70 20.5 
  
51 13 
  
73 23.5 
  
78 28 
  
79 29 
  
76 26 
  
61 17 
  
48 11 
  
47 10 
  
50 12 
  
TA 458   
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Calculated U value using above data 
 
𝑈 = (23)(8) + 
23(23 + 1)
2
− 458 
 
Therefore  
 
𝑈 = 2 
 
Once the U value has been calculated this can then be used to calculate the z value. The 
equation to calculate the z value is:  
 
Equation 2 
 
 
 
𝑧 =
𝑈 − 
𝑛𝑎𝑛𝑏
2
√𝑛𝑎𝑛𝑏(𝑛𝑎 + 𝑛𝑏 + 1)
12
  𝑧 =
2 − 
(23)(8)
2
√(23)(8)(23 + 8 + 1)
12
 
 
𝑧 = -4.06 
 
As the z value is less than -1.96 the null hypothesis is rejected and there is a significant 
difference between the purity of the two types of Ecstasy examined.  
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Appendix VI: Additional Material for Chapter 8 
Table 8.i: Description of first set of samples collected from Parkside Police Station (collected 
March 2013) (* sample and packaging weight) 
Sample Description 
Weight 
(g) 
A4 
White circular tablet 
Unidentifiable imprint (possibly bulls head) -poor 
quality imprint 
Diameter: 9mm 
Depth: 3mm 
0.3065 
A29 Cream crystals 4.6178* 
A30 White crystals 1.3567* 
A31 White powder 1.3707* 
A35 Brown crystals 1.5041* 
A40 Cream powder 3.6085* 
A41 Cream Power 1.2580* 
A42 Cream powder 3.2975* 
A44 Cream crystals 1.7798* 
A45 Large cream crystals 1.6144* 
A47 
Pale blue circular tablet 
Mickey mouse imprint on one side, 
Fantasia hat on other 
Diameter: 8mm 
Depth: 3mm 
0.2075 
A48 
Teal heart shaped tablet 
with gold flecks 
Height: 1cm 
Width: 8mm 
Depth: 3mm 
0.4225 
A49 
Pale red circular tablet 
Cupid design on one side 
Blank on other side 
Diameter: 8mm 
Depth: 4mm 
0.3225 
A50 
Dark orange circular tablet 
Armani design 
Blank on other side 
Diameter: 9mm 
Depth: 3mm 
0.3156 
A51 White rectangular crystals 2.4193* 
A52 White powdered crystals 0.7720* 
A53 Brown crystals 0.6291 
A54 Brown crystals 2.1894 
A55 Brown powder 0.6424* 
 
 
 
 
 395 
 
 
Table 8.ii: Description of second set of samples included in chemical analysis (* sample and 
packaging weight) 
Sample Description 
Weight 
(g) 
A3 
Green circular tablet 
CND Logo design 
(homogenised before measurements taken) 
0.3097 
A7 
Yellow circular tablet 
Star imprinted design 
(homogenised before measurements taken) 
0.2655 
A9 
Pink circular tablet 
No identified design 
(homogenised before measurements taken) 
0.2229 
A11 
Orange circular tablet 
Star imprint design 
(homogenised before measurements taken) 
0.2908 
A12 White powder 5.8806* 
A27   Pale brown crystals 6.2204* 
A28   Pale brown crystals 1.1955* 
A32 White powder 1.3583* 
A37   Pale brown crystals 0.8614* 
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Table 8.iii: Description of third set of samples included in chemical analysis (collected from 
Parkside Police station February 2014) (* sample and packaging weight) 
Sample Description 
Weight 
(g) 
A61 White powder 0.269* 
A63 Pale brown crystals 2.397* 
A64a 
Pale brown crystals 
(in wrap/bomb) 
0.083 
A64b 
Pale brown crystals 
(in wrap/bomb) 
0.073 
A64c 
Pale brown crystals 
(in wrap/bomb) 
0.163 
A64d 
Pale brown crystals 
(in wrap/bomb) 
0.105 
A64e 
Pale brown crystals 
(in wrap/bomb) 
0.088 
A65 White crystals 1.050* 
A66 White crystals 1.802* 
A67 White crystals 1.803* 
A68 Pale brown crystals 1.882* 
A69 Large brown crystals 2.055* 
A70a 
Pale brown crystals 
(in wrap/bomb) 
0.914* 
A70b 
Brown powder/crystals 
(in wrap/bomb) 
0.144 
A70c 
Pale brown crystals 
(in wrap/bomb) 
0.142 
A71 
Pale brown powder/crystals 
(in a wrap) 
0.075 
A72 
Pale cream crystal 
(in a wrap) 
0.088 
A73a 
Pale cream crystal 
(in wrap/bomb) 
0.055 
A73b 
Pale cream crystal 
(in wrap/bomb) 
0.040 
A73c 
Pale cream crystal 
(in wrap/bomb) 
0.082 
A74 Pale brown crystal 1.846* 
A75 Large pale brown crystals 2.063* 
A76 Pale brown crystals 2.283* 
A77 Pale brown crystals 1.921* 
A78 White powder 2.254* 
A79a Pale cream crystal/ powder 0.417* 
A79b 
Red  circular tablet 
No Design, rough top & Bottom 
Diameter: 8mm 
Depth: 4mm 
0.223 
A80 
White Circular Tablet 
Star Design, blank other side 
Diameter: 1cm 
Depth: 4.5mm 
0.326 
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Table 8.vi: Concentration conversion table for MDMA HCl to Free base in GCMS standards 
Approximate 
Concentration 
(mg/mL) 
Starting 
Concentration 
as Salt Form 
(mg/mL) 
Conversion 
to Free 
Base 
(mg/mL) 
Volume 
Taken 
(ml) 
Final 
Volume 
(ml) 
Final 
Concentration 
(mg/mL) 
0.05 2.044 1.717 0.0025 0.100 0.043 
0.1 2.044 1.717 0.0050 0.100 0.086 
0.2 2.044 1.717 0.0100 0.100 0.172 
0.3 2.044 1.717 0.0150 0.100 0.258 
0.4 2.044 1.717 0.0200 0.100 0.343 
0.5 2.044 1.717 0.0250 0.100 0.429 
0.6 2.044 1.717 0.0300 0.100 0.515 
0.7 2.044 1.717 0.0350 0.100 0.601 
0.8 2.044 1.717 0.0400 0.100 0.687 
0.9 2.044 1.717 0.0450 0.100 0.773 
1.0 2.044 1.717 0.0500 0.100 0.858 
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Figure 8.i: Exemplar chromatogram displaying integrated peaks for MDMA and IS (n-hexadecane) used to calculate PAR 
   
Abundance 
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Table 8.v: The retention times recorded for the analytical standard compounds  
Group Compound 
Retention 
Time 
 (Minutes) 
Relative 
Retention Factor 
Base Ion 
m/z 
Confirmation Ions 
Amphetamine Type Stimulants 
(ATS) 
Amphetamine 6.05 0.339 44 39, 42, 45, 65, 91, 
Methamphetamine 7.38 0.413 58 42, 56, 59, 65, 91  
3,4-Methylenedioxyamphetamine  
(MDA) 
15.01 0.840 44 42, 51, 77, 135, 136 
3,4-Metheylenedioxymethamphetamine 
(MDMA) 
16.39 0.918 58 51, 56, 77, 135,  136 
3,4-Metheylenedioxyethylamphetamine 
(MDEA) 
17.52 0.981 72 44, 70, 73, 77, 135 
Para-Methoxyamphetamine (PMA) 12.52 0.701 44 45, 77, 78, 121, 122 
Para-Methoxymethamphetamine (PMMA) 13.95 0.781 58 42, 56, 59, 77, 121 
Cathinone Derivatives 
Methcathinone (MCat) 11.38 0.637 58 51, 56, 77, 105, 148 
4-Methylmethcathinone  
(4-MMC/Mephedrone) 
14.47 0.810 58 56, 91, 65, 42, 119 
4-Methylethcathinone (4-MEC) 15.92 0.891 72 42, 44, 65, 70, 91 
3,4-Methylenedioxymethcatinone  
(MDMC/Methylone) 
20.73 1.161 58 56, 59, 63, 65, 149  
Piperazine Derivatives 
3-Trifluoromethylphenylpiperazine 
 (TFMPP) 
16.34 0.915 188 56, 95, 145, 172, 230 
1-Benzylpiparazine (BZP) 15.37 0.861 91 56, 65, 92, 134, 176 
Adulterant Caffeine 23.38 1.309 194 55, 67, 82, 109, 165 
Internal Standard n-Hexadecane 17.86 1.000 194 42, 55, 67, 82, 109 
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Table 8.vi: Calibration results table for MDMA standards 
Concentration 
(mg/mL) 
MDMA PAR 
1st 
PAR 
2nd 
PAR 
3rd 
PAR 
Mean  
Standard 
Deviation  
0.043 0.038 0.021 0.022 0.027 0.010 
0.086 0.048 0.058 0.099 0.068 0.027 
0.172 0.171 0.169 0.214 0.185 0.025 
0.258 0.351 0.335 0.320 0.335 0.016 
0.343 0.495 0.499 0.483 0.492 0.008 
0.429 0.782 0.771 0.768 0.774 0.007 
0.515 1.211 1.055 1.034 1.100 0.097 
0.601 1.394 1.292 1.377 1.354 0.055 
0.687 1.502 1.593 1.658 1.584 0.078 
0.773 1.900 1.778 1.969 1.882 0.097 
0.858 2.105 2.063 2.086 2.085 0.021 
 
Table 8.vii: Calibration Table for MDMA using selected ions (m/z 58 for MDMA divided by m/z 
57 for the IS) 
 
Table 8.viii: Calculated Residuals for EIC Calibration Data 
Concentration  
(mg/mL) 
Actual Y for EIC Estimated Y for EIC  Residuals 
0.172 0.406 0.106 0.300 
0.258 0.737 0.755 -0.018 
0.343 1.049 1.396 -0.347 
0.429 2.022 2.045 -0.023 
0.515 2.541 2.694 -0.153 
0.601 3.572 3.343 0.229 
0.687 3.861 3.992 -0.131 
0.773 4.743 4.640 0.103 
0.858 5.32 5.282 0.038 
Concentration 
(mg/mL) 
1st Calibration 
 point 
2nd Calibration 
point 
3rd  Calibration 
point 
Mean  
Standard 
Deviation  
0.043 0.119 0.057 0.058 0.078 0.071 
0.086 0.089 0.126 0.129 0.115 0.022 
0.172 0.411 0.318 0.489 0.406 0.086 
0.258 0.748 0.843 0.619 0.737 0.112 
0.343 0.977 1.044 1.126 1.049 0.075 
0.429 2.067 1.895 2.104 2.022 0.112 
0.515 2.491 2.306 2.827 2.541 0.264 
0.601 3.632 3.455 3.628 3.572 0.101 
0.687 3.338 4.741 3.504 3.861 0.767 
0.773 4.969 4.523 4.738 4.743 0.223 
0.858 5.142 5.466 5.351 5.320 0.164 
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Table 8.ix:  Original concentrations for samples of the street samples analysed by GC-MS 
Sample 
Weight 
(mg) 
Concentration  
Salt Form 
(mg/mL) 
Concentration 
Free Base 
(mg/mL) 
Final Sample 
Concentration 
(mg/mL) 
A3 20.23 2.02 1.70 0.68 
A4 40.50 4.05 3.40 1.36 
A7 19.00 1.90 1.60 0.64 
A9 20.40 2.04 1.71 0.69 
A11 19.00 1.90 1.60 0.64 
A27 20.80 2.08 1.75 0.70 
A28 23.24 2.32 1.95 0.78 
A37 19.90 1.99 1.67 0.67 
A44 22.30 2.23 1.87 0.75 
A48 21.30 2.13 1.79 0.72 
A50 21.10 2.11 1.77 0.71 
A53 19.90 1.99 1.67 0.67 
A54 20.20 2.02 1.70 0.68 
A55 21.20 2.12 1.78 0.71 
A63 25.96 2.60 2.18 0.87 
A64a 20.15 2.02 1.69 0.68 
A64b 19.70 1.97 1.65 0.66 
A64c 20.69 2.07 1.74 0.70 
A64d 22.25 2.23 1.87 0.75 
A64e 20.81 2.08 1.75 0.70 
A69 21.62 2.16 1.82 0.73 
A71 22.28 2.23 1.87 0.75 
A72 21.69 2.17 1.82 0.73 
A73a 19.89 1.99 1.67 0.67 
A73b 20.00 2.00 1.68 0.67 
A73c 20.83 2.08 1.75 0.70 
A74 23.50 2.35 1.97 0.79 
A76 28.62 2.86 2.40 0.96 
A77 19.70 1.97 1.65 0.66 
A79a 22.31 2.23 1.87 0.75 
A80 21.25 2.125 1.79 0.71 
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Table 8.x: Instrumental response for street samples in triplicate  
Sample 
1st Calibration 
point 
2nd Calibration 
point 
3rd Calibration 
point 
Average 
Std 
Deviation 
A3 0.401 0.338 0.341 0.360 0.036 
A4 0.327 0.249 0.261 0.279 0.042 
A7 0.522 0.359 0.482 0.454 0.085 
A9 0.35 0.45 0.317 0.372 0.069 
A11 0.524 0.399 0.38 0.434 0.078 
A27 0.439 0.395 0.482 0.439 0.044 
A28 1.008 0.836 0.861 0.902 0.093 
A47 0.451 0.704 0.646 0.600 0.133 
A44 0.667 0.741 0.76 0.723 0.049 
A48 0.19 0.27 0.349 0.270 0.080 
A50 0.38 0.335 0.337 0.351 0.025 
A53 0.853 0.973 0.957 0.928 0.065 
A54 1.066 0.852 0.982 0.967 0.108 
A55 1.265 1.169 1.122 1.185 0.073 
A63 1.433 1.55 1.479 1.487 0.059 
A64a 1.266 1.36 1.316 1.314 0.047 
A64b 0.91 0.962 1.088 0.987 0.092 
A64c 1.649 1.095 1.198 1.314 0.295 
A64d 1.13 1.06 1.263 1.151 0.103 
A64e 0.804 0.996 0.967 0.922 0.104 
A69 1.116 0.998 1.115 1.076 0.068 
A71 0.703 0.706 0.692 0.700 0.007 
A72 1.192 1.08 1.137 1.136 0.056 
A74 1.433 1.356 1.378 1.389 0.040 
A76 2.04 1.762 1.615 1.806 0.216 
A77 1.058 1.088 0.986 1.044 0.052 
A79a 0.933 0.969 0.89 0.931 0.040 
A80 0.25 0.342 0.301 0.298 0.046 
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Table 8.xi: Calculation for concentrations of street samples as free base MDMA and as a 
percentage of original sample 
Sample Y Value 
Calculated X 
(mg/mL) 
Original Concentration 
 (mg/mL) 
Purity (%) 
A3 0.360 0.27 0.68 39% 
A4 0.279 0.24 1.36 17% 
A7 0.454 0.30 0.64 46% 
A9 0.372 0.27 0.69 39% 
A11 0.434 0.29 0.64 45% 
A27 0.439 0.29 0.7 42% 
A28 0.902 0.45 0.78 58% 
A47 0.60 0.35 0.67 52% 
A44 0.723 0.39 0.75 52% 
A48 0.270 0.23 0.72 33% 
A50 0.351 0.26 0.71 37% 
A53 0.928 0.46 0.67 69% 
A54 0.967 0.47 0.68 70% 
A55 1.185 0.55 0.71 77% 
A63 1.487 0.65 0.87 75% 
A64a 1.314 0.59 0.68 87% 
A64b 0.987 0.48 0.66 73% 
A64c 1.314 0.59 0.7 85% 
A64d 1.151 0.54 0.75 72% 
A64e 0.922 0.46 0.7 65% 
A69 1.076 0.51 0.73 70% 
A71 0.7 0.38 0.75 51% 
A72 1.136 0.53 0.73 73% 
A74 1.389 0.62 0.79 78% 
A76 1.806 0.76 0.96 79% 
A77 1.044 0.50 0.66 76% 
A79a 0.931 0.46 0.75 61% 
A80 0.298 0.24 0.71 34% 
 
  
 404 
 
Table 8.xii: The calibration data for the Mephedrone standards run in triplicate 
Calibration Point 
Concentration 
(mg/mL)  
1st  
PAR 
2nd 
PAR 
3rd 
PAR 
Mean  
Standard 
Deviation  
1 0.049 0.014 0.009 0.010 0.011 0.003 
2 0.098 0.038 0.043 0.043 0.041 0.003 
3 0.197 0.135 0.082 0.119 0.112 0.027 
4 0.295 0.219 0.222 0.179 0.207 0.024 
5 0.393 0.341 0.332 0.316 0.330 0.013 
6 0.492 0.472 0.485 0.454 0.470 0.016 
7 0.590 0.623 0.643 0.632 0.633 0.010 
8 0.688 0.795 0.753 0.751 0.766 0.025 
9 0.786 0.925 0.881 0.918 0.908 0.024 
10 0.885 1.012 0.951 1.058 1.007 0.054 
11 0.983 1.132 1.147 1.116 1.132 0.016 
 
Table 8.xiii: Residuals calculated from Mephedrone Calibration Data 
Concentration (x) 
(mg/mL) Actual Y Estimated Y Residual 
0.049 0.011 -0.052 0.063 
0.098 0.041 0.009 0.032 
0.197 0.112 0.134 -0.022 
0.295 0.207 0.257 -0.051 
0.393 0.33 0.381 -0.051 
0.492 0.47 0.506 -0.035 
0.59 0.633 0.629 0.004 
0.688 0.766 0.752 0.014 
0.786 0.908 0.876 0.032 
0.885 1.007 1.000 0.007 
0.983 1.132 1.124 0.008 
 
Table 8.xiv: Instrumental response and calculated concentration value for seized Mephedrone 
samples 
Sample 1st 2nd 3rd  Mean 
Standard 
Deviation  
Calculated 
Concentration 
(mg/mL) 
A12 0.712 0.726 0.843 0.760 0.072 0.696 
A29 0.970 1.110 1.293 1.124 0.162 0.966 
A40 0.636 0.598 0.549 0.594 0.044 0.572 
A42 0.615 0.611 0.625 0.617 0.007 0.589 
A51 0.743 0.676 0.618 0.679 0.063 0.635 
A52 0.272 0.284 0.290 0.282 0.009 0.340 
A61 0.972 0.814 0.839 0.875 0.085 0.781 
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Table 8.xv: Actual concentrations of samples produced from precise weight 
Sample 
Weight  
(mg) 
Concentration  
(mg/mL) 
Volume Taken  
(mL) 
Final Volume 
(mL) 
Final Concentration 
(mg/mL) 
A12 22.16 2.216 0.04 0.1 0.886 
A29 36.83 3.683 0.04 0.1 1.473 
A40 20.63 2.063 0.04 0.1 0.825 
A42 19.88 1.988 0.04 0.1 0.795 
A51 20.53 2.053 0.04 0.1 0.821 
A52 9.03 0.903 0.075 0.1 0.677 
A61 19.5 1.95 0.04 0.1 0.781 
 
